	ac	Pharm	ucina	Introd
--	----	-------	-------	--------

2

Api	ril	2022	
/olume	10	Number	2

Editor:

Kave Wilson & Sophie Mollov email: enquiry@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9, 40 Mercer Street PO Box 10 254 Wellington 6143

Freephone Information Line 0800 66 00 50 (9am - 5pm weekdays)

Circulation

Accessible in an electronic format at no cost from the Pharmac website www.pharmac.govt.nz/schedule.

You can register to have an electronic version of the Pharmaceutical Schedule. Section H for Hospital Pharmaceuticals (link to PDF copy) emailed to your nominated email address each month by subscribing at schedule.pharmac.govt.nz/subscribe.

Production

Typeset automatically from XML and T_FX. XML version of the Schedule available from schedule.pharmac.govt.nz/pub/HML

Programmers

Anrik Drenth & John Geering

email: texschedule@pharmac.govt.nz

©Pharmaceutical Management Agency (\mathbf{i}) (cc BY

ISSN 1179-3708 pdf

This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to Pharmac and abide by the other licence terms. To view a copy of this licence, visit: creativecommons.org/licenses/by/4.0/. Attribution to Pharmac should be in written form and not by reproduction of the Pharmac logo. While care has been taken in compiling this Schedule, Pharmac takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Part I	General Rules	4
Part II	Alimentary Tract and Metabolism	5
	Blood and Blood Forming Organs	27
	Cardiovascular System	41
	Dermatologicals	56
	Genito-Urinary System	63
	Hormone Preparations	67
	Infections	78
	Musculoskeletal System	101
	Nervous System	110
	Oncology Agents and Immunosuppressants	135
	Respiratory System and Allergies	218
	Sensory Organs	226
	Various	233
	Extemporaneous Compounds (ECPs)	241
	Special Foods	244
	Vaccines	260

Part III

Optional Pharmaceuticals 271

> Index 272

Introducing Pharmac

The Pharmaceutical Management Agency (Pharmac) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. Pharmac negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

Pharmac's role:

"Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided."

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about Pharmac and the way we make funding decisions can be found on the Pharmac website at https://www.pharmac.govt.nz/about.

Glossary


Units of Measure

gram g kilogram kg international unit iu	microgram mcg milligram mg millilitre	millimole mmol unit u
Abbreviations		
applicationapp capsulecap creamcrm dispersibledisp effervescenteff emulsioneff	enteric coatedEC granulesgrans injectioninj liquidliq lotionlotn ointmentoint	suppositorysuppos tablettab

HSS Hospital Supply Status

Guide to Section H listings

Example



General Rules for Section H of the Pharmaceutical Schedule are included in Section A.

Read the General Rules : https://www.pharmac.govt.nz/section-a.

PART II: ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
Antacids and Antiflatulents			
Antacids and Reflux Barrier Agents			
ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND S Tab 200 mg with magnesium hydroxide 200 mg and simeticone 2 Oral liq 400 mg with magnesium hydroxide 400 mg and simeticon 30 mg per 5 ml	20 mg		e.g. Mylanta e.g. Mylanta Double
SIMETICONE Oral drops 100 mg per ml Oral drops 20 mg per 0.3 ml Oral drops 40 mg per ml			Strength
SODIUM ALGINATE WITH MAGNESIUM ALGINATE Powder for oral soln 225 mg with magnesium alginate 87.5 mg, s SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM Tab 500 mg with sodium bicarbonate 267 mg and calcium carbon	I CARBONATE		e.g. Gaviscon Infant
160 mg			e.g. Gaviscon Double Strength
Oral liq 500 mg with sodium bicarbonate 267 mg and calcium can 160 mg per 10 ml SODIUM CITRATE		500 ml	Acidex
Oral liq 8.8% (300 mmol/l) - 5% DV Jan-22 to 2024	25.00	90 ml	Biomed
Phosphate Binding Agents			
ALUMINIUM HYDROXIDE Tab 600 mg			
CALCIUM CARBONATE – Restricted see terms below ↓ Oral liq 250 mg per ml (100 mg elemental per ml) → Restricted (RS1698)		500 ml	Roxane
Initiation Only when prescribed for patients unable to swallow calcium carbona inappropriate	te tablets or where c	alcium carb	onate tablets are
Antidiarrhoeals and Intestinal Anti-Inflammatory A	gents		
Antipropulsives			
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHAT Tab 2.5 mg with atropine sulphate 25 mcg	E		
LOPERAMIDE HYDROCHLORIDE Tab 2 mg Cap 2 mg – 1% DV Oct-19 to 2022		400 400	Nodia Diamide Relief
Rectal and Colonic Anti-Inflammatories			
BUDESONIDE – Restricted see terms on the next page Cap 3 mg			

Price			Brand or
(ex man. excl.	GST)	_	Generic
\$		Per	Manufacturer

→ Restricted (RS1723)

Initiation - Crohn's disease

Both:

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
- 2 Any of the following:
 - 2.1 Diabetes; or
 - 2.2 Cushingoid habitus; or
 - 2.3 Osteoporosis where there is significant risk of fracture; or
 - 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
 - 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initiation - Collagenous and lymphocytic colitis (microscopic colitis)

Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initiation - Gut Graft versus Host disease

Patient has gut Graft versus Host disease following allogenic bone marrow transplantation.

Initiation - non-cirrhotic autoimmune hepatitis

Re-assessment required after 6 months

All of the following:

- 1 Patient has autoimmune hepatitis*; and
- 2 Patient does not have cirrhosis; and
- 3 Any of the following:
 - 3.1 Diabetes; or
 - 3.2 Cushingoid habitus; or
 - 3.3 Osteoporosis where there is significant risk of fracture; or
 - 3.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 3.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 3.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or

7

Pentasa

- 3.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated); or
- 3.8 Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth).

Note: Indications marked with * are unapproved indications.

Continuation - non-cirrhotic autoimmune hepatitis

Re-assessment required after 6 months

Treatment remains appropriate and the patient is benefitting from the treatment.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC free (14 applications)	26.55	21.1 g	Colifoam
HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE Topical Aerosol foam, 1% with pramoxine hydrochloride 1%			
MESALAZINE			
Tab EC 400 mg		100	Asacol
Tab long-acting 500 mg - 1% DV Jul-20 to 2023		100	Pentasa
Tab 800 mg	85.50	90	Asacol
Modified release granules 1 g	118.10	100 g	Pentasa
Suppos 500 mg	22.80	20	Asacol
Suppos 1 g	50.96	28	Pentasa

	Price . excl. GST)		Brand or Generic
(6A man	\$	Per	Manufacturer
DLSALAZINE			
Tab 500 mg	93.37	100	Dipentum
Cap 250 mg	53.00	100	Dipentum
REDNISOLONE SODIUM			
Rectal foam 20 mg per dose (14 applications)	74.10	1	Essential Prednisolone
ODIUM CROMOGLICATE			
Cap 100 mg			
SULFASALAZINE			
Tab 500 mg	14 00	100	Salazopyrin
Tab EC 500 mg – 1% DV Dec-19 to 2022		100	Salazopyrin EN
			.,
Local Preparations for Anal and Rectal Disorders			
Antihaemorrhoidal Preparations			
INCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE			
Oint 5 mg with hydrocortisone 5 mg per g	. 15.00	30 g	Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g	9.90	12	Proctosedyl
LUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND C	INCHOCAIN	IE	
Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine			
hydrochloride 5 mg per g	. 11.06	30 g	Ultraproct
Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine		Ū	
hydrochloride 1 mg	7.30	12	Ultraproct
Management of Anal Fissures			
BLYCERYL TRINITRATE			
Oint 0.2% - 5% DV Sep-21 to 2024	22.00	30 g	Rectogesic
Rectal Sclerosants			
ILY PHENOL [PHENOL OILY] Inj 5%, 5 ml vial			
Antispasmodics and Other Agents Altering Gut Motility			
GLYCOPYRRONIUM BROMIDE			
Inj 200 mcg per ml, 1 ml ampoule	65.45	10	Max Health
IYOSCINE BUTYLBROMIDE			
Tab 10 mg - 1% DV Oct-20 to 2023	6.35	100	Buscopan
Inj 20 mg, 1 ml ampoule – 1% DV Jul-20 to 2023	6.35	5	Buscopan
IEBEVERINE HYDROCHLORIDE			
Tab 135 mg - 1% DV Jul-20 to 2023	9.20	90	Colofac
Antiulcerants			
Antisecretory and Cytoprotective			
IISOPROSTOL Tab 200 mcg	44.50	120	Cytotec

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	F (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
H2 Antagonists					
CIMETIDINE Tab 200 mg Tab 400 mg					
FAMOTIDINE Tab 20 mg Tab 40 mg Inj 10 mg per ml, 2 ml vial Inj 10 mg per ml, 4 ml vial					
RANITIDINE - Restricted see terms below ↓ Tab 150 mg ↓ Tab 300 mg ↓ Inj 25 mg per ml, 2 ml ampoule → Restricted (RS1703) Initiation Either:					
 For continuation use; or Routine prevention of allergic reactions 					
Proton Pump Inhibitors					
LANSOPRAZOLE Cap 15 mg - 5% DV Dec-21 to 2024 Cap 30 mg - 5% DV Dec-21 to 2024 OMEPRAZOLE ↓ Tab dispersible 10 mg → Restricted (RS1027) Initiation				100 100	Lanzol Relief Lanzol Relief
Only for use in tube-fed patients. ↓ Tab dispersible 20 mg → Restricted (RS1027) Initiation					
Only for use in tube-fed patients. Cap 10 mg - 1% DV Aug-21 to 2023 Cap 20 mg - 1% DV Aug-21 to 2023 Cap 40 mg - 1% DV Aug-21 to 2023 Powder for oral liq Inj 40 mg ampoule with diluent - 1% DV Oct-19 to 2022 Inj 40 mg vial - 1% DV Oct-19 to 2022		1.86 3.11 .42.50 .33.98		90 90 90 5 g 5 5	Omeprazole actavis 10 Omeprazole actavis 20 Omeprazole actavis 40 Midwest Dr Reddy's Omeprazole Omezol IV
PANTOPRAZOLE Tab EC 20 mg – 1% DV Oct-19 to 2022 Tab EC 40 mg – 1% DV Oct-19 to 2022 Inj 40 mg vial		2.02		100 100	Panzop Relief Panzop Relief
Site Protective Agents					
COLLOIDAL BISMUTH SUBCITRATE Tab 120 mg SUCRALFATE Tab 1 g		.14.51		50	Gastrodenol

t Item restricted (see → above); t Item restricted (see → below)

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer
Bile and Liver Therapy			
L-ORNITHINE L-ASPARTATE - Restricted see terms below ↓ Grans for oral liquid 3 g → Restricted (RS1261) Initiation			
For patients with chronic hepatic encephalopathy who have not respo where lactulose is contraindicated. RIFAXIMIN – Restricted see terms below	nded to treatment with	n, or are ir	tolerant to lactulose, or
↓ Tab 550 mg - 1% DV Mar-21 to 2023	625.00	56	Xifaxan
For patients with hepatic encephalopathy despite an adequate trial of	maximum tolerated d	oses of la	ctulose.
Diabetes			
Alpha Glucosidase Inhibitors			
ACARBOSE			
Tab 50 mg – 5% DV Dec-21 to 2024 Tab 100 mg – 5% DV Dec-21 to 2024		90 90	Accarb Accarb
Hyperglycaemic Agents			
DIAZOXIDE - Restricted see terms below			
Cap 25 mg		100	Proglicem
Cap 100 mg		100	Proglicem
 ↓ Oral liq 50 mg per ml → Restricted (RS1028) 		30 ml	Proglycem
Initiation			
For patients with confirmed hypoglycaemia caused by hyperinsulinism	n.		
GLUCAGON HYDROCHLORIDE			
Inj 1 mg syringe kit – 1% DV Jul-20 to 2023	32.00	1	Glucagen Hypokit
GLUCOSE [DEXTROSE]		·	andougen Hypokit
Tab 1.5 g Tab 3.1 g			
Tab 4 g Oral soln 15 g per 80 ml sachet – 1% DV Jan-22 to 2023	70.00	50	HypoPak Glucose
Gel 40%			
GLUCOSE WITH SUCROSE AND FRUCTOSE Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet			
Insulin - Intermediate-Acting Preparations			
INSULIN ASPART WITH INSULIN ASPART PROTAMINE Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u pr 3 ml prefilled pen		5	NovoMix 30 FlexPen
INSULIN ISOPHANE Inj insulin human 100 u per ml, 10 ml vial		-	
Inj insulin human 100 u per ml, 3 ml cartridge			

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
NSULIN LISPRO WITH INSULIN LISPRO PROTAMINE			
Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per 3 ml cartridge		5	Humalog Mix 25
Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per 3 ml cartridge		5	Humalog Mix 50
NSULIN NEUTRAL WITH INSULIN ISOPHANE			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 vial			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 cartridge	ml		
Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 cartridge	ml		
Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 cartridge	ml		
Insulin - Long-Acting Preparations			
NSULIN GLARGINE Inj 100 u per ml, 3 ml disposable pen	04.50	5	Lantus SoloStar
Inj 100 u per ml, 3 ml cartridge		5 5	Lantus Solosiai
Inj 100 u per ml, 10 ml vial		1	Lantus
Insulin - Rapid-Acting Preparations			
NSULIN ASPART Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
Inj 100 u per ml, 3 ml syringe	51.19	5	NovoRapid FlexPen
NSULIN GLULISINE			
Inj 100 u per ml, 10 ml vial		1	Apidra
Inj 100 u per ml, 3 ml cartridge		5 5	Apidra Apidra Salastar
Inj 100 u per ml, 3 ml disposable pen		э	Apidra Solostar
NSULIN LISPRO Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
Insulin - Short-Acting Preparations			
NSULIN NEUTRAL			
Inj human 100 u per ml, 10 ml vial			
Inj human 100 u per ml, 3 ml cartridge			
Oral Hypoglycaemic Agents			
GLIBENCLAMIDE Tab 5 mg – 5% DV Jan-22 to 2024		100	Daonil
GLICLAZIDE			
	15.18	500	Glizide
Tab 80 mg – 1% DV Nov-20 to 2023			
Tab 80 mg – 1% DV Nov-20 to 2023 ALIPIZIDE Tab 5 mg – 5% DV Mar-22 to 2024	4.58	100	Minidiab

Price (ex man. excl. 0 \$	GST) Per	Brand or Generic Manufacturer
METFORMIN HYDROCHLORIDE		
Tab immediate-release 500 mg - 1% DV Mar-22 to 2024	1,000	Metformin Mylan
Tab immediate-release 850 mg - 1% DV Mar-22 to 2024 11.28	500	Metformin Mylan
PIOGLITAZONE		
Tab 15 mg - 5% DV Jan-22 to 20246.80	90	Vexazone
Tab 30 mg - 5% DV Jan-22 to 20247.30	90	Vexazone
Tab 45 mg - 5% DV Jan-22 to 2024 12.25	90	Vexazone
VILDAGLIPTIN		
Tab 50 mg	60	Galvus
VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE		
Tab 50 mg with 1,000 mg metformin hydrochloride	60	Galvumet
Tab 50 mg with 850 mg metformin hydrochloride	60	Galvumet

GLP-1 Agonists

➡ Restricted (RS1857)

Initiation

Any of the following:

- 1 For continuation use; or
- 2 Patient has previously had an initial approval for an SGLT-2 inhibitor; or
- 3 All of the following:
 - 3.1 Patient has type 2 diabetes; and
 - 3.2 Any of the following:
 - 3.2.1 Patient is Māori or any Pacific ethnicity*; or
 - 3.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
 - 3.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
 - 3.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
 - 3.2.5 Patient has diabetic kidney disease (see note b)*; and
 - 3.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.
- Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.
 - a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
 - b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m2 in the presence of diabetes, without alternative cause.

DULAGLUTIDE - Restricted see terms above

- Note: Not to be given in combination with a funded SGLT-2 inhibitor.
- t Inj 1.5 mg per 0.5 ml prefilled pen 115.23 4 Trulicity

SGLT2 Inhibitors

→ Restricted (RS1852) Initiation

Any of the following:

continued...

F	Price		Brand or
(ex man.	excl. G	GST)	Generic
	\$	Per	Manufacturer

continued...

- 1 For continuation use; or
- 2 Patient has previously had an initial approval for a GLP-1 agonist; or
- 3 All of the following:
 - 3.1 Patient has type 2 diabetes; and
 - 3.2 Any of the following:
 - 3.2.1 Patient is Māori or any Pacific ethnicity*; or
 - 3.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
 - 3.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
 - 3.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
 - 3.2.5 Patient has diabetic kidney disease (see note b)*; and
 - 3.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.

Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

- a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
- b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m2 in the presence of diabetes, without alternative cause.

EMPAGLIFLOZIN - Restricted see terms on the previous page

Note: Not to be given in combination with a funded GLP-1 agonist.	

t	Tab 10 mg58.56	30	Jardiance
t	Tab 25 mg	30	Jardiance

EMPAGLIFLOZIN WITH METFORMIN HYDROCHLORIDE - Restricted see terms on the previous page

Note: Not to be given in combination with a funded GLP-1 agonist.

t	Tab 5 mg with 1,000 mg metformin hydrochloride	60	Jardiamet
t	Tab 5 mg with 500 mg metformin hydrochloride	60	Jardiamet
t	Tab 12.5 mg with 1,000 mg metformin hydrochloride	60	Jardiamet
t	Tab 12.5 mg with 500 mg metformin hydrochloride	60	Jardiamet

Digestives Including Enzymes

PANCREATIC ENZYME

Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,250 U protease))		
Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur		
U, total protease 600 Ph Eur U) - 5% DV Jun-22 to 2024	100	Creon 10000
Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph		
Eur U, total protease 1,000 Ph Eur U) - 5% DV Jun-22 to 2024	100	Creon 25000
Modified release granules pancreatin 60.12 mg (amylase 3,600 Ph Eur		
U, lipase 5,000 Ph Eur U, protease 200 Ph Eur U)	20 g	Creon Micro
Powder pancreatin 60.12 mg (3,600 Ph. Eur. u/amylase, 5,000 Ph.	•	
Eur. u/lipase and 200 Ph. Eur. u/protease)		
URSODEOXYCHOLIC ACID - Restricted see terms on the next page		
	100	Ursosan
		0.000un

Price (ex man. excl. GST)		Brand or Generic
 (on main onon oron) \$	Per	Manufacturer

→ Restricted (RS1824)

Initiation – Alagille syndrome or progressive familial intrahepatic cholestasis Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initiation - Chronic severe drug induced cholestatic liver injury

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initiation – Primary biliary cholangitis

Both:

- 1 Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis.

Initiation – Pregnancy

Patient diagnosed with cholestasis of pregnancy.

Initiation - Haematological transplant

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Initiation – Total parenteral nutrition induced cholestasis Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
- 2 Liver function has not improved with modifying the TPN composition.

Initiation - prevention of sinusoidal obstruction syndrome

Limited to 6 months treatment

Both:

- 1 The patient is enrolled in the Children's Oncology Group AALL1732 trial; and
- 2 The patient has leukaemia/lymphoma and is receiving inotuzumab ozogamicin.

Laxatives

Bowel-Cleansing Preparations

CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE

Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet	e.g. PicoPrep
MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE	
Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate	
80.62 mg per g, 70 g sachet - 5% DV Jan-22 to 2024	Glycoprep-C
80.62 mg per g, 210 g sachet	e.g. Glycoprep-C

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
 MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE, MAGNESIUM OXIDE AND SODIUM PICOSULFATE Powder for oral soln 52.9 g with ascorbic acid 6 g, potassium chlori 740 mg, sodium chloride 2.6 g and sodium sulphate 5.6 g per sachet (1) and powder for oral soln citric acid 12 g with magne oxide 3.5 g and sodium picosulfate 10 mg per sachet (2) MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARB Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulp 5.685 g per sachet – 1% DV Aug-19 to 2022 	de sium ONATE, SODIUM 1 hate		e.g. Prepkit-C
Bulk-Forming Agents			
ISPAGHULA (PSYLLIUM) HUSK Powder for oral soln – 1% DV Nov-20 to 2023 STERCULIA WITH FRANGULA – Restricted: For continuation only → Powder for oral soln		500 g	Konsyl-D
Faecal Softeners			
DOCUSATE SODIUM Tab 50 mg – 1% DV Oct-20 to 2023 Tab 120 mg – 1% DV Oct-20 to 2023 DOCUSATE SODIUM WITH SENNOSIDES		100 100	Coloxyl Coloxyl
Tab 50 mg with sennosides 8 mg PARAFFIN Oral liquid 1 mg per ml Enema 133 ml	4.20	200	Laxsol
POLOXAMER Oral drops 10% - 1% DV Nov-20 to 2023		30 ml	Coloxyl
Opioid Receptor Antagonists - Peripheral			
METHYLNALTREXONE BROMIDE – Restricted see terms below Inj 12 mg per 0.6 ml vial	36.00 246.00	1 7	Relistor Relistor
 The patient is receiving palliative care; and Either: Oral and rectal treatments for opioid induced constipation Oral and rectal treatments for opioid induced constipation 			
Osmotic Laxatives			
GLYCEROL Suppos 1.27 g Suppos 2.55 g Suppos 3.6 g		20	PSM
LACTULOSE Oral liq 10 g per 15 ml – 1% DV Nov-19 to 2022		500 ml	Laevolac

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

14

	(ex man.	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARB	ONATE	AND S	Sodiui	M CHLOF	RIDE
Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodi bicarbonate 89.3 mg and sodium chloride 175.4 mg Powder for oral soln 13.125 g with potassium chloride 46.6 mg, so bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV Oct-20 to 2023	dium /	6.70	0	30	Molaxole
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml DV Nov-19 to 2022 SODIUM PHOSPHATE WITH PHOSPHORIC ACID Oral liq 16.4% with phosphoric acid 25.14% Enema 10% with phosphoric acid 6.58%				50 1	Micolette Fleet Phosphate Enema
Stimulant Laxatives					
BISACODYL					
Tab 5 mg – 5% DV Jun-22 to 2024		5.99 5.80		200	Lax-Tabs Pharmacy Health
Suppos 10 mg – 5% DV Dec-21 to 2024 (<i>Lax-Tabs Tab 5 mg to be delisted 1 June 2022</i>) SENNOSIDES Tab 7.5 mg		3.69	9	10	Lax-Suppositories
SODIUM PICOSULFATE - Restricted see terms below ↓ Oral soln 7.5 mg per ml		7.40	0	30 ml	Dulcolax SP Drop

Both:

- 1 The patient is a child with problematic constipation despite an adequate trial of other oral pharmacotherapies including macrogol where practicable; and
- 2 The patient would otherwise require a high-volume bowel cleansing preparation.

Metabolic Disorder Agents

ALGLUCOSIDASE ALFA – Restricted see terms below			
Inj 50 mg vial	1	Myozyme	
→ Restricted (RS1793)			

Initiation

Metabolic physician

Re-assessment required after 12 months All of the following:

1 The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and

2 Any of the following:

- 2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
- 2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
- 2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a

continued...

Pi	rice			Brand or
(ex man.	excl.	GST)	_	Generic
	\$		Per	Manufacturer

continued...

- disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
- 2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
- 3 Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
- 4 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
- 5 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

Continuation

Metabolic physician

Re-assessment required after 12 months

All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
- 3 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 4 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
- 5 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6 There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
- 7 There is no evidence of new or progressive cardiomyopathy.

ARGININE

Tab 1,000 mg Cap 500 mg Powder Inj 500 mg per ml, 10 ml vial Inj 600 mg per ml, 25 ml vial

BETAINE - Restricted see terms below

→ Restricted (RS1794)

Initiation

Metabolic physician

Re-assessment required after 12 months

All of the following:

- 1 The patient has a confirmed diagnosis of homocystinuria; and
- 2 Any of the following:
 - 2.1 A cystathionine beta-synthase (CBS) deficiency; or
 - 2.2 A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency; or
 - 2.3 A disorder of intracellular cobalamin metabolism; and
- 3 An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation.

Continuation

Metabolic physician

Re-assessment required after 12 months

The treatment remains appropriate and the patient is benefiting from treatment.

BIOTIN - Restricted see terms on the next page

- Cap 100 mg
- Inj 10 mg per ml, 5 ml vial

	Price				Brand or		
	(ex man.	excl. \$	GST)	Per	Generic Manufacturer		
→ Restricted (RS1330)							
Metabolic physician or metabolic disorders dietitian							
CARGLUMIC ACID – Restricted see terms below							
Tab disp 200 mg							
➡ Restricted (RS1831)							
Initiation							
Metabolic physician							
For the acute in-patient treatment of organic acidaemias as an alte	rnative to hae	emofil	tration.				
COENZYME Q10 - Restricted see terms below							
Cap 120 mg							
Cap 160 mg							
→ Restricted (RS1832)							
Initiation							
Metabolic physician							
Re-assessment required after 6 months	annand to an		010		ontation		
The patient has a suspected inborn error of metabolism that may re Continuation	espond to coe	enzyn		supplem			
Metabolic physician							
Re-assessment required after 24 months							
Both:							
1 The patient has a confirmed diagnosis of an inborn error of	metaholism t	hat ro	enonde	to coen-	zume Ω10 supplementation:		
and		natio	sponus		Lynne are supplementation,		
2 The treatment remains appropriate and the patient is benefi	tina from tree	atmen	t				
	ang nom roc						
GALSULFASE – Restricted see terms below	0.	0010	^	4	Naglazima		
Inj 1 mg per ml, 5 ml vial ■ Destricted (DS1705)	Z,	234.0	0	1	Naglazyme		
→ Restricted (RS1795) Initiation							
Metabolic physician							
Re-assessment required after 12 months							
Both:							
1 The patient has been diagnosed with mucopolysaccharidos	is VI: and						
2 Either:	10 v1, and						
2.1 Diagnosis confirmed by demonstration of N-acetyl-g	alactosamine	-4-su	lfatase	arvlsulfa	tase B) deficiency confirmed		
by either enzyme activity assay in leukocytes or skin			inataoo	aryiouna			
2.2 Detection of two disease causing mutations and pati			vho is kr	nown to h	nave mucopolysaccharidosis		
VI.		5			·····		
Continuation							
Metabolic physician							
Re-assessment required after 12 months							
All of the following:							
1 The treatment remains appropriate for the patient and the p	atient is bene	fiting	from tre	eatment;	and		
2 Patient has not had severe infusion-related adverse reaction	ns which wer	e not	prevent	able by a	appropriate pre-medication		
and/or adjustment of infusion rates; and				-			
3 Patient has not developed another life threatening or severe	e disease whe	ere th	e long t	erm prog	nosis is unlikely to be		
influenced by Enzyme Replacement Therapy (ERT); and							
4 Patient has not developed another medical condition that m	ight reasonal	oly be	expect	ed to cor	npromise a response to		
ERT.							
HAEM ARGINATE							

Inj 25 mg per ml, 10 ml ampoule

	(ex man	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
IDURSULFASE – Restricted see terms below ↓ Inj 2 mg per ml, 3 ml vial	4,	608.3	0	1	Elaprase
Initiation Metabolic physician <i>Limited to 24 weeks</i> treatment All of the following:					
1 The patient has been diagnosed with Hunter Syndrome (muce 2 Either:	opolysacch	ardos	is II); a	nd	
 2.1 Diagnosis confirmed by demonstration of iduronate 2-s assay in cultured skin fibroblasts; or 2.2 Detection of a disease causing mutation in the idurona 3 Patient is going to proceed with a haematopoietic stem cell traidursulfase would be bridging treatment to transplant; and 4 Patient has not required long-term invasive ventilation for resp (ERT); and 5 Idursulfase to be administered for a total of 24 weeks (equival greater than 0.5 mg/kg every week. 	ate 2-sulfata ansplant (H piratory fail	ase ge ISCT) ure pri	ene; an within ior to s	d the next tarting E	t 3 months and treatment with
LARONIDASE – Restricted see terms below ↓ Inj 100 U per ml, 5 ml vial	1,	335.1	6	1	Aldurazyme
Metabolic physician <i>Limited to 24 weeks</i> treatment All of the following: 1 The patient has been diagnosed with Hurler Syndrome (mucc 2 Either:	polysaccha	ardosi	s I-H);	and	
 2.1 Diagnosis confirmed by demonstration of alpha-L-idurd assay in cultured skin fibroblasts; or 2.2 Detection of two disease causing mutations in the alph to have Hurler syndrome; and 					
 3 Patient is going to proceed with a haematopoietic stem cell tra- laronidase would be bridging treatment to transplant; and 4 Patient has not required long-term invasive ventilation for resp (ERT); and 5 Long-idage to be administered for a total of 24 works (against 	piratory fail	ure pri	ior to s	tarting E	Enzyme Replacement Therapy
5 Laronidase to be administered for a total of 24 weeks (equiva than 100 units/kg every week.		VEEKS	pre- ai	iu 12 pc	SI-HSCT) at usses no greater
LEVOCARNITINE - Restricted see terms below Tab 500 mg Cap 250 mg Cap 500 mg Oral liq 500 mg per 10 ml Oral soln 1,000 mg per 10 ml Inj 200 mg per ml, 5 ml vial Restricted (RS1035) Neurologist, metabolic physician or metabolic disorders dietitian					

PYRIDOXAL-5-PHOSPHATE - Restricted see terms below

■ Tab 50 mg

18

➡ Restricted (RS1331)

Neurologist, metabolic physician or metabolic disorders dietitian

Price	Brand or	
(ex man. excl. GST)	Generic	
\$	Per Manufacturer	

RIBOFLAVIN – **Restricted** see terms below

- Tab 100 mg
- Cap 100 mg

➡ Restricted (RS1833)

Initiation

Metabolic physician or neurologist

Re-assessment required after 6 months

The patient has a suspected inborn error of metabolism that may respond to riboflavin supplementation.

Continuation

Metabolic physician or neurologist

Re-assessment required after 24 months

Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to riboflavin supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

SAPROPTERIN DIHYDROCHLORIDE - Restricted see terms below

↓ Tab soluble 100 mg	1,452.70	30	Kuvan	
→ Restricted (RS1796)				
Initiation				
Metabolic physician				
Re-assessment required after 1 month				
All of the following:				
1 Patient has phenylketonuria (PKU) and is pregnant or actively plann	ning to become pre	gnant; a	and	
2 Treatment with sapropterin is required to support management of Pl	KU during pregnar	ncy; and		
3 Sapropterin to be administered at doses no greater than a total daily	v dose of 20 ma/ka	: and		

- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

Continuation

Metabolic physician

Re-assessment required after 12 months

- All of the following:
 - 1 Either:
 - 1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or
 - 1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and
 - 2 Any of the following:
 - 2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or
 - 2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or
 - 2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and
 - 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
 - 4 Sapropterin to be used alone or in combination with PKU dietary management; and
 - 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

SODIUM BENZOATE

Cap 500 mg Powder Soln 100 mg per ml Inj 20%, 10 ml ampoule

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SODIUM PHENYLBUTYRATE - Some items restricted see term	s below		
Tab 500 mg			
Grans 483 mg per g	2,016.00	174 g	Pheburane
Oral liq 250 mg per ml			
Inj 200 mg per ml, 10 ml ampoule			
→ Restricted (RS1797) Initiation			
Metabolic physician			
Re-assessment required after 12 months			
For the chronic management of a urea cycle disorder involving a de	ficiency of carbamylpho	sphate svi	nthetase, ornithine
transcarbamylase or argininosuccinate synthetase.	, ,,		,
Continuation			
Metabolic physician			
Re-assessment required after 12 months			
The treatment remains appropriate and the patient is benefiting from	n treatment.		
TALIGLUCERASE ALFA – Restricted see terms below			
Inj 200 unit vial	1,072.00	1	Elelyso
→ Restricted (RS1034)			
Initiation	nal		
Only for use in patients with approval by the Gaucher Treatment Pa	lilei.		
TAURINE – Restricted see terms below			
Cap 500 mg			
Cap 1,000 mg Powder			
➡ Restricted (RS1834)			
Initiation			
Metabolic physician			
Re-assessment required after 6 months			
The patient has a suspected specific mitochondrial disorder that ma	ay respond to taurine su	pplementa	tion.
Continuation			
Metabolic physician			
Re-assessment required after 24 months			
Both:			
 The patient has a confirmed diagnosis of a specific mitochoi The treatment remains appropriate and the patient is benefit 		ponds to t	aurine supplementation; and
TRIENTINE DIHYDROCHLORIDE			
Cap 300 mg			
Minerals			
Calcium			
CALCIUM CARBONATE			
Tab 1.25 g (500 mg elemental) - 1% DV May-21 to 2023	6.69	250	Calci-Tab 500
Tab eff 1.25 g (500 mg elemental)			
Tab eff 1.75 g (1 g elemental)			
CALCIUM LACTATE GLUCONATE WITH CALCIUM CARBONATE			
Tab eff 2.94 g with calcium carbonate 0.3 g (500 mg elemental)		e.g. Calcium-Sandoz
			Forte

(ex man.	rice excl. GS ⁻ \$	T) Per	Brand or Generic Manufacturer
Fluoride			
SODIUM FLUORIDE Tab 1.1 mg (0.5 mg elemental)			
lodine			
POTASSIUM IODATE Tab 253 mcg (150 mcg elemental iodine) – 1% DV Oct-20 to 2023 POTASSIUM IODATE WITH IODINE Oral liq 10% with iodine 5%	4.58	90	NeuroTabs
Iron			
FERROUS FUMARATE Tab 200 mg (65 mg elemental) - 5% DV May-22 to 2024	3.04	100	Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID Tab 310 mg (100 mg elemental) with folic acid 350 mcg – 5% DV Aug-22 to 2024	5.98	100	Ferro-F-Tabs
FERROUS GLUCONATE WITH ASCORBIC ACID Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg			
FERROUS SULFATE Tab long-acting 325 mg (105 mg elemental) Oral liq 30 mg (6 mg elemental) per ml – 1% DV Nov-19 to 2022		30 500 ml	Ferrograd Ferodan
FERROUS SULFATE WITH ASCORBIC ACID Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg			
IRON (AS FERRIC CARBOXYMALTOSE) – Restricted see terms below ↓ Inj 50 mg per ml, 10 ml vial	50.00	1	Ferinject
Initiation Treatment with oral iron has proven ineffective or is clinically inappropriate.			
IRON (AS SUCROSE) Inj 20 mg per ml, 5 ml ampoule1 IRON POLYMALTOSE	00.00	5	Venofer
Inj 50 mg per ml, 2 ml ampoule	34.50	5	Ferrosig
Magnesium			
MAGNESIUM AMINO ACID CHELATE			

Cap 750 mg (150 mg elemental) MAGNESIUM CHLORIDE Inj 1 mmol per 1 ml, 100 ml bag MAGNESIUM HYDROXIDE Tab 311 mg (130 mg elemental) Suspension 8% MAGNESIUM OXIDE Cap 663 mg (400 mg elemental) Cap 696 mg (420 mg elemental)

	f (ex man.	Price excl.	GST)		Brand or Generic
		\$	01.12	Per	Manufacturer
 MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIU Cap 500 mg with magnesium aspartate 100 mg, magnesium ami chelate 100 mg and magnesium citrate 100 mg (360 mg eler magnesium) MAGNESIUM SULPHATE Inj 0.4 mmol per ml, 250 ml bag Inj 2 mmol per ml, 5 ml ampoule – 1% DV Jul-21 to 2023 Inj 100 mg per ml, 50 ml bag 	ino acid mental			ATE AND	MAGNESIUM CITRATE
Zinc					
ZINC Oral liq 5 mg per 5 drops ZINC CHLORIDE Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule ZINC SULPHATE					
Cap 137.4 mg (50 mg elemental) - 1% DV Dec-19 to 2022		.11.0	0	100	Zincaps
Mouth and Throat					
Agents Used in Mouth Ulceration					
 BENZYDAMINE HYDROCHLORIDE Soln 0.15% Spray 0.15% Spray 0.3% BENZYDAMINE HYDROCHLORIDE WITH CETYLPYRIDINIUM CHL Lozenge 3 mg with cetylpyridinium chloride CARBOXYMETHYLCELLULOSE Oral spray CARMELLOSE SODIUM WITH PECTIN AND GELATINE Paste Powder CHLORHEXIDINE GLUCONATE Mouthwash 0.2% CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE Adhesive gel 8.7% with cetalkonium chloride 0.01% DICHLOROBENZYL ALCOHOL WITH AMYLMETACRESOL Lozenge 1.2 mg with amylmetacresol 0.6 mg TRIAMCINOLONE ACETONIDE Paste 0.1% - 1% DV Nov-20 to 2023 		5.3	3	5 g	Kenalog in Orabase
Oropharyngeal Anti-Infectives			-	- 3	
AMPHOTERICIN B					
Lozenge 10 mg		5.8	6	20	Fungilin
MICONAZOLE Oral gel 20 mg per g – 5% DV Dec-21 to 2024		4.7	4	40 g	Decozol
NYSTATIN Oral liquid 100,000 u per ml – 1% DV Oct-20 to 2023		1.7	6	24 ml	Nilstat

1 Item restricted (see \Rightarrow above); **1** Item restricted (see \Rightarrow below)

22

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Other Oral Agents			
HYALURONIC ACID WITH LIDOCAINE [LIGNOCAINE] Inj 20 mg per ml SODIUM HYALURONATE [HYALURONIC ACID] – Restricted sea Inj 20 mg per ml, 1 ml syringe	e terms below		
→ Restricted (RS1175) Otolaryngologist			
Vitamins			
Multivitamin Preparations			
MULTIVITAMIN AND MINERAL SUPPLEMENT – Restricted see		180	Clinicians Multivit & Mineral Boost
Restricted (RS1498) Initiation Limited to 3 months treatment Both:			Winter and Doose
 Patient was admitted to hospital with burns; and Any of the following: Burn size is greater than 15% of total body surface a Burn size is greater than 10% of BSA for mid-dermal Nutritional status prior to admission or dietary intake 	or deep dermal burns; o		
MULTIVITAMIN RENAL – Restricted see terms below ↓ Cap	6.49	30	Clinicians Renal Vit

Either:

1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or

2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73m² body surface area (BSA).

		Price excl. GST) \$	Per	Brand or Generic Manufacturer
MULTIVITAMINS				
 Tab (BPC cap strength) – 1% DV Mar-20 to 2022 cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, a tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 mg cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg 	lpha ,	.11.45	1,000	Mvite e.g. Vitabdeck
→ Restricted (RS1620)				-
Initiation Any of the following:				
 Patient has cystic fibrosis with pancreatic insufficiency; or Patient is an infant or child with liver disease or short gut syndror Patient has severe malabsorption syndrome. 	ne; or			
 I Powder vitamin A 3200 mcg with vitamin D 100 mcg, vitamin E 54.2 vitamin C 400 mg, vitamin K1 108 mcg thiamine 3.2 mg, riboflar 4.4 mg, niacin 41 mg, vitamin B6 3.6 mg, folic acid 600 mcg, vit B12 9 mcg, biotin 120 mcg, pantothenic acid 24 mg, choline 1250 mg and inositol 700 mg → Restricted (RS1178) 	/in			e.g. Paediatric Seravit
Initiation				
Patient has inborn errors of metabolism.				
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxir hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 50 with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxir hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 50	0 mg (1) 1e			e.g. Pabrinex IV
with nicotinamide 160 mg, 2 ml ampoule (1) Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxir hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 m	ie			e.g. Pabrinex IM
ampoule (1)				e.g. Pabrinex IV
Vitamin A				
RETINOL Tab 10,000 iu Cap 25,000 iu Oral liq 150,000 iu per ml Oral liq 666.7 mcg per 2 drops, 10 ml Oral liq 666.7 mcg per 2 drops, 10 ml				
Vitamin B				
HYDROXOCOBALAMIN				
Inj 1 mg per ml, 1 ml ampoule		2.84	3	Neo-B12
PYRIDOXINE HYDROCHLORIDE				
Tab 25 mg – 1% DV Oct-20 to 2023 Tab 50 mg			90 500	Vitamin B6 25 Apo-Pyridoxine
140 00 mg		23.45	500	Pyridoxine multichem
Inj 100 mg per ml, 2 ml vial Inj 100 mg per ml, 1 ml ampoule Inj 100 mg per ml, 30 ml vial (Apo-Pyridoxine Tab 50 mg to be delisted 1 May 2022)				

t Item restricted (see \Rightarrow above); **t** Item restricted (see \Rightarrow below)

(ex	Price man. excl. GST \$) Per	Brand or Generic Manufacturer
THIAMINE HYDROCHLORIDE Tab 50 mg Tab 100 mg	7.09	100	Max Health
Inj 100 mg per ml, 1 ml vial Inj 100 mg per ml, 2 ml vial			e.g. Benerva
VITAMIN B COMPLEX Tab strong, BPC	7.15	500	Bplex
Vitamin C			
ASCORBIC ACID Tab 100 mg – 1% DV Mar-20 to 2022 Tab chewable 250 mg	9.90	500	Cvite
Vitamin D			
ALFACALCIDOL Cap 0.25 mcg Cap 1 mcg Oral drops 2 mcg per ml	87.98	100 100 20 ml	One-Alpha One-Alpha One-Alpha
CALCITRIOL Cap 0.25 mcg – 1% DV Oct-19 to 2022 Cap 0.5 mcg – 1% DV Oct-19 to 2022 Oral liq 1 mcg per ml Inj 1 mcg per ml, 1 ml ampoule		100 100	Calcitriol-AFT Calcitriol-AFT
COLECALCIFEROL Cap 1.25 mg (50,000 iu) – 1% DV Feb-21 to 2023 Oral liq 188 mcg per ml (7,500 iu per ml)		12 4.8 ml	Vit.D3 Puria

Vitamin E

ALPHA TOCOPHERYL - Restricted see terms below

I Oral liq 156 u per ml

➡ Restricted (RS1632)

Initiation – Cystic fibrosis

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:
 - 2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically
 - inappropriate for the patient.

Initiation – Osteoradionecrosis

For the treatment of osteoradionecrosis.

Initiation - Other indications

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:
 - 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
 - 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

	Price			Brand or
(ex ma	n. excl.	GST)		Generic
	\$		Per	Manufacturer

ALPHA TOCOPHERYL ACETATE - Restricted see terms below

- ↓ Cap 500 u

↓ Oral lig 156 u per ml

→ Restricted (RS1176)

Initiation - Cystic fibrosis

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:
 - 2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
 - 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Initiation – Osteoradionecrosis

For the treatment of osteoradionecrosis.

Initiation - Other indications

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:
 - 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
 - 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

	Price (ex man. excl. GST)	Per	Brand or Generic Manufacturer	
Antianaemics	Ŷ	1 01	Manadotaron	

Hypoplastic and Haemolytic

EPOETIN ALFA - Restricted see terms below

t	Inj 1,000 iu in 0.5 ml syringe - 1% DV Apr-19 to 2022	06	3	Binocrit
t	inj 2,000 iu in 1 ml syringe - 1% DV Apr-19 to 2022	06	3	Binocrit
t	Inj 3,000 iu in 0.3 ml syringe - 1% DV Apr-19 to 2022	06	6	Binocrit
t	Inj 4,000 iu in 0.4 ml syringe - 1% DV Apr-19 to 2022	06	6	Binocrit
t	Inj 5,000 iu in 0.5 ml syringe - 1% DV Apr-19 to 2022	06	6	Binocrit
t	Inj 6,000 iu in 0.6 ml syringe - 1% DV Apr-19 to 2022	06	6	Binocrit
t	Inj 8,000 iu in 0.8 ml syringe - 1% DV Apr-19 to 2022	06	6	Binocrit
t	Inj 10,000 iu in 1 ml syringe - 1% DV Apr-19 to 2022	06	6	Binocrit
t	Inj 40,000 iu in 1 ml syringe - 1% DV Apr-19 to 2022	0 1	l	Binocrit

➡ Restricted (RS1660)

Initiation - chronic renal failure

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Either:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
- 4 Patient is on haemodialysis or peritoneal dialysis.

Initiation - myelodysplasia*

Re-assessment required after 2 months

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation – myelodysplasia*

Re-assessment required after 12 months

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with epoetin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation - all other indications

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

Note: Indications marked with * are unapproved indications

	Price		Brand or
(ex	x man. excl. GST		Generic
	\$	Per	Manufacturer

EPOETIN BETA - Restricted see terms below

Note: Epoetin beta is considered a Discretionary Variance Pharmaceutical for epoetin alfa.

- Inj 2,000 iu in 0.3 ml syringe
- Inj 3,000 iu in 0.3 ml syringe
- Inj 4,000 iu in 0.3 ml syringe
- Inj 5,000 iu in 0.3 ml syringe
- Inj 6,000 iu in 0.3 ml syringe
- Inj 10,000 iu in 0.6 ml syringe

➡ Restricted (RS1661)

Initiation - chronic renal failure

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Either:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
- 4 Patient is on haemodialysis or peritoneal dialysis.

Initiation - myelodysplasia*

Re-assessment required after 12 months

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation - myelodysplasia*

Re-assessment required after 2 months

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with epoetin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation - all other indications

Haematologist.

For use in patients where blood transfusion is not a viable treatment alternative. *Note: Indications marked with * are unapproved indications.

Megaloblastic

FOLIC ACID			
Tab 0.8 mg		1,000	Apo-Folic Acid
J. J	26.60		Folic Acid multichem
Tab 5 mg - 1% DV Dec-21 to 2024		100	Folic Acid Mylan
Oral liq 50 mcg per ml		25 ml	Biomed
Inj 5 mg per ml, 10 ml vial			

(Apo-Folic Acid Tab 0.8 mg to be delisted 1 May 2022)

	Price (ex man. excl. G \$	ST) Per	Brand or Generic Manufacturer
Antifibrinolytics, Haemostatics and Local Scleros	ants		
ALUMINIUM CHLORIDE - Restricted see terms below ↓ Topical soln 20% w/v → Restricted (R\$1500) Initiation			e.g. Driclor
For use as a haemostatis agent.			
APROTININ – Restricted see terms below ↓ Inj 10,000 klU per ml (equivalent to 200 mg per ml), 50 ml vial → Restricted (RS1332) Initiation			
Cardiac anaesthetist Either:			
 Paediatric patient undergoing cardiopulmonary bypass proce Adult patient undergoing cardiac surgical procedure where the adverse effects of the drug. 		nassive blee	eding outweighs the potential
ELTROMBOPAG - Restricted see terms below Tab 25 mg Tab 50 mg Restricted (RS1648) Initiation - idiopathic thrombocytopenic purpura - post-splened		28 28	Revolade Revolade
Haematologist <i>Re-assessment required after 6 weeks</i> All of the following:	long		
 Patient has had a splenectomy; and Two immunosuppressive therapies have been trialled and fai and 	iled after therapy of 3	3 months ea	ch (or 1 month for rituximab)
 3 Any of the following: 3.1 Patient has a platelet count of 20,000 to 30,000 platel 	ets per microlitre an	d has avida	ace of significant
mucocutaneous bleeding; or	·		Ū
3.2 Patient has a platelet count of less than or equal to 20 bleeding; or3.3 Patient has a platelet count of less than or equal to 10			has evidence of active
Initiation - idiopathic thrombocytopenic purpura - preparation f		iorona o.	
Haematologist Limited to 6 weeks treatment			
The patient requires eltrombopag treatment as preparation for splen Continuation – idiopathic thrombocytopenic purpura - post-sple			
Haematologist Re-assessment required after 12 months			
The patient has obtained a response (see Note) from treatment duri further treatment is required.			uent renewal periods and
Note: Response to treatment is defined as a platelet count of > 30, Initiation – idiopathic thrombocytopenic purpura contraindicate Haematologist		rolitre	
Re-assessment required after 3 months All of the following:			
1 Patient has a significant and well-documented contraindication	on to splenectomy fo	r clinical rea	isons: and

1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and

continued...

	Price		Brand or	
(ex ma	(ex man. excl. GST)		Generic	
	\$	Per	Manufacturer	

continued...

- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Either:
 - 3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Continuation - idiopathic thrombocytopenic purpura contraindicated to splenectomy

Haematologist

Re-assessment required after 12 months

All of the following:

- 1 The patient's significant contraindication to splenectomy remains; and
- 2 The patient has obtained a response from treatment during the initial approval period; and
- 3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
- 4 Further treatment with eltrombopag is required to maintain response.

Initiation - severe aplastic anaemia

Haematologist

Re-assessment required after 3 months

Both:

- 1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
- 2 Either:
 - 2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Continuation - severe aplastic anaemia

Haematologist

Re-assessment required after 12 months Both:

- 1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
- 2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

EMICIZUMAB - Restricted see terms below

t	Inj 30 mg in 1 ml vial	0 1	Hemlibra
t	Inj 60 mg in 0.4 ml vial7,138.0	0 1	Hemlibra
	Inj 105 mg in 0.7 ml vial		Hemlibra
	Inj 150 mg in 1 ml vial17,846.0		Hemlibra

⇒ Restricted (RS1780)

Initiation

Haematologist

Re-assessment required after 6 months

All of the following:

1 Patient has severe congenital haemophilia A and history of bleeding and bypassing agent usage within the last six months; and

2 Either:

2.1 Patient has had greater than or equal to 6 documented and treated spontaneous bleeds within the last 6 months if on an on-demand bypassing agent regimen; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2.2 Patient has had greater than or equal to 2 documented and treated spontaneous bleeds within the last 6 months if on a bypassing agent prophylaxis regimen; and
- 3 Patient has a high-titre inhibitor to Factor VIII (greater than or equal to 5 Bethesda units per ml) which has persisted for six months or more; and
- 4 There is no immediate plan for major surgery within the next 12 months; and
- 5 Either:
 - 5.1 Patient has failed immune tolerance induction (ITI) after an initial period of 12 months; or
 - 5.2 The Haemophilia Treaters Group considers the patient is not a suitable candidate for ITI; and
- 6 Treatment is to be administered at a maximum dose of 3 mg/kg weekly for 4 weeks followed by the equivalent of 1.5 mg/kg weekly.

Continuation

Haematologist

Re-assessment required after 6 months

Both:

- 1 Patient has had no more than two spontaneous and clinically significant treated bleeds after the end of the loading dose period (i.e. after the first four weeks of treatment until the end of the 24-week treatment period); and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

FERRIC SUBSULFATE

Gel 25.9% Soln 500 ml

POLIDOCANOL

Inj 0.5%, 30 ml vial

SODIUM TETRADECYL SULPHATE Inj 3%, 2 ml ampoule

nj 3%, 2 mi ampo

THROMBIN Powder

TRANEXAMIC ACID

9.45	60	Mercury Pharma
5.95	5	Tranexamic-AFT
5.95	5	Tranexamic-AFT
	5.95	5.95 5

Anticoagulant Reversal Agents

IDARUCIZUMAB – Restricted see terms below			
Inj 50 mg per ml, 50 ml vial	4,250.00	2	Praxbind
Destricted (DC1525)			

Restricted (RS1535)

Initiation

For the reversal of the anticoagulant effects of dabigatran when required in situations of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures.

Blood Factors

EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] - Restricted see terms on the next page					
t	Inj 250 iu vial612.50) 1	Alprolix		
	Inj 500 iu vial		Alprolix		
t	Inj 1,000 iu vial2,450.00) 1	Alprolix		
t	Inj 2,000 iu vial) 1	Alprolix		
t	Inj 3,000 iu vial) 1	Alprolix		

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
➤ Restricted (RS1684)			
itiation			
or patients with haemophilia B receiving prophylaxis treatment. reaters Group in conjunction with the National Haemophilia Mar		ent is mar	naged by the Haemophilia
PTACOG ALFA [RECOMBINANT FACTOR VIIA] – Restricted		1	NovoSeven RT
Inj 1 mg syringe Inj 2 mg syringe		1	NovoSeven RT
Inj 5 mg syringe		1	NovoSeven RT
Inj 8 mg syringe		1	NovoSeven RT
Restricted (RS1704)		1	
litiation			
or patients with haemophilia. Access to funded treatment is ma	naged by the Haemophili	a Treaters	s Group in conjunction wit
ne National Haemophilia Management Group. Rare Clinical Circ			
se. Access to funded treatment for > 14 days predicted use is b			
ubject to access criteria.	7		
ACTOR EIGHT INHIBITOR BYPASSING FRACTION - Restric	ted see terms below		
Inj 500 U		1	FEIBA NF
Inj 1,000 U		1	FEIBANF
Inj 2,500 U	,	1	FEIBA NF
→ Restricted (RS1705)			
nitiation			
or patients with haemophilia. Preferred Brand of bypassing age	nt for > 14 days predicted	luse. Ac	cess to funded treatment
nanaged by the Haemophilia Treaters Group in conjunction with	<i>,</i> ,		
IOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] - Restri			p
Inj 250 iu prefilled syringe		1	Xyntha
Inj 500 iu prefilled syringe		1	Xyntha
Inj 1,000 iu prefilled syringe		1	Xyntha
Inj 2,000 iu prefilled syringe		1	Xyntha
Inj 3,000 iu prefilled syringe		1	Xyntha
Restricted (RS1706)			Aynana
nitiation			
or patients with haemophilia. Rare Clinical Circumstances Bran	d of short half-life recomb	oinant fact	or VIII. Access to funded
reatment is managed by the Haemophilia Treaters Group in conj			
ubject to criteria.			0 17
IONACOG GAMMA, [RECOMBINANT FACTOR IX] - Restricted	d see terms below		
Inj 500 iu vial		1	RIXUBIS
Inj 1,000 iu vial		1	RIXUBIS
Inj 2,000 iu vial		1	RIXUBIS
Inj 3,000 iu vial	,	1	RIXUBIS
→ Restricted (RS1679)	,		
nitiation			
or patients with haemophilia. Access to funded treatment is ma	naged by the Haemophili	a Treaters	Group in conjunction wit
ne National Haemophilia Management Group.			
ie National nachophila Management Group.	Restricted see terms on	the next r	age
		1	Advate
CTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE)		1	Advate
CTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) -			
CTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) - Inj 250 iu vial Inj 500 iu vial		-	Advate
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial	420.00 840.00	1 1	Advate Advate
DCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial	420.00 	1	Advate
DCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,500 iu vial		1	

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

→ Restricted (RS1707)

Initiation

For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) - Restricted see terms below

l	lnj 250 iu vial		1	Kogenate FS
			1	Kogenate FS
			1	Kogenate FS
l	Ini 2.000 iu vial		1	Kogenate FS
		2,850.00	1	Kogenate FS
	Postricted (PS1709)	-,		

Restricted (RS1708)

Initiation

For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.

RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] - Restricted see terms below

t	Inj 250 iu vial		1	Adynovate
t	Inj 500 iu vial	600.00	1	Advnovate
	Inj 1,000 iu vial		1	Advnovate
	Inj 2,000 iu vial		1	Adynovate
	Proteinted (PC1020)	,		,

➡ Restricted (RS1682)

Initiation

For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Vitamin K

PHYTOMENADIONE			
Inj 2 mg in 0.2 ml ampoule	8.00	5	Konakion MM
Inj 10 mg per ml, 1 ml ampoule	9.21	5	Konakion MM

Antithrombotics

Anticoagulants

BIVALIRUDIN - Restricted see terms below

- Inj 250 mg vial
- → Restricted (RS1181)

Initiation

Either:

1 For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance; or

2 For use in patients undergoing endovascular procedures.

CITRATE SODIUM

Inj 4% (200 mg per 5 ml), 5 ml ampoule

Inj 46.7% (1.4 g per 3 ml), 3 ml syringe

Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule

DABIGATRAN

Cap 75 mg76.36	60	Pradaxa
Cap 110 mg76.36	60	Pradaxa
Cap 150 mg76.36	60	Pradaxa

Data Particle Per Manufacturer DAVAPAROID - Restricted see terms below In [750] to 6 mt ampoule In [750] to 10 mt In [750] to 10 mt In [750] to 10 mt - Restricted (RS1182) Initiation Initiation Initiation For use in hepain-induced thrombocytopaenia, hepain resistance or hepain intolerance. DEFIBROTIDE - Restricted see terms below I Initiation Hearnatologist - Restricted (RS1183) Initiation Hearnatologist Patent has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities. DEXTROSE WITH SODIUM OITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A] Ini (24 mt) mt sodium citate 22 mg and citric acid 7.3 mg per ml, 100 ml bag ENOXAPARIN SODIUM Intarpoule		Price (ex man. excl. GST)		Brand or Generic
In 1750 uin 0.6 ml ampoule Restricted (RS1182) Initiation For use in hepatrin-induced thrombocytopaenia, hepatrin resistance or hepatrin intolerance. DEFIBROTIDE - Restricted see terms below In 30 mg per ml, 2.5 ml ampoule Restricted (RS1183) Initiation Heamatologist Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities. DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A] Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag EXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A] Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag EXOXAPARIN SODIUM Inj 20 mg in 0.2 ml syringe				
Prestricted (RS1182) Initiation For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance. DEFIBROTIDE - Restricted see terms below In glo ong per ml, 2.5 ml ampoule Restricted (RS1183) Initiation Haamatologist Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities. DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A] Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag ENOXAPARIN SODIUM Inj 20 mg in 0.2 ml syringe	DANAPAROID – Restricted see terms below			
Initiation For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance. DEFIBROTIDE - Restricted see terms below I hig 0 mg per ml, 2.5 ml ampoule Restricted (RS1183) Initiation Haematologist Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities. DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A] Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 mb lag ENOXAPARIN SODIUM Inj 20 mg in 0.4 ml syringe	Inj 750 u in 0.6 ml ampoule			
For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance. DEFIBROTIDE - Restricted see terms below I nij 20 mg nml 2.5 m ampoule REVEAVARIN SODUUM Inj 20 mg in 0.2 ml syringe. Inj 4.4 manatogi 1.4 mampule Inj 4.4 mg in 0.4 ml syringe. Inj 4.4 must an extended the set terms below I mi 20 mg in 0.8 ml syringe I mj 7.5 mg in 0.6 ml syringe I mj 7.5 mg in 0.6 ml syringe I mj 7.5 mg in 0.6 ml syringe I mg in 7.5 mg in 0.6 ml syringe I mg in 7.5 mg in 0.6 ml syringe I mg in 7.5 mg in 0.6 ml syringe I mg in 1.6 must set terms below I mi 20 mg in 0.4 ml syringe. Inj 10 mg mm, 5 ml ampoule Inj 5.0 mg in ml 5.5 ml ampoule Inj 5.0 mg in mm set terms below I mi 10 mg mm, 5 ml ampoule Inj 5.0 mg in mm set terms below I mg in 0.6 mg mm set terms below I mg in 0.6 must set term				
DEFIBROTIDE - Restricted see terms below I hig 80 mg per ml, 2:5 ml ampoule - Restricted (RS1183) Initiation Haematologist Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities. DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID (ACID CITRATE DEXTROSE A) Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag ENOXAPARIN SODIUM Inj 20 mg in 0.2 ml syringe				
I inj 80 mg per ml, 2.5 ml ampoule restricted (IRS1183) initiation Heamatologist Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities. DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A] Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag ENOXAPARIN SODIUM Inj 20 mg in 0.4 ml syringe	For use in heparin-induced thrombocytopaenia, heparin resistance	or heparin intolerance.		
Restricted (RS1183) Initiation Haematologist Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities. DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A] In] 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag ENOXAPARIN SODIUM In] 20 mg in 0.2 ml syringe	_			
Initiation Haematologis Haematologist Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities. DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A] Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 mb ag ENOXAPARIN SODIUM Inj 20 mg in 0.2 ml syringe				
Haematologist Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities. DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A] In] 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag ENOXAPARIN SODIUM In] 20 mg in 0.2 ml syringe				
Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities. DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A] In 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 mi bag ENOXAPARIN SODIUM Inj 20 mg in 0.4 ml syringe				
DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A] In 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag ENOXAPARIN SODIUM In 20 mg in 0.4 ml ampoule In 40 mg in 0.4 ml ampoule In 40 mg in 0.4 ml syringe		s a result of chemothera	ov or regi	imon-related toxicities
Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag ENOXAPARIN SODIUM Inj 20 mg in 0.2 ml syringe				
100 ml bag ENXAPARIN SODIUM Inj 20 mg in 0.2 ml syringe	•			
Inj 20 mg in 0.2 ml syringe31.2810ClexaneInj 40 mg in 0.4 ml syringe42.4910ClexaneInj 60 mg in 0.4 ml syringe60.6710ClexaneInj 60 mg in 0.8 ml syringe60.6710ClexaneInj 80 mg in 0.8 ml syringe101.3010ClexaneInj 100 mg in 1 ml syringe125.8710Clexane ForteInj 120 mg in 0.8 ml syringe125.8710Clexane ForteInj 120 mg in 0.8 ml syringe125.8710Clexane ForteFONDAPARINUX SODIUM- Restricted see terms belowIInj 2.5 mg in 0.5 ml syringeI Inj 7.5 mg in 0.5 ml syringe- Restricted (RS1184)InitiationFor use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance.HEPARIN SODIUMInj 100 iu per ml, 250 ml bag11, 100 iu per ml, 5 ml ampoule70.335Inj 1,000 iu per ml, 5 ml ampoule70.335HospiraInj 5,000 iu per ml, 5 ml ampoule289.0550PfizerInj 5,000 iu per ml, 5 ml ampoule289.0550PfizerInj 100 iu per ml, 5 ml ampoule65.4850PfizerInj 100 iu per ml, 5 ml ampoule70.335HospiraInj 100 iu per ml, 5 ml ampoule70.335PfizerInj 100 iu per ml, 5 ml ampoule70.335<		er mi,		
Inj 40 mg in 0.4 ml simpoule 10 Clexane Inj 60 mg in 0.6 ml syringe	ENOXAPARIN SODIUM			
Inj 40 mg in 0.4 ml syringe.42.4910ClexaneInj 60 mg in 0.6 ml syringe.60.6710ClexaneInj 80 mg in 0.8 ml syringe.101.3010ClexaneInj 120 mg in 0.8 ml syringe.125.8710ClexaneInj 120 mg in 0.8 ml syringe.125.8710Clexane ForteInj 120 mg in 0.8 ml syringe.143.8610Clexane ForteInj 125 mg in 0.5 ml syringe.143.8610Clexane ForteFONDAPARINUX SODIUM - Restricted see terms belowIInj 2.5 mg in 0.5 ml syringeInj 2.5 mg in 0.5 ml syringeInj 12.5 mg in 0.6 ml syringeInj 2.5 mg in 0.5 ml syringeInj 1.50 mg in 0.6 ml syringeInj 1.50 mg in 0.6 ml syringeInj 12.5 mg in 0.5 ml syringeInj 1.00 iu per ml, 250 ml bagInj 1.00 iu per ml, 250 ml bagInj 1.00 iu per ml, 1 ml ampouleInj 100 iu per ml, 5 ml ampoule.72.8450PfizerInj 5.000 iu per ml, 5 ml ampouleInj 5.000 iu per ml, 5 ml ampoule.70.335HospiraInj 5.000 iu per ml, 5 ml ampoule.70.335PfizerInj 100 iu per ml, 5 ml ampoule.65.4850PfizerInj 10 iu per ml, 5 ml ampoule.65.4850PfizerInj 10 iu per ml, 5 ml ampoule.65.4850PfizerInj 10 mg mm, 5 ml ampoule.70.33.65.48	, , , ,	31.28	10	Clexane
Inj 60 mg in 0.6 ml syringe.60.6710ClexaneInj 80 mg in 0.8 ml syringe.80.8910ClexaneInj 100 mg in 0.8 ml syringe.101.3010ClexaneInj 120 mg in 0.8 ml syringe.125.8710Clexane ForteInj 120 mg in 0.8 ml syringe.143.8610Clexane ForteFONDAPARINUX SODIUM - Restricted see terms belowIInj 2.5 mg in 0.5 ml syringeIcexaneInj 12.5 mg in 0.5 ml syringeIcexaneIcexaneIcexaneInj 17.5 mg in 0.6 ml syringeIcexaneIcexaneIcexaneInj 17.5 mg in 0.6 ml syringeIcexaneIcexaneIcexaneInj 100 iu per ml, 5 ml anpoule245.2650HospiraInj 1,000 iu per ml, 5 ml ampoule70.335HospiraInj 5,000 iu per ml, 5 ml ampoule70.335HospiraInj 5,000 iu per ml, 5 ml ampoule289.0550PfizerInj 100 iu per ml, 5 ml ampoule65.4850PfizerInj 100 iu per ml, 5 ml ampoulePfizerInj 100 iu per ml, 5 ml ampoulePfizerInj 100 iu per ml, 5 ml ampoulePfizerPfizerIfizerInj 100 iu per ml, 5 ml ampoulePfizerPfizerIfizerInj 100 iu per ml, 5 ml ampoulePfizerIfizerIfizerInj 100 iu per ml, 5 ml ampoulePfizerIfizerIfizerInj 100 iu per ml, 5 ml ampoulePfizerIfizerIfizerInj 100 iu per ml, 5 ml ampouleIfizerIfizerIfizerInj 100 iu per ml, 5 ml am				-
Inj 80 mg in 0.8 ml syringe	, , , ,			
Inj 100 mg in 1 ml syringe101.3010ClexaneInj 120 mg in 0.8 ml syringe125.8710Clexane ForteInj 150 mg in 1 ml syringe143.8610Clexane ForteFONDAPARINUX SODIUM - Restricted see terms belowInj 2.5 mg in 0.5 ml syringeInj 7.5 mg in 0.6 ml syringeInj 2.5 mg in 0.5 ml syringeInj 7.5 mg in 0.6 ml syringeInj 7.5 mg in 0.6 ml syringeInj 2.5 mg in 0.5 ml syringeInj 7.5 mg in 0.6 ml syringeInj 7.5 mg in 0.6 ml syringeInj 100 iu per ml, 5 ml anyoule245.2650HospiraInj 100 iu per ml, 250 ml bagInj 1.000 iu per ml, 1 ml ampoule72.8450Inj 1,000 iu per ml, 5 ml ampoule70.335HospiraInj 5,000 iu per ml, 5 ml ampoule70.335HospiraInj 5,000 iu per ml, 5 ml ampoule.70.335PfizerInj 100 iu per ml, 5 ml ampoule.65.4850PfizerInj 100 iu per ml, 5 ml ampoule.65.4850Pfizer				
Inj 120 mg in 0.8 ml syringe	, , , ,			
Inj 150 mg in 1 ml syringe	, , , ,			
FONDAPARINUX SODIUM - Restricted see terms below Inj 2.5 mg in 0.5 ml syringe Restricted (RS1184) Initiation For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance. HEPARIN SODIUM Inj 100 iu per ml, 250 ml bag Inj 1,000 iu per ml, 250 ml bag Inj 1,000 iu per ml, 5 ml ampoule	, , , ,			
 Inj 2.5 mg in 0.5 ml syringe Inj 7.5 mg in 0.6 ml syringe Restricted (RS1184) Initiation For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance. HEPARIN SODIUM Inj 100 iu per ml, 250 ml bag Inj 1,000 iu per ml, 5 ml ampoule .245.26 50 Hospira Inj 1,000 iu per ml, 5 ml ampoule .72.84 50 Pfizer Inj 5,000 iu per ml, 5 ml ampoule .70.33 5 Hospira Inj 5,000 iu per ml, 5 ml ampoule .70.33 5 Hospira Inj 5,000 iu per ml, 5 ml ampoule .70.33 5 Hospira Inj 5,000 iu per ml, 5 ml ampoule .70.33 5 Hospira Inj 100 iu per ml, 5 ml ampoule .289.05 50 Pfizer HEPARINISED SALINE Inj 100 iu per ml, 5 ml ampoule .65.48 50 Pfizer Inj 100 iu per ml, 5 ml ampoule .72.84 50 Pfizer Inj 100 iu per ml, 5 ml ampoule .289.05 Pfizer Inj 100 iu per ml, 5 ml ampoule .289.05 Pfizer Inj 100 iu per ml, 5 ml ampoule .289.05 Pfizer Inj 100 iu per ml, 5 ml ampoule .289.05 Pfizer Inj 100 iu per ml, 5 ml ampoule PHENINDIONE Tab 10 mg Tab 10 mg PROTAMINE SULPHATE Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg .83.10 Xarelto 			10	Olexane i one
 Inj 7.5 mg in 0.6 ml syringe → Restricted (RS1184) Initiation For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance. HEPARIN SODIUM Inj 100 iu per ml, 250 ml bag Inj 1,000 iu per ml, 5 ml ampoule 				
 → Restricted (RS1184) Initiation For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance. HEPARIN SODIUM Inj 100 iu per ml, 250 ml bag Inj 1,000 iu per ml, 5 ml ampoule Inj 5,000 iu in 0.2 ml ampoule Inj 5,000 iu per ml, 5 ml ampoule Inj 5,000 iu per ml, 5 ml ampoule Inj 5,000 iu per ml, 5 ml ampoule Inj 10 iu per ml, 5 ml ampoule PHENINDIONE Tab 10 mg Tab 50 mg PROTAMINE SULPHATE Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg Sal.10 Xarelto 				
Initiation For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance. HEPARIN SODIUM Inj 100 iu per ml, 250 ml bag Inj 1,000 iu per ml, 1 ml ampoule 1nj 1,000 iu per ml, 5 ml ampoule Inj 5,000 iu in 0.2 ml ampoule Inj 5,000 iu per ml, 1 ml ampoule Inj 5,000 iu per ml, 5 ml ampoule Inj 10 iu per ml, 5 ml ampoule Inj 100 iu per ml, 5 ml ampoule Inj 100 iu per ml, 5 ml ampoule Inj 100 iu per ml, 5 ml ampoule PHENINDIONE Tab 10 mg Tab 50 mg PROTAMINE SULPHATE Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg Tab 10 mg Magazine RIVAROXABAN Tab 10 mg Tab 10 mg </td <td>, , , ,</td> <td></td> <td></td> <td></td>	, , , ,			
HEPARIN SODIUM Inj 100 iu per ml, 250 ml bag Inj 1,000 iu per ml, 1 ml ampoule Inj 1,000 iu per ml, 5 ml ampoule Inj 5,000 iu in 0.2 ml ampoule Inj 5,000 iu per ml, 1 ml ampoule Inj 5,000 iu per ml, 1 ml ampoule Inj 5,000 iu per ml, 5 ml ampoule Inj 5,000 iu per ml, 5 ml ampoule Inj 10 iu per ml, 5 ml ampoule Inj 100 iu per ml, 5 ml ampoule PHENINDIONE Tab 10 mg Tab 50 mg PROTAMINE SULPHATE Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg Tab 10 mg RIVAROXABAN Tab 10 mg Tab 10 mg RIVAROXABAN Tab 10 mg Tab 10 mg Name RivaroxabaN Tab 10 mg Sal.10 30				
Inj 100 iu per ml, 250 ml bag Inj 1,000 iu per ml, 1 ml ampoule	For use in heparin-induced thrombocytopaenia, heparin resistance	or heparin intolerance.		
Inj 1,000 iu per ml, 1 ml ampoule245.2650HospiraInj 1,000 iu per ml, 5 ml ampoule72.8450PfizerInj 5,000 iu per ml, 1 ml ampoule70.335HospiraInj 5,000 iu per ml, 5 ml ampoule289.0550PfizerHEPARINISED SALINE10 iu per ml, 5 ml ampoule65.4850PfizerInj 100 iu per ml, 2 ml ampoule65.4850PfizerInj 100 iu per ml, 5 ml ampoule70.335PfizerInj 100 iu per ml, 5 ml ampoule70.335PfizerPHENINDIONE70.33777Tab 10 mg7777Inj 10 mg per ml, 5 ml ampoule777RIVAROXABAN783.1030Xarelto	HEPARIN SODIUM			
Inj 1,000 iu per ml, 1 ml ampoule245.2650HospiraInj 1,000 iu per ml, 5 ml ampoule72.8450PfizerInj 5,000 iu per ml, 1 ml ampoule70.335HospiraInj 5,000 iu per ml, 5 ml ampoule289.0550PfizerHEPARINISED SALINE10 iu per ml, 5 ml ampoule65.4850PfizerInj 100 iu per ml, 2 ml ampoule65.4850PfizerInj 100 iu per ml, 5 ml ampoule70.335PfizerInj 100 iu per ml, 5 ml ampoule70.335PfizerPHENINDIONE70.33777Tab 10 mg7777Inj 10 mg per ml, 5 ml ampoule777RIVAROXABAN783.1030Xarelto	Inj 100 iu per ml, 250 ml bag			
In 5,000 iu in 0.2 ml ampoule In 5,000 iu per ml, 1 ml ampoule		245.26	50	Hospira
In 5,000 iu per ml, 1 ml ampoule	Inj 1,000 iu per ml, 5 ml ampoule	72.84	50	Pfizer
In 5,000 iu per ml, 5 ml ampoule				
HEPARINISED SALINE Inj 10 iu per ml, 5 ml ampoule Inj 100 iu per ml, 2 ml ampoule 65.48 50 Prizer File Inj 100 iu per ml, 5 ml ampoule 7 PHENINDIONE 7 Tab 10 mg 7 Tab 50 mg 7 PROTAMINE SULPHATE 10 mg per ml, 5 ml ampoule RIVAROXABAN 83.10 30 Xarelto 30 Xarelto				•
Inj 10 iu per ml, 5 ml ampoule			50	Pfizer
In 100 iu per ml, 2 ml ampoule Inj 100 iu per ml, 5 ml ampoule PHENINDIONE Tab 10 mg Tab 25 mg Tab 50 mg PROTAMINE SULPHATE Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg				
Inj 100 iu per ml, 5 ml ampoule PHENINDIONE Tab 10 mg Tab 25 mg Tab 50 mg PROTAMINE SULPHATE Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg		65.48	50	Pfizer
PHENINDIONE Tab 10 mg Tab 25 mg Tab 50 mg PROTAMINE SULPHATE Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg				
Tab 10 mg Tab 25 mg Tab 50 mg PROTAMINE SULPHATE Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg				
Tab 25 mg Tab 50 mg PROTAMINE SULPHATE Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg				
Tab 50 mg PROTAMINE SULPHATE Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg				
PROTAMINE SULPHATE Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg				
Inj 10 mg per ml, 5 ml ampoule RIVAROXABAN Tab 10 mg	-			
RIVAROXABAN Tab 10 mg				
Tab 10 mg 30 Xarelto				
	-			
rad is mg//.56 28 Xarelto				
Tab 20 mg77.56 28 Xarelto	1 au 20 1119		20	Adienu

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

34

Tab 1 mg		Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
per ml, 5,000 ml bag ARFARIN SODIUM Tab 1 mg 6.46 100 Marevan Tab 2 mg 10.03 100 Marevan Tab 3 mg 10.03 100 Marevan Tab 5 mg 10.03 100 Marevan Antiplatelets 11.48 100 Marevan SPIRIN 1.95 90 Ethics Aspirin EC Suppos 300 mg 10.80 990 Ethics Aspirin EC Suppos 300 mg 10.80 90 Ptics Aspirin EC Suppos 300 mg 10.80 90 Ptics Aspirin EC Suppos 300 mg 10.90 60 Pytazen SR Inj 5 mg per ml, 2 ml ampoule 138.75 1 Integrilin PTIFIBATIDE - Restricted see terms below 138	SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CH	ILORIDE		
Tab 1 mg	, ,	6 mcg		
Tab 2 mg 10.03 100 Marevan Antiplatelets 11.48 100 Marevan SPIRIN 10.80 90 Ethics Aspirin EC Suppos 300 mg 10.80 990 Ethics Aspirin EC Suppos 300 mg 10.80 900 Ethics Aspirin EC LOPIDOGREL 10.80 900 Ethics Aspirin EC Tab 75 mg - 1% DV May-20 to 2022 4.60 84 Clopidogrel Multichem IPYRIDAMOLE 10.90 60 Pytazen SR 11/1 f30 Tab 25 mg 7 mb rom vial 138.75 1 Integrilin Inj 5 mg per ml, 10 ml vial 138.75 1 Integrilin Inj 750 mc gper ml, 100 ml vial 405.00 1 Integrilin PREstricted (RS1759) Integrilin 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or 2 For use in patients with definite or strongly suspacted intra-coronary thrombus on coronary angiography; or 3 For use in patients undergoing intra-cranial intervention. YSINE ACETYLSALICYLATE [LYSINE ASPRIN] – Restricted see terms below e.g. Aspegic Prestricted (RS1689) e.g. Aspegic Itiation	WARFARIN SODIUM			
Tab 5 mg	•	6.46	100	Marevan
Antiplatelets SPIRIN Tab 100 mg - 10% DV Nov-19 to 2022 10.80 990 Ethics Aspirin EC Suppos 300 mg LOPIDOGREL Tab 75 mg - 1% DV May-20 to 2022 4.60 84 Clopidogrel Multichem IPYRIDAMOLE Tab 25 mg Tab long-acting 150 mg - 1% DV Oct-19 to 2022 10.90 60 Pytazen SR Inj 5 mg per ml, 2 ml ampoule 138.75 1 Integrilin PTIFIBATIDE - Restricted see terms below 11,375 1 Integrilin Inj 750 mcg per ml, 10 ml vial 138.75 1 Integrilin PT 750 mcg per ml, 10 ml vial 405.00 1 Integrilin Inj 750 mcg per ml, 100 ml vial 405.00 1 Integrilin Ny of the following: 1 ror use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or 2 For use in patients with acute coronary syndromes undergoing percutaneous coronary angiography; or 3 For use in patients with acute coronary syndromes undergoing percutaneous coronary angiography; or 3 For use in patients with acute coronary syndromes undergoing percutaneous coronary angiography; or 3 For use in patients with acute coronary syndromes undergoing percutaneous cor	Tab 3 mg		100	
SPIRIN 1.95 90 Ethics Aspirin EC Tab 100 mg - 10% DV Nov-19 to 2022 10.80 990 Ethics Aspirin EC Suppos 300 mg 10.80 990 Ethics Aspirin EC COPIDOGREL Tab 75 mg - 1% DV May-20 to 2022 4.60 84 Clopidogrel Multichem IPYRIDAMOLE Tab 25 mg 10.90 60 Pytazen SR Inj 5 mg per ml, 2 ml ampoule 10.90 60 Pytazen SR PTIFIBATIDE - Restricted see terms below 1 1 Integrilin Inj 750 mcg per ml, 100 ml vial. 138.75 1 Integrilin No of the following: 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or 2 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography; or 3 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography; or 3 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography; or Stillation Ng 00 mg e.g. Aspegic Restricted (RS1689) Itiation 1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventiona cardiology procedure	Tab 5 mg	11.48	100	Marevan
Tab 100 mg - 10% DV Nov-19 to 2022	Antiplatelets			
10.80 990 Ethics Aspirin EC Suppos 300 mg 10.80 990 Ethics Aspirin EC LOPIDOGREL Tab 75 mg - 1% DV May-20 to 2022	ASPIRIN			
Suppos 300 mg LOPIDOGREL Tab 75 mg - 1% DV May-20 to 2022 Tab 25 mg Tab long-acting 150 mg - 1% DV Oct-19 to 2022 Inj 5 mg per ml, 2 ml ampoule PTIFIBATIDE - Restricted see terms below Inj 2 mg per ml, 10 ml vial. Tab 100 ml vial. 138.75 1 Integrilin PTIFIBATIDE - Restricted see terms below Inj 7 mg per ml, 10 ml vial. 138.75 1 Integrilin PA Festricted (RS1759) itiation ny of the following: 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or 2 For use in patients undergoing intra-cranial intervention. YSINE ACETYLSALICYLATE [LYSINE ASPRIN] - Restricted see terms below Inj 500 mg e.g. Aspegic PRestricted (RS1689) itiation oth: 1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventiona cardiology procedure; and 2 Administration of oral aspirin would delay the procedure. CAGRELOR - Restricted see terms below Tab 90 mg	Tab 100 mg - 10% DV Nov-19 to 2022	1.95	90	
LOPIDOGREL Tab 75 mg - 1% DV May-20 to 2022	a	10.80	990	Ethics Aspirin EC
Tab 75 mg - 1% DV May-20 to 2022				
IPYRIDAMOLE Tab long-acting 150 mg - 1% DV Oct-19 to 2022 10.90 60 Pytazen SR Inj 5 mg per ml, 2 ml ampoule PTIFIBATIDE - Restricted see terms below Inj 2 mg per ml, 10 ml vial		4.60	04	Clanidageal Multicham
Tab 25 mg Tab long-acting 150 mg - 1% DV Oct-19 to 2022	· ·	4.00	64	Ciopidogrei Multichem
Tab long-acting 150 mg - 1% DV Oct-19 to 2022				
Inj 5 mg per ml, 2 ml ampoule PTIFIBATIDE – Restricted see terms below Inj 2 mg per ml, 10 ml vial	0	10.90	60	Pytazen SR
Inj 2 mg per ml, 10 ml vial	5 5 F			
In 750 mcg per ml, 100 ml vial	EPTIFIBATIDE – Restricted see terms below			
 Restricted (RS1759) itiation ny of the following: For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography; or For use in patients undergoing intra-cranial intervention. (SINE ACETYLSALICYLATE [LYSINE ASPRIN] - Restricted see terms below lnj 500 mg Restricted (RS1689) (RS1689) itiation oth: For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and Administration of oral aspirin would delay the procedure. CAGRELOR - Restricted see terms below Tab 90 mg Mathematical antiplatelet Procedure. 	Inj 2 mg per ml, 10 ml vial		1	Integrilin
 itiation ny of the following: For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography; or For use in patients undergoing intra-cranial intervention. YSINE ACETYLSALICYLATE [LYSINE ASPRIN] - Restricted see terms below Inj 500 mg Restricted (RS1689) itiation For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventiona cardiology procedure; and Administration of oral aspirin would delay the procedure. CAGRELOR - Restricted see terms below Tab 90 mg Section (RS1774) itiation 			1	Integrilin
 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or 2 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography; or 3 For use in patients undergoing intra-cranial intervention. YSINE ACETYLSALICYLATE [LYSINE ASPRIN] - Restricted see terms below Inj 500 mg e.g. Aspegic Restricted (RS1689) itiation oth: 1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventiona cardiology procedure; and 2 Administration of oral aspirin would delay the procedure. CAGRELOR - Restricted see terms below Tab 90 mg Setticted (RS1774) itiation 				
 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or 2 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography; or 3 For use in patients undergoing intra-cranial intervention. YSINE ACETYLSALICYLATE [LYSINE ASPRIN] - Restricted see terms below Inj 500 mg e.g. Aspegic Restricted (RS1689) itiation oth: 1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and 2 Administration of oral aspirin would delay the procedure. CAGRELOR - Restricted see terms below Tab 90 mg Section (RS1774) itiation 				
 2 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography; or 3 For use in patients undergoing intra-cranial intervention. YSINE ACETYLSALICYLATE [LYSINE ASPRIN] - Restricted see terms below Inj 500 mg e.g. Aspegic Restricted (RS1689) itiation oth: 1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and 2 Administration of oral aspirin would delay the procedure. CAGRELOR - Restricted see terms below Tab 90 mg 90.00 56 Brilinta Restricted (RS1774) itiation 	, , , , , , , , , , , , , , , , , , , ,	percutaneous coron	arv interv	ention: or
 Inj 500 mg Restricted (RS1689) itiation oth: For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and Administration of oral aspirin would delay the procedure. CAGRELOR - Restricted see terms below Tab 90 mg Serviced (RS1774) itiation 	2 For use in patients with definite or strongly suspected intra-coro			
 Restricted (RS1689) itiation oth: For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and	YSINE ACETYLSALICYLATE [LYSINE ASPRIN] - Restricted see te	erms below		
 itiation oth: 1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and 2 Administration of oral aspirin would delay the procedure. CAGRELOR - Restricted see terms below Tab 90 mg	Inj 500 mg			e.g. Aspegic
oth: 1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and 2 Administration of oral aspirin would delay the procedure. CAGRELOR - Restricted see terms below Tab 90 mg	→ Restricted (RS1689)			
 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and Administration of oral aspirin would delay the procedure. CAGRELOR - Restricted see terms below Tab 90 mg Restricted (RS1774) itiation 				
2 Administration of oral aspirin would delay the procedure. CAGRELOR - Restricted see terms below Tab 90 mg	1 For use when an immediate antiplatelet effect is required prior t	o an urgent interven	tional neu	iro-radiology or interventiona
Tab 90 mg90.00 56 Brilinta ▶ Restricted (RS1774) itiation				
▶ Restricted (RS1774) itiation	TICAGRELOR – Restricted see terms below			
itiation			56	Brilinta
	→ Restricted (RS1774)			
estricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been	nitiation	tionto who have read	nth (11.11	in the last CO days) have

Restricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Price			Brand or
(ex man. exc	I. GST)		Generic
\$		Per	Manufacturer

continued...

Initiation – thrombosis prevention neurological stenting

Re-assessment required after 12 months

Both:

1 Either:

- 1.1 Patient has had a neurological stenting procedure* in the last 60 days; or
- 1.2 Patient is about to have a neurological stenting procedure performed*; and
- 2 Either:
 - 2.1 Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor; or
 - 2.2 Either:
 - 2.2.1 Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event; or
 - 2.2.2 Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent.

Continuation - thrombosis prevention neurological stenting

Re-assessment required after 12 months

Both:

- 1 Patient is continuing to benefit from treatment; and
- 2 Treatment continues to be clinically appropriate.

Initiation - Percutaneous coronary intervention with stent deployment

Limited to 12 months treatment

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.

Initiation - Stent thrombosis

Patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Initiation – Myocardial infarction

Limited to 1 week treatment

For short term use while in hospital following ST-elevated myocardial infarction.

Notes: Indications marked with * are unapproved indications.

Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment

TICLOPIDINE

Tab 250 mg

Fibrinolytic Agents

ALTEPLASE

Inj 2 mg vial Inj 10 mg vial Inj 50 mg vial

TENECTEPLASE

Inj 50 mg vial

UROKINASE

Inj 5,000 iu vial Inj 10,000 iu vial Inj 50,000 iu vial Inj 100,000 iu vial Inj 250,000 iu vial Inj 500,000 iu vial

Pric (ex man. e: \$	xcl. GST)	Per	Brand or Generic Manufacturer
Colony-Stimulating Factors			
Drugs Used to Mobilise Stem Cells			
PLERIXAFOR – Restricted see terms below ↓ Inj 20 mg per ml, 1.2 ml vial	0.00	1	Mozobil
L <i>imited to 3 days</i> treatment All of the following:			
 Patient is to undergo stem cell transplantation; and Patient has not had a previous unsuccessful mobilisation attempt with plena Any of the following: 3.1 Both: 	xafor; and		
3.1.1 Patient is undergoing G-CSF mobilisation; and 3.1.2 Either:			
3.1.2.1 Has a suboptimal peripheral blood CD34 count of less 4 days of G-CSF treatment; or			
3.1.2.2 Efforts to collect > 1 \times 10 ⁶ CD34 cells/kg have failed a 3.2 Both:	after one a	pheresis	procedure; or
 3.2.1 Patient is undergoing chemotherapy and G-CSF mobilisation 3.2.2 Any of the following: 3.2.2.1 Both: 	i; and		
3.2.2.1 Both. 3.2.2.1.1 Has rising white blood cell counts of $> 5 \times 10^9/L$ 3.2.2.1.2 Has a suboptimal peripheral blood CD34 count 3.2.2.2 Efforts to collect $> 1 \times 10^6$ CD34 cells/kg have failed a 3.2.2.3 The peripheral blood CD34 cell counts are decreasing 3.3 A previous mobilisation attempt with G-CSF or G-CSF plus chemoth	of less that after one a before th	pheresis e target h	procedure; or
Granulocyte Colony-Stimulating Factors			
FILGRASTIM - Restricted see terms below Inj 300 mcg in 0.5 ml prefilled syringe - 5% DV Dec-21 to 2024	0.00	10 4 10	Nivestim Neupogen Nivestim
PEGFILGRASTIM – Restricted see terms below ↓ Inj 6 mg per 0.6 ml syringe	0.00	1	Neulastim

Initiation

For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5%*).

Note: *Febrile neutropenia risk greater than or equal to 5% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Fluids and Electrolytes			
Intravenous Administration			
CALCIUM CHLORIDE			
Inj 100 mg per ml, 10 ml vial Inj 100 mg per ml, 50 ml syringe			e.g. Baxter
CALCIUM GLUCONATE Inj 10%, 10 ml ampoule			e.g. Max Health
COMPOUND ELECTROLYTES			
Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/ chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 50	00 ml		
bag Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/ oblavida 00 mmol/l, costata 07 mmol/l, ducenata 00 mmol/l		18	Plasma-Lyte 148
chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 1,000 ml bag	27.24	12	Plasma-Lyte 148
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]			
Inj sodium 140 mmol/l, 5 mmol/l potassium, 1.5 mmol/l magnesium			
98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate glucose 23 mmol/l (5%), 1,000 ml bag	1	12	Plasma-Lyte 148 & 5% Glucose
COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]			0.00000
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l,			
bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag	23.40	18	Baxter
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 1,000 ml bag	15 72	12	Baxter
GLUCOSE [DEXTROSE]			Baxtor
Inj 5%, 1,000 ml bag		10	Fresenius Kabi
Inj 5%, 100 ml bag	77.50	50	Fresenius Kabi
Inj 5%, 250 ml bag	52.50	30	Fresenius Kabi
Inj 5%, 50 ml bag		60	Baxter Glucose 5%
Inj 5%, 500 ml bag		20	Fresenius Kabi
Inj 10%, 1,000 ml bag		12	Baxter Glucose 10%
Inj 10%, 500 ml bag		18	Baxter Glucose 10%
Inj 50%, 10 ml ampoule – 1% DV Nov-20 to 2023		5	Biomed
Inj 50%, 500 ml bag		18 1	Baxter Glucose 50%
Inj 50%, 90 ml bottle – 1% DV Nov-20 to 2023	15.00	I	Biomed
GLUCOSE WITH POTASSIUM CHLORIDE			
Inj 10% glucose with 20 mmol/l potassium chloride, 500 ml bag			
GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE			
Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium ch 0.45%, 3,000 ml bag			
Inj 10% glucose with potassium chloride 10 mmol/l and sodium chl 15 mmol/l, 500 ml bag			
Inj 4% glucose with potassium chloride 20 mmol/l and sodium chlo 0.18%, 1,000 ml bag		12	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chlo 0.45%, 1,000 ml bag		12	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chlo 0.9%, 1,000 ml bag	ride	12	Baxter

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST)		Brand or Generic
	\$	Per	Manufacturer
GLUCOSE WITH SODIUM CHLORIDE			
Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag			
Inj 4% glucose and sodium chloride 0.18%, 1,000 ml bag		12	Baxter
Inj 5% glucose and sodium chloride 0.45%, 1,000 ml bag		12	Baxter
Inj 5% glucose and sodium chloride 0.9%, 1,000 ml bag	173.40	12	Baxter
POTASSIUM CHLORIDE			
Inj 75 mg (1 mmol) per ml, 10 ml ampoule Inj 225 mg (3 mmol) per ml, 20 ml ampoule			
POTASSIUM CHLORIDE WITH SODIUM CHLORIDE			
Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 n	0	48	Baxter
Inj 20 mmol potassium chloride with 0.9% sodium chloride, 1,000 r		12	Baxter
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 1,000 r		12	Baxter
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml	bag 772.32	48	Baxter
POTASSIUM DIHYDROGEN PHOSPHATE			
Inj 1 mmol per ml, 10 ml ampoule	174.57	10	Hospira
RINGER'S SOLUTION			
Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/ chloride 156 mmol/l, 1,000 ml bag	1,		
SODIUM ACETATE			
Inj 4 mmol per ml, 20 ml ampoule			
SODIUM BICARBONATE			
Inj 8.4%, 10 ml vial			
Inj 8.4%, 50 ml vial		1	Biomed
Inj 8.4%, 100 ml vial	21.95	1	Biomed
SODIUM CHLORIDE			
Inj 0.9%, 5 ml ampoule – 1% DV Dec-19 to 2022		20	Fresenius Kabi
Inj 0.9%, 10 ml ampoule – 1% DV Dec-19 to 2022		50	Fresenius Kabi
 Inj 0.9%, 3 ml syringe, non-sterile pack Restricted (RS1297) 		480	BD PosiFlush
Initiation			
For use in flushing of in-situ vascular access devices only.			
Inj 0.9%, 5 ml syringe, non-sterile pack		480	BD PosiFlush
➡ Restricted (RS1297)			
Initiation			
For use in flushing of in-situ vascular access devices only.			
Inj 0.9%, 10 ml syringe, non-sterile pack	177.60	480	BD PosiFlush
→ Restricted (RS1297)			
Initiation			
For use in flushing of in-situ vascular access devices only.			

For use in flushing of in-situ vascular access devices only.

	Price		Brand or
	(ex man. excl. GST		Generic
	\$	Per	Manufacturer
Inj 0.9%, 20 ml ampoule - 1% DV Dec-19 to 2022	5.00	20	Fresenius Kabi
Inj 23.4% (4 mmol/ml), 20 ml ampoule		5	Biomed
Inj 0.45%, 500 ml bag		18	Baxter
Inj 3%, 1,000 ml bag		12	Baxter
Inj 0.9%, 50 ml bag		60	Baxter
, ,	137.25	75	Baxter-Viaflo
Inj 0.9%, 100 ml bag		48	Baxter
	97.80	60	Baxter-Viaflo
Inj 0.9%, 250 ml bag		24	Baxter
Inj 0.9%, 500 ml bag		18	Baxter
Inj 0.9%, 1,000 ml bag		12	Baxter
Inj 1.8%, 500 ml bottle			Baxtor
SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHAT	-E1		
Inj 1 mmol per ml, 20 ml ampoule	•	5	Biomed
	40.70	5	Diomeu
WATER			
Inj 10 ml ampoule		50	Pfizer
Inj 20 ml ampoule	5.00	20	Fresenius Kabi
			Multichem
lnj 250 ml bag			
Inj 500 ml bag			
Inj, 1,000 ml bag	19.08	12	Baxter
Oral Administration			
CALCIUM POLYSTYRENE SULPHONATE Powder		300 g	Calcium Resonium
COMPOUND ELECTROLYTES Powder for oral soln – 1% DV Apr-20 to 2022	0.77	50	Electral
•	9.77	50	Liectiai
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE] Soln with electrolytes (2 × 500 ml)	6.55	1,000 ml	Pedialyte - Bubblegum
PHOSPHORUS			
Tab eff 500 mg (16 mmol)			
POTASSIUM CHLORIDE			
Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)			
Tab long-acting 600 mg (8 mmol)	8.90	200	Span-K
Oral lig 2 mmol per ml		200	opanik
SODIUM BICARBONATE	0.50	100	Ondihia
Cap 840 mg	8.52	100	Sodibic
SODIUM CHLORIDE			
Tab 600 mg			
Oral liq 2 mmol/ml			
SODIUM POLYSTYRENE SULPHONATE			
Powder		454 g	Resonium A
Plasma Volume Expanders		-	
•			
GELATINE, SUCCINYLATED	100.00	10	Oalafuaina
Inj 4%, 500 ml bag		10	Gelofusine

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Agents Affecting the Renin-Angiotensin System			
ACE Inhibitors			
CAPTOPRIL Gral liq 5 mg per ml		95 ml	Capoten
 → Restricted (RS1263) Initiation Any of the following: For use in children under 12 years of age; or For use in tube-fed patients; or For management of rebound transient hypertension following 	cardiac surgery.		
CILAZAPRIL – Restricted: For continuation only ➡ Tab 0.5 mg – 1% DV Sep-19 to 2022 ➡ Tab 2.5 mg – 1% DV Feb-20 to 2022 ➡ Tab 5 mg – 1% DV Feb-20 to 2022	4.80	90 90 90	Zapril Zapril Zapril
ENALAPRIL MALEATE Tab 5 mg – 1% DV Jun-20 to 2022 Tab 10 mg – 1% DV Jun-20 to 2022 Tab 20 mg – 1% DV Jun-20 to 2022		100 100 100	Acetec Acetec Acetec
LISINOPRIL Tab 5 mg Tab 10 mg Tab 20 mg		90 90 90	Ethics Lisinopril Ethics Lisinopril Ethics Lisinopril
PERINDOPRIL Tab 2 mg – 5% DV Jan-22 to 2024 Tab 4 mg – 5% DV Jan-22 to 2024		30 30	Coversyl Coversyl
QUINAPRIL Tab 5 mg – 5% DV Feb-22 to 2024 Tab 10 mg – 5% DV Feb-22 to 2024 Tab 20 mg – 5% DV Feb-22 to 2024	5.18	90 90 90	Arrow-Quinapril 5 Arrow-Quinapril 10 Arrow-Quinapril 20
ACE Inhibitors with Diuretics			
QUINAPRIL WITH HYDROCHLOROTHIAZIDE Tab 10 mg with hydrochlorothiazide 12.5 mg - 5% DV Mar-22 to Tab 20 mg with hydrochlorothiazide 12.5 mg - 5% DV Mar-22 to		30 30	Accuretic 10 Accuretic 20
Angiotensin II Antagonists			
CANDESARTAN CILEXETIL Tab 4 mg - 5% DV Dec-21 to 2024 Tab 8 mg - 5% DV Dec-21 to 2024 Tab 16 mg - 5% DV Dec-21 to 2024 Tab 32 mg - 5% DV Dec-21 to 2024	2.28 3.31	90 90 90 90	Candestar Candestar Candestar Candestar

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LOSARTAN POTASSIUM Tab 12.5 mg – 1% DV Jan-21 to 2023 Tab 25 mg – 1% DV Jan-21 to 2023 Tab 50 mg – 1% DV Jan-21 to 2023 Tab 100 mg – 1% DV Jan-21 to 2023	1.84 2.25	84 84 84 84	Losartan Actavis Losartan Actavis Losartan Actavis Losartan Actavis
Angiotensin II Antagonists with Diuretics			
LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE Tab 50 mg with hydrochlorothiazide 12.5 mg	15.25	30	Arrow-Losartan & Hydrochlorothiazid
Angiotensin II Antagonists with Neprilysin Inhibi	tors		
 SACUBITRIL WITH VALSARTAN – Restricted see terms below Tab 24.3 mg with valsartan 25.7 mg		tioner the	patient would benefit from
Alpha-Adrenoceptor Blockers			
Tab 2 mg	17.35	500	Apo-Doxazosin Doxazosin Clinect
Tab 4 mg (Apo-Doxazosin Tab 2 mg to be delisted 1 September 2022) (Apo-Doxazosin Tab 4 mg to be delisted 1 September 2022) PHENOXYBENZAMINE HYDROCHLORIDE Cap 10 mg Inj 50 mg per ml, 1 ml ampoule Inj 50 mg per ml, 2 ml ampoule	20.94	500	Apo-Doxazosin Doxazosin Clinect

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PHENTOLAMINE MESYLATE Inj 5 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 1 ml ampoule			
PRAZOSIN	5 50	100	
Tab 1 mg	5.53	100	Apo-Prazosin Arrotex-Prazosin S29
Tab 2 mg	7.00	100	Apo-Prazosin Arrotex-Prazosin S29
Tab 5 mg	11.70	100	Apo-Prazosin
(Apo-Prazosin Tab 1 mg to be delisted 1 May 2022) (Apo-Prazosin Tab 2 mg to be delisted 1 May 2022) (Apo-Prazosin Tab 5 mg to be delisted 1 May 2022)			Arrotex-Prazosin S29
TERAZOSIN – Restricted: For continuation only → Tab 1 mg			
Antiarrhythmics			
ADENOSINE	00.70	•	
Inj 3 mg per ml, 2 ml vial − 1% DV Feb-20 to 2022 ↓ Inj 3 mg per ml, 10 ml vial → Restricted (RS1266)	62.73	6	Adenocor
Initiation For use in cardiac catheterisation, electrophysiology and MRI.			
AJMALINE - Restricted see terms below ↓ Inj 5 mg per ml, 10 ml ampoule → Restricted (RS1001) Cardiologist			
AMIODARONE HYDROCHLORIDE			
Tab 100 mg - 1% DV Dec-19 to 2022 Tab 200 mg - 1% DV Dec-19 to 2022		30 30	Aratac Aratac
Inj 50 mg per ml, 3 ml ampoule – 1% DV Feb-20 to 2022		10	Max Health
ATROPINE SULPHATE			
Inj 600 mcg per ml, 1 ml ampoule - 5% DV Jan-22 to 2024	15.09	10	Martindale
DIGOXIN Tab 62.5 mcg - 1% DV Nov-19 to 2022	7.00	240	Lanoxin PG
Tab 250 mcg – 1% DV Nov-19 to 2022 Oral liq 50 mcg per ml Inj 250 mcg per ml, 2 ml vial		240	Lanoxin
DISOPYRAMIDE PHOSPHATE Cap 100 mg			
FLECAINIDE ACETATE			
Tab 50 mg - 1% DV Feb-20 to 2022		60	Flecainide BNM
Cap long-acting 100 mg - 1% DV Dec-19 to 2022		90	Flecainide Controlled Release Teva
Cap long-acting 200 mg - 1% DV Dec-19 to 2022	61.06	90	Flecainide Controlled Release Teva
Inj 10 mg per ml, 15 ml ampoule		5	Tambocor
IVABRADINE − Restricted see terms on the next page ↓ Tab 5 mg			

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price		Brand or		
	(ex man.			Per	Generic Manufacturer
→ Restricted (RS1566)		•			
Initiation					
Both:					
1 Patient is indicated for computed tomography coronary angiog	raphy; and				
2 Either:	outo while	toling o	-	mallut	alerated dage of bate blocker
2.1 Patient has a heart rate of greater than 70 beats per min or	iute write	taking a	max	many u	Dieraled dose of bela blocker
2.2 Patient is unable to tolerate beta blockers.					
MEXILETINE HYDROCHLORIDE					
Cap 150 mg		62.00		100	Teva
Cap 250 mg				100	Teva
PROPAFENONE HYDROCHLORIDE					
Tab 150 mg					
Antihypotensives					
MIDODRINE – Restricted see terms below I Tab 2.5 mg					
↓ Tab 5 mg					
→ Restricted (RS1427)					
Initiation					
Patient has disabling orthostatic hypotension not due to drugs.					
Beta-Adrenoceptor Blockers					
ATENOLOL					
Tab 50 mg - 5% DV Jan-22 to 2024		9.33		500	Mylan Atenolol
Tab 100 mg - 5% DV Jan-22 to 2024		14.20		500	Mylan Atenolol
Oral liq 5 mg per ml		49.85	3	00 ml	Atenolol-AFT
BISOPROLOL FUMARATE					
Tab 2.5 mg - 1% DV Apr-21 to 2023				90	Bisoprolol Mylan
Tab 5 mg - 1% DV Apr-21 to 2023				90	Bisoprolol Mylan
Tab 10 mg - 1% DV Apr-21 to 2023		1.72		30 90	Bosvate Bisoprolol Mylan
CARVEDILOL		0.02		30	
Tab 6.25 mg		2 24		60	Carvedilol Sandoz
Tab 12.5 mg				60	Carvedilol Sandoz
Tab 25 mg				60	Carvedilol Sandoz
CELIPROLOL – Restricted: For continuation only					
→ Tab 200 mg					
ESMOLOL HYDROCHLORIDE					
Inj 10 mg per ml, 10 ml vial					
LABETALOL					
Tab 50 mg					
Tab 100 mg - 1% DV Sep-20 to 2024				100	Trandate
Tab 200 mg - 1% DV Sep-20 to 2024		.27.00		100	Trandate
Inj 5 mg per ml, 20 ml ampoule					

	Price (ex man. excl. GST)		Brand or Generic
	(ex man. excl. GST) \$	Per	Manufacturer
METOPROLOL SUCCINATE			
Tab long-acting 23.75 mg		30	Betaloc CR
Tab long-acting 47.5 mg		30	Betaloc CR
Tab long-acting 95 mg		30	Betaloc CR
Tab long-acting 190 mg		30	Betaloc CR
METOPROLOL TARTRATE			
Tab 50 mg – 1% DV Mar-22 to 2024		100	IPCA-Metoprolol
Tab 100 mg - 1% DV Mar-22 to 2024		60	IPCA-Metoprolol
Tab long-acting 200 mg		28	Slow-Lopresor
Inj 1 mg per ml, 5 ml vial		5	Metoprolol IV Mylan
NADOLOL			,,
Tab 40 mg – 1% DV Mar-22 to 2024	19 19	100	Nadolol BNM
Tab 80 mg - 1% DV Mar-22 to 2024		100	Nadolol BNM
C C		100	
PINDOLOL – Restricted: For continuation only	10.00	100	Ann Dindalal
➡ Tab 5 mg		100	Apo-Pindolol
➡ Tab 10 mg		100	Apo-Pindolol
➡ Tab 15 mg		100	Apo-Pindolol
(Apo-Pindolol Tab 5 mg to be delisted 1 May 2022)			
(Apo-Pindolol Tab 10 mg to be delisted 1 May 2022)			
(Apo-Pindolol Tab 15 mg to be delisted 1 May 2022)			
PROPRANOLOL			
Tab 10 mg – 1% DV Mar-22 to 2024		100	Drofate
Tab 40 mg – 1% DV Mar-22 to 2024		100	IPCA-Propranolol
Cap long-acting 160 mg		100	Cardinol LA
Oral liq 4 mg per ml			
Inj 1 mg per ml, 1 ml ampoule			
SOTALOL			
Tab 80 mg - 1% DV Oct-19 to 2022		500	Mylan
Tab 160 mg - 1% DV Oct-19 to 2022		100	Mylan
Calcium Channel Blockers			
Dihydropyridine Calcium Channel Blockers			
AMLODIPINE	1.00	00	Veeeway
Tab 2.5 mg - 1% DV Jun-21 to 2023		90 90	Vasorex Vasorex
Tab 5 mg - 1% DV Jun-21 to 2023		90 90	
Tab 10 mg - 1% DV Jun-21 to 2023	1.19	90	Vasorex
FELODIPINE			
Tab long-acting 2.5 mg		30	Plendil ER
Tab long-acting 5 mg – 5% DV Jan-22 to 2024		90	Felo 5 ER
Tab long-acting 10 mg - 5% DV Jan-22 to 2024	4.32	90	Felo 10 ER
SRADIPINE			
Tab 2.5 mg			
Cap 2.5 mg			
	a navt naga		

NICARDIPINE HYDROCHLORIDE - Restricted see terms on the next page

Inj 2.5 mg per ml, 10 ml vial

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
→ Restricted (RS1699) nitiation			
Anaesthetist, intensivist, cardiologist or paediatric cardiologist Any of the following:			
 Patient has hypertension requiring urgent treatment with an Patient has excessive ventricular afterload; or Patient is awaiting or undergoing cardiac surgery using card 			
	opannenaly sypacer		
Tab long-acting 10 mg	18.80	56	Tensipine MR10
Tab long-acting 20 mg		100	Nyefax Retard
Tab long-acting 30 mg		100	Mylan (24 hr release)
	4.78	14	Mylan Italy (24 hr release)
Tab long-acting 60 mg Cap 5 mg		100	Mylan (24 hr release)
VIMODIPINE			
Tab 30 mg – 1% DV Jul-20 to 2022		100	Nimotop
Inj 200 mcg per ml, 50 ml vial – 1% DV Jul-20 to 2022		1	Nimotop
Other Calcium Channel Blockers			
DILTIAZEM HYDROCHLORIDE			
Tab 30 mg			
Cap extended-release 120 mg		100	Accord
Cap long-acting 120 mg		500	Apo-Diltiazem CD
Cap long-acting 180 mg - 1% DV Mar-22 to 2024		30	Cardizem CD
Cap long-acting 240 mg – 1% DV Mar-22 to 2024 Inj 5 mg per ml, 5 ml vial	9.30	30	Cardizem CD
PERHEXILINE MALEATE			
Tab 100 mg - 1% DV Oct-19 to 2022	62.90	100	Pexsig
/ERAPAMIL HYDROCHLORIDE			
Tab 40 mg	7.01	100	Isoptin
Tab 80 mg	11.74	100	Isoptin
Tab long-acting 120 mg		100	Isoptin SR
Tab long-acting 240 mg		30	Isoptin SR
Inj 2.5 mg per ml, 2 ml ampoule		5	Isoptin
Centrally-Acting Agents			
CLONIDINE			
Patch 2.5 mg, 100 mcg per day - 1% DV Nov-20 to 2023		4	Mylan
Patch 5 mg, 200 mcg per day - 1% DV Nov-20 to 2023		4	Mylan
Patch 7.5 mg, 300 mcg per day - 1% DV Nov-20 to 2023	16.93	4	Mylan
CLONIDINE HYDROCHLORIDE			
Tab 25 mcg	8.75	112	Clonidine BNM
-	36.50		Clonidine Teva
Tab 150 mcg - 5% DV Jan-22 to 2024		100	Catapres
Inj 150 mcg per ml, 1 ml ampoule - 5% DV Jan-22 to 2024		10	Medsurge
/ETHYLDOPA			
Tab 250 mg		100	Methyldopa Mylan
ů – Elektrik Alektrik – Elektrik			

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
Diuretics			
Loop Diuretics			
3UMETANIDE Tab 1 mg Inj 500 mcg per ml, 4 ml vial 5UROSEMIDE [FRUSEMIDE] Tab 40 mg – 1% DV Mar-21 to 2024	8.00	100 1,000	Burinex IPCA-Frusemide
Tab 500 mg Oral liq 10 mg per ml – 1% DV Jan-20 to 2022 Inj 10 mg per ml, 2 ml ampoule Inj 10 mg per ml, 25 ml ampoule – 1% DV Jan-20 to 2022	11.20 1.15	50 30 ml 5 6	Urex Forte Lasix Furosemide-Baxter Lasix
Osmotic Diuretics			
/ANNITOL Inj 10%, 1,000 ml bag Inj 20%, 500 ml bag		12 18	Baxter Baxter
Potassium Sparing Combination Diuretics			
MILORIDE HYDROCHLORIDE WITH FUROSEMIDE Tab 5 mg with furosemide 40 mg MILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDI Tab 5 mg with hydrochlorothiazide 50 mg	Ē		
Potassium Sparing Diuretics			
MILORIDE HYDROCHLORIDE Tab 5 mg Oral lig 1 mg per ml		25 ml	Biomed
 ■ PLERENONE – Restricted see terms below ■ Tab 25 mg – 5% DV Jun-22 to 2024 ■ Tab 50 mg – 5% DV Jun-22 to 2024 ■ Restricted (RS1640) nitiation Both: Patient has heart failure with ejection fraction less than 40% Either: Patient is intolerant to optimal dosing of spironolactor Patient has experienced a clinically significant adverse 		30 30	Inspra Inspra
SPIRONOLACTONE Tab 25 mg - 5% DV Sep-22 to 2025		100	Spiractin
Tab 100 mg – 5% DV Sep-22 to 2025 Oral liq 5 mg per ml – 1% DV Nov-19 to 2022		100 25 ml	Spiractin Biomed
Thiazide and Related Diuretics			
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE] Tab 2.5 mg – 1% DV Dec-20 to 2023 Tab 5 mg – 1% DV Dec-20 to 2023		500 500	Arrow-Bendrofluazide Arrow-Bendrofluazide

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

(ex ma	Price n. excl. GST) \$	Per	Brand or Generic Manufacturer
	φ	Fei	Wanulacturer
CHLOROTHIAZIDE Oral liq 50 mg per ml	07 00	25 ml	Biomed
	27.02	23 111	Diomeu
	6 50	50	Unaveten
Tab 25 mg – 1% DV Dec-19 to 2022	0.00	50	Hygroton
NDAPAMIDE Tab 2.5 mg – 1% DV Nov-20 to 2023	10.45	90	Dono Tobo
-	10.45	90	Dapa-Tabs
Tab 5 mg			
Lipid-Modifying Agents			
Fibrates			
BEZAFIBRATE			
Tab 200 mg – 5% DV Feb-22 to 2024	19.46	90	Bezalip
Tab long-acting 400 mg - 5% DV Feb-22 to 2024		30	Bezalip Retard
HMG CoA Reductase Inhibitors (Statins)			
ATORVASTATIN			
Tab 10 mg – 5% DV Dec-21 to 2024	6 16	500	Lorstat
Tab 20 mg - 5% DV Dec-21 to 2024		500	Lorstat
Tab 40 mg – 5% DV Dec-21 to 2024		500	Lorstat
Tab 80 mg - 5% DV Dec-21 to 2024	26.54	500	Lorstat
PRAVASTATIN			
Tab 10 mg			
Tab 20 mg - 1% DV Apr-21 to 2023		28	Pravastatin Mylan
Tab 40 mg - 1% DV Apr-21 to 2023	3.61	28	Pravastatin Mylan
ROSUVASTATIN – Restricted see terms below			
Tab 5 mg - 1% DV May-22 to 2023	1.70	30	Rosuvastatin Viatris
Tab 10 mg - 1% DV May-22 to 2023		30	Rosuvastatin Viatris
Tab 20 mg - 1% DV May-22 to 2023		30	Rosuvastatin Viatris
Tab 40 mg - 1% DV May-22 to 2023	5.28	30	Rosuvastatin Viatris
→ Restricted (RS1868)			

Initiation - cardiovascular disease risk

Either:

1 Both:

- 1.1 Patient is considered to be at risk of cardiovascular disease; and
- 1.2 Patient is Māori or any Pacific ethnicity; or
- 2 Both:
 - 2.1 Patient has a calculated risk of cardiovascular disease of at least 15% over 5 years; and
 - 2.2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initiation - familial hypercholesterolemia

Both:

- 1 Patient has familial hypercholesterolemia (defined as a Dutch Lipid Criteria score greater than or equal to 6); and
- 2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

S Per Manufacturer

continued...

Initiation – established cardiovascular disease

Both:

- 1 Any of the following:
 - 1.1 Patient has proven coronary artery disease (CAD); or
 - 1.2 Patient has proven peripheral artery disease (PAD); or
 - 1.3 Patient has experienced an ischaemic stroke; and
- 2 LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initiation – recurrent major cardiovascular events Both:

- 1 Patient has experienced a recurrent major cardiovascular event (defined as myocardial infarction, ischaemic stroke, coronary revascularisation, hospitalisation for unstable angina) in the last 2 years; and
- 2 LDL cholesterol has not reduced to less than 1.0 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

SIMVASTATIN

Tab 10 mg - 1% DV Nov-20 to 2023	1.23	90	Simvastatin Mylan
Tab 20 mg - 1% DV Nov-20 to 2023	2.03	90	Simvastatin Mylan
Tab 40 mg - 1% DV Nov-20 to 2023		90	Simvastatin Mylan
Tab 80 mg - 1% DV Nov-20 to 2023		90	Simvastatin Mylan

Resins

CHOLESTYRAMINE

Powder for oral liq 4 g

COLESTIPOL HYDROCHLORIDE

Grans for oral liq 5 g

Selective Cholesterol Absorption Inhibitors

EZETIMIBE - Restricted see terms below ↓ Tab 10 mg - 1% DV Oct-20 to 2023	95	30	Ezetimibe Sandoz
All of the following:			
 Patient has a calculated absolute risk of cardiovascular disease of at least 15% Patient's LDL cholesterol is 2.0 mmol/litre or greater; and Any of the following: The patient has rhabdomyolysis (defined as muscle aches and creating treated with one statin; or The patient is intolerant to both simvastatin and atorvastatin; or The patient has not reduced their LDL cholesterol to less than 2.0 mmod dose of atorvastatin. 	e kinase I	more tha	an 10 × normal) when
EZETIMIBE WITH SIMVASTATIN - Restricted see terms on the next page			
Tab 10 mg with simvastatin 10 mg5.1	5	30	Zimybe
Tab 10 mg with simvastatin 20 mg6.1	5	30	Zimybe

Price		Brand or	
(ex man. excl. (GST)	Generic	
 \$	Per	Manufacturer	

→ Restricted (RS1006)

Initiation

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Other Lipid-Modifying Agents

ACIPIMOX

Cap 250 mg

Nitrates

GLYCERYL TRINITRATE

Inj 1 mg per ml, 5 ml ampoule			
Inj 1 mg per ml, 10 ml ampoule			
Inj 1 mg per ml, 50 ml vial			
Inj 5 mg per ml, 10 ml ampoule	118.00	5	Hospira
Oral pump spray, 400 mcg per dose	6.09	250 dose	Nitrolingual Pump Spray
Patch 25 mg, 5 mg per day	15.73	30	Nitroderm TTS 5
Patch 50 mg, 10 mg per day		30	Nitroderm TTS 10
ISOSORBIDE MONONITRATE			
Tab 20 mg – 1% DV Nov-20 to 2023		100	Ismo 20
Tab long-acting 40 mg - 1% DV Nov-20 to 2023	8.20	30	Ismo 40 Retard
Tab long-acting 60 mg - 1% DV Nov-20 to 2023	9.25	90	Duride

Other Cardiac Agents

LEVOSIMENDAN - Restricted see terms below

- Inj 2.5 mg per ml, 5 ml vial
- Inj 2.5 mg per ml, 10 ml vial

➡ Restricted (RS1007)

Initiation - Heart transplant

Either:

- 1 For use as a bridge to heart transplant, in patients who have been accepted for transplant; or
- 2 For the treatment of heart failure following heart transplant.

Initiation - Heart failure

Cardiologist or intensivist

For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.

Sympathomimetics		
ADRENALINE		
Inj 1 in 1,000, 1 ml ampoule4.98	5	Aspen Adrenaline
10.76		DBL Adrenaline
lnj 1 in 1,000, 30 ml vial		
Inj 1 in 10,000, 10 ml ampoule49.00	10	Aspen Adrenaline
27.00	5	Hospira
Inj 1 in 10,000, 10 ml syringe		

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
DOBUTAMINE	Ŷ		
Inj 12.5 mg per ml, 20 ml ampoule - 5% DV Dec-21 to 2024	61 13	5	Dobutamine-hameln
	01.15	5	Dobulannie-nameni
DOPAMINE HYDROCHLORIDE	20 65	10	Max Haalth I td
Inj 40 mg per ml, 5 ml ampoule - 5% DV Jan-22 to 2024		10	Max Health Ltd
EPHEDRINE			
Inj 3 mg per ml, 10 ml syringe Inj 30 mg per ml, 1 ml ampoule – 1% DV Oct-20 to 2023	20.62	10	Max Health
		10	
ISOPRENALINE [ISOPROTERENOL]			
Inj 200 mcg per ml, 1 ml ampoule			
Inj 200 mcg per ml, 5 ml ampoule			
METARAMINOL			
Inj 0.5 mg per ml, 10 ml syringe Inj 0.5 mg per ml, 20 ml syringe			
Inj 0.5 mg per ml, 5 ml syringe			
Inj 1 mg per ml, 1 ml ampoule			
Inj 1 mg per ml, 10 ml syringe			
Inj 10 mg per ml, 1 ml ampoule - 1% DV Jan-21 to 2023		10	Torbay
NORADRENALINE			-
Inj 0.06 mg per ml, 100 ml bag			
Inj 0.06 mg per ml, 50 ml syringe			
Inj 0.1 mg per ml, 100 ml bag			
Inj 0.1 mg per ml, 50 ml syringe			
Inj 0.12 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 50 ml syringe			
Inj 0.16 mg per ml, 50 ml syringe			
Inj 1 mg per ml, 100 ml bag Inj 1 mg per ml, 4 ml ampoule – 1% DV Oct-19 to 2022	45.00	10	Noradrenaline BNM
		10	
PHENYLEPHRINE HYDROCHLORIDE Inj 10 mg per ml, 1 ml ampoule	140.07	25	Necos monhring LICI
	142.07	25	Neosynephrine HCL
Vasodilators			
ALPROSTADIL HYDROCHLORIDE			
Inj 500 mcg per ml, 1 ml ampoule		5	Prostin VR
DIAZOXIDE			
Inj 15 mg per ml, 20 ml ampoule			
HYDRALAZINE HYDROCHLORIDE			
Tab 25 mg			
→ Restricted (RS1008)			
Initiation			
Either:			
1 For the treatment of refractory hypertension; or			
2 For the treatment of heart failure, in combination with a nitrate ACE inhibitors and/or angiotensin receptor blockers.	, in patients who are in	tolerant	or have not responded to
Inj 20 mg ampoule	25.90	5	Apresoline
MILRINONE			
Inj 1 mg per ml, 10 ml ampoule - 5% DV Dec-21 to 2024	71.00	10	Milrinone-Baxter
MINOXIDIL			
Tab 10 mg	70.00	100	Loniten
.			

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NICORANDIL			
Tab 10 mg – 1% DV Dec-19 to 2022 Tab 20 mg – 1% DV Dec-19 to 2022		60 60	lkorel Ikorel
PAPAVERINE HYDROCHLORIDE Inj 30 mg per ml, 1 ml vial Inj 12 mg per ml, 10 ml ampoule		5	Hospira
PENTOXIFYLLINE [OXPENTIFYLLINE] Tab 400 mg			·
SODIUM NITROPRUSSIDE Inj 50 mg vial			
Endothelin Receptor Antagonists			
AMBRISENTAN – Restricted see terms below			
 ↓ Tab 5 mg - 1% DV Mar-21 to 2023 ↓ Tab 10 mg - 1% DV Mar-21 to 2023 → Restricted (RS1621) 	,	30 30	Ambrisentan Mylan Ambrisentan Mylan
Initiation			
Either: 1 For use in patients with a valid Special Authority approval for or	or ambrisentan by the Pu	Imonary	Arterial Hypertension Panel;
2 In-hospital stabilisations in emergency situations.			
BOSENTAN - Restricted see terms below ↓ Tab 62.5 mg - 5% DV Dec-21 to 2024 ↓ Tab 125 mg - 5% DV Dec-21 to 2024 → Restricted (RS1622)		60 60	Bosentan Dr Reddy's Bosentan Dr Reddy's
Initiation – Pulmonary arterial hypertension Re-assessment required after 6 months Either:			
1 All of the following:			
 1.1 Patient has pulmonary arterial hypertension (PAH); 1.2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinic 1.3 PAH is at NYHA/WHO functional class II, III, or IV; a 1.4 Any of the following: 1.4.1 Both: 	cal classifications; and		
1.4.1.1 Bosentan is to be used as PAH monot 1.4.1.2 Either:	herapy; and		
1.4.1.2.1 Patient is intolerant or contraind 1.4.1.2.2 Patient is a child with idiopathic		to conce	nital heart disease [,] or
1.4.2 Both:	1741 of 1741 becondary	to oongei	indi nouri diocube, or
1.4.2.1 Bosentan is to be used as PAH dual th 1.4.2.2 Either:	nerapy; and		
1.4.2.2.1 Patient has tried a PAH monoth 1.4.2.2.2 Patient deteriorated while on a		nonths an	d failed to respond; or
1.4.3 Both: 1.4.3.1 Bosentan is to be used as PAH triple t	herapy: and		

Price	Brand or
(ex man. excl. GST)	Generic
\$	Per Manufacturer

continued...

- 1.4.3.2.1 Patient is on the lung transplant list; or
- 1.4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
- 1.4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
- 1.4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy; or

2 In-hospital stabilisation in emergency situations.

Continuation - Pulmonary arterial hypertension

Re-assessment required after 6 months

Any of the following:

- 1 Both:
 - 1.1 Bosentan is to be used as PAH monotherapy; and
 - 1.2 Patient is stable or has improved while on bosentan; or

2 Both:

- 2.1 Bosentan is to be used as PAH dual therapy; and
- 2.2 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated; or
- 3 Both:
 - 3.1 Bosentan is to be used as PAH triple therapy; and
 - 3.2 Any of the following:
 - 3.2.1 Patient is on the lung transplant list; or
 - 3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
 - 3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
 - 3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – Restricted see terms below		
↓ Tab 25 mg - 5% DV Jan-22 to 20240.85	4	Vedafil
↓ Tab 50 mg - 5% DV Jan-22 to 2024 1.70		Vedafil
	12	Vedafil
· · · · · · · · · · · · · · · · · · ·		

Inj 0.8 mg per ml, 12.5 ml vial

➡ Restricted (RS1798)

Initiation - tablets Raynaud's Phenomenon

All of the following:

- 1 Patient has Raynaud's phenomenon; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

Initiation - tablets Pulmonary arterial hypertension

Any of the following:

Pi	rice		Brand or
(ex man.	excl. G	ST)	Generic
	\$	Per	Manufacturer

continued...

- 1 All of the following:
 - 1.1 Patient has pulmonary arterial hypertension (PAH); and
 - 1.2 Any of the following:
 - 1.2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or
 - 1.2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications; or
 - 1.2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and
 - 1.3 Any of the following:
 - 1.3.1 PAH is in NYHA/WHO functional class II; or
 - 1.3.2 PAH is in NYHA/WHO functional class III; or
 - 1.3.3 PAH is in NYHA/WHO functional class IV; and
 - 1.4 Either:
 - 1.4.1 All of the following:
 - 1.4.1.1 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and 1.4.1.2 Either:
 - 1.4.1.2.1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or
 - 1.4.1.2.2 Patient is peri Fontan repair; and
 - 1.4.1.3 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least 240 International Units (dyn s cm-5); or
 - 1.4.2 Testing for PCWP, PAPm, or PVR cannot be performed due to the patient's young age; or
- 2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
- 3 In-hospital stabilisation in emergency situations.

Initiation - tablets other conditions

Any of the following:

- 1 For use in weaning patients from inhaled nitric oxide; or
- 2 For perioperative use in cardiac surgery patients; or
- 3 For use in intensive care as an alternative to nitric oxide; or
- 4 For use in the treatment of erectile dysfunction secondary to spinal cord injury in patients being treated in a spinal unit.

Initiation - injection

Both:

- 1 For use in the treatment of pulmonary hypertension in infants or children being treated in paediatric intensive care units and neonatal intensive care units when the enteral route is not accessible; and
- 2 Any of the following:
 - 2.1 For perioperative use following cardiac surgery; or
 - 2.2 For use in persistent pulmonary hypertension of the newborn (PPHN); or
 - 2.3 For use in congenital diaphragmatic hernia.

Prostacyclin Analogues

EPOPROSTENC	L – Restricted see terms below		
Inj 500 mcg v	ial	1	Veletri
Inj 1.5 mg via	l	1	Veletri
Bootriptod /	21694)		

➡ Restricted (RS1624)

Initiation

Either:

- 1 For use in patients with a valid Special Authority approval for epoprostenol by the Pulmonary Arterial Hypertension Panel; or
- 2 In-hospital stabilisation in emergency situations.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer	
ILOPROST Inj 50 mcg in 0.5 ml ampoule - 1% DV Jan-20 to 2022	305.00	5	Clinect	
I Nebuliser soln 10 mcg per ml, 2 ml − 1% DV Jan-20 to 2022 → Restricted (RS1625)		30	Ventavis	

Initiation

Any of the following:

1 For use in patients with a valid Special Authority approval for iloprost by the Pulmonary Arterial Hypertension Panel; or

2 For diagnostic use in catheter laboratories; or

3 For use following mitral or tricuspid valve surgery; or

4 In-hospital stabilisation in emergency situations.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
HYDROGEN PEROXIDE Crm 1% Soln 3% (10 vol)	8.56	15 g	Crystaderm
MAFENIDE ACETATE - Restricted see terms below ↓ Powder 50 g sachet → Restricted (RS1299)			
Initiation For the treatment of burns patients. MUPIROCIN			
Oint 2% SODIUM FUSIDATE [FUSIDIC ACID]			
Crm 2% - 5% DV Dec-21 to 2024		5 g 5 g	Foban Foban
SULFADIAZINE SILVER Crm 1%		50 g	Flamazine
Antifungals			
AMOROLFINE Nail soln 5% – 1% DV Oct-20 to 2023	14 93	5 ml	MycoNail
CICLOPIROX OLAMINE			
Nail soln 8% → Soln 1% - Restricted: For continuation only (Apo-Ciclopirox Nail soln 8% to be delisted 1 May 2022)	5.72	7 ml	Apo-Ciclopirox
CLOTRIMAZOLE Crm 1%	0.77	20 g	Clomazol
 → Soln 1% - Restricted: For continuation only ECONAZOLE NITRATE → Crm 1% - Restricted: For continuation only Foaming soln 1% 			
KETOCONAZOLE Shampoo 2% - 1% DV Nov-20 to 2023	3 23	100 ml	Sebizole
METRONIDAZOLE Gel 0.75%		100 11	
 MICONAZOLE NITRATE Crm 2% - 1% DV Feb-21 to 2023 ➡ Lotn 2% - Restricted: For continuation only Tinc 2% 	0.81	15 g	Multichem
NYSTATIN Crm 100,000 u per g			
Antiparasitics			
DIMETHICONE Lotn 4% – 1% DV Oct-19 to 2022	4.98	200 ml	healthE Dimethicone 4% Lotion

t Item restricted (see → above); t Item restricted (see → below)

56

e.g. Brand indicates brand example only. It is not a contracted product.

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer
MALATHION [MALDISON]			
Lotn 0.5%			
Shampoo 1%			
PERMETHRIN			
Crm 5% - 1% DV Nov-20 to 2023		30 g	Lyderm
Lotn 5% - 1% DV Nov-20 to 2023		30 ml	A-Scabies
		00 111	A OUDICO
PHENOTHRIN			
Shampoo 0.5%			
Antiacne Preparations			
ADAPALENE			
Crm 0.1%			
Gel 0.1%			
BENZOYL PEROXIDE			
Soln 5%			
ISOTRETINOIN			
Cap 5 mg - 5% DV Mar-22 to 2024	11.26	60	Oratane
Cap 10 mg - 5% DV Mar-22 to 2024		120	Oratane
Cap 20 mg – 5% DV Mar-22 to 2024		120	Oratane
Crm 0.05% - 5% DV Jan-22 to 2024		50 g	ReTrieve
Antipruritic Preparations			
CALAMINE	4.00	100	0 I I III
Crm, aqueous, BP - 5% DV May-22 to 2024		100 g	Calamine-AFT
	1.26		healthE Calamine
			Aqueous Cream BP
(healthE Calamine Aqueous Cream BP Crm, aqueous, BP to be deli	sted 1 May 2022)		
CROTAMITON			
Crm 10% – 5% DV Dec-21 to 2024	3 20	20 g	Itch-Soothe
0111 10/0 - 3/0 DV Dec-21 to 2024		20 y	lich-Soothe
Parrier Creama and Emallianta			
Barrier Creams and Emollients			
Barrier Creams			
DIMETHICONE			
DIMETHICONE			
Crm 5% tube - 1% DV Oct-19 to 2022	1.53	100 g	healthE Dimethicone
Over 50/ every heattle		500 ·	5%
Crm 5% pump bottle		500 ml	healthE Dimethicone 5%
Crm 10% pump bottle	4.52	500 ml	healthE Dimethicone
			10%
ZINC			
Crm			e.g. Zinc Cream (Orion-)
			;Zinc Cream (PSM)
			, (· • • • • • • • • • • • • • • • • • •
Oint			e.g. Zinc oxide (PSM)
Paste			5 - (-)

		Price excl. GST) \$	Per	Brand or Generic Manufacturer
INC AND CASTOR OIL				
Crm		1.63	20 g	Orion
Oint		4.65	500 g	Boucher
Note: DV limit applies to the pack sizes of greater than 30 g.			-	
Oint, BP		1.26	20 g	healthE
Note: DV limit applies to the pack sizes of 30 g or less.				
INC WITH WOOL FAT				
Crm zinc 15.25% with wool fat 4%				e.g. Sudocrem
Emollients				
QUEOUS CREAM				
Crm 100 g				
Note: DV limit applies to the pack sizes of 100 g or less.				
Crm 500 g – 5% DV Jul-22 to 2024		1.73	500 g	Boucher
				GEM Aqueous Crean
Note: DV limit applies to the pack sizes of greater than 100 g.				
Boucher Crm 500 g to be delisted 1 August 2022)				
ETOMACROGOL				
Crm BP, 500 g - 5% DV May-22 to 2024		1.99	500 g	Cetomacrogol-AFT
		2.48		healthE
Crm BP, 100 g				
ealthE Crm BP, 500 g to be delisted 1 May 2022)				
ETOMACROGOL WITH GLYCEROL				
Crm 90% with glycerol 10%, -1% DV Dec-19 to 2022		1.65	100 g	healthE
Note: DV limit applies to the pack sizes of 100 g or less.		0.05	500 ml	Dauahan
Crm 90% with glycerol 10% - 1% DV Mar-20 to 2022			500 ml 1,000 ml	Boucher Boucher
Note: DV limit applies to the pack sizes of greater than 100 g.		3.10	1,000 111	Doucher
MULSIFYING OINTMENT Oint BP - 1% DV Oct-20 to 2023		1 0/	100 a	lovohom
Note: DV limit applies to pack sizes of less than 200 g.	•••••	1.04	100 g	Jaychem
Oint BP, 500 g – 1% DV Mar-21 to 2023		3.40	500 g	Emulsifying Ointmen
			3	ADE
Note: DV limit applies to pack sizes of greater than 200 g.				
LYCEROL WITH PARAFFIN				
Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%	6			e.g. QV cream
IL IN WATER EMULSION				
Crm, 500 g - 5% DV Sep-22 to 2025		2.04	500 g	Fatty Cream AFT
- ·		2.19	-	O/W Fatty Emulsion Cream
Note: DV limit applies to the pack sizes of greater than 100 g.				0.000
Crm, 100 g - 5% DV Aug-22 to 2024		1.59	1	healthE Fatty Cream
Note: DV limit applies to the pack sizes of 100 g or less.				
0/W Fatty Emulsion Cream Crm, 500 g to be delisted 1 September 202	22)			

	Price		Brand or
	(ex man. excl. GS	Г)	Generic
	`\$	Per	Manufacturer
PARAFFIN			
Oint liquid paraffin 50% with white soft paraffin 50%		100 g	healthE
Note: DV limit applies to the pack sizes of 100 g or greate		•	
White soft		10 g	healthE
Note: DV limit applies to pack sizes of 30 g or less, and to			
White soft, - 1% DV Apr-20 to 2022	4.99	450 g	healthE
Yellow soft			a a OV Bath Oil
Lotn liquid paraffin 85%			e.g QV Bath Oil
PARAFFIN WITH WOOL FAT			
Lotn liquid paraffin 15.9% with wool fat 0.6%			e.g. AlphaKeri;BK ;DP;
Late liquid paraffin 01 7% with wool fat 2%			Hydroderm Lotn
Lotn liquid paraffin 91.7% with wool fat 3%			e.g. Alpha Keri Bath Oil
JREA	4.07	100	
Crm 10%	1.37	100 g	healthE Urea Cream
NOOL FAT			
Crm			
Corticosteroids			
Conticosteroids			
BETAMETHASONE DIPROPIONATE			
Crm 0.05% - 1% DV Feb-21 to 2023		50 g	Diprosone
Note: DV limit applies to the pack sizes of greater than 30	g.	•	
Oint 0.05% - 1% DV Feb-21 to 2023		50 g	Diprosone
Note: DV limit applies to the pack sizes of greater than 30	g.		
BETAMETHASONE VALERATE			
Crm 0.1% - 5% DV Jan-22 to 2024	4.53	50 g	Beta Cream
Oint 0.1% - 5% DV Jan-22 to 2024	5.84	50 g	Beta Ointment
Lotn 0.1% – 5% DV Mar-22 to 2024	25.00	50 ml	Betnovate
CLOBETASOL PROPIONATE			
Crm 0.05% – 1% DV Nov-19 to 2022	2.18	30 g	Dermol
Oint 0.05% - 1% DV Nov-19 to 2022	2.12	30 g	Dermol
CLOBETASONE BUTYRATE			
Crm 0.05%			
DIFLUCORTOLONE VALERATE - Restricted: For continuation	only		
→ Crm 0.1%	,		
→ Fatty oint 0.1%			
IYDROCORTISONE			
Crm 1%, 100 g - 1% DV Sep-20 to 2022	3.70	100 g	Hydrocortisone (PSM)
Note: DV limit applies to the pack sizes of less than or equi	ual to 100 g.	•	
Crm 1%, 500 g - 1% DV Dec-20 to 2023	17.15	500 g	Hydrocortisone (PSM)
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN			
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% $-$ 1% DV	Oct-20		
to 2023		250 ml	DP Lotn HC
HYDROCORTISONE BUTYRATE			
Crm 0.1%		100 g	Locoid Lipocream
Oint 0.1% - 5% DV Dec-21 to 2024		100 g	Locoid
Milky emul 0.1% - 5% DV Dec-21 to 2024		100 ml	Locoid Crelo
METHYLPREDNISOLONE ACEPONATE			
Crm 0.1% - 1% DV Dec-20 to 2023		15 g	Advantan
Oint 0.1% – 1% DV Dec-20 to 2023	4.46	15 g	Advantan

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price		Brand or
	(ex man. excl. GST)	Generic
	\$	Per	Manufacturer
MOMETASONE FUROATE			
Crm 0.1% – 5% DV Feb-22 to 2024	1 05	15 a	Elecon Alechal Erec
GIII 0.1% – 5% DV Feb-22 l0 2024		15 g	Elocon Alcohol Free
	3.10	50 g	Elocon Alcohol Free
Oint 0.1% - 5% DV Feb-22 to 2024		15 g	Elocon
	2.90	50 g	Elocon
Lotn 0.1% - 5% DV Feb-22 to 2024	4.50	30 ml	Elocon
TRIAMCINOLONE ACETONIDE			
Crm 0.02% – 1% DV Nov-20 to 2023	6.00	100 ~	Aristocort
		100 g	
Oint 0.02% - 1% DV Nov-20 to 2023		100 g	Aristocort
Corticosteroids with Anti-Infective Agents			
BETAMETHASONE VALERATE WITH CLIOQUINOL – Restricted s	ee terms below		
Crm 0.1% with cliquiniol 3%			
→ Restricted (RS1125) Initiation			
Either:			
1 For the treatment of intertrigo; or			
2 For continuation use.			
BETAMETHASONE VALERATE WITH SODIUM FUSIDATE (FUSIDI			
Crm 0.1% with sodium fusidate (fusidic acid) 2%	o noib]		
HYDROCORTISONE WITH MICONAZOLE			
Crm 1% with miconazole nitrate 2% - 5% DV Dec-21 to 2024	1.89	15 g	Micreme H
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN			
Crm 1% with natamycin 1% and neomycin sulphate 0.5%	3 35	15 g	Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%		15 g	Pimafucort
, , ,			Fillialucolt
(Pimafucort Crm 1% with natamycin 1% and neomycin sulphate 0.5%	-		
TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRA	AMICIDIN AND NYST	FATIN	
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and	ł		
gramicidin 250 mcg per g			
Psoriasis and Eczema Preparations			
ACITRETIN			
Cap 10 mg - 1% DV Oct-20 to 2023	17.86	60	Novatretin
Cap 25 mg - 1% DV Oct-20 to 2023		60	Novatretin
BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL			
	50.05	<u> </u>	Fratilar
Foam spray 500 mcg with calcipotriol 50 mcg per g		60 g	Enstilar
Gel 500 mcg with calcipotriol 50 mcg per g - 5% DV Dec-21 to 2		60 g	Daivobet
Oint 500 mcg with calcipotriol 50 mcg per g $-$ 5% DV Dec-21 to 2	2024 15.90	30 g	Daivobet
CALCIPOTRIOL			
Oint 50 mcg per g		120 g	Daivonex
COAL TAR WITH SALICYLIC ACID AND SULPHUR			
Oint 12% with salicylic acid 2% and sulphur 4%			
METHOXSALEN [8-METHOXYPSORALEN]			
Tab 10 mg			
Lotn 1.2%			
PIMECROLIMUS – Restricted see terms on the next page			
Crm 1% – 1% DV Mar-21 to 2023		15 g	Elidel

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

				DERI	IATOLOGICALS
	(ex man	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
→ Restricted (RS1781) Initiation					
Dermatologist, paediatrician or ophthalmologist Both:					
 Patient has atopic dermatitis on the eyelid; and Patient has at least one of the following contraindications to topic documented epidermal atrophy, documented allergy to topical co pressure. 					
PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCEIN					
Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – 1% Nov-20 to 2023		4.44	4	500 ml	Pinetarsol
POTASSIUM PERMANGANATE Tab 400 mg Crystals			-		
TACROLIMUS					
 ↓ Oint 0.1% - 1% DV Mar-22 to 2023		33.00	0	30 g	Zematop
Initiation					
Dermatologist or paediatrician Both:					
 Patient has atopic dermatitis on the face; and Patient has at least one of the following contraindications to topic documented epidermal atrophy or documented allergy to topical 				eriorificial	dermatitis, rosacea,
Scalp Preparations					
BETAMETHASONE VALERATE					
Scalp app 0.1% - 5% DV Jan-22 to 2024		9.84	4	100 ml	Beta Scalp
CLOBETASOL PROPIONATE Scalp app 0.05% – 1% DV Nov-19 to 2022		5.69	9	30 ml	Dermol
HYDROCORTISONE BUTYRATE					
Scalp lotn 0.1% - 5% DV Dec-21 to 2024		6.5	7	100 ml	Locoid
Wart Preparations					
IMIQUIMOD					
Crm 5%, 250 mg sachet		21.72	2	24	Perrigo
PODOPHYLLOTOXIN					
Soln 0.5% SILVER NITRATE		33.60	U	3.5 ml	Condyline
Sticks with applicator					
Other Skin Preparations					
· ·					
DIPHEMANIL METILSULFATE Powder 2%					

SUNSCREEN, PROPRIETARY			
Lotn - 1% DV Mar-20 to 20225.	.10 2	00 g	Marine Blue Lotion SPF
		-	50+

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	(ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
Antineoplastics					
FLUOROURACIL SODIUM Crm 5% - 5% DV Dec-21 to 2024 METHYL AMINOLEVULINATE HYDROCHLORIDE - Restricted see ↓ Crm 16% → Restricted (RS1127) Dermatologist or plastic surgeon			5	20 g	Efudix
Wound Management Products					
CALCIUM GLUCONATE					

Gel 2.5%

62

e.g. Orion

Price (ex man. excl. GST)		Brand or Generic
(or mail or act) \$	Per	Manufacturer
Anti-Infective Agents		
ACETIC ACID Soln 3%		
Soln 5%		
ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator		
CHLORHEXIDINE GLUCONATE		
Lotn 1% CLOTRIMAZOLE		
Vaginal crm 1% with applicator – 1% DV Jan-20 to 2022	35 g 20 g	Clomazol Clomazol
MICONAZOLE NITRATE Vaginal crm 2% with applicator – 1% DV Nov-20 to 2023 6.89	40 g	Micreme
NYSTATIN Vaginal crm 100,000 u per 5 g with applicator(s) – 1% DV Oct-20 to 2023 4.00	75 g	Nilstat
Contraceptives		
Antiandrogen Oral Contraceptives		
CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets – 1% DV Apr-21 to 2023	168	Ginet
Combined Oral Contraceptives		
ETHINYLOESTRADIOL WITH DESOGESTREL Tab 20 mcg with desogestrel 150 mcg Tab 30 mcg with desogestrel 150 mcg		
ETHINYLOESTRADIOL WITH LEVONORGESTREL Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets	84	Microgynon 20 ED
Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets 1.77 Tab 20 mcg with levonorgestrel 100 mcg	84	Levlen ED
Tab 30 mcg with levonorgestrel 150 mcg ETHINYLOESTRADIOL WITH NORETHISTERONE Tab 25 mcg with perethistoreng 1 mg		
Tab 35 mcg with norethisterone 1 mg Tab 35 mcg with norethisterone 1 mg and 7 inert tab – 1% DV Mar-20 to 2022	84	Brevinor 1/28
Tab 35 mcg with norethisterone 500 mcg	04	Brevinor 1/20
NORETHISTERONE WITH MESTRANOL Tab 1 mg with mestranol 50 mcg		
Contraceptive Devices		
NTRA-UTERINE DEVICE IUD 29.1 mm length × 23.2 mm width – 1% DV Nov-19 to 2022	1	Choice TT380 Short
IUD 33.6 mm length × 29.9 mm width – 1% DV Nov-19 to 2022	1 1	Choice TT380 Standard Choice Load 375
Products with Hospital Supply Status (HSS) are in bold		61

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

GENITO-URINARY SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Emergency Contraception			
LEVONORGESTREL Tab 1.5 mg - 1% DV Mar-22 to 2022	4.95	1	Postinor-1
Progestogen-Only Contraceptives			
LEVONORGESTREL Tab 30 mcg - 1% DV May-20 to 2022 Subdermal implant (2 × 75 mg rods) - 1% DV Dec-20 to 2023 Intra-uterine device 52 mg - 1% DV Nov-19 to 31 Oct 2022 Intra-uterine device 13.5 mg - 1% DV Nov-19 to 31 Oct 2022 MEDROXYPROGESTERONE ACETATE Inj 150 mg per ml, 1 ml syringe - 1% DV Dec-19 to 2022 NORETHISTERONE Tab 350 mcg - 5% DV Mar-22 to 2024		84 1 1 1 1 84	Microlut Jadelle Mirena Jaydess Depo-Provera Noriday 28
Obstetric Preparations			
Antiprogestogens			
MIFEPRISTONE Tab 200 mg			
Oxytocics			
CARBOPROST TROMETAMOL Inj 250 mcg per ml, 1 ml ampoule DINOPROSTONE Pessaries 10 mg Vaginal gel 1 mg in 3 g Vaginal gel 2 mg in 3 g		1 1	Prostin E2 Prostin E2
ERGOMETRINE MALEATE Inj 500 mcg per ml, 1 ml ampoule	160.00	5	DBL Ergometrine
OXYTOCIN Inj 5 iu per ml, 1 ml ampoule Inj 10 iu per ml, 1 ml ampoule OXYTOCIN WITH ERGOMETRINE MALEATE Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule -	4.98 - 5%	5 5	Oxytocin BNM Oxytocin BNM
DV Jan-22 to 2024		5	Syntometrine
Tocolytics			
PROGESTERONE – Restricted see terms below ↓ Cap 100 mg	16.50	30	Utrogestan
5000			

continued...

GENITO-URINARY SYSTEM

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1 For the prevention of pre-term labour*; and
- 2 Either:
 - 2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
 - 2.2 The patient has a history of pre-term birth at less than 28 weeks.

Continuation

Gynaecologist or obstetrician

Re-assessment required after 12 months All of the following:

- 1 For the prevention of pre-term labour*; and
- 2 Treatment is required for second or subsequent pregnancy; and

3 Either:

- 3.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
- 3.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are unapproved indications.

TERBUTALINE – **Restricted** see terms below

Inj 500 mcg ampoule

➡ Restricted (RS1130)

Obstetrician

Oestrogens

OESTRIOL

Crm 1 mg per g with applicator - 1% DV Oct-20 to 2023	15 g	Ovestin
Pessaries 500 mcg - 1% DV Oct-20 to 2023	15	Ovestin

Urologicals

5-Alpha Reductase Inhibitors

FINASTERIDE – Restricted see terms below		
↓ Tab 5 mg - 1% DV Apr-21 to 2023	100	Ricit
→ Restricted (RS1131)		
Initiation		
Both:		
1 Patient has symptomatic benign prostatic hyperplasia; and		

2 Either:

2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or

2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

Alpha-1A Adrenoceptor Blockers

TAMSULOSIN HYDROCHLORIDE - Restricted see terms below		
Cap 400 mcg – 1% DV Jan-20 to 2022 17.73	100	Tamsulosin-Rex
→ Restricted (RS1132)		
Initiation		
Both:		
4. Definition a summitiant of the solution of the form and the form and the solution of the		

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

(Price ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
Urinary Alkalisers			
POTASSIUM CITRATE - Restricted see terms below ↓ Oral liq 3 mmol per ml	31.80	200 ml	Biomed
 The patient has recurrent calcium oxalate urolithiasis; and The patient has had more than two renal calculi in the two years p 	rior to the applic	ation.	
SODIUM CITRO-TARTRATE Grans eff 4 g sachets – 1% DV Oct-20 to 2023	2.22	28	Ural
Urinary Antispasmodics			
OXYBUTYNIN – Restricted: For continuation only → Tab 5 mg → Oral liq 5 mg per 5 ml (<i>Apo-Oxybutynin Tab 5 mg to be delisted 1 May 2022</i>) (<i>Apo-Oxybutynin Oral liq 5 mg per 5 ml to be delisted 1 May 2022</i>) SOLIFENACIN SUCCINATE	11.70	100 500 473 ml	Alchemy Oxybutynin Apo-Oxybutynin Apo-Oxybutynin
SOLIFENACIN SUCCINATE Tab 5 mg - 5% DV Dec-21 to 2024 Tab 10 mg - 5% DV Dec-21 to 2024		30 30	Solifenacin Mylan Solifenacin Mylan

HORMONE PREPARATIONS

(ex man. excl. GST) Generic \$ Per Manufacturer		
--	--	--

Anabolic Agents

OXANDROLONE

Tab 2.5 mg

→ Restricted (RS1302)

Initiation

For the treatment of burns patients.

Androgen Agonists and Antagonists

CYPROTERONE ACETATE Tab 50 mg - 5% DV Jan-22 to 2024	14.37	50	Siterone
Tab 100 mg - 5% DV Jan-22 to 2024		50	Siterone
TESTOSTERONE			
Patch 5 mg per day	90.00	30	Androderm
TESTOSTERONE CIPIONATE			
Inj 100 mg per ml, 10 ml vial	85.00	1	Depo-Testosterone
TESTOSTERONE ESTERS			
Inj testosterone decanoate 100 mg, testosterone isocarproate 60 mg, testosterone phenylpropionate 60 mg and testosterone propionate 30 mg per ml, 1 ml ampoule			
TESTOSTERONE UNDECANOATE			
➡ Cap 40 mg – Restricted: For continuation only Inj 250 mg per ml, 4 ml vial		60 1	Andriol Testocaps Reandron 1000
Calcium Homeostasis			
CALCITONIN Inj 100 iu per ml, 1 ml ampoule	121.00	5	Miacalcic

 CINACALCET
 - Restricted see terms below

 I
 Tab 30 mg
 - 5% DV Apr-22 to 2024
 42.06
 28
 Cinacalet Devatis

 I
 Tab 60 mg
 - 5% DV Apr-22 to 2024
 84.12
 28
 Cinacalet Devatis

→ Restricted (RS1540)

Initiation

Nephrologist or endocrinologist *Re-assessment required after 6 months* Either:

- 1 All of the following:
 - 1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
 - 1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
 - 1.3 The patient is symptomatic; or

2 All of the following:

- 2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriolopathy); and
- 2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
- 2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium

continued...

	l (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
continued					
thiosulfate.					
Continuation					
Vephrologist or endocrinologist 3oth:					
1 The patient's serum calcium level has fallen to < 3mmol/L; a	nd				
2 The patient has experienced clinically significant symptom ir					
Note: This does not include parathyroid adenomas unless these ha			nant		
ZOLEDRONIC ACID		mangi	iant.		
Inj 4 mg per 5 ml, vial – 5% DV Dec-21 to 2024		18.0	n	1	Zoledronic acid Mylan
Restricted (RS1883)		. 10.0	0	'	Loicaronno aola mylan
nitiation – bone metastases					
Any of the following:					
1 Patient has hypercalcaemia of malignancy; or					
2 Both:					
2.1 Patient has bone metastases or involvement; and					
2.2 Patient has severe bone pain resistant to standard fir	rst-line treatm	nents;	or		
3 Both:					
3.1 Patient has bone metastases or involvement; and					the second strain to be seen as
3.2 Patient is at risk of skeletal-related events (pathologic	cal fracture, s	spinal	cord c	ompress	sion, radiation to bone or
surgery to bone). nitiation – early breast cancer*					
All of the following:					
1 Treatment to be used as adjuvant therapy for early breast ca	ancer: and				
2 Patient has been amenorrhoeic for 12 months or greater, eit		or inc	duced.	with end	locrine levels consistent with
a postmenopausal state; and	,		,		
3 Treatment to be administered at a minimum interval of 6-mo	nthly for a m	aximu	im of 3	years.	
Note: Indications marked with * are unapproved indications.					
nitiation – symptomatic hypercalcaemia*					
Any relevant practitioner					
Patient has symptomatic hypercalcaemia. Note: Indications marked with * are unapproved indications.					
vole. Indications marked with are unapproved indications.					

Corticosteroids

BETAMETHASONE

Tab 500 mcg

Inj 4 mg per ml, 1 ml ampoule

BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE

Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

DEXAMETHASONE

Tab 0.5 mg - 5% DV Jan-22 to 2024	30	Dexmethsone
Tab 4 mg - 5% DV Jan-22 to 2024	30	Dexmethsone
Oral liq 1 mg per ml	25 ml	Biomed

HORMONE PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DEXAMETHASONE PHOSPHATE			
Inj 4 mg per ml, 1 ml ampoule – 1% DV Jul-20 to 2022	9.25	10	Dexamethasone Phosphate Panpharma
Inj 4 mg per ml, 2 ml ampoule – 1% DV Jul-20 to 2022		10	Dexamethasone Phosphate Panpharma
FLUDROCORTISONE ACETATE Tab 100 mcg		100	Florinef
HYDROCORTISONE			
Tab 5 mg	8 10	100	Douglas
Tab 20 mg		100	Douglas
Inj 100 mg vial - 5% DV Nov-21 to 2024		1	Solu-Cortef
METHYLPREDNISOLONE (AS SODIUM SUCCINATE)			
Tab 4 mg	112.00	100	Medrol
Tab 100 mg		20	Medrol
Inj 40 mg vial		1	Solu-Medrol Act-O-Vial
Inj 125 mg vial		1	Solu-Medrol Act-O-Vial
Inj 500 mg vial		1	Solu-Medrol Act-O-Vial
Inj 1 g vial		1	Solu-Medrol
METHYLPREDNISOLONE ACETATE			
Inj 40 mg per ml, 1 ml vial	47.06	5	Depo-Medrol
PREDNISOLONE		U U	
Oral liq 5 mg per ml – 5% DV Dec-21 to 2024	6.00	30 ml	Redipred
Enema 200 mcg per ml, 100 ml		00 111	neupreu
PREDNISONE			
Tab 1 mg		500	Apo-Prednisone
Table 0.5 mm	04.04	500	Prednisone Clinect
Tab 2.5 mg	21.04	500	Apo-Prednisone
Tob 5 mg	10.00	500	Prednisone Clinect
Tab 5 mg		500	Apo-Prednisone Prednisone Clinect
Tab 20 mg	50.51	500	Apo-Prednisone
		500	Prednisone Clinect
(Apo-Prednisone Tab 1 mg to be delisted 1 November 2022) (Apo-Prednisone Tab 2.5 mg to be delisted 1 November 2022) (Apo-Prednisone Tab 5 mg to be delisted 1 November 2022) (Apo-Prednisone Tab 20 mg to be delisted 1 November 2022) TRIAMCINOLONE ACETONIDE			
Inj 10 mg per ml, 1 ml ampoule – 5% DV Apr-21 to 2023	20.80	5	Kenacort-A 10
Inj 40 mg per ml, 1 ml ampoule – 1% DV Apr-21 to 2020 TRIAMCINOLONE HEXACETONIDE Inj 20 mg per ml, 1 ml vial		5	Kenacort-A 40

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Hormono Bonlocomont Therapy	φ 	FU	
Hormone Replacement Therapy			
Oestrogens			
OESTRADIOL Tab 1 mg Patch 25 mcg per day Patch 50 mcg per day Patch 75 mcg per day Patch 100 mcg per day OESTRADIOL VALERATE Tab 1 mg Tab 2 mg OESTROGENS (CONJUGATED EQUINE) Tab 300 mcg Tab 625 mcg	7.04 7.91 7.91	8 8 8 84 84	Estradot Estradot Estradot Estradot Progynova Progynova
Progestogen and Oestrogen Combined Preparation	S		
OESTRADIOL WITH NORETHISTERONE ACETATE Tab 1 mg with 0.5 mg norethisterone acetate Tab 2 mg with 1 mg norethisterone acetate Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oes (12) and tab 1 mg oestradiol (6) OESTROGENS WITH MEDROXYPROGESTERONE ACETATE Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate			
Progestogens			
MEDROXYPROGESTERONE ACETATE Tab 2.5 mg Tab 5 mg Tab 10 mg	17.50	30 100 30	Provera Provera Provera
Other Endocrine Agents CABERGOLINE - Restricted see terms below I Tab 0.5 mg		2	Dostinex
 → Restricted (RS1855) Initiation Any of the following: Inhibition of lactation; or Patient has hyperprolactinemia; or Patient has acromegaly. Note: Indication marked with * is an unapproved indication. CLOMIFENE CITRATE Tab 50 mg Tab 50 mg 	15.20	8	Dostinex Mylan Clomiphen

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

HORMONE PREPARATIONS

(ex n	Pric nan.ex \$	e :cl. GST)	Per	Brand or Generic Manufacturer
GESTRINONE Cap 2.5 mg METYRAPONE Cap 250 mg PENTAGASTRIN Inj 250 mcg per ml, 2 ml ampoule				
Other Oestrogen Preparations				
ETHINYLOESTRADIOL – Restricted: For continuation only → Tab 10 mcg	17	 60	100	NZ Medical and Scientific
OESTRADIOL Implant 50 mg OESTRIOL Tab 2 mg – 1% DV Sep-20 to 2023	7	.00	30	Ovestin
Other Progestogen Preparations				
Tab 100 mg NORETHISTERONE Tab 5 mg			100 30	Provera HD Primolut N
Pituitary and Hypothalamic Hormones and Analogues CORTICORELIN (OVINE) Inj 100 mcg vial THYROTROPIN ALFA Inj 900 mcg vial				
Adrenocorticotropic Hormones				
TETRACOSACTIDE [TETRACOSACTRIN] Inj 250 mcg per ml, 1 ml ampoule Inj 1 mg per ml, 1 ml ampoule			1 1	Synacthen Synacthen Depot
GnRH Agonists and Antagonists				
BUSERELIN Inj 1 mg per ml, 5.5 ml vial GONADORELIN Inj 100 mcg vial GOSERELIN				-
Implant 3.6 mg, syringe – 1% DV May-21 to 2023 Implant 10.8 mg, syringe – 1% DV May-21 to 2023 LEUPRORELIN ACETATE Inj 3.75 mg prefilled dual chamber syringe	122	2.37	1 1 1	Teva Teva Lucrin Depot 1-month
Inj 11.25 mg prefilled dual chamber syringe			1	Lucrin Depot 3-month

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer	
Gonadotrophins				
CHORIOGONADOTROPIN ALFA Inj 250 mcg in 0.5 ml syringe				
Growth Hormone				
SOMATROPIN - Restricted see terms below ↓ Inj 5 mg cartridge - 5% DV Jan-22 to 2024 ↓ Inj 10 mg cartridge - 5% DV Jan-22 to 2024 ↓ Inj 15 mg cartridge - 5% DV Jan-22 to 2024 → Restricted (RS1826) Initiation - growth hormone deficiency in children Endocringlogist or naedistric endocringlogist	69.75	1 1 1	Omnitrope Omnitrope Omnitrope	

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

- Either:
 - 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or
 - 2 All of the following:
 - 2.1 Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
 - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and</p>
 - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
 - 2.5 Appropriate imaging of the pituitary gland has been obtained.

Continuation - growth hormone deficiency in children

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initiation – Turner syndrome

Endocrinologist or paediatric endocrinologist *Re-assessment required after 12 months*

All of the following:

72

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

continued...

(ex m	an. excl.	GST)		Generic
	\$		Per	Manufacturer

Continuation - Turner syndrome

Endocrinologist or paediatric endocrinologist *Re-assessment required after 12 months* All of the following:

- 1 Height velocity greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
- 3 A current bone age is 14 years or under; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initiation - short stature without growth hormone deficiency

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Continuation - short stature without growth hormone deficiency

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 Current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initiation – short stature due to chronic renal insufficiency

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of a endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
 - 6.1 The patient has a GFR less than or equal to 30 ml/min/1.73 m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m²) in a child who may or may not be receiving dialysis; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

6.2 The patient has received a renal transplant and has received < 5mg/ m² /day of prednisone or equivalent for at least 6 months.

Continuation - short stature due to chronic renal insufficiency

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of a endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initiation - Prader-Willi syndrome

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient is aged six months or older; and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 The patient is aged two years or older; and
 - 5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
 - 5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Continuation - Prader-Willi syndrome

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist con siders is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initiation - adults and adolescents

Endocrinologist or paediatric endocrinologist *Re-assessment required after 12 months*

He-assessment required after 12 mo

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Continuation - adults and adolescents

Endocrinologist or paediatric endocrinologist *Re-assessment required after 12 months* Any of the following:

1 All of the following:

- 1.1 The patient has been treated with somatropin for < 12 months; and
- 1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
- 1.3 Serum IGF-I levels have increased to within ±1SD of the mean of the normal range for age and sex; and
- 1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- 2 All of the following:
 - 2.1 The patient has been treated with somatropin for more than 12 months; and
 - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
 - 2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
- 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients; or 3 All of the following:
 - 3.1 The patient has had a Special Authority approval for somatropin for childhood deficiency in children and no longer meets the renewal criteria under this indication; and
 - 3.2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
 - 3.3 The patient has severe growth hormone deficiency (see notes); and

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

- 3.4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 3.5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Thyroid and Antithyroid Preparations

CARBIMAZOLE

CARDINAZULE Tab 5 mg 5% DV Cap 22 to 2025	7 5 6	100	Neo-Mercazole
Tab 5 mg – 5% DV Sep-22 to 2025	/ .50	100	Neo-mercazoie
IODINE			
Soln BP 50 mg per ml			
LEVOTHYROXINE			
Tab 25 mcg			
Tab 50 mcg			
Tab 100 mcg			
LIOTHYRONINE SODIUM			
Tab 20 mcg			
→ Restricted (RS1301)			
Initiation			
For a maximum of 14 days' treatment in patients with thyroid cancer who are due	to receive i	adioiodin	e therapy.
Inj 20 mcg vial			
Inj 100 mcg vial			
POTASSIUM IODATE			
Tab 170 mg			
POTASSIUM PERCHLORATE			
Cap 200 mg			
PROPYLTHIOURACIL – Restricted see terms below			
Tab 50 mg	35.00	100	PTU
→ Restricted (RS1276)			
Initiation			
Both:			
1 The patient has hyperthyroidism; and			
2 The patient is intolerant of carbimazole or carbimazole is contraindicated.			
Note: Propylthiouracil is not recommended for patients under the age of 18 year	s unless the	patient is	pregnant and other
treatments are contraindicated.			
PROTIRELIN			

Inj 100 mcg per ml, 2 ml ampoule

e.g. Brand indicates brand example only. It is not a contracted product.

HORMONE PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Vasopressin Agents			
ARGIPRESSIN [VASOPRESSIN] Inj 20 u per ml, 1 ml ampoule			
DESMOPRESSIN Wafer 120 mcg	47.00	30	Minirin Melt
DESMOPRESSIN ACETATE Tab 100 mcg		30	Minirin
Tab 200 mcg Nasal spray 10 mcg per dose – 1% DV Nov-20 to 2023 Inj 4 mcg per ml, 1 ml ampoule Inj 15 mcg per ml, 1 ml ampoule Nasal drops 100 mcg per ml		30 6 ml	Minirin Desmopressin-PH&T
TERLIPRESSIN Inj 0.1 mg per ml, 8.5 ml ampoule Inj 1 mg per 8.5 ml ampoule		5 5	Glypressin Glypressin



	Price		Brand or
	(ex man. excl. GS		Generic
	\$	Per	Manufacturer
Antibacterials			
Aminoglycosides			
AMIKACIN - Restricted see terms below			
Inj 5 mg per ml, 10 ml syringe	10.10		D . 1
 Inj 5 mg per ml, 5 ml syringe Inj 15 mg per ml, 5 ml syringe 	19.43	1	Biomed
 Inj 15 mg per ml, 5 ml symge Inj 250 mg per ml, 2 ml vial – 5% DV Dec-21 to 2024 	100.05	5	DBL Amikacin
Restricted (RS1041)		5	
Clinical microbiologist, infectious disease specialist or respiratory specia	alist		
GENTAMICIN SULPHATE			
Inj 10 mg per ml, 1 ml ampoule	95.00	5	DBL Gentamicin
Inj 10 mg per ml, 2 ml ampoule		Ū	DDE Gonamon
Inj 40 mg per ml, 2 ml ampoule	17.50	10	Pfizer
PAROMOMYCIN – Restricted see terms below			
Cap 250 mg	126.00	16	Humatin
→ Restricted (RS1603)		10	- Turnatin
Clinical microbiologist, infectious disease specialist or gastroenterologis	t		
TREPTOMYCIN SULPHATE – Restricted see terms below			
Ini 400 mg per ml, 2.5 ml ampoule			
→ Restricted (RS1043)			
Clinical microbiologist, infectious disease specialist or respiratory specia	alist		
OBRAMYCIN			
Powder			
→ Restricted (RS1475)			
nitiation			
For addition to orthopaedic bone cement.			
Inj 40 mg per ml, 2 ml vial – 5% DV Jan-22 to 2024		5	Tobramycin Mylan
→ Restricted (RS1044)			
Clinical microbiologist, infectious disease specialist or respiratory specia	alist		
Inj 100 mg per ml, 5 ml vial			
→ Restricted (RS1044)			
Clinical microbiologist, infectious disease specialist or respiratory specia			
Solution for inhalation 60 mg per ml, 5 ml – 1% DV May-21 to 202	3	56 dose	Tobramycin BNM
→ Restricted (RS1435)			
nitiation			
atient has cystic fibrosis.			
Carbapenems			
RTAPENEM – Restricted see terms below			
Inj 1 g vial – 1% DV Aug-19 to 2022	70.00	1	Invanz
→ Restricted (RS1045)			
Clinical microbiologist or infectious disease specialist			
MIPENEM WITH CILASTATIN - Restricted see terms on the next page	·		
Inj 500 mg with 500 mg cilastatin vial – 1% DV Jul-19 to 2022	60.00	1	Imipenem+Cilastatin
			RBX

	Price (ex man. excl. G \$	ST) Per	Brand or Generic Manufacturer
→ Restricted (RS1046)			
Clinical microbiologist or infectious disease specialist			
MEROPENEM – Restricted see terms below			
Inj 500 mg vial – 1% DV Apr-21 to 2023		10 10	Meropenem-AFT
Inj 1 g vial – 1% DV Apr-21 to 2023 → Restricted (RS1047)	45.04	10	Meropenem-AFT
Clinical microbiologist or infectious disease specialist			
Cephalosporins and Cephamycins - 1st Generation			
CEFALEXIN Cap 250 mg – 1% DV Nov-19 to 2022	3 33	20	Cephalexin ABM
Cap 500 mg		20	Cephalexin ABM
Grans for oral lig 25 mg per ml		100 ml	Cefalexin Sandoz
Grans for oral lig 50 mg per ml		100 ml	Cefalexin Sandoz
CEFAZOLIN			
Inj 500 mg vial – 1% DV Nov-20 to 2023		5	AFT
Inj 1 g vial – 1% DV Nov-20 to 2023	3.49	5	AFT
Cephalosporins and Cephamycins - 2nd Generation			
CEFACLOR			
Cap 250 mg - 1% DV Oct-19 to 2022		100	Ranbaxy-Cefaclor
Grans for oral liq 25 mg per ml – 1% DV Oct-19 to 2022	3.53	100 ml	Ranbaxy-Cefaclor
CEFOXITIN			
Inj 1 g vial			
	(5.00		_
Tab 250 mg – 1% DV Feb-20 to 2022 Inj 750 mg vial – 1% DV Jun-21 to 2023		50 10	Zinnat Cefuroxime-AFT
Inj 1.5 g vial – 1% DV Jun-21 to 2023		10	Cefuroxime-AFT
Cephalosporins and Cephamycins - 3rd Generation			
CEFOTAXIME Inj 500 mg vial	1 90	1	Cefotaxime Sandoz
Inj 1 g vial – 1% DV Nov-20 to 2023		10	DBL Cefotaxime
CEFTAZIDIME – Restricted see terms below			
↓ Inj 1 g vial – 1% DV Dec-20 to 2023	2.69	1	Ceftazidime-AFT
→ Restricted (RS1048)			
Clinical microbiologist, infectious disease specialist or respiratory specia	list		
CEFTRIAXONE			
Inj 500 mg vial – 1% DV Jan-20 to 2022		1	Ceftriaxone-AFT
Inj 1 g vial – 1% DV Jan-20 to 2022 Inj 2 g vial – 1% DV Jan-20 to 2022		5 1	Ceftriaxone-AFT Ceftriaxone-AFT
Cephalosporins and Cephamycins - 4th Generation		1	
CEFEPIME – Restricted see terms below	05.00	10	Cofonima Kahi
 Inj 1 g vial – 5% DV Jan-22 to 2024 Inj 2 g vial – 5% DV Jan-22 to 2024 		10 10	Cefepime Kabi
 Inj 2 g vial - 5% DV Jan-22 to 2024 → Restricted (RS1049) 		10	Cefepime Kabi
Clinical microbiologist or infectious disease specialist			
- '			

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated. INFECTIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Cephalosporins and Cephamycins - 5th Generatio	n		
CEFTAROLINE FOSAMIL – Restricted see terms below Inj 600 mg vial		10 pies.	Zinforo
Macrolides			
AZITHROMYCIN - Restricted see terms below Tab 250 mg Tab 500 mg - 1% DV Dec-21 to 2024 Grans for oral liq 200 mg per 5 ml (40 mg per ml) Apo-Azithromycin Tab 250 mg to be delisted 1 May 2022) → Restricted (RS1598) nitiation - bronchiolitis obliterans syndrome, cystic fibrosis an Any of the following:	2.57 16.97	30 2 15 ml	Apo-Azithromycin Zithromax Zithromax
 Patient has received a lung transplant, stem cell transplant of bronchiolitis obliterans syndrome*; or Patient has received a lung transplant and requires prophylax Patient has cystic fibrosis and has chronic infection with Pseu negative organisms*; or Patient has an atypical Mycobacterium infection. 	xis for bronchiolitis oblit	erans syn	drome*; or
Note: Indications marked with * are unapproved indications nitiation – non-cystic fibrosis bronchiectasis * Respiratory specialist or paediatrician <i>Re-assessment required after 12 months</i> All of the following: 1 For prophylaxis of exacerbations of non-cystic fibrosis bronch 2 Potratic cased 19 and under and	niectasis*; and		

- 2 Patient is aged 18 and under; and
- 3 Either:
 - 3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
 - 3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

Continuation - non-cystic fibrosis bronchiectasis*

Respiratory specialist or paediatrician

Re-assessment required after 12 months

All of the following:

- 1 The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
- 2 Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
- 3 The patient will not receive more than a total of 24 months' azithromycin cumulative treatment (see note).

				INFECTIONS
		Price excl. GS \$	T) Per	Brand or Generic Manufacturer
continued				
Note: Indications marked with * are unapproved indications. A ma	ximum of 24	months o	f azithromy	cin treatment for non-cystic
ibrosis will be subsidised in the community.				
nitiation – other indications				
Re-assessment required after 5 days				
or any other condition.				
Re-assessment required after 5 days				
for any other condition.				
CLARITHROMYCIN – Restricted see terms below Tab 250 mg – 1% DV Feb-22 to 2024		9 5 2	14	Klacid
Tab 500 mg – 1% DV Feb-22 to 2024			14	Klacid
Grans for oral lig 50 mg per ml			50 ml	Klacid
Inj 500 mg vial – 1% DV Dec-20 to 2023			1	Martindale
→ Restricted (RS1709)			I	martindale
nitiation – Tab 250 mg and oral liquid				
inv of the following:				
1 Atypical mycobacterial infection; or				
2 Mycobacterium tuberculosis infection where there is drug re	sistance or in	tolerance	to standar	d pharmaceutical agents:
3 Helicobacter pylori eradication; or				
4 Prophylaxis of infective endocarditis associated with surgica	l or dental pr	ocedures	if amoxicilli	n is contra-indicated.
nitiation – Tab 500 mg	•			
lelicobacter pylori eradication.				
nitiation – Infusion				
ny of the following:				
1 Atypical mycobacterial infection; or				
2 Mycobacterium tuberculosis infection where there is drug re	sistance or in	tolerance	to standar	d pharmaceutical agents;
3 Community-acquired pneumonia.				· · · · ·
ERYTHROMYCIN (AS ETHYLSUCCINATE)				
Tab 400 mg		16 05	100	E-Mycin
Grans for oral lig 200 mg per 5 ml			100 ml	E-Mycin
Grans for oral liq 400 mg per 5 ml			100 ml	E-Mycin
		0.77	100 111	
ERYTHROMYCIN (AS LACTOBIONATE)		10.00		Emathere aim IV
Inj 1 g vial – 1% DV Dec-19 to 2022		.10.00	1	Erythrocin IV
RYTHROMYCIN (AS STEARATE) – Restricted: For continuation	on only			
→ Tab 250 mg				
→ Tab 500 mg				
ROXITHROMYCIN – Some items restricted see terms below				
Tab dispersible 50 mg		8.29	10	Rulide D
Tab 150 mg - 1% DV Sep-19 to 2022		8.28	50	Arrow-Roxithromycin
Tab 300 mg - 1% DV Sep-19 to 2022		.16.33	50	Arrow-Roxithromycin
→ Restricted (RS1569)				
nitiation				

Only for use in patients under 12 years of age.

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
Penicillins			
AMOXICILLIN			
Cap 250 mg - 1% DV Apr-20 to 2022		500	Alphamox
Cap 500 mg - 1% DV Apr-20 to 2022		500	Alphamox
Grans for oral liq 125 mg per 5 ml - 1% DV Nov-20 to 2023		100 ml	Alphamox 125
Grans for oral liq 250 mg per 5 ml - 1% DV Nov-20 to 2023		100 ml	Alphamox 250
Inj 250 mg vial		10	Ibiamox
Inj 500 mg vial		10	lbiamox
Inj 1 g vial	21.64	10	lbiamox
AMOXICILLIN WITH CLAVULANIC ACID			
Tab 500 mg with clavulanic acid 125 mg - 1% DV Jul-21 to 2023.		10	Curam Duo 500/125
Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml		100 ml	Augmentin
Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml		100 ml	Curam
Inj 500 mg with clavulanic acid 100 mg vial – 5% DV Dec-21 to 20		10	Amoxiclav multichem
Inj 1,000 mg with clavulanic acid 200 mg vial - 5% DV Dec-21 to 2	2 024 26.90	10	Amoxiclav multichem
BENZATHINE BENZYLPENICILLIN			
Inj 900 mg (1.2 million units) in 2.3 ml syringe		10	Bicillin LA
BENZYLPENICILLIN SODIUM [PENICILLIN G]			
Inj 600 mg (1 million units) vial – 1% DV Nov-20 to 2023	11.09	10	Sandoz
		10	Cunuc
FLUCLOXACILLIN	15 70	050	Flucloxacillin-AFT
Cap 250 mg - 5% DV May-22 to 2024	15.79	250	
Cap 500 mg – 5% DV May-22 to 2024	50.00	500	Staphlex Flucloxacillin-AFT
Cap 500 mg - 5% DV May-22 to 2024		500	Staphlex
Grans for oral liq 25 mg per ml – 5% DV Jan-22 to 2024	2.00	100 ml	AFT
Grans for oral lig 50 mg per ml – 5% DV Jan-22 to 2024		100 ml	AFT
Inj 250 mg vial		100 11	Flucloxin
Inj 500 mg vial		10	Flucloxin
Inj 300 mg viai		5	Fluci
		5	
(Staphlex Cap 250 mg to be delisted 1 May 2022) (Staphlex Cap 500 mg to be delisted 1 May 2022)			
PHENOXYMETHYLPENICILLIN [PENICILLIN V]			.
Cap 250 mg - 5% DV Jan-22 to 2024		50	Cilicaine VK
Cap 500 mg - 5% DV Jan-22 to 2024		50	Cilicaine VK
Grans for oral liq 125 mg per 5 ml – 1% DV Jan-20 to 2022		100 ml	AFT
Grans for oral liq 250 mg per 5 ml – 1% DV Jan-20 to 2022		100 ml	AFT
PIPERACILLIN WITH TAZOBACTAM – Restricted see terms below			
Inj 4 g with tazobactam 0.5 g vial		10	PipTaz Sandoz
			PiperTaz Sandoz
→ Restricted (RS1053)			
Clinical microbiologist, infectious disease specialist or respiratory special	alist		
PROCAINE PENICILLIN			
Inj 1.5 g in 3.4 ml syringe		5	Cilicaine
TICARCILLIN WITH CLAVULANIC ACID - Restricted see terms below	N		
Inj 3 g with clavulanic acid 0.1 mg vial			
→ Restricted (RS1054)			
Clinical microbiologist, infectious disease specialist or respiratory specia	alist		
3 ,			

e.g. Brand indicates brand example only. It is not a contracted product.

INFECTIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Quinolones			
CIPROFLOXACIN - Restricted see terms below Tab 250 mg - 1% DV Nov-20 to 2023 Tab 500 mg - 1% DV Nov-20 to 2023 Tab 750 mg - 1% DV Nov-20 to 2023 Cral liq 50 mg per ml	3.40	28 28 28	Cipflox Cipflox Cipflox
Inj 2 mg per ml Inj 2 mg per ml, 100 ml bag Restricted (R\$1055)		10	Cipflox
Clinical microbiologist or infectious disease specialist MOXIFLOXACIN – Restricted see terms below Tab 400 mg – 1% DV Dec-20 to 2023 Inj 1.6 mg per ml, 250 ml bottle – 1% DV Apr-20 to 2022 Restricted (RS1644) Initiation – Mycobacterium infection Infectious disease specialist, clinical microbiologist or respiratory spe Any of the following:		5 1	Avelox Moxifloxacin Kabi
 1.1 Active tuberculosis; and 1.2 Any of the following: 1.2.1 Documented resistance to one or more first-line i area with known resistance), as part of regimer 1.2.3 Impaired visual acuity (considered to preclude 1.2.4 Significant pre-existing liver disease or hepatol 1.2.5 Significant documented intolerance and/or side or 2 Mycobacterium avium-intracellulare complex not responding: Patient is under five years of age and has had close contact or Initiation – Pneumonia Infectious disease specialist or clinical microbiologist Either: Immunocompromised patient with pneumonia that is unrespo Pneumococcal pneumonia or other invasive pneumococcal d Initiation – Penetrating eye injury Ophthalmologist Five days treatment for patients requiring prophylaxis following a per Initiation – Mycoplasma genitalium All of the following: Has nucleic acid amplification test (NAAT) confirmed Mycopla Either: Has tried and failed to clear infection using azithromyc Has tried and failed to clear infection using azithromyc Has laboratory confirmed azithromycin resistance; and 	medications (tuberculos n containing other seco ethambutol use); or toxicity from tuberculosi e effects following a rea- to other therapy or whe with a confirmed multi-d insive to first-line treatm isease highly resistant t netrating eye injury. asma genitalium and is cin; or	nd-line a s medica sonable f re such t rug resis ent; or o other a	gents; or titons; or trial of first-line medications; herapy is contraindicated; or tant tuberculosis case.

	Price . excl. GST) \$	Per	Brand or Generic Manufacturer
Tetracyclines			
DEMECLOCYCLINE HYDROCHLORIDE Tab 150 mg Cap 150 mg Cap 300 mg			
DOXYCYCLINE → Tab 50 mg – Restricted: For continuation only Tab 100 mg Inj 5 mg per ml, 20 ml vial	 64.43	500	Doxine
MINOCYCLINE Tab 50 mg → Cap 100 mg – Restricted: For continuation only			
TETRACYCLINE Tab 250 mg Cap 500 mg	 21.42	28	Accord
TIGECYCLINE - Restricted see terms below ↓ Inj 50 mg vial → Restricted (RS1059) Clinical microbiologist or infectious disease specialist			
Other Antibacterials			
AZTREONAM – Restricted see terms below ↓ Inj 1 g vial	 364.92	10	Azactam
CLINDAMYCIN - Restricted see terms below Cap 150 mg - 1% DV Apr-20 to 2022	 4.61	24	Dalacin C
 Oral liq 15 mg per ml Inj 150 mg per ml, 4 ml ampoule - 1% DV Oct-19 to 2022 Restricted (RS1061) Clinical microbiologist or infectious disease specialist 	 39.00	10	Dalacin C
COLISTIN SULPHOMETHATE [COLESTIMETHATE] - Restricted su ↓ Inj 150 mg per ml, 1 ml vial		1	Colistin-Link
DAPTOMYCIN – Restricted see terms below ↓ Inj 500 mg vial	 243.52	1	Cubicin
FOSFOMYCIN – Restricted see terms below ↓ Powder for oral solution, 3 g sachet → Restricted (RS1315) Clinical microbiologist or infectious disease specialist			e.g. UroFos

e.g. Brand indicates brand example only. It is not a contracted product.

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
LINCOMYCIN - Restricted see terms below	•		
Inj 300 mg per ml, 2 ml vial			
→ Restricted (RS1065)			
Clinical microbiologist or infectious disease specialist			
LINEZOLID – Restricted see terms below			
I Tab 600 mg − 5% DV Dec-21 to 2024		10	Zyvox
Oral liq 20 mg per ml		150 ml	Zyvox
↓ Inj 2 mg per ml, 300 ml bottle - 5% DV Dec-21 to 2024		10	Linezolid Kabi
→ Restricted (RS1066)			
Clinical microbiologist or infectious disease specialist			
METHENAMINE (HEXAMINE) HIPPURATE			
Tab 1 g	40.01	100	Hiprex
NITROFURANTOIN			
Tab 50 mg		100	Nifuran
Tab 100 mg		100	Nifuran
Cap modified-release 100 mg - 1% DV Aug-21 to 2023		100	Macrobid
PIVMECILLINAM – Restricted see terms below			
↓ Tab 200 mg			
→ Restricted (RS1322)			
Clinical microbiologist or infectious disease specialist			
SODIUM FUSIDATE [FUSIDIC ACID] – Restricted see terms below			
↓ Tab 250 mg	67.85	36	Fucidin
→ Restricted (RS1064)			
Clinical microbiologist or infectious disease specialist			
SULPHADIAZINE – Restricted see terms below			
Tab 500 mg			
→ Restricted (RS1067)			
Clinical microbiologist, infectious disease specialist or maternal-foetal m	iedicine specialist		
TEICOPLANIN – Restricted see terms below	10.05		_
Inj 400 mg vial – 5% DV Jun-22 to 2024		1	Targocid
(Teicoplanin Mylan Inj 400 mg vial to be delisted 1 June 2022)	56.50		Teicoplanin Mylan
→ Restricted (RS1068)			
Clinical microbiologist or infectious disease specialist			
TRIMETHOPRIM			
Tab 100 mg			
Tab 300 mg – 5% DV Jan-22 to 2024	18.55	50	ТМР
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE			
Tab 80 mg with sulphamethoxazole 400 mg - 5% DV Jan-22 to 20		500	Trisul
Oral lig 8 mg with sulphamethoxazole 40 mg per ml.		100 ml	Deprim
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule	2.07		- op
VANCOMYCIN – Restricted see terms below			
Inj 500 mg vial – 1% DV Oct-20 to 2023	2 35	1	Mylan
→ Restricted (RS1069)		•	,
Clinical microbiologist or infectious disease specialist			
ů i			

INFECTIONS



Antifungals				
Imidazoles				
ETOCONAZOLE Tab 200 mg • Restricted (RS1410) Dincologist				
Polyene Antimycotics				
MPHOTERICIN B Inj (liposomal) 50 mg vial	3,4	50.00	10	AmBisome
★ Restricted (RS1071) httation				
linical microbiologist, haematologist, infectious disease specialist, on ither:	icologist, re	spiratory s	pecialist c	or transplant specialist
 Proven or probable invasive fungal infection, to be prescribed u Both: 	under an es	stablished	protocol; c	pr
2.1 Possible invasive fungal infection; and2.2 A multidisciplinary team (including an infectious disease treatment to be appropriate.	e physician	or a clinica	al microbic	ologist) considers the
 Inj 50 mg vial Restricted (RS1316) Ilinical microbiologist, haematologist, infectious disease specialist, on 	cologist, re	espiratory s	pecialist c	or transplant specialist
IYSTATIN				
Tab 500,000 u Cap 500,000 u			50 50	Nilstat Nilstat
Triazoles				
LUCONAZOLE – Restricted see terms below				
Cap 50 mg – 1% DV Nov-20 to 2023 Cap 150 mg – 1% DV Nov-20 to 2023			28 1	Mylan Mylan
Cap 150 mg – 1% DV Nov-20 to 2023			28	Mylan Mylan
Oral liquid 50 mg per 5 ml			35 ml	Diflucan
Inj 2 mg per ml, 50 ml vial – 1% DV Jul-21 to 2022			1	Fluconazole-Baxter
 Inj 2 mg per ml, 100 ml vial – 1% DV May-21 to 2022 Restricted (RS1072) 		3.45	1	Fluconazole-Baxter
[RACONAZOLE – Restricted see terms below		4.07	15	Itranolo
Cap 100 mg – 1% DV Nov-19 to 2022		4.21	15	Itrazole
 Oral liquid 10 mg per ml Restricted (RS1073) 				
 Restricted (RS1073) linical immunologist, clinical microbiologist, dermatologist or infectiou 	ıs disease	specialist		
→ Restricted (RS1073)			24	Noxafil

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

Price Brand or (ex man. excl. GST) Generic \$ Per Manufacturer
--

⇒ Restricted (RS1074)

Initiation

Haematologist or infectious disease specialist *Re-assessment required after 6 weeks* Both:

Both:

- 1 Either:
 - 1.1 Patient has acute myeloid leukaemia; or
 - 1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
- 2 Patient is to be treated with high dose remission induction therapy or re-induction therapy.

Continuation

Haematologist or infectious disease specialist

Re-assessment required after 6 weeks

Both:

- 1 Patient has previously received posaconazole prophylaxis during remission induction therapy; and
- 2 Any of the following:
 - 2.1 Patient is to be treated with high dose remission re-induction therapy; or
 - 2.2 Patient is to be treated with high dose consolidation therapy; or
 - 2.3 Patient is receiving a high risk stem cell transplant.

VORICONAZOLE - Restricted see terms below

(
lealth

→ Restricted (RS1075)

Initiation – Proven or probable aspergillus infection

Clinical microbiologist, haematologist or infectious disease specialist Both:

- 1 Patient is immunocompromised; and
- 2 Patient has proven or probable invasive aspergillus infection.

Initiation - Possible aspergillus infection

Clinical microbiologist, haematologist or infectious disease specialist All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient has possible invasive aspergillus infection; and
- 3 A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

Initiation - Resistant candidiasis infections and other moulds

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

- 1 Patient is immunocompromised; and
- 2 Either:
 - 2.1 Patient has fluconazole resistant candidiasis; or
 - 2.2 Patient has mould strain such as Fusarium spp. and Scedosporium spp; and
- 3 A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.

Other Antifungals

CA	SPOFUNGIN – Restricted see terms on the next page			
t	Inj 50 mg vial - 1% DV Dec-19 to 2022	0.28	1	Max Health
t	Inj 70 mg vial - 1% DV Dec-19 to 2022	4.63	1	Max Health

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

((ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
→ Restricted (RS1076)					
Initiation Clinical microbiologist, haematologist, infectious disease specialist, oncol Either:	ogist, r	espira	atory sp	ecialist	or transplant specialist
 Proven or probable invasive fungal infection, to be prescribed und Both: 	er an e	stabli	shed p	rotocol;	or
2.1 Possible invasive fungal infection; and2.2 A multidisciplinary team (including an infectious disease ph treatment to be appropriate.	iysiciar	n or a	clinical	microbi	ologist) considers the
FLUCYTOSINE - Restricted see terms below ↓ Tab 500 mg ↓ Cap 500 mg → Restricted (RS1279) Clinical microbiologist or infectious disease specialist					
TERBINAFINE Tab 250 mg – 1% DV Aug-21 to 2023		8.1	5	84	Deolate
Antimycobacterials					
Antileprotics					
CLOFAZIMINE – Restricted see terms below Cap 50 mg Restricted (RS1077) Clinical microbiologist, dermatologist or infectious disease specialist DAPSONE – Restricted see terms below Tab 25 mg Tab 100 mg Restricted (RS1078) Clinical microbiologist, dermatologist or infectious disease specialist				100 100	Dapsone Dapsone
Antituberculotics					
CYCLOSERINE – Restricted see terms below ↓ Cap 250 mg → Restricted (RS1079) Clinical microbiologist, infectious disease specialist or respiratory speciali ETHAMBUTOL HYDROCHLORIDE – Restricted see terms below ↓ Tab 100 mg	st				
↓ Tab 400 mg		.49.3	4	56	Myambutol
SONIAZID – Restricted see terms below ↓ Tab 100 mg – 5% DV Jan-22 to 2024 → Restricted (RS1281)		.23.0	0	100	PSM
Clinical microbiologist, dermatologist, paediatrician, public health physicia SONIAZID WITH RIFAMPICIN - Restricted see terms on the next page		ternal	medic	ine phys	ician
Tab 100 mg with rifampicin 150 mg				100	Rifinah
		179.1	3	100	Rifinah

(ex m	Price an. excl. GST) \$	Per	Brand or Generic Manufacturer
→ Restricted (RS1282)			
Clinical microbiologist, dermatologist, paediatrician, public health physician or	r internal medic	ine physic	cian
PARA-AMINOSALICYLIC ACID – Restricted see terms below			
Grans for oral liq 4 g	280.00	30	Paser
→ Restricted (RS1083)			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
PROTIONAMIDE – Restricted see terms below			
Tab 250 mg	305.00	100	Peteha
→ Restricted (RS1084)			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
PYRAZINAMIDE – Restricted see terms below			
Tab 500 mg			
→ Restricted (RS1085)			
Clinical microbiologist, infectious disease specialist or respiratory specialist			
RIFABUTIN – Restricted see terms below			
Cap 150 mg	299.75	30	Mycobutin
→ Restricted (RS1086)			
Clinical microbiologist, gastroenterologist, infectious disease specialist or resp	piratory special	ist	
RIFAMPICIN – Restricted see terms below			
Cap 150 mg - 1% DV Nov-20 to 2023		100	Rifadin
Cap 300 mg – 1% DV Nov-20 to 2023		100	Rifadin
• Oral liq 100 mg per 5 ml – 1% DV Nov-20 to 2023		60 ml	Rifadin
Inj 600 mg vial – 1% DV Nov-20 to 2023	134.98	1	Rifadin
➡ Restricted (RS1087)			

Clinical microbiologist, dermatologist, internal medicine physician, paediatrician or public health physician

Antiparasitics

Anthelmintics

ALBENDAZOLE - Restricted see terms below ↓ Tab 200 mg ↓ Tab 400 mg → Restricted (RS1088) Clinical microbiologist or infectious disease specialist		
IVERMECTIN - Restricted see terms below ↓ Tab 3 mg → Restricted (RS1283) Clinical microbiologist, dermatologist or infectious disease specialist	4	Stromectol
MEBENDAZOLE Tab 100 mg - 5% DV Jan-22 to 2024	6	Vermox
Tab 600 mg		

Antiprotozoals

ARTEMETHER WITH LUMEFANTRINE - Restricted see terms on the next page

↓ Tab 20 mg with lumefantrine 120 mg

INFECTIONS

		Price excl. GST) \$	Per	Brand or Generic Manufacturer
→ Restricted (RS1090)				
Clinical microbiologist or infectious disease specialist				
ARTESUNATE – Restricted see terms below				
Inj 60 mg vial				
➡ Restricted (RS1091)				
Clinical microbiologist or infectious disease specialist				
ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE - Restric				
Tab 62.5 mg with proguanil hydrochloride 25 mg			12	Malarone Junior
↓ Tab 250 mg with proguanil hydrochloride 100 mg → Restricted (RS1092)		.64.00	12	Malarone
Clinical microbiologist or infectious disease specialist				
CHLOROQUINE PHOSPHATE – Restricted see terms below				
I Tab 250 mg				
→ Restricted (RS1093)				
Clinical microbiologist, dermatologist, infectious disease specialist o	r rheumatolo	ogist		
MEFLOQUINE - Restricted see terms below		-		
Tab 250 mg				
➡ Restricted (RS1094)				
Clinical microbiologist, dermatologist, infectious disease specialist o	r rheumatolo	ogist		
METRONIDAZOLE				
Tab 200 mg - 1% DV Dec-20 to 2023			250	Metrogyl
Tab 400 mg - 1% DV Dec-20 to 2023			21	Metrogyl
Oral liq benzoate 200 mg per 5 ml Inj 5 mg per ml, 100 ml bag – 1% DV Feb-21 to 2023			100 ml 10	Flagyl-S Baxter
Suppos 500 mg			10	Flagyl
NITAZOXANIDE – Restricted see terms below		.24.40	10	riagyi
Tab 500 mg	16	580.00	30	Alinia
 I oral liq 100 mg per 5 ml 			00	/ III IIQ
→ Restricted (RS1095)				
Clinical microbiologist or infectious disease specialist				
ORNIDAZOLE				
Tab 500 mg - 5% DV Dec-21 to 2024		.36.16	10	Arrow-Ornidazole
PENTAMIDINE ISETHIONATE - Restricted see terms below				
Inj 300 mg vial – 1% DV Nov-19 to 2022	2	216.00	5	Pentacarinat
→ Restricted (RS1096)				
Clinical microbiologist or infectious disease specialist				
PRIMAQUINE – Restricted see terms below				
Tab 15 mg				
↓ Tab 7.5 mg → Restricted (RS1097)				
Clinical microbiologist or infectious disease specialist				
PYRIMETHAMINE – Restricted see terms below				
↓ Tab 25 mg				
→ Restricted (RS1098)				
Clinical microbiologist, infectious disease specialist or maternal-foeta	al medicine s	specialist		
QUININE DIHYDROCHLORIDE - Restricted see terms on the new	d page			
	" pugo			
 Inj 60 mg per ml, 10 ml ampoule Inj 300 mg per ml, 2 ml vial 	a pago			

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

➡ Restricted (RS1099)

Clinical microbiologist or infectious disease specialist

SODIUM STIBOGLUCONATE - Restricted see terms below

Inj 100 mg per ml, 1 ml vial

→ Restricted (RS1100)

Clinical microbiologist or infectious disease specialist

SPIRAMYCIN - Restricted see terms below

↓ Tab 500 mg

→ Restricted (RS1101)

Maternal-foetal medicine specialist

Antiretrovirals

Non-Nucleoside Reverse Transcriptase Inhibitors

→ Restricted (RS1571)

Initiation – Confirmed HIV

Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation - Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

EFAVIRENZ – Restricted see terms above		
t Tab 200 mg 190.15	90	Stocrin
t Tab 600 mg63.38	30	Stocrin
t Oral liq 30 mg per ml		
ETRAVIRINE – Restricted see terms above		
t Tab 200 mg770.00	60	Intelence
NEVIRAPINE - Restricted see terms above		
t Tab 200 mg – 5% DV Jan-22 to 2024	60	Nevirapine Alphapharm
t Oral suspension 10 mg per ml203.55	240 ml	Viramune Suspension

Nucleoside Reverse Transcriptase Inhibitors

→ Restricted (RS1572)

Initiation – Confirmed HIV

Patient has confirmed HIV infection.

	(ex man	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
ontinued					
itiation – Prevention of maternal transmission					
ither:					
1 Prevention of maternal foetal transmission; or					
2 Treatment of the newborn for up to eight weeks.					
itiation – Post-exposure prophylaxis following non-occupation of the second state o	onal exposu	re to I	HIV		
oth:					
 Treatment course to be initiated within 72 hours post exposu Any of the following: 	ure; and				
2.1 Patient has had unprotected receptive anal intercours	oo with o kny	own Ll	Vnooi	tivo noro	0.0. Or
 2.1 Patient has hard inprotected receptive and infectors 2.2 Patient has shared intravenous injecting equipment v 2.3 Patient has had non-consensual intercourse and the 	vith a known	HIV p	ositive	person;	or
prophylaxis is required.					
itiation – Percutaneous exposure					
atient has percutaneous exposure to blood known to be HIV positi	ive.				
BACAVIR SULPHATE - Restricted see terms on the previous pa	age				
Tab 300 mg - 1% DV Jul-19 to 2022				60	Ziagen
Oral liq 20 mg per ml		256.3	1	240 ml	Ziagen
BACAVIR SULPHATE WITH LAMIVUDINE – Restricted see terr Tab 600 mg with lamivudine 300 mg – 1% DV Jul-19 to 2022.				30	Kivexa
FAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPRO	XIL – Resti	ricted	see tei	rms <mark>on t</mark> h	e previous page
Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil					
(300 mg as a maleate) - 1% DV Jun-19 to 2022		106.88	3	30	Mylan
MTRICITABINE - Restricted see terms on the previous page					
Cap 200 mg - 1% DV Jul-19 to 2022		307.20)	30	Emtriva
AMIVUDINE - Restricted see terms on the previous page					
Tab 150 mg – 1% DV Nov-20 to 2023		84.50)	60	Lamivudine
, , , , , , , , , , , , , , , , , , ,					Alphapharm
Oral liq 10 mg per ml					
TAVUDINE – Restricted see terms on the previous page					
Cap 30 mg					
Cap 40 mg					
Powder for oral soln 1 mg per ml					
IDOVUDINE [AZT] - Restricted see terms on the previous page		152.25		100	Retrovir
Cap 100 mg				200 ml	Retrovir
Cap 100 mg Oral liq 10 mg per ml					D · · · · ·
Cap 100 mg Oral liq 10 mg per ml Inj 10 mg per ml, 20 ml vial		750.00)	5	Retrovir IV
Cap 100 mg Oral liq 10 mg per ml	on the previo	750.00 us pag) ge		Retrovir IV Alphapharm

Protease Inhibitors

→ Restricted (RS1573)

Initiation – Confirmed HIV Patient has confirmed HIV infection.

INFECTI	ONS
---------	-----

Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer
continued		
Initiation – Prevention of maternal transmission		
Either:		
1 Prevention of maternal foetal transmission; or		
2 Treatment of the newborn for up to eight weeks.		
Initiation - Post-exposure prophylaxis following non-occupational exposure to HIV		
Both:		
1 Treatment course to be initiated within 72 hours post exposure; and		
2 Any of the following:		
2.1 Patient has had unprotected receptive anal intercourse with a known HIV p		
2.2 Patient has shared intravenous injecting equipment with a known HIV position		
2.3 Patient has had non-consensual intercourse and the clinician considers the	at the risk as	sessment indicates
prophylaxis is required.		
Initiation – Percutaneous exposure		
Patient has percutaneous exposure to blood known to be HIV positive.		
ATAZANAVIR SULPHATE – Restricted see terms on the previous page		_
Cap 150 mg - 1% DV Jun-19 to 2022	60	Teva
t Cap 200 mg – 1% DV Jun-19 to 2022	60	Teva
DARUNAVIR – Restricted see terms on the previous page		
Tab 400 mg - 1% DV Apr-21 to 2023	60	Darunavir Mylan
t Tab 600 mg - 1% DV Apr-21 to 2023	60	Darunavir Mylan
INDINAVIR – Restricted see terms on the previous page		
Cap 200 mg		
t Cap 400 mg		
LOPINAVIR WITH RITONAVIR – Restricted see terms on the previous page		
Tab 100 mg with ritonavir 25 mg – 5% DV Feb-22 to 2024	60	Lopinavir/Ritonavir
		Mylan
Tab 200 mg with ritonavir 50 mg – 5% DV Feb-22 to 2024	120	Lopinavir/Ritonavir
• • • • • • • • • • • • • • • • • • •		Mylan
t Oral liq 80 mg with ritonavir 20 mg per ml	300 ml	Kaletra
RITONAVIR – Restricted see terms on the previous page		
t Tab 100 mg - 1% DV Jul-19 to 2022	30	Norvir

Strand Transfer Inhibitors

➡ Restricted (RS1574)

Initiation – Confirmed HIV Patient has confirmed HIV infection. Initiation – Prevention of maternal transmission Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:

	Price (ex man. excl. \$	GST)	Per	Brand or Generic Manufacturer
 continued 2.1 Patient has had unprotected receptive anal intercour 2.2 Patient has shared intravenous injecting equipment 2.3 Patient has had non-consensual intercourse and the prophylaxis is required. 	with a known HIV p	ositive	person; o	r
nitiation – Percutaneous exposure Patient has percutaneous exposure to blood known to be HIV posi	tive			
DOLUTEGRAVIR – Restricted see terms on the previous page Tab 50 mg)	30	Tivicay
BALTEGRAVIR POTASSIUM Restricted see terms on the prev Tab 400 mg Tab 600 mg			60 60	lsentress Isentress HD
Antivirals				
Hepatitis B				
NTECAVIR Tab 0.5 mg)	30	Entecavir Sandoz
AMIVUDINE Tab 100 mg – 1% DV Nov-20 to 2023 Oral liq 5 mg per ml			28 240 ml	Zetlam Zeffix
ENOFOVIR DISOPROXIL Tab 245 mg (300.6 mg as a succinate))	30	Tenofovir Disoproxil Teva
Hepatitis C				
GLECAPREVIR WITH PIBRENTASVIR Note: the supply of treatment is via Pharmac's approved direc Pharmac's website https://www.pharmac.govt.nz/maviret.	,			
Tab 100 mg with pibrentasvir 40 mg EDIPASVIR WITH SOFOSBUVIR – Restricted see terms below)	84	Maviret
↓ Tab 90 mg with sofosbuvir 400 mg	atment Panel (Hep0	CTP). A		
Herpesviridae				
CICLOVIR	1.60		25	Lovir
1 an algorithm 200 ma = 1% 100 (1ct-10 to 2022)	1 6/	1		

Tab dispersible 200 mg - 1% DV Oct-19 to 2022	25	Lovir
Tab dispersible 400 mg - 1% DV Oct-19 to 2022	56	Lovir
Tab dispersible 800 mg - 1% DV Oct-19 to 2022	35	Lovir
Inj 250 mg vial – 5% DV Jan-22 to 202410.00	5	Aciclovir-Baxter

CIDOFOVIR - Restricted see terms below

Inj 75 mg per ml, 5 ml vial

→ Restricted (RS1108)

Clinical microbiologist, infectious disease specialist, otolaryngologist or oral surgeon

INFECTIONS

FOSCARNET SODIUM - Restricted see terms below In j24 mg per ml, 250 ml bottle - Restricted (RS1109) Clinical microbiologist or infectious disease specialist GANCICLOVIR - Restricted see terms below In j500 mg vial - Restricted (RS1110) Clinical microbiologist or infectious disease specialist VALACICLOVIR Tab 100 mg - 5% DV Jan-22 to 2024		Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Pestricted (RS1109) Clinical microbiologist or infectious disease specialist GANCICLOVIR - Restricted see terms below Ini 500 mg vial	FOSCARNET SODIUM – Restricted see terms below			
Clinical microbiologist of infectious disease specialist GANCICLOVIR - Restricted see terms below Inition microbiologist or infectious disease specialist VALACICLOVIR Tab 500 mg - 5% DV Jan-22 to 2024	Inj 24 mg per ml, 250 ml bottle			
GANCICLOVIR - Restricted see terms below I ni 300 mg vial Restricted (RS1110) Clinical microbiologist or infectious disease specialist VALACICLOVIR Tab 500 mg - 5% DV Jan-22 to 2024 ACCICLOVIR Tab 500 mg - 5% DV Jan-22 to 2024 Tab 500 mg - 5% DV Jan-22 to 2010 mg Jan 500 mg - 5% DV Jan-22 to 2010 mg Jan 500 mg - 5% DV Jan-22 to 2010 mg Jan 500 mg - 5% DV Jan-22 to 2010 mg Jan 500 mg - 5% DV Jan-22 to 2010 mg Jan 500 mg - 5% DV Jan-22 to 2010 mg Jan 500 mg - 5% DV Jan-22 to 2010 mg Jan 500 mg - 5% DV Jan-22 to 2010 mg Jan 500 mg - 5% DV Jan-22 mg - 5% DV Jan 22 mg - 5% DV Jan 28 mg - 5% DV Jan 28 mg - 5%				
 Inj 500 mg vial	Clinical microbiologist or infectious disease specialist			
 → Restricted (RS110) Clinical microbiologist or infectious disease specialist VALACICLOVIR Tab 500 mg - 5% DV Jan-22 to 2024	GANCICLOVIR – Restricted see terms below			
Clinical microbiologist or infectious disease specialist VALACICLOVIR Tab 50.00 g - 5% DV Jan-22 to 2024			5	Cymevene
 VALACICLOVIR Tab 500 mg - 5% DV Jan-22 to 2024				
Tab 500 mg - 5% DV Jan-22 to 2024 6.50 30 Vaclovir Tab 1,000 mg - 5% DV Jan-22 to 2024 13.76 30 Vaclovir VALGANCICLOVIR - Restricted see terms below 132.00 60 Valganciclovir My + Tab 450 mg - 5% DV Dec21 to 2024 132.00 60 Valganciclovir My + Restricted (RS1799) Initiation - Transplant cytomegalovirus prophylaxis Re-assessment required after 3 months Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis. Continuation - Transplant cytomegalovirus prophylaxis Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valgancicl therapy for CMV prophylaxis; and 1.2 1.1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclo therapy for CMV prophylaxis; and 2.2 1.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or 2.2 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir threapy CMV prophylaxis; and 2.2 2.2 Patient has received a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation – Lung transplant cytomegalovirus prophylaxis Foreciviti antreapilati cytomegalovirus prophylaxis	-			
Tab 1,000 mg - 5% DV Jan-22 to 2024 13.76 30 Vaclovir VALCANCICLOVIR - Restricted see terms below Image: Control of the set of t				
 VALGANCICLOVIR - Restricted see terms below I Tab 450 mg - 5% DV Dec-21 to 2024	•			
Tab 450 mg – 5% DV Dec-21 to 2024		13.76	30	vaciovir
 → Restricted (RS1799) Initiation - Transplant cytomegalovirus prophylaxis <i>Re-assessment required after 3 months</i> Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis. Continuation - Transplant cytomegalovirus prophylaxis <i>Re-assessment required after 3 months</i> Either: Both: 				
Initiation – Transplant cytomegalovirus prophylaxis Re-assessment required after 3 months Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis. Continuation – Transplant cytomegalovirus prophylaxis Re-assessment required after 3 months Either: 1 Both: 1.1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valgancicl therapy for CMV prophylaxis; and 1.2 Patient has received a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or 2 Both: 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and 2.2 Patient has received a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation – Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: 1 Patient has undergone a lung transplant; and 2 Either: 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or 2.2 The recipient is cytomegalovirus positive and the patient is cytomegalovirus negative; or 2.1 Patient has a high risk of CMV disease. Initiation – Cytomegalovirus in immunocompromised patients Both: 1 Patient is immunocompromised; and 2 Any of the following: 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or 2.2 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page 4 Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)		132.00	60	Valganciclovir Mylan
 Re-assessment required after 3 months Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis. Continuation – Transplant cytomegalovirus prophylaxis Re-assessment required after 3 months Either: Both: Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valgancicl therapy for CMV prophylaxis; and Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; oi Both: Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; oi Both: Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy for CMV prophylaxis; and Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation – Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: Patient has a undergone a lung transplant; and Either: The donor was cytomegalovirus positive; and Patient has a high risk of CMV disease. Initiation – Cytomegalovirus in immunocompromised patients Both: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has cytomegalovirus reinitits. HV Prophylaxis and Treatment EMU Prophylaxis				
 Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis. Continuation - Transplant cytomegalovirus prophylaxis Re-assessment required after 3 months Either: Both: Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valgancicl therapy for CMV prophylaxis; and Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or Both: Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy for CMV prophylaxis; and Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and Patient has received maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation - Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: Patient has undergone a lung transplant, and Either: The donor was cytomegalovirus positive; and Patient has a high risk of CMV disease. Initiation - Cytomegalovirus in immunocompromised patients Both: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has cytomegalovirus reninitis. HV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)				
 Continuation – Transplant cytomegalovirus prophylaxis Re-assessment required after 3 months Either: Both: Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valgancicl therapy for CMV prophylaxis; and Patient has receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or Both: Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and Patient has receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation – Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: Patient has undergone a lung transplant; and Either: The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or The donor was cytomegalovirus positive; and Patient has a high risk of CMV disease. Initiation – Cytomegalovirus in immunocompromised patients Both: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has cytomegalovirus retinitis. HV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 		clovir for CMV prophyla	axis.	
 Re-assessment required after 3 months Either: Both: Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valgancicl therapy for CMV prophylaxis; and Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or Both: Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and Patient has to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation - Lung transplant cytomegalovirus prophylaxis Relevant specialist Imited to 12 months treatment All of the following: Patient has undergone a lung transplant; and Either: The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or The donor was cytomegalovirus positive; and Patient has a high risk of CMV disease. Initiation - Cytomegalovirus in immunocompromised patients Both: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL - Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)				
 1 Both: Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valgancicl therapy for CMV prophylaxis; and Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or 2 Both: Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation - Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: Patient has undergone a lung transplant; and Either: The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or The recipient is cytomegalovirus positive; and Patient has a high risk of CMV disease. Initiation - Cytomegalovirus in immunocompromised patients Both: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has cytomegalovirus retinitis. HV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL - Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)				
 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valgancicl therapy for CMV prophylaxis; and Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; of Both: Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation - Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: Patient has undergone a lung transplant; and Either: The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or The recipient is cytomegalovirus positive; and Patient has a high risk of CMV disease. Initiation - Cytomegalovirus in immunocompromised patients Both: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has cytomegalovirus reinitits. HV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)	Either:			
 therapy for CMV prophylaxis; and 1.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or 2 Both: 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. nitiation - Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: 1 Patient has undergone a lung transplant; and 2 Either: 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or 2.2 The recipient is cytomegalovirus positive; and 3 Patient has a high risk of CMV disease. nitiation - Cytomegalovirus in immunocompromised patients 3oth: 1 Patient has cytomegalovirus syndrome or tissue invasive disease; or 2.2 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMU DVDNA in absence of disease; or 2.3 Patient has cytomegalovirus retinitis. 	1 Both:			
 1.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or 2 Both: 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. nitiation - Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: 1 Patient has undergone a lung transplant; and 2 Either: 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or 2.2 The recipient is cytomegalovirus positive; and 3 Patient has a high risk of CMV disease. nitiation - Cytomegalovirus in immunocompromised patients Both: 1 Patient has cytomegalovirus syndrome or tissue invasive disease; or 2.2 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMITRICITABINE WITH TENOFOVIR DISOPROXIL - Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)		ceived anti-thymocyte g	lobulin a	nd requires valganciclovir
 2 Both: 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation - Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: 1 Patient has undergone a lung transplant; and 2 Either: 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or 2.2 The recipient is cytomegalovirus positive; and 3 Patient has a high risk of CMV disease. Initiation - Cytomegalovirus in immunocompromised patients Both: 1 Patient is immunocompromised; and 2 Any of the following: 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or 2.2 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL - Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)				
 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy CMV prophylaxis; and 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation - Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: Patient has undergone a lung transplant; and Either: The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or The donor was cytomegalovirus positive; and Patient has a high risk of CMV disease. Initiation - Cytomegalovirus in immunocompromised patients Both: Patient is immunocompromised; and Any of the following: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has rapidly rising plasma CMV DNA in absence of disease; or Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 	, , ,	clovir prophylaxis follow	ving anti-	thymocyte globulin; or
CMV prophylaxis; and 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation – Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: 1 Patient has undergone a lung transplant; and 2 Either: 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or 2.2 The recipient is cytomegalovirus positive; and 3 Patient has a high risk of CMV disease. Initiation – Cytomegalovirus in immunocompromised patients Both: 1 Patient is immunocompromised; and 2 Any of the following: 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or 3.3 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page 4 Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)				
 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone. Initiation - Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: Patient has undergone a lung transplant; and Either: The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or The recipient is cytomegalovirus positive; and Patient has a high risk of CMV disease. Initiation - Cytomegalovirus in immunocompromised patients Both: Patient is immunocompromised; and Any of the following: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL - Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)		te rejection and require	s further	valganciclovir therapy for
Initiation – Lung transplant cytomegalovirus prophylaxis Relevant specialist Limited to 12 months treatment All of the following: 1 Patient has undergone a lung transplant; and 2 Either: 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or 2.2 The recipient is cytomegalovirus positive; and 3 Patient has a high risk of CMV disease. Initiation – Cytomegalovirus in immunocompromised patients Both: 1 Patient is immunocompromised; and 2 Any of the following: 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or 2.3 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)		de la completa de la Collec		e an ether de me de la element
 Relevant specialist Limited to 12 months treatment All of the following: Patient has undergone a lung transplant; and Either: The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or The recipient is cytomegalovirus positive; and Patient has a high risk of CMV disease. Initiation – Cytomegalovirus in immunocompromised patients Both: Patient is immunocompromised; and Any of the following: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has rapidly rising plasma CMV DNA in absence of disease; or Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 		ciovir prophylaxis follow	ving puis	e metnyipreanisoione.
Limited to 12 months treatment All of the following:				
All of the following:	1			
 Patient has undergone a lung transplant; and Either: 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or 2.2 The recipient is cytomegalovirus positive; and Patient has a high risk of CMV disease. Initiation - Cytomegalovirus in immunocompromised patients Both: Patient is immunocompromised; and Any of the following: 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or 2.3 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 				
 2 Either: The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or 2. The recipient is cytomegalovirus positive; and 3 Patient has a high risk of CMV disease. Initiation – Cytomegalovirus in immunocompromised patients Both: Patient is immunocompromised; and Any of the following: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has rapidly rising plasma CMV DNA in absence of disease; or Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)	-			
 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or 2.2 The recipient is cytomegalovirus positive; and 3 Patient has a high risk of CMV disease. nitiation - Cytomegalovirus in immunocompromised patients Both: Patient is immunocompromised; and Any of the following: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has rapidly rising plasma CMV DNA in absence of disease; or Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL - Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 	• • •			
 2.2 The recipient is cytomegalovirus positive; and 3 Patient has a high risk of CMV disease. Initiation - Cytomegalovirus in immunocompromised patients Both: Patient is immunocompromised; and Any of the following: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has rapidly rising plasma CMV DNA in absence of disease; or Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL - Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 	2.1 The donor was cytomegalovirus positive and the patier	nt is cvtomegalovirus ne	egative: c	or
 3 Patient has a high risk of CMV disease. nitiation - Cytomegalovirus in immunocompromised patients Both: Patient is immunocompromised; and Any of the following: Patient has cytomegalovirus syndrome or tissue invasive disease; or Patient has rapidly rising plasma CMV DNA in absence of disease; or Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL - Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 			J	
Both:				
 Patient is immunocompromised; and Any of the following: 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or 2.3 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 	nitiation – Cytomegalovirus in immunocompromised patients			
 2 Any of the following: 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or 2.3 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 	Both:			
 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or 2.3 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)	1 Patient is immunocompromised; and			
 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or 2.3 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 	2 Any of the following:			
 2.3 Patient has cytomegalovirus retinitis. HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 				
HIV Prophylaxis and Treatment EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)		e of disease; or		
EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms on the next page Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)	2.3 Patient has cytomegalovirus retinitis.			
Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)	HIV Prophylaxis and Treatment			
Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)	EMTRICITABINE WITH TENOFOVIR DISOPROXIL - Restricted se	e terms on the next pa	ge	
– 1% DV Jun-19 to 202261.15 30 Teva	Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succession)	cinate)		
	– 1% DV Jun-19 to 2022	61.15	30	Teva

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.



Price Brand or (ex man. excl. GST) Generic \$ Per Manufacturer
--

→ Restricted (RS1800)

Initiation – Confirmed HIV

Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

Initiation – Pre-exposure prophylaxis

Re-assessment required after 3 months

All of the following:

- 1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
- 2 Patient has undergone testing for HIV, syphilis and Hep B if not immune and a full STI screen in the previous two weeks; and
- 3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 3 months and is not contraindicated for treatment; and
- 4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
- 5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
- 6 Either:

6.1 All of the following:

- 6.1.1 Patient is male or transgender; and
- 6.1.2 Patient has sex with men; and
- 6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
- 6.1.4 Any of the following:
 - 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
 - 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
 - 6.1.4.3 Patient has used methamphetamine in the last three months; or
- 6.2 All of the following:
 - 6.2.1 Patient has a regular partner who has HIV infection; and
 - 6.2.2 Partner is either not on treatment or has a detectable viral load; and
 - $6.2.3 \ \ \mbox{Condoms have not been consistently used}.$

Continuation – Pre-exposure prophylaxis

Re-assessment required after 3 months

All of the following:

1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and

INFECTIONS

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2 Patient has undergone testing for HIV, syphilis and Hep B if not immune and a full STI screen in the previous two weeks; and
- 3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months and is not contraindicated for treatment; and
- 4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
- 5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
- 6 Either:
 - 6.1 All of the following:
 - 6.1.1 Patient is male or transgender; and
 - 6.1.2 Patient has sex with men; and
 - 6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
 - 6.1.4 Any of the following:
 - 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
 - 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
 - 6.1.4.3 Patient has used methamphetamine in the last three months; or
 - 6.2 All of the following:
 - 6.2.1 Patient has a regular partner who has HIV infection; and
 - 6.2.2 Partner is either not on treatment or has a detectable viral load; and
 - 6.2.3 Condoms have not been consistently used.

Influenza

OSELTAMIVIR - Restricted see terms below

Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- Powder for oral suspension 6 mg per ml

→ Restricted (RS1307)

Initiation

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

ZANAMIVIR

Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

Powder for inhalation 5 mg....... 37.38 20 dose Relenza Rotadisk

→ Restricted (RS1369)

Initiation

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

COVID-19 Treatments

МС	DLNUPIRAVIR – Restricted see terms on the next page		
t	Cap 200 mg0.00	40	Lagevrio

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	l (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
→ Restricted (RS1893) Initiation					
Only if patient meets access criteria (as per https://pharmac.govt.nz/cov Pharmac's approved distribution process. Refer to the Pharmac websit					
NIRMATRELVIR WITH RITONAVIR – Restricted see terms below ↓ Tab 150 mg with ritonavir 100 mg		0.0	0	30	Paxlovid
Only if patient meets access criteria (as per https://pharmac.govt.nz/cov Pharmac's approved distribution process. Refer to the Pharmac websi					
Immune Modulators					
INTERFERON ALFA-2B Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen					
INTERFERON GAMMA – Restricted see terms below ↓ Inj 100 mcg in 0.5 ml vial → Restricted (RS1113)					
Initiation Patient has chronic granulomatous disease and requires interferon gam	nma				
PEGYLATED INTERFERON ALFA-2A – Restricted see terms below	inna.				
Inj 180 mcg prefilled syringe	!	500.0	0	4	Pegasys
➡ Restricted (RS1827) Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or c	o-infecti	ion w	ith HIV	or aen	otype 2 or 3 post liver
transplant				J	-,,,
Limited to 48 weeks treatment Any of the following:					
 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; c Patient has chronic hepatitis C and is co-infected with HIV; or Patient has chronic hepatitis C genotype 2 or 3 and has received 		ransp	lant.		
Notes: Consider stopping treatment if there is absence of a virological load) following 12 weeks of treatment since this is predictive of treatment Consider reducing treatment to 24 weeks if serum HCV RNA level at W 50IU/mI) AND Baseline serum HCV RNA is less than 400,000IU/mI. Continuation – Chronic hepatitis C - genotype 1 infection Gastroenterologist, infectious disease specialist or general physician <i>Re-assessment required after 48 weeks</i> All of the following:	nt failure.				Ū
1 Patient has chronic hepatitis C, genotype 1; and					

- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; and
- $\label{eq:particular} 4 \ \ \mbox{Patient is to be treated in combination with boceprevir.}$

	Р	rice			Brand or	
(ex m	an.	excl.	GST)		Generic	
		\$		Per	Manufacturer	

Initiation - Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior

Gastroenterologist, infectious disease specialist or general physician Limited to 48 weeks treatment

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir.

Initiation - Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV

Limited to 6 months treatment

Patient has chronic hepatitis C, genotype 2 or 3 infection.

Initiation – Hepatitis B

Gastroenterologist, infectious disease specialist or general physician

Limited to 48 weeks treatment

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 Serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (greater than or equal to Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon.

Notes: Approved dose is 180 mcg once weekly.

The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.

In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.

In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines. Pegylated Interferon alfa-2a is not approved for use in children.

Initiation - myeloproliferative disorder or cutaneous T cell lymphoma

Re-assessment required after 12 months

Any of the following:

- 1 Patient has a cutaneous T cell lymphoma*; or
- 2 All of the following:
 - 2.1 Patient has a myeloproliferative disorder*; and
 - 2.2 Patient is intolerant of hydroxyurea; and
 - 2.3 Treatment with anagrelide and busulfan is not clinically appropriate; or

3 Both:

3.1 Patient has a myeloproliferative disorder; and

continued...

INFECTIONS

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

3.2 Patient is pregnant, planning pregnancy or lactating.

Continuation - myeloproliferative disorder or cutaneous T cell lymphoma

Re-assessment required after 12 months

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment; and

3 Either:

- 3.1 Patient has a cutaneous T cell lymphoma*; or
- 3.2 Both:
 - 3.2.1 Patient has a myeloproliferative disorder*; and
 - 3.2.2 Either:
 - 3.2.2.1 Remains intolerant of hydroxyurea and treatment with anagrelide and busulfan remains clinically inappropriate; or
 - 3.2.2.2 Patient is pregnant, planning pregnancy or lactating.

Note: Indications marked with * are unapproved indications

Initiation - ocular surface squamous neoplasia

Ophthalmologist

Re-assessment required after 12 months

Patient has ocular surface squamous neoplasia*.

Continuation - ocular surface squamous neoplasia

Ophthalmologist

Re-assessment required after 12 months

The treatment remains appropriate and patient is benefitting from treatment.

Note: Indications marked with * are unapproved indications

Initiation – post-allogenic bone marrow transplant

Re-assessment required after 3 months

Patient has received an allogeneic bone marrow transplant* and has evidence of disease relapse.

Continuation - post-allogenic bone marrow transplant

Re-assessment required after 3 months

Patient is responding and ongoing treatment remains appropriate.

Note: Indications marked with * are unapproved indications

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer
Anticholinesterases			
EDROPHONIUM CHLORIDE – Restricted see terms below Inj 10 mg per ml, 15 ml vial Inj 10 mg per ml, 1 ml ampoule Restricted (RS1015) Initiation			
For the diagnosis of myasthenia gravis.			
NEOSTIGMINE METILSULFATE Inj 2.5 mg per ml, 1 ml ampoule – 5% DV Mar-22 to 2024		10	Max Health
NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BRON Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml amp	oule -	40	Marcella alle
5% DV Dec-21 to 2024 PYRIDOSTIGMINE BROMIDE		10	Max Health
Tab 60 mg - 1% DV Nov-19 to 2022		100	Mestinon
Antirheumatoid Agents			
HYDROXYCHLOROQUINE - Restricted see terms below Tab 200 mg	8.78	100	Plaquenil
→ Restricted (RS1776) Initiation			
 Any of the following: 1 Rheumatoid arthritis; or 2 Systemic or discoid lupus erythematosus; or 3 Malaria treatment or suppression; or 4 Relevant dermatological conditions (cutaneous forms of lupus ulceration); or 5 Sarcoidosis (pulmonary and non-pulmonary). 	and lichen planus, cu	taneous v	vasculitides and mucosal
LEFLUNOMIDE Tab 10 mg - 1% DV Dec-20 to 2023	6.00	30	Arava
Tab 20 mg - 1% DV Dec-20 to 2023		30	Arava
PENICILLAMINE Tab 125 mg	67.23	100	D-Penamine
Tab 250 mg SODIUM AUROTHIOMALATE Inj 10 mg in 0.5 ml ampoule Inj 20 mg in 0.5 ml ampoule Inj 50 mg in 0.5 ml ampoule	110.12	100	D-Penamine
Drugs Affecting Bone Metabolism			
Bisphosphonates			
ALENDRONATE SODIUM Tab 70 mg – 1% DV Apr-19 to 2022	2.44	4	Fosamax
ALENDRONATE SODIUM WITH COLECALCIFEROL Tab 70 mg with colecalciferol 5,600 iu - 1% DV Apr-19 to 2022	1.51	4	Fosamax Plus

	Price (ex man. excl. GS	τ\	Brand or Generic
	(ex man. excl. GS \$	Per	Manufacturer
PAMIDRONATE DISODIUM			
Inj 3 mg per ml, 10 ml vial		1	Pamisol
Inj 6 mg per ml, 10 ml vial		1	Pamisol
Inj 9 mg per ml, 10 ml vial		1	Pamisol
RISEDRONATE SODIUM			
Tab 35 mg – 1% DV Oct-19 to 2022		4	Risedronate Sandoz
ZOLEDRONIC ACID			
Inj 5 mg per 100 ml, vial – 1% DV Oct-19 to 2022		100 ml	Aclasta
→ Restricted (RS1884)			
Initiation – Inherited bone fragility disorders			
Any specialist			
Patient has been diagnosed with an inherited bone fragility disord	der (e.g. osteogenesis in	nperfecta).	
Initiation – Osteoporosis		, ,	
Any specialist			
Therapy limited to 3 doses			
Both:			
1 Any of the following:			
1 1 History of one significant estepheratic fracture den	constrated radiologically	and doour	nted hone mineral dans

- 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
- 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 1.4 Documented T-Score greater than or equal to -3.0 (see Note); or
- 1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initiation - glucocorticosteroid therapy

Any specialist

Re-assessment required after 12 months

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation – glucocorticosteroid therapy

Any specialist

Re-assessment required after 12 months Both:

1 The patient is continuing systemic glucocorticosteriod therapy (greater than or equal to 5 mg per day prednisone

102

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

continued...

equivalents); and

2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initiation - Paget's disease

Any specialist

Re-assessment required after 12 months All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation - Paget's disease

Any specialist

Re-assessment required after 12 months Both:

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initiation – spinal cord injury*

Re-assessment required after 12 months

All of the following:

- 1 Patient has experienced an acute traumatic spinal cord injury in the last six months; and
- 2 Patient is being managed by a specialist spinal acute care and rehabilitation unit; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Note: Indications marked with * are unapproved indications.

Continuation – spinal cord injury*

Re-assessment required after 6 months

Both:

- 1 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period; and
- 2 The patient has not received more than two doses of zoledronic acid for this indication.

Note: The patient must not have had more than 1 prior approval. No further renewals will be subsidised. A maximum of 2 vials of zoledronic acid treatment for spinal cord injury will be subsidised. Indications marked with * are unapproved indications. Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a

Price		Brand or
(ex man. excl. GS		Generic
 \$	Per	Manufacturer

continued...

fall from a standing height or less.

d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

DENOSUMAB - Restricted see terms below

➡ Restricted (RS1665)

Initiation

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 Either:
 - 2.1 The patient is female and postmenopausal; or
 - 2.2 The patient is male or non-binary; and
- 3 Any of the following:
 - 3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or

Prolia

- 3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
- 3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 3.4 Documented T-Score less than or equal to -3.0 (see Note); or
- 3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 3.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 4 Zoledronic acid is contraindicated because the patient's creatinine clearance is less than 35 mL/min; and
- 5 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes); and
- 6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

28

Evista

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- continued...
 - e) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

⇒ Restricted (RS1666)

Initiation

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score greater than or equal to -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

TERIPARATIDE - Restricted see terms below

1	Inj 250 mcg per ml, 2.4 ml cartridge	 1	Forteo
-	Restricted (RS1143)		

Initiation

Limited to 18 months treatment

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

	Price			Brand or
(ex ma	in. excl	GST)	-	Generic
	\$		Per	Manufacturer

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Enzymes

HYALURONIDASE

Inj 1,500 iu ampoule

Hyperuricaemia and Antigout

ALLOPURINO

ALLOPURINOL			
Tab 100 mg - 1% DV Nov-20 to 2023	11.47	500	DP-Allopurinol
Tab 300 mg - 1% DV Nov-20 to 2023		500	DP-Allopurinol
BENZBROMARONE - Restricted: For continuation only			
➡ Tab 50 mg			
➡ Tab 100 mg		100	Benzbromaron AL 100
COLCHICINE			
Tab 500 mcg - 5% DV Sep-22 to 2025	6.00	100	Colgout
FEBUXOSTAT – Restricted see terms below			
		28	Febuxostat multichem
Tab 120 mg – 1% DV Jan-22 to 2023		28	Febuxostat multichem
→ Restricted (RS1844)			

Initiation – Gout

Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); or
 - 2.4 The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout..

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

Initiation - Tumour lysis syndrome

Haematologist or oncologist

Re-assessment required after 6 weeks Both:

1 Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome; and

2 Patient has a documented history of allopurinol intolerance.

Continuation – Tumour lysis syndrome

Haematologist or oncologist

Re-assessment required after 6 weeks

The treatment remains appropriate and patient is benefitting from treatment.

PROBENECID

Tab 500 mg

RASBURICASE - Restricted see terms below

Inj 1.5 mg vial

→ Restricted (RS1016)

Haematologist

Muscle Relaxants and Related Agents

ATRACURIUM BESYLATE

ATRACURIUM BE					
, ,,	nl, 2.5 ml ampoule		5	Tracrium	
, ,,	nl, 5 ml ampoule		5	Tracrium	
BACLOFEN					
•		4.20	100	Pacifen	
Oral liq 1 mg p					
lnj 0.05 mg per	ml, 1 ml ampoule	11.55	1	Lioresal Intrathecal	
Inj 2 mg per m	I, 5 ml ampoule - 5% DV Dec-21 to 2024		5	Medsurge	
CLOSTRIDIUM BC	TULINUM TYPE A TOXIN				
Inj 100 u vial			1	Botox	
Inj 300 u vial			1	Dysport	
Inj 500 u vial		1,295.00	2	Dysport	
DANTROLENE					
Cap 25 mg		97.50	100	Dantrium	
Cap 50 mg		77.00	100	Dantrium	
Inj 20 mg vial .			6	Dantrium IV	
MIVACURIUM CHI	ORIDE				
Inj 2 mg per m	, 5 ml ampoule		5	Mivacron	
Inj 2 mg per m	, 10 ml ampoule				
(Mivacron Inj 2 mg	per ml, 5 ml ampoule to be delisted 1 August 2022	<u>?)</u>			
ORPHENADRINE	CITRATE				
Tab 100 mg -	5% DV Jan-22 to 2024	20.76	100	Norflex	
PANCURONIUM B					
	, 2 ml ampoule				
ROCURONIUM BE					
	nl, 5 ml ampoule – 1% DV Aug-20 to 2022	31 1/	10	HameIn	
			10		
SUXAMETHONIUN		00.40	10	Montindala	
inj 50 mg per n	nl, 2 ml ampoule - 1% DV Feb-21 to 2023	23.40	10	Martindale	
					_

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. \$	GST) Per	Brand or Generic Manufacturer
ECURONIUM BROMIDE Inj 10 mg vial			
Reversers of Neuromuscular Blockade			
UGAMMADEX – Restricted see terms below			
Inj 100 mg per ml, 2 ml vial - 5% DV Aug-22 to 2024	1,200.0 384.0		Bridion Sugammadex BNM
Inj 100 mg per ml, 5 ml vial - 5% DV Aug-22 to 2024			Bridion Sugammadex BNM
Bridion Inj 100 mg per ml, 2 ml vial to be delisted 1 August 2022) Bridion Inj 100 mg per ml, 5 ml vial to be delisted 1 August 2022) Restricted (R\$1370) Itiation			
ny of the following:			
 Patient has an unexpectedly difficult airway that cannot be int neuromuscular blockade; or The duration of the patient's surgery is unexpectedly short; or Neostigmine or a neostigmine/anticholinergic combination is of disease, morbid obesity or COPD); or Patient has a partial residual block after conventional reversal 	contraindicated (f		
New Charaidal Anti Inflommatory Druga			
Non-Steroidal Anti-Inflammatory Drugs			
ELECOXIB			
		0 60	Celecoxib Pfizer
ELECOXIB			Celecoxib Pfizer Celecoxib Pfizer
ELECOXIB Cap 100 mg			•••••
ELECOXIB Cap 100 mg Cap 200 mg	3.3) 30	•••••
ELECOXIB Cap 100 mg Cap 200 mg ICLOFENAC SODIUM	3.3) 30 9 50	Celecoxib Pfizer Diclofenac Sandoz Voltaren D
ELECOXIB Cap 100 mg Cap 200 mg ICLOFENAC SODIUM Tab EC 25 mg – 5% DV Jan-22 to 2024 Tab 50 mg dispersible Tab EC 50 mg – 5% DV Jan-22 to 2024		30 30 30 50 20 30	Celecoxib Pfizer Diclofenac Sandoz
ELECOXIB Cap 100 mg Cap 200 mg ICLOFENAC SODIUM Tab EC 25 mg – 5% DV Jan-22 to 2024 Tab 50 mg dispersible		30 30 50 20 50 50 50 50 50 50	Celecoxib Pfizer Diclofenac Sandoz Voltaren D Diclofenac Sandoz Apo-Diclo SR
ELECOXIB Cap 100 mg Cap 200 mg ICLOFENAC SODIUM Tab EC 25 mg – 5% DV Jan-22 to 2024 Tab 50 mg dispersible Tab EC 50 mg – 5% DV Jan-22 to 2024 Tab long-acting 75 mg		30 30 <td>Celecoxib Pfizer Diclofenac Sandoz Voltaren D Diclofenac Sandoz Apo-Diclo SR Voltaren SR</td>	Celecoxib Pfizer Diclofenac Sandoz Voltaren D Diclofenac Sandoz Apo-Diclo SR Voltaren SR
ELECOXIB Cap 100 mg Cap 200 mg ICLOFENAC SODIUM Tab EC 25 mg – 5% DV Jan-22 to 2024 Tab 50 mg dispersible Tab EC 50 mg – 5% DV Jan-22 to 2024 Tab long-acting 75 mg Tab long-acting 100 mg		30 30 <td>Celecoxib Pfizer Diclofenac Sandoz Voltaren D Diclofenac Sandoz Apo-Diclo SR Voltaren SR Apo-Diclo SR</td>	Celecoxib Pfizer Diclofenac Sandoz Voltaren D Diclofenac Sandoz Apo-Diclo SR Voltaren SR Apo-Diclo SR
ELECOXIB Cap 100 mg Cap 200 mg ICLOFENAC SODIUM Tab EC 25 mg - 5% DV Jan-22 to 2024 Tab 50 mg dispersible Tab EC 50 mg - 5% DV Jan-22 to 2024 Tab Iong-acting 75 mg Tab Iong-acting 100 mg Inj 25 mg per ml, 3 ml ampoule		30 30 50 20 50 <td>Celecoxib Pfizer Diclofenac Sandoz Voltaren D Diclofenac Sandoz Apo-Diclo SR Voltaren SR Apo-Diclo SR Voltaren</td>	Celecoxib Pfizer Diclofenac Sandoz Voltaren D Diclofenac Sandoz Apo-Diclo SR Voltaren SR Apo-Diclo SR Voltaren
ELECOXIB Cap 100 mg Cap 200 mg ICLOFENAC SODIUM Tab EC 25 mg – 5% DV Jan-22 to 2024 Tab 50 mg dispersible Tab EC 50 mg – 5% DV Jan-22 to 2024 Tab Iong-acting 75 mg Tab Iong-acting 100 mg Inj 25 mg per ml, 3 ml ampoule Suppos 12.5 mg		30 30 9 50 0 20 9 50 0 500 0 100 5 500 0 5 4 10	Celecoxib Pfizer Diclofenac Sandoz Voltaren D Diclofenac Sandoz Apo-Diclo SR Voltaren SR Apo-Diclo SR Voltaren Voltaren Voltaren
ELECOXIB Cap 100 mg Cap 200 mg ICLOFENAC SODIUM Tab EC 25 mg - 5% DV Jan-22 to 2024 Tab 50 mg dispersible Tab EC 50 mg - 5% DV Jan-22 to 2024 Tab Iong-acting 75 mg Tab Iong-acting 100 mg Inj 25 mg per ml, 3 ml ampoule		30 30 9 50 0 20 9 50 0 500 0 100 5 500 0 5 4 10	Celecoxib Pfizer Diclofenac Sandoz Voltaren D Diclofenac Sandoz Apo-Diclo SR Voltaren SR Apo-Diclo SR Voltaren

(Apo-Diclo SR Tab long-acting 75 mg to be delisted 1 May 2022) (Apo-Diclo SR Tab long-acting 100 mg to be delisted 1 May 2022)

ETORICOXIB - Restricted see terms below

- Tab 60 mg
- ↓ Tab 90 mg
- ↓ Tab 120 mg

→ Restricted (RS1592)

Initiation

For in-vivo investigation of allergy only.

t Item restricted (see → above); t Item restricted (see → below) e.g. Brand indicates brand example only. It is not a contracted product.

MUSCULOSKELETAL SYSTEM

	Price excl. GST) \$	Per	Brand or Generic Manufacturer
IBUPROFEN			
Tab 200 mg - 1,000 tablet pack – 1% DV Feb-21 to 2024 Tab 200 mg - 12 tablet pack Tab 200 mg - 20 tablet pack	 .21.40	1,000	Relieve
Tab 200 mg - 24 tablet pack Tab 200 mg - 48 tablet pack → Tab 400 mg - Restricted: For continuation only → Tab 600 mg - Restricted: For continuation only Tab long-acting 800 mg - 5% DV Jan-22 to 2024 Oral liq 20 mg per ml - 5% DV Apr-22 to 2024 Inj 5 mg per ml, 2 ml ampoule Inj 10 mg per ml, 2 ml vial		30 200 ml	Brufen SR Ethics
INDOMETHACIN Cap 25 mg Cap 50 mg Cap long-acting 75 mg Inj 1 mg vial Suppos 100 mg			
KETOPROFEN Cap long-acting 200 mg	.12.07	28	Oruvail SR
MEFENAMIC ACID – Restricted: For continuation only Cap 250 mg			
NAPROXEN			
Tab 250 mg - 5% DV Jan-22 to 2024		500	Noflam 250
Tab 500 mg - 5% DV Jan-22 to 2024		250	Noflam 500
Tab long-acting 750 mg – 5% DV Jan-22 to 2024		28	Naprosyn SR 750
Tab long-acting 1 g – 5% DV Jan-22 to 2024	 8.02	28	Naprosyn SR 1000
PARECOXIB Inj 40 mg vial SULINDAC	 100.00	10	Dynastat
Tab 100 mg Tab 200 mg			
TENOXICAM			
Tab 20 mg - 1% DV Oct-19 to 2022	 9.15	100	Tilcotil
Inj 20 mg vial		1	AFT
Topical Products for Joint and Muscular Pain			
CAPSAICIN - Restricted see terms below ↓ Crm 0.025% - 1% DV Apr-21 to 2023 → Restricted (RS1309) Initiation	 9.75	45 g	Zostrix

Initiation

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Agents for Parkinsonism and Related Disorders			
Agents for Essential Tremor, Chorea and Related	Disorders		
RILUZOLE - Restricted see terms below ↓ Tab 50 mg - 5% DV Dec-21 to 2024 → Restricted (RS1351) Initiation Neurologist or respiratory specialist <i>Re-assessment required after 6 months</i> All of the following:	130.00	56	Rilutek
 1 The patient has amyotrophic lateral sclerosis with disease du 2 The patient has at least 60 percent of predicted forced vital ci 3 The patient has not undergone a tracheostomy; and 4 The patient has not experienced respiratory failure; and 5 Any of the following: 5.1 The patient is ambulatory; or 5.2 The patient is able to use upper limbs; or 5.3 The patient is able to swallow. 			e initial application; and
Continuation Re-assessment required after 18 months All of the following: 1 The patient has not undergone a tracheostomy; and 2 The patient has not experienced respiratory failure; and 3 Any of the following: 3.1 The patient is ambulatory; or 3.2 The patient is able to use upper limbs; or 3.3 The patient is able to swallow.			
TETRABENAZINE Tab 25 mg – 1% DV Oct-19 to 2022	91.10	112	Motetis
Anticholinergics			
BENZATROPINE MESYLATE Tab 2 mg Inj 1 mg per ml, 2 ml ampoule – 1% DV Dec-20 to 2023 PROCYCLIDINE HYDROCHLORIDE Tab 5 mg		60 5	Benztrop Phebra
Dopamine Agonists and Related Agents			
AMANTADINE HYDROCHLORIDE Cap 100 mg APOMORPHINE HYDROCHLORIDE		60	Symmetrel
 Inj 10 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2023 Inj 10 mg per ml, 5 ml ampoule – 1% DV Feb-20 to 2023 BROMOCRIPTINE → Tab 2.5 mg – Restricted: For continuation only Cap 5 mg (Any Tab 2.5 mg to be delisted 1 September 2022) 		5 5	Movapo Movapo

110

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST)	Brand or Generic
	(ex man. excl. GST \$	Per	Manufacturer
ENTACAPONE			
Tab 200 mg - 5% DV Apr-22 to 2024		100	Comtan
LEVODOPA WITH BENSERAZIDE			
Tab dispersible 50 mg with benserazide 12.5 mg		100	Madopar Rapid
Cap 50 mg with benserazide 12.5 mg		100	Madopar 62.5
Cap 100 mg with benserazide 25 mg		100	Madopar 125
Cap long-acting 100 mg with benserazide 25 mg		100	Madopar HBS
Cap 200 mg with benserazide 50 mg		100	Madopar 250
EVODOPA WITH CARBIDOPA			
Tab 100 mg with carbidopa 25 mg - 1% DV Dec-20 to 2023		100	Sinemet
Tab long-acting 100 mg with carbipoda 25 mg			
Tab long-acting 200 mg with carbidopa 50 mg - 1% DV Feb-2	1 to 2023 43.65	100	Sinemet CR
Tab 250 mg with carbidopa 25 mg - 1% DV Dec-20 to 2023		100	Sinemet
PRAMIPEXOLE HYDROCHLORIDE			
Tab 0.25 mg - 1% DV Oct-19 to 2022		100	Ramipex
Tab 1 mg - 1% DV Oct-19 to 2022		100	Ramipex
RASAGILINE			
Tab 1mg - 1% DV Jan-22 to 2024		30	Azilect
ROPINIROLE HYDROCHLORIDE			
Tab 0.25 mg - 1% DV Mar-20 to 2022		84	Ropin
Tab 1 mg - 1% DV Mar-20 to 2022		84	Ropin
Tab 2 mg - 1% DV Mar-20 to 2022		84	Ropin
Tab 5 mg - 1% DV Mar-20 to 2022		84	Ropin
SELEGILINE HYDROCHLORIDE – Restricted: For continuation	only		
→ Tab 5 mg			
TOLCAPONE			
Tab 100 mg	152.38	100	Tasmar
· 22 · 00 ·	102100		laonai
Anaesthetics			
Or word America that's a			
General Anaesthetics			
DESFLURANE			_
Soln for inhalation 100%, 240 ml bottle	1,350.00	6	Suprane
DEXMEDETOMIDINE			
Inj 100 mcg per ml, 2 ml vial - 1% DV Mar-21 to 2023		5	Dexmedetomidine-Tev
ETOMIDATE			
Inj 2 mg per ml, 10 ml ampoule			
SOFLURANE			
Soln for inhalation 100%, 250 ml bottle		6	Aerrane
KETAMINE	,	-	
Inj 1 mg per ml, 100 ml bag - 1% DV Feb-20 to 2022	135.00	5	Biomed
Inj 10 mg per ml, 10 ml syringe – 1% DV Feb-20 to 2022		5	Biomed
Inj 100 mg per ml, 2 ml ampoule		5	Ketamine-Baxter
Inj 100 mg per ml, 2 ml vial		5	Ketalar
Ketamine-Baxter Inj 100 mg per ml, 2 ml ampoule to be delisted 1		-	
METHOHEXITAL SODIUM			
Ini 10 ma por ml. 50 ml viol			

Inj 10 mg per ml, 50 ml vial

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
PROPOFOL			
Inj 10 mg per ml, 20 ml ampoule – 10% DV Dec-19 to 2022	4.35	5	Fresofol 1% MCT/LCT
Inj 10 mg per ml, 50 ml vial - 10% DV Oct-19 to 2022	19.50	10	Fresofol 1% MCT/LCT
Inj 10 mg per ml, 100 ml vial – 10% DV Oct-19 to 2022		10	Fresofol 1% MCT/LCT
SEVOFLURANE			
Soln for inhalation 100%, 250 ml bottle	930.00	6	Baxter
THIOPENTAL [THIOPENTONE] SODIUM			
Inj 500 mg ampoule			
Local Anaesthetics			
ARTICAINE HYDROCHLORIDE			
Inj 1%			
ARTICAINE HYDROCHLORIDE WITH ADRENALINE			
Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge			
Inj 4% with adrenaline 1:100,000, 1.8 ml dental cartridge			
Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge			
Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge			
Inj 4% with adrenaline 1:200,000 1.8 ml dental cartridge Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge			
,			
BENZOCAINE Gel 20%			
BENZOCAINE WITH TETRACAINE HYDROCHLORIDE Gel 18% with tetracaine hydrochloride 2%			e.g. ZAP Topical
Ger To % with tetracame hydrochlonde 2 %			Anaesthetic Gel
BUPIVACAINE HYDROCHLORIDE			
Inj 5 mg per ml, 4 ml ampoule – 1% DV Oct-20 to 2023		5	Marcain Isobaric
Inj 2.5 mg per ml, 20 ml ampoule			
Inj 2.5 mg per ml, 20 ml ampoule sterile pack - 1% DV Aug-20 to		5	Marcain
Inj 5 mg per ml, 10 ml ampoule sterile pack – 1% DV Aug-20 to 20)23 16.20	5	Marcain
Inj 5 mg per ml, 20 ml ampoule Inj 5 mg per ml, 20 ml ampoule sterile pack – 1% DV Aug-20 to 20	123 16 56	5	Marcain
Inj 1.25 mg per ml, 100 ml bag	20 10.00	5	Marcall
Inj 1.25 mg per ml, 200 ml bag			
Inj 2.5 mg per ml, 100 ml bag - 1% DV Oct-20 to 2023	150.00	5	Marcain
Inj 2.5 mg per ml, 200 ml bag			
Inj 1.25 mg per ml, 500 ml bag			
BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE			
Inj 2.5 mg per ml with adrenaline 1:200,000, 10 ml ampoule			
Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial - 1% DV Au		_	
to 2022		5	Marcain with
Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – 1% DV Aug	ı-19		Adrenaline
to 2022	•	5	Marcain with
			Adrenaline

112

	Price		Brand or
	(ex man. excl. GS		Generic
	\$	Per	Manufacturer
BUPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag	00		
Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag – 1% DV Apr- to 2022		5	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe		0	Diomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag - 1% DV Nov-1	9		
to 2022		5	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag - 1% DV Nov-1		_	_ <i>i</i>
to 2022	117.50	5	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe	36.00	5	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe		5	Biomed
BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE		Ū	Biomod
Inj 0.5% with glucose 8%, 4 ml ampoule – 5% DV Sep-22 to 2025.	26.67	5	Marcain Heavy
COCAINE HYDROCHLORIDE		0	maroann neavy
Paste 5%			
Soln 15%, 2 ml syringe			
Soln 4%, 2 ml syringe		1	Biomed
COCAINE HYDROCHLORIDE WITH ADRENALINE			
Paste 15% with adrenaline 0.06%			
Paste 25% with adrenaline 0.06%			
ETHYL CHLORIDE			
Spray 100%			
LIDOCAINE [LIGNOCAINE]			
Crm 4%		5 g	LMX4
	27.00	30 g	LMX4
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE		-	
Gel 2%	4.87	20 g	Orion
Soln 4%			
Spray 10% - 1% DV Jul-19 to 2022		50 ml	Xylocaine
Oral (gel) soln 2%		200 ml	Mucosoothe
Inj 1%, 20 ml ampoule, sterile pack Inj 2%, 20 ml ampoule, sterile pack			
Inj 2%, 20 ml ampoule, sterile pack	8 75	25	Lidocaine-Baxter
Inj 1%, 20 ml vial – 1% DV Jul-19 to 2022		5	Lidocaine-Claris
Inj 2%, 5 ml ampoule – 1% DV Jul-21 to 2022		25	Lidocaine-Baxter
Inj 2%, 20 ml vial – 1% DV Jul-21 to 2022		5	Lidocaine-Baxter
			Lidocaine-Claris
Gel 2%, 11 ml urethral syringe - 1% DV Apr-20 to 2022		10	Instillagel Lido
(Lidocaine-Claris Inj 2%, 20 ml vial to be delisted 1 June 2022)			
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE			
Inj 1% with adreanline 1:100,000, 20 ml vial			
Inj 1% with adrenaline 1:100,000, 5 ml ampoule - 1% DV Nov-19	~~~~	40	Vulassina
to 2022 Inj 1% with adrenaline 1:200,000, 20 ml vial		10 5	Xylocaine Xylocaine
Inj 2% with adrenaline 1:200,000, 20 mi viar Inj 2% with adrenaline 1:100,000, 1.7 ml dental cartridge		5	Aylocallie
Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge			
Inj 2% with adrenaline 1:200,000, 20 ml vial	60.00	5	Xylocaine

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

(Price ex man. excl. GST \$) Per	Brand or Generic Manufacturer
IDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AN Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 r		HYDROC	HLORIDE
syringe	18.75	1	Topicaine
DOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINI			
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe		10	Pfizer
DOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRIN Nasal spray 5% with phenylephrine hydrochloride 0.5%	E HYDROCHLO	RIDE	
DOCAINE [LIGNOCAINE] WITH PRILOCAINE			
Crm 2.5% with prilocaine 2.5%	45.00	30 g	EMLA
Patch 25 mcg with prilocaine 25 mcg		20	EMLA
Crm 2.5% with prilocaine 2.5%, 5 g	45.00	5	EMLA
EPIVACAINE HYDROCHLORIDE			
Inj 3%, 1.8 ml dental cartridge	43.60	50	Scandonest 3%
Inj 3%, 2.2 ml dental cartridge	43.60	50	Scandonest 3%
IEPIVACAINE HYDROCHLORIDE WITH ADRENALINE Inj 2% with adrenaline 1:100,000, 1.8 ml dental cartridge Inj 2% with adrenaline 1:100,000, 2.2 ml dental cartridge			
RILOCAINE HYDROCHLORIDE			
Inj 0.5%, 50 ml vial		5	Citanest
lnj 2%, 5 ml ampoule			
RILOCAINE HYDROCHLORIDE WITH FELYPRESSIN			
Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge			
Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge			
OPIVACAINE HYDROCHLORIDE			
Inj 2 mg per ml, 10 ml ampoule - 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
Inj 2 mg per ml, 20 ml ampoule – 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
Inj 2 mg per ml, 100 ml bag – 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
Inj 2 mg per ml, 200 ml bag – 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
Inj 7.5 mg per ml, 10 ml ampoule – 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
Inj 7.5 mg per ml, 20 ml ampoule – 1% DV Nov-20 to 2023 Inj 10 mg per ml, 10 ml ampoule – 1% DV Nov-20 to 2023		5 5	Ropivacaine Kabi Ropivacaine Kabi
Inj 10 mg per ml, 20 ml ampoule – 1% DV Nov-20 to 2023		5	Ropivacaine Kabi
		5	
OPIVACAINE HYDROCHLORIDE WITH FENTANYL	109 50	Б	Naronin
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag		5 5	Naropin Naropin
		5	Haropin
ETRACAINE [AMETHOCAINE] HYDROCHLORIDE			

Gel 4%

Analgesics

Non-Opioid Analgesics

ASPIRIN		
Tab dispersible 300 mg - 1% DV Oct-19 to 2022	100	Ethics Aspirin
CAPSAICIN – Restricted see terms below		
Crm 0.075% – 1% DV Apr-21 to 2023	45 g	Zostrix HP
→ Restricted (RS1145)	•	
Initiation		

For post-herpetic neuralgia or diabetic peripheral neuropathy.

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price))	Brand or
(6	ex man. excl. GS \$	ST) Per	Generic Manufacturer
METHOXYFLUBANE - Restricted see terms below	Ŷ		manatation
Soln for inhalation 99.9%, 3 ml bottle			
→ Restricted (RS1292)			
Initiation			
Both:			
1 Patient is undergoing a painful procedure with an expected duratio	n of less than c	ne hour and	1
2 Only to be used under supervision by a medical practitioner or nurs			
NEFOPAM HYDROCHLORIDE			
Tab 30 mg			
PARACETAMOL – Some items restricted see terms below			
Tab soluble 500 mg			
Tab 500 mg - blister pack - 1,000 tablet pack – 1% DV Feb-22 to 202	24 1975	1,000	Pacimol
Tab 500 mg - blister pack - 1,000 tablet pack - 1,000 tablet pack		1,000	
Tab 500 mg - blister pack - 20 tablet pack			
Tab 500 mg - bottle pack – 1% DV Feb-22 to 2024	17 92	1,000	Noumed Paracetamol
Oral lig 120 mg per 5 ml - 20% DV Nov-20 to 2023		1,000 ml	Paracare
Oral lig 250 mg per 5 ml – 20% DV Nov-20 to 2023		1,000 ml	Paracare Double
		1,000 111	Strength
Inj 10 mg per ml, 100 ml vial − 1% DV Nov-20 to 2023	8 90	10	Paracetamol Kabi
Suppos 25 mg – 1% DV Nov-19 to 2022.		20	Biomed
Suppos 50 mg – 1% DV Nov-19 to 2022		20	Biomed
Suppos 125 mg		10	Gacet
Suppos 250 mg		10	Gacet
Suppos 500 mg		50	Gacet
→ Restricted (RS1146)			
Initiation			
Intravenous paracetamol is only to be used where other routes are unavail	ilable or imprac	tical. or wher	e there is reduced
absorption. The need for IV paracetamol must be re-assessed every 24 h			
SUCROSE			
Oral liq 25% – 1% DV Feb-20 to 2022	13.00	25 ml	Biomed
 Oral lig 66.7% (preservative free) 		20111	Diomea
→ Restricted (RS1763)			
Initiation			
For use in neonatal patients only.			
Opioid Analgesics			
ALFENTANIL			
Inj 0.5 mg per ml, 2 ml ampoule - 1% DV Nov-20 to 2023	24.75	10	Hameln
CODEINE PHOSPHATE			
Tab 15 mg – 1% DV Nov-20 to 2023	6 25	100	PSM
Tab 30 mg - 1% DV Nov-20 to 2023		100	PSM
Tab 60 mg - 1% DV Nov-20 to 2023		100	PSM
		100	
	0.00	<u></u>	DUO Cantinua

DHC Continus

60

	Price	Brand or	
	(ex man. excl. GST) \$	Per	Generic Manufacturer
ENTANYL	¥		manarataron
Inj 10 mcg per ml, 10 ml syringe			
Inj 50 mcg per ml, 2 ml ampoule – 5% DV Apr-22 to 2024	2 75	10	Boucher and Muir
Inj 10 mcg per ml, 50 ml bag		10	Biomed
Inj 10 mcg per ml, 50 ml syringe		10	Biomed
Inj 50 mcg per ml, 10 ml ampoule - 5% DV Apr-22 to 2024		10	Boucher and Muir
Inj 10 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022		5	Biomed
Inj 20 mcg per ml, 50 ml syringe		5 1	Biomed
, , , , ,	10.74	I	Diomeu
Inj 20 mcg per ml, 100 ml bag	C 00	F	Fontonul Condor
Patch 12.5 mcg per hour – 5% DV Jan-22 to 2024		5	Fentanyl Sandoz
Patch 25 mcg per hour - 5% DV Jan-22 to 2024		5	Fentanyl Sandoz
Patch 50 mcg per hour - 5% DV Jan-22 to 2024		5	Fentanyl Sandoz
Patch 75 mcg per hour - 5% DV Jan-22 to 2024		5	Fentanyl Sandoz
Patch 100 mcg per hour - 5% DV Jan-22 to 2024		5	Fentanyl Sandoz
IETHADONE HYDROCHLORIDE			
Tab 5 mg - 1% DV Sep-19 to 2022	1.40	10	Methatabs
Oral liq 2 mg per ml - 5% DV Jan-22 to 2024	6.40	200 ml	Biodone
Oral liq 5 mg per ml - 5% DV Jan-22 to 2024	6.40	200 ml	Biodone Forte
Oral liq 10 mg per ml - 5% DV Jan-22 to 2024	7.50	200 ml	Biodone Extra Forte
Inj 10 mg per ml, 1 ml vial	61.00	10	AFT
IORPHINE HYDROCHLORIDE			
Oral lig 1 mg per ml	9.28	200 ml	RA-Morph
Oral lig 2 mg per ml		200 ml	RA-Morph
Oral lig 5 mg per ml		200 ml	RA-Morph
Oral liq 10 mg per ml		200 ml	RA-Morph
		200 11	
NORPHINE SULPHATE	0.00	40	0
Tab immediate-release 10 mg – 1% DV Nov-20 to 2023		10	Sevredol
Tab immediate-release 20 mg - 1% DV Nov-20 to 2023		10	Sevredol
Cap long-acting 10 mg – 1% DV Jan-20 to 2022		10	m-Eslon
Cap long-acting 30 mg - 1% DV Jan-20 to 2022		10	m-Eslon
Cap long-acting 60 mg – 1% DV Jan-20 to 2022		10	m-Eslon
Cap long-acting 100 mg – 1% DV Jan-20 to 2022		10	m-Eslon
Inj 1 mg per ml, 100 ml bag - 1% DV Nov-20 to 2023		5	Biomed
Inj 1 mg per ml, 10 ml syringe – 1% DV Nov-20 to 2023		5	Biomed
Inj 1 mg per ml, 50 ml syringe – 1% DV Nov-20 to 2023	52.00	5	Biomed
Inj 1 mg per ml, 2 ml syringe			
Inj 2 mg per ml, 30 ml syringe		10	Biomed
Inj 5 mg per ml, 1 ml ampoule		5	DBL Morphine Sulphat
Inj 10 mg per ml, 1 ml ampoule	5.61	5	DBL Morphine Sulphat
Inj 10 mg per ml, 100 mg cassette			
Inj 10 mg per ml, 100 ml bag			
Inj 15 mg per ml, 1 ml ampoule	7.08	5	DBL Morphine Sulphat
Inj 30 mg per ml, 1 ml ampoule	7.28	5	DBL Morphine Sulphat
Inj 200 mcg in 0.4 ml syringe			
Inj 300 mcg in 0.3 ml syringe			

MORPHINE TARTRATE

116

Inj 80 mg per ml, 1.5 ml ampoule

	Price			
	(ex man. excl. GS		Generic	
	\$	Per	Manufacturer	
OXYCODONE HYDROCHLORIDE				
Tab controlled-release 5 mg - 5% DV Jun-22 to 2024	2.69	20	Oxycodone Sandoz	
Tab controlled-release 10 mg - 5% DV Jun-22 to 2024	2.69	20	Oxycodone Sandoz	
Tab controlled-release 20 mg - 5% DV Jun-22 to 2024		20	Oxycodone Sandoz	
Tab controlled-release 40 mg - 5% DV Jun-22 to 2024	5.49	20	Oxycodone Sandoz	
Tab controlled-release 80 mg - 5% DV Jun-22 to 2024		20	Oxycodone Sandoz	
Cap immediate-release 5 mg - 5% DV Dec-21 to 2024		20	OxyNorm	
Cap immediate-release 10 mg - 5% DV Dec-21 to 2024		20	OxyNorm	
Cap immediate-release 20 mg - 5% DV Dec-21 to 2024		20	OxyNorm	
Oral lig 5 mg per 5 ml – 5% DV Sep-21 to 2024		250 ml	OxyNorm	
Inj 1 mg per ml, 100 ml bag		200	•Ajiieiiii	
Inj 10 mg per ml, 1 ml ampoule – 5% DV Jul-22 to 2024	5.82	5	Hameln	
	7.28	U U	OxyNorm	
Inj 10 mg per ml, 2 ml ampoule - 5% DV Jul-22 to 2024		5	Hameln	
	14.36	Ū	OxyNorm	
Inj 50 mg per ml, 1 ml ampoule – 5% DV Jul-22 to 2024		5	Hameln	
	30.60	0	OxyNorm	
(OxyNorm Inj 10 mg per ml, 1 ml ampoule to be delisted 1 July 2022)	00.00		Олунопп	
(OxyNorm Inj 10 mg per ml, 2 ml ampoule to be delisted 1 July 2022)				
(OxyNorm Inj 50 mg per ml, 1 ml ampoule to be delisted 1 July 2022)				
PARACETAMOL WITH CODEINE				
Tab paracetamol 500 mg with codeine phosphate 8 mg	26.51	1,000	Paracetamol + Codeine (Relieve)	
PETHIDINE HYDROCHLORIDE				
Tab 50 mg – 5% DV Jan-22 to 2024	4.70	10	PSM	
Inj 5 mg per ml, 10 ml syringe				
Inj 5 mg per ml, 100 ml bag				
Inj 10 mg per ml, 100 ml bag				
Inj 10 mg per ml, 50 ml syringe				
Inj 50 mg per ml, 1 ml ampoule		5	DBL Pethidine	
			Hydrochloride	
Inj 50 mg per ml, 2 ml ampoule		5	DBL Pethidine	
			Hydrochloride	
REMIFENTANIL			•	
Inj 1 mg vial – 1% DV Oct-20 to 2023		5	Remifentanil-AFT	
Inj 2 mg vial – 1% DV Oct-20 to 2023		5	Remifentanil-AFT	
TRAMADOL HYDROCHLORIDE		v		
	1 50	20	Tramal SR 100	
Tab sustained-release 100 mg - 1% DV Nov-20 to 2023		20 20		
Tab sustained-release 150 mg – 1% DV Nov-20 to 2023			Tramal SR 150	
Tab sustained-release 200 mg – 1% DV Nov-20 to 2023		20	Tramal SR 200	
Cap 50 mg - 1% DV Dec-20 to 2023	2.80	100	Arrow-Tramadol	
Oral soln 10 mg per ml				
Inj 10 mg per ml, 100 ml bag		_		
Inj 50 mg per ml, 1 ml ampoule - 1% DV Oct-20 to 2023	4.50	5	Tramal 50	
Inj 50 mg per ml, 2 ml ampoule - 1% DV Oct-20 to 2023	3.83	5	Tramal 100	

		rice		Brand or
	(ex man.	excl. GST) \$	Per	Generic Manufacturer
Antidepressants				
Cyclic and Related Agents				
MITRIPTYLINE				
Tab 10 mg – 1% DV Dec-20 to 2023 Tab 25 mg – 1% DV Dec-20 to 2023			100 100	Arrow-Amitriptyline Arrow-Amitriptyline
Tab 50 mg – 1% DV Dec-20 to 2023			100	Arrow-Amitriptyline
Tab 10 mg - 1% DV Feb-22 to 2024			30	Clomipramine Teva
Tab 25 mg – 1% DV Feb-22 to 2024			30	Clomipramine Teva
DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE - Restricted: For			50	Decularia Mulan
 Cap 25 mg OXEPIN HYDROCHLORIDE – Restricted: For continuation only 		7.03	50	Dosulepin Mylan
 Cap 10 mg 				
→ Cap 25 mg				
→ Cap 50 mg				
		- 10		- / "
Tab 10 mg		5.48 6.58	50 60	Tofranil Tofranil
Tab 25 mg			50	Tofranil
APROTILINE HYDROCHLORIDE - Restricted: For continuation	n only			
→ Tab 25 mg	,			
→ Tab 75 mg				
/IANSERIN HYDROCHLORIDE – Restricted: For continuation or → Tab 30 mg	nly			
IORTRIPTYLINE HYDROCHLORIDE				
Tab 10 mg – 1% DV Oct-19 to 2022 Tab 25 mg – 1% DV Oct-19 to 2022			100 180	Norpress Norpress
•			100	Norpress
Monoamine-Oxidase Inhibitors - Non-Selective				
PHENELZINE SULPHATE Tab 15 mg				
RANYLCYPROMINE SULPHATE				
Tab 10 mg				
Monoamine-Oxidase Type A Inhibitors				
/OCLOBEMIDE				
Tab 150 mg – 5% DV Jan-22 to 2024			60 60	Aurorix Aurorix
Tab 300 mg - 5% DV Jan-22 to 2024		19.20	60	Aurorix
Other Antidepressants				
/IRTAZAPINE				
Tab 30 mg – 1% DV Jan-22 to 2024		2 60	28	Noumed
Tab 45 mg – 1% DV Jan-22 to 2024			28	Noumed

118

	Price		Brand or
	(ex man. excl. GST)		Generic
	(ex man. exci. dor) \$	Per	Manufacturer
	ð	rei	Manufacturer
VENLAFAXINE			
Cap 37.5 mg	6.29	84	Enlafax XR
Cap 75 mg		84	Enlafax XR
Cap 150 mg		84	Enlafax XR
Selective Serotonin Reuptake Inhibitors			
CITALOPRAM HYDROBROMIDE			
Tab 20 mg - 5% DV Feb-22 to 2024	1 01	84	DSM Citalonrom
Tab 20 mg - 5% DV Feb-22 to 2024	1.91	04	PSM Citalopram
ESCITALOPRAM			
Tab 10 mg - 1% DV Oct-21 to 2023	1 07	28	Escitalopram (Ethics)
			• • • •
Tab 20 mg - 1% DV Oct-21 to 2023	1.92	28	Escitalopram (Ethics)
FLUOXETINE HYDROCHLORIDE			
	1.00	20	Fluox
Tab dispersible 20 mg, scored - 1% DV Feb-21 to 2022		30	
Cap 20 mg - 1% DV Feb-21 to 2022	2.91	84	Fluox
PAROXETINE			
	0.01	~~	
Tab 20 mg - 1% DV Mar-20 to 2022		90	Loxamine
SERTRALINE			
	0.00	00	Caturana
Tab 50 mg - 1% DV Mar-20 to 2022		30	Setrona
Tab 100 mg - 1% DV Mar-20 to 2022	1.61	30	Setrona
Antiepilepsy Drugs			
ennehnehe) = måe			
Agents for the Control of Status Epilepticus			
CLONAZEPAM			
Inj 1 mg per ml, 1 ml ampoule			
DIAZEPAM			
Inj 5 mg per ml, 2 ml ampoule	23.66	5	Hospira
Rectal tubes 5 mg		5	Stesolid
Rectal tubes 10 mg			
LORAZEPAM			
Inj 2 mg vial			
Inj 4 mg per ml, 1 ml vial			
PARALDEHYDE			
Soln 97%			
Inj 5 ml ampoule			
PHENYTOIN SODIUM			
Inj 50 mg per ml, 2 ml ampoule		5	Hospira
Inj 50 mg per ml, 5 ml ampoule		5	Hospira
,		-	
Control of Epilepsy			
CARBAMAZEPINE			
Tab 200 mg	14.53	100	Tegretol
Tab long-acting 200 mg		100	Tegretol CR
		100	Tegretol
Tab 400 mg			0
Tab long-acting 400 mg		100	Tegretol CR
Oral liq 20 mg per ml		250 ml	Tegretol
			-
CLOBAZAM			
Tab 10 mg			

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
CLONAZEPAM			
Oral drops 2.5 mg per ml			
ETHOSUXIMIDE			
Cap 250 mg	140.88	100	Zarontin
Oral liq 50 mg per ml		200 ml	Zarontin
GABAPENTIN			
Note: Gabapentin not to be given in combination with pregabalin			
Cap 100 mg - 1% DV Feb-22 to 2024	6.45	100	Nupentin
Cap 300 mg - 1% DV Feb-22 to 2024	8.45	100	Nupentin
Cap 400 mg - 1% DV Feb-22 to 2024	10.26	100	Nupentin
LACOSAMIDE – Restricted see terms below			
Tab 50 mg		14	Vimpat
Tab 100 mg		14	Vimpat
	200.24	56	Vimpat
Tab 150 mg	75.10	14	Vimpat
_	300.40	56	Vimpat
 Tab 200 mg Inj 10 mg per ml, 20 ml vial 	400.55	56	Vimpat

➡ Restricted (RS1151)

Initiation

Re-assessment required after 15 months Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Continuation

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective

LAMOTRIGINE

Tab dispersible 2 mg		30	Lamictal
Tab dispersible 5 mg		30	Lamictal
Tab dispersible 25 mg - 5% DV Oct-19 to 2022	2.76	56	Logem
Tab dispersible 50 mg - 5% DV Oct-19 to 2022	3.31	56	Logem
Tab dispersible 100 mg - 5% DV Oct-19 to 2022	4.40	56	Logem
LEVETIRACETAM			
Tab 250 mg - 1% DV Aug-19 to 2022	4.99	60	Everet
Tab 500 mg - 1% DV Aug-19 to 2022		60	Everet
Tab 750 mg - 1% DV Aug-19 to 2022	14.39	60	Everet
Tab 1,000 mg - 1% DV Aug-19 to 2022		60	Everet
Oral liq 100 mg per ml		300 ml	Levetiracetam-AFT
Inj 100 mg per ml, 5 ml vial - 1% DV Oct-19 to 2022		10	Levetiracetam-AFT
PHENOBARBITONE			
Tab 15 mg		500	PSM
Tab 30 mg		500	PSM

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PHENYTOIN	φ	Fei	Manulaciulei
Tab 50 mg			
PHENYTOIN SODIUM			
Cap 30 mg			
Cap 100 mg			
Oral liq 6 mg per ml			
PREGABALIN			
Note: Pregabalin not to be given in combination with gabapentin			
Cap 25 mg	2.25	56	Pregabalin Pfizer
Cap 75 mg		56	Pregabalin Pfizer
Cap 150 mg	4.01	56	Pregabalin Pfizer
Cap 300 mg	7.38	56	Pregabalin Pfizer
PRIMIDONE			
Tab 250 mg			
SODIUM VALPROATE			
Tab 100 mg			
Tab EC 200 mg			
Tab EC 500 mg			
Oral liq 40 mg per ml			
Inj 100 mg per ml, 4 ml vial	9.98	1	Epilim IV
STIRIPENTOL – Restricted see terms below			
Cap 250 mg		60	Diacomit
Powder for oral liq 250 mg sachet	509.29	60	Diacomit
→ Restricted (RS1152)			
Initiation			
Paediatric neurologist			
Re-assessment required after 6 months Both:			
1 Patient has confirmed diagnosis of Dravet syndrome; and			
2 Seizures have been inadequately controlled by appropriate cou	rses of sodium valoro	ate cloba	azam and at least two of the
following: topiramate, levetiracetam, ketogenic diet.			
Continuation			
Paediatric neurologist			
Patient continues to benefit from treatment as measured by reduced se	eizure frequency from	baseline.	
TOPIRAMATE			
Tab 25 mg	11.07	60	Arrow-Topiramate
	26.04		Topamax
	11.07		Topiramate Actavis
Tab 50 mg		60	Arrow-Topiramate
	44.26		Topamax
T 100	18.81		Topiramate Actavis
Tab 100 mg		60	Arrow-Topiramate
	75.25 31.99		Topamax Topiramate Actavis
Tab 200 mg		60	Arrow-Topiramate
	129.85	00	Topamax
	55.19		Topiramate Actavis
Cap sprinkle 15 mg		60	Topamax
Cap sprinkle 25 mg		60	Topamax
-			

	Pri	rice			Brand or
(ex	x man. 🧉	excl.	GST)		Generic
	9	\$		Per	Manufacturer

VIGABATRIN – **Restricted** see terms below

→ Restricted (RS1865)

Initiation

Re-assessment required after 15 months Both:

- 1 Any of the following:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; or
 - 1.3 Patient has tuberous sclerosis complex; and

2 Either:

- 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
- 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Continuation

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

Acute Migraine Treatment

DIHYDROERGOTAMINE MESYLATE

Inj 1 mg per ml, 1 ml ampoule

METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL

Tab 5 mg with paracetamol 500 mg

Tab orodispersible 10 mg – 1% DV Oct-20 to 2023	30	Rizamelt
SUMATRIPTAN		
Tab 50 mg - 1% DV Feb-22 to 2024	90	Sumagran
Tab 100 mg - 1% DV Feb-22 to 2024	90	Sumagran
Inj 12 mg per ml, 0.5 ml prefilled pen – 1% DV Sep-20 to 2022	2	Imigran

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
Prophylaxis of Migraine			
PIZOTIFEN Tab 500 mcg	23.21	100	Sandomigran
Antinausea and Vertigo Agents			
APREPITANT - Restricted see terms below ↓ Cap 2 × 80 mg and 1 × 125 mg - 5% DV Dec-21 to 2024 → Restricted (RS1154)		3	Emend Tri-Pack
Initiation Patient is undergoing highly emetogenic chemotherapy and/or anthra malignancy.	acycline-based chemo	therapy fo	or the treatment of
BETAHISTINE DIHYDROCHLORIDE Tab 16 mg - 1% DV Feb-22 to 2023		100 84	Serc Vergo 16
(Vergo 16 Tab 16 mg to be delisted 1 July 2022) CYCLIZINE HYDROCHLORIDE		2.	- 3
Tab 50 mg - 5% DV Dec-21 to 2024	0.49	10	Nausicalm
CYCLIZINE LACTATE Inj 50 mg per ml, 1 ml ampoule – 1% DV May-21 to 2022	21.53	10	HameIn
DOMPERIDONE Tab 10 mg - 5% DV Feb-22 to 2024	2.85	100	Pharmacy Health
DROPERIDOL Inj 2.5 mg per ml, 1 ml ampoule – 1% DV May-20 to 2022		10	Droleptan
GRANISETRON			·
Inj 1 mg per ml, 3 ml ampoule – 1% DV Jan-21 to 2023 HYOSCINE HYDROBROMIDE	1.20	1	Deva
Inj 400 mcg per ml, 1 ml ampoule ↓ Patch 1.5 mg	14.11	2	Scopoderm TTS
 Initiation Any of the following: Control of intractable nausea, vomiting, or inability to swallow where the patient cannot tolerate or does not adequately resp Control of clozapine-induced hypersalivation where trials of at ineffective; or For treatment of post-operative nausea and vomiting where criteffective, are not tolerated or are contraindicated. 	oond to oral anti-nause t least two other alterr	ea agents; ative treat	or ments have proven
METOCLOPRAMIDE HYDROCHLORIDE Tab 10 mg - 1% DV Oct-20 to 2023	1.30	100	Metoclopramide Actavis 10
Oral liq 5 mg per 5 ml Inj 5 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022	9.50	10	Pfizer

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
ONDANSETRON			
Tab 4 mg - 1% DV Apr-20 to 2022	2.68	50	Onrex
Tab dispersible 4 mg - 1% DV Oct-20 to 2023	0.76	10	Ondansetron ODT-DRLA
Tab 8 mg - 1% DV Apr-20 to 2022	4.57	50	Onrex
Tab dispersible 8 mg - 1% DV Oct-20 to 2023		10	Ondansetron ODT-DRLA
Inj 2 mg per ml, 2 ml ampoule	1.50	5	Ondansetron-Baxter
Inj 2 mg per ml, 4 ml ampoule	2.20	5	Ondansetron Kabi
PROCHLORPERAZINE Tab buccal 3 mg Tab 5 mg – 1% DV Dec-20 to 2023 Inj 12.5 mg per ml, 1 ml ampoule Suppos 25 mg	8.00	250	Nausafix

TROPISETRON

Inj 1 mg per ml, 2 ml ampoule Inj 1 mg per ml, 5 ml ampoule

Antipsychotic Agents

General

AMISULPRIDE			
Tab 100 mg - 1% DV Nov-19 to 2022	5.15	30	Sulprix
Tab 200 mg - 1% DV Nov-19 to 2022	14.96	60	Sulprix
Tab 400 mg - 1% DV Feb-20 to 2022	29.78	60	Sulprix
Oral liq 100 mg per ml			
ARIPIPRAZOLE			
Tab 5 mg		30	Aripiprazole Sandoz
Tab 10 mg		30	Aripiprazole Sandoz
Tab 15 mg		30	Aripiprazole Sandoz
Tab 20 mg	17.50	30	Aripiprazole Sandoz
Tab 30 mg		30	Aripiprazole Sandoz
CHLORPROMAZINE HYDROCHLORIDE			
Tab 10 mg - 1% DV Jan-20 to 2022	14.83	100	Largactil
Tab 25 mg - 1% DV Jan-20 to 2022	15.62	100	Largactil
Tab 100 mg - 1% DV Jan-20 to 2022		100	Largactil
Oral liq 10 mg per ml			
Oral liq 20 mg per ml			
Inj 25 mg per ml, 2 ml ampoule - 1% DV Jan-20 to 2022		10	Largactil

	Price		Brand or
	(ex man. excl. GST		Generic
	\$	Per	Manufacturer
CLOZAPINE			
Tab 25 mg	6.69	50	Clopine
	13.37	100	Clopine
	5.69	50	Clozaril
	11.36	100	Clozaril
Tab 50 mg	8.67	50	Clopine
	17.33	100	Clopine
Tab 100 mg		50	Clopine
	34.65	100	Clopine
	14.73	50	Clozaril
	29.45	100	Clozaril
Tab 200 mg		50	Clopine
	69.30	100	Clopine
Oral liq 50 mg per ml	67.62	100 ml	Versacloz
HALOPERIDOL			
Tab 500 mcg – 1% DV Oct-19 to 2022	6.23	100	Serenace
Tab 1.5 mg – 1% DV Oct-19 to 2022		100	Serenace
Tab 5 mg - 1% DV Oct-19 to 2022		100	Serenace
Oral lig 2 mg per ml – 1% DV Oct-19 to 2022		100 ml	Serenace
Inj 5 mg per ml, 1ml ampoule – 1% DV Oct-19 to 2022		100	Serenace
		10	Selenace
LEVOMEPROMAZINE			
Tab 25 mg - 1% DV Sep-19 to 2022		100	Nozinan
Tab 100 mg - 1% DV Sep-19 to 2022	41.75	100	Nozinan
LEVOMEPROMAZINE HYDROCHLORIDE			
Inj 25 mg per ml, 1 ml ampoule - 1% DV Apr-20 to 2022		10	Nozinan
LITHIUM CARBONATE			
Tab long-acting 400 mg - 5% DV Sep-21 to 2024	72 00	100	Priadel
Cap 250 mg		100	Douglas
			2 ouglao
OLANZAPINE	1.05	00	7
Tab 2.5 mg – 1% DV Nov-20 to 2023		28	Zypine
Tab 5 mg – 1% DV Nov-20 to 2023		28	Zypine
Tab orodispersible 5 mg – 1% DV Nov-20 to 2023		28	Zypine ODT
Tab 10 mg – 1% DV Nov-20 to 2023		28	Zypine
Tab orodispersible 10 mg – 1% DV Nov-20 to 2023 Inj 10 mg vial	2.38	28	Zypine ODT
PERICYAZINE			
Tab 2.5 mg			
Tab 10 mg			
QUETIAPINE			
Tab 25 mg - 1% DV Nov-20 to 2023		90	Quetapel
Tab 100 mg - 1% DV Nov-20 to 2023		90	Quetapel
Tab 200 mg - 1% DV Nov-20 to 2023		90	Quetapel
Tab 300 mg - 1% DV Nov-20 to 2023		90	Quetapel
RISPERIDONE			
Tab 0.5 mg – 1% DV Dec-20 to 2023		60	Risperidone (Teva)
Tab 1 mg – 1% DV Dec-20 to 2023		60	Risperidone (Teva)
Tab 2 mg - 1% DV Dec-20 to 2023		60	Risperidone (Teva)
Tab 3 mg - 1% DV Dec-20 to 2023		60	Risperidone (Teva)
Tab 4 mg - 1% DV Dec-20 to 2023		60	Risperidone (Teva)
Oral lig 1 mg per ml – 1% DV Nov-20 to 2023		30 ml	Risperon
		00 111	

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price		Brand or
(ex r	nan. excl. GST		Generic
	\$	Per	Manufacturer
ZIPRASIDONE			
Cap 20 mg	14.50	60	Zusdone
Cap 40 mg	24.70	60	Zusdone
Cap 60 mg	33.80	60	Zusdone
Cap 80 mg	39.70	60	Zusdone
ZUCLOPENTHIXOL ACETATE			
Inj 50 mg per ml, 1 ml ampoule			
Inj 50 mg per ml, 2 ml ampoule			
Tab 10 mg	31.45	100	Clopixol
		100	Оюріхої
Depot Injections			
Beperingeonono			
FLUPENTHIXOL DECANOATE			
Inj 20 mg per ml, 1 ml ampoule	13.14	5	Fluanxol
Inj 20 mg per ml, 2 ml ampoule	20.90	5	Fluanxol
Inj 100 mg per ml, 1 ml ampoule		5	Fluanxol
HALOPERIDOL DECANOATE			
Inj 50 mg per ml, 1 ml ampoule		5	Haldol
Inj 100 mg per ml, 1 ml ampoule		5	Haldol Concentrate
OLANZAPINE – Restricted see terms below		5	
Inj 210 mg vial	252.00	1	Zyprexa Relprevv
 Inj 210 mg vial Inj 300 mg vial 		1	Zyprexa Relprevv
 Inj 300 mg viai Inj 405 mg viai 		1	Zyprexa Relprevv
 ► Restricted (RS1379) 		1	Zypieza neipievv

Initiation

Re-assessment required after 12 months Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE - Restricted see terms below

1	Inj 25 mg syringe	 1	Invega Sustenna
t	Inj 50 mg syringe	 1	Invega Sustenna
	Inj 75 mg syringe	1	Invega Sustenna
	Inj 100 mg syringe	1	Invega Sustenna
	Inj 150 mg syringe	1	Invega Sustenna
	Destricted (DC1001)	 -	

→ Restricted (RS1381) Initiation

Re-assessment required after 12 months Either:

Price	В	rand or
(ex man. excl. GST)	G	eneric
		lanufacturer
Ф F	Per IVI	lanulacturer

continued...

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PIPOTHIAZINE PALMITATE - Restricted: For continuation only

- → Inj 50 mg per ml, 1 ml ampoule
- → Inj 50 mg per ml, 2 ml ampoule

RISPERIDONE - Restricted see terms below

t	Inj 25 mg vial	135.98	1	Risperdal Consta
t	Inj 37.5 mg vial	178.71	1	Risperdal Consta
t	Inj 50 mg vial	217.56	1	Risperdal Consta
⇒	Restricted (RS1380)			

Initiation

Re-assessment required after 12 months Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

ZUCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule	5	Clopixol e.g. Clopixol Conc
Anxiolytics		
BUSPIRONE HYDROCHLORIDE		
Tab 5 mg - 5% DV May-22 to 2024	100	Buspirone Viatris
20.23		Orion
Tab 10 mg - 5% DV May-22 to 202412.50	100	Buspirone Viatris
13.16		Orion
(Orion Tab 5 mg to be delisted 1 May 2022)		
(Orion Tab 10 mg to be delisted 1 May 2022)		
CLONAZEPAM		
Tab 500 mcg5.64	100	Paxam
Tab 2 mg	100	Paxam
DIAZEPAM		
Tab 2 mg - 1% DV Dec-20 to 2023	500	Arrow-Diazepam
Tab 5 mg - 1% DV Dec-20 to 2023	500	Arrow-Diazepam
		·····

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LORAZEPAM			
Tab 1 mg - 5% DV Dec-21 to 2024	9.72	250	Ativan
Tab 2.5 mg - 5% DV Dec-21 to 2024	12.50	100	Ativan

Multiple Sclerosis Treatments

→ Restricted (RS1842)

Initiation – Multiple sclerosis

Neurologist or general physician

Re-assessment required after 12 months All of the following:

- 1 Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2 Patients must have Clinically Definite Relapsing multiple sclerosis with or without underlying progression; and
- 3 Patients must have an EDSS score between 0 6.0 (inclusive); and
- 4 Patient has had at least 1 significant relapse of multiple sclerosis in the previous 12 months or 2 significant relapses in the past 24 months; and
- 5 All of the following:
 - 5.1 Each significant relapse must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic); and
 - 5.2 Each significant relapse is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s); and
 - 5.3 Each significant relapse has lasted at least one week and has started at least one month after the onset of a previous relapse; and
 - 5.4 Each significant relapse can be distinguished from the effects of general fatigue; and is not associated with a fever (T> 37.5°C); and
 - 5.5 Either:
 - 5.5.1 Each significant relapse is severe enough to change either the EDSS or at least one of the Kurtze Functional System scores by at least 1 point; or
 - 5.5.2 Each significant relapse is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom); and
- 6 Evidence of new inflammatory activity on an MR scan within the past 24 months; and

7 Any of the following:

- 7.1 A sign of that new inflammatory activity is a gadolinium enhancing lesion; or
- 7.2 A sign of that new inflammatory activity is a lesion showing diffusion restriction; or
- 7.3 A sign of that new inflammatory is a T2 lesion with associated local swelling; or
- 7.4 A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse that occurred within the last 2 years; or
- 7.5 A sign of that new inflammatory activity is new T2 lesions compared with a previous MR scan.

Note: Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier. Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Continuation – Multiple sclerosis

Neurologist or general physician

128

Patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use unilateral or bilateral aids at any time in the last six months (i.e. the patient has walked 100 metres or more with or without aids in the last six months).

DIMETHYL FUMARATE - Restricted see terms above

	Note: Treatment on two or more funded multiple sclerosis treatments simultaneous	sly is not pe	rmitted.
t	Cap 120 mg	14	Tecfidera
t	Cap 240 mg2,000.00	56	Tecfidera

e.g. Brand indicates brand example only. It is not a contracted product.

(av man aval CCT) Or and	
(ex man. excl. GST) Generic \$ Per Manufacturer	
Restricted see terms on the previous page	
ment on two or more funded multiple sclerosis treatments simultaneously is not permitted.	
CETATE – Restricted see terms on the previous page	
ment on two or more funded multiple sclerosis treatments simultaneously is not permitted.	
efilled syringe2,275.00 12 Copaxone	
ETA-1-ALPHA – Restricted see terms on the previous page	
ment on two or more funded multiple sclerosis treatments simultaneously is not permitted.	
u in 0.5 ml pen injector1,170.00 4 Avonex Pen u in 0.5 ml syringe1,170.00 4 Avonex	
ETA-1-BETA – Restricted see terms on the previous page ment on two or more funded multiple sclerosis treatments simultaneously is not permitted.	
u per ml, 1 ml vial	
- Restricted see terms on the previous page	
ment on two or more funded multiple sclerosis treatments simultaneously is not permitted.	
r ml, 15 ml vial	
- Restricted see terms on the previous page	
ment on two or more funded multiple sclerosis treatments simultaneously is not permitted.	
r ml, 10 ml vial	
E - Restricted see terms on the previous page	
ment on two or more funded multiple sclerosis treatments simultaneously is not permitted.	
- 1% DV Jun-21 to 2023	
nd Hypnotics	
RATE	
mg per ml	
mg per ml	
M – Restricted: For continuation only	
Restricted see terms below	
d-release 2 mg – 5% DV Apr-22 to 202411.50 30 Vigisom	
g:	
nd Hypnotics RATE mg per ml mg per ml M - Restricted: For continuation only Restricted see terms below	

- 1 Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder); and
- 2 Behavioural and environmental approaches have been tried or are inappropriate; and
- 3 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
- 4 Patient is aged 18 years or under.

continued...

Price		Brand or
(ex man. excl. GST)	_	Generic
 \$	Per	Manufacturer

continued			
Continuation – insomnia secondary to neurodevelopmental disorder Psychiatrist, paediatrician, neurologist or respiratory specialist			
Re-assessment required after 12 months			
All of the following:			
1 Patient is aged 18 years or under; and			
2 Patient has demonstrated clinically meaningful benefit from funded modified-rel			
3 Patient has had a trial of funded modified-release melatonin discontinuation with recurrence of persistent and distressing insomnia; and	nin the p	bast 12 r	months and has had a
4 Funded modified-release melatonin is to be given at doses no greater than 10 r	ng per d	lav.	
Initiation - insomnia where benzodiazepines and zopiclone are contraindicated	01		
Both:			
1 Patient has insomnia and benzodiazepines and zopiclone are contraindicated; a	and		
2 For in-hospital use only.			
Tab 7.5 mg Oral lig 2 mg per ml			
Inj 1 mg per ml, 5 ml ampoule – 5% DV Jan-22 to 2024		10	Mylan Midazolam
Inj 5 mg per ml, 3 ml ampoule – 5% DV Jan-22 to 2024		5	Mylan Midazolam
PHENOBARBITONE			
Inj 130 mg per ml, 1 ml vial Inj 200 mg per ml, 1 ml ampoule			
TFMAZEPAM			
Tab 10 mg – 1% DV Nov-20 to 20231.33		25	Normison
TRIAZOLAM – Restricted: For continuation only		_0	
➡ Tab 125 mcg			
➡ Tab 250 mcg			
ZOPICLONE			
Tab 7.5 mg			
Stimulants / ADHD Treatments			

Stimulants / ADHD Treatments

130

ATOMOXETINE 28 **Generic Partners** 28 **Generic Partners** 28 Generic Partners 28 Generic Partners 28 Generic Partners 28 **Generic Partners** 28 Generic Partners CAFFEINE Tab 100 mg DEXAMFETAMINE SULFATE - Restricted see terms below 100 PSM → Restricted (RS1169) Initiation – ADHD Paediatrician or psychiatrist Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

			Price excl. GST)		Brand or Generic
		(ex man.	\$	Per	Manufacturer
1	ntinued				
	tiation – Narcolepsy				
	urologist or respiratory specialist				
	-assessment required after 24 months				
	tient suffers from narcolepsy.				
	ntinuation – Narcolepsy				
	urologist or respiratory specialist				
	-assessment required after 24 months				
	e treatment remains appropriate and the patient is benefiting from				
	THYLPHENIDATE HYDROCHLORIDE – Restricted see terms				
	Tab extended-release 18 mg			30	Concerta
			7.75		Methylphenidate ER
	Tab extended-release 27 mg		CE 11	30	Teva
	Tab exterioeu-release 27 mg		.05.44 11.45	30	Concerta Methylphenidate ER -
			11.45		Teva
	Tab extended-release 36 mg		.71.93	30	Concerta
	· · · · · · · · · · · · · · · · · · ·		15.50		Methylphenidate ER
					Teva
	Tab extended-release 54 mg		.86.24	30	Concerta
			22.25		Methylphenidate ER
					Teva
	Tab immediate-release 5 mg			30	Rubifen
	Tab immediate-release 10 mg		3.00	30	Ritalin
	Tablian adiata sala ang 00 mar		7.05		Rubifen
	Tab immediate-release 20 mg			30	Rubifen
	Tab sustained-release 20 mg			30	Rubifen SR
	Cap modified-release 10 mg			30 30	Ritalin LA Ritalin LA
	Cap modified-release 20 mg Cap modified-release 30 mg			30 30	Ritalin LA
				30 30	Ritalin LA
	Cap modified-release 40 mg Restricted (RS1294)		. 30.00	30	
	tiation – ADHD (immediate-release and sustained-release for	mulations)			
	ediatrician or psychiatrist	mulationsj			
	tient has ADHD (Attention Deficit and Hyperactivity Disorder), dia	anosed acc	ording to DS	M-IV or	CD 10 criteria
	tiation – Narcolepsy (immediate-release and sustained-release	•	•		IOD TO Ontona.
	urologist or respiratory specialist		,		
	-assessment required after 24 months				
	tient suffers from narcolepsy.				
)	ntinuation – Narcolepsy (immediate-release and sustained-re	elease form	ulations)		
)	urologist or respiratory specialist		,		
2	-assessment required after 24 months				
1	e treatment remains appropriate and the patient is benefiting from	n treatment.			
ľ	tiation - Extended-release and modified-release formulations	6			
a	ediatrician or psychiatrist				
0	th:				
	1 Patient has ADHD (Attention Deficit and Hyperactivity Disord	ler), diagnos	ed according	g to DSN	I-IV or ICD 10 criteria; ar
	2 Either:	-			
	2.1 Patient is taking a currently listed formulation of methy	ylphenidate	hydrochlorid	e (imme	diate-release or
	sustained-release) which has not been effective due t	o significant	administrati	on and/o	or compliance difficulties;
	2.2 There is significant concern regarding the risk of diver	rsion or abu	se of immedi	ate-relea	ase methylphenidate

2.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

r (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
	φ		rei	Manulaclurer
MODAFINIL - Restricted see terms below	00.4	`	<u></u>	Madavial
Tab 100 mg - 5% DV Mar-22 to 2024 ⇒ Restricted (RS1803)	.29.1	3	60	Modavigil
nitiation – Narcolepsy				
Neurologist or respiratory specialist				
Re-assessment required after 24 months				
All of the following:				
 The patient has a diagnosis of narcolepsy and has excessive daytime sle almost daily for three months or more; and Fither: 	eepine	ess ass	ociated	with narcolepsy occurring
				anual to 10 minutes and 0
2.1 The patient has a multiple sleep latency test with a mean sleep la more sleep onset rapid eve movement periods; or	tency	or less	than or	equal to 10 minutes and 2
2.2 The patient has at least one of: cataplexy, sleep paralysis or hyp	nauor	nic hallı	icination	is: and
3 Either:	nagot	jio nam	acination	io, and
3.1 An effective dose of a listed formulation of methylphenidate or deal	vamnl	hetami	ne has h	een trialled and discontinue
because of intolerable side effects; or	kumpi	lotarini		
3.2 Methylphenidate and dexamphetamine are contraindicated.				
Continuation – Narcolepsy				
Neurologist or respiratory specialist				
Re-assessment required after 24 months				
The treatment remains appropriate and the patient is benefiting from treatment.				
Tractments for Demonstic				
Treatments for Dementia				
DONEPEZIL HYDROCHLORIDE				
Tab 5 mg - 1% DV Dec-20 to 2023	4.3	4	90	Donepezil-Rex
Tab 10 mg - 1% DV Dec-20 to 2023	6.6	4	90	Donepezil-Rex
RIVASTIGMINE – Restricted see terms below				
• • · · · · · · · · · · · · · · · · · ·				

Rivastigmine Patch BNM 5

Rivastigmine Patch

BNM 10

➡ Restricted (RS1436)

Initiation

Re-assessment required after 6 months

Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Continuation

Re-assessment required after 12 months Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

Т	reatments for Substance Dependence		
	PRENORPHINE WITH NALOXONE – Restricted see terms on the next page Tab 2 mg with naloxone 0.5 mg – 1% DV Apr-20 to 2022	28	Buprenorphine
t	Tab 8 mg with naloxone 2 mg - 1% DV Apr-20 to 2022	28	Naloxone BNM Buprenorphine Naloxone BNM

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
• Restricted (RS1172)			
nitiation – Detoxification			
Il of the following:			
1 Patient is opioid dependent; and			
2 Patient is currently engaged with an opioid treatment servi		ry of Hea	Ith; and
3 Prescriber works in an opioid treatment service approved I	by the Ministry of Health.		
nitiation – Maintenance treatment			
II of the following:			
1 Patient is opioid dependent; and			
2 Patient will not be receiving methadone; and			
3 Patient is currently enrolled in an opioid substitution treatm and	nent program in a service a	approved	by the Ministry of Health;
4 Prescriber works in an opioid treatment service approved l	by the Ministry of Health.		
UPROPION HYDROCHLORIDE			
Tab modified-release 150 mg - 1% DV Mar-21 to 2023	11.00	30	Zyban
ISULFIRAM			
Tab 200 mg - 5% DV Nov-21 to 2024		100	Antabuse
ALTREXONE HYDROCHLORIDE – Restricted see terms belo	NA/		
Tab 50 mg – 1% DV Jan-21 to 2023		30	Naltraccord
Restricted (RS1173)		00	Manaobora
hitiation – Alcohol dependence			
•			
oth:			
1 Patient is currently enrolled, or is planned to be enrolled, ir	n a recognised compreher	nsive trea	tment programme for alcoh
 Patient is currently enrolled, or is planned to be enrolled, ir dependence; and 			
 Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Naltrexone is to be prescribed by, or on the recommendation 			
 Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Naltrexone is to be prescribed by, or on the recommendati nitiation – Constipation 			
 Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Naltrexone is to be prescribed by, or on the recommendati itiation – Constipation or the treatment of opioid-induced constipation. 			
 Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Naltrexone is to be prescribed by, or on the recommendati itiation – Constipation or the treatment of opioid-induced constipation. ICOTINE – Some items restricted see terms below 	ion of, a physician working) in an Ald	cohol and Drug Service.
 Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Naltrexone is to be prescribed by, or on the recommendati itiation – Constipation or the treatment of opioid-induced constipation. ICOTINE – Some items restricted see terms below Patch 7 mg per 24 hours 	ion of, a physician working	g in an Ald 28	cohol and Drug Service. Habitrol
Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Natrexone is to be prescribed by, or on the recommendati nitiation – Constipation or the treatment of opioid-induced constipation. ICOTINE – Some items restricted see terms below Patch 7 mg per 24 hours Patch 14 mg per 24 hours	on of, a physician working) in an Ald 28 28	cohol and Drug Service. Habitrol Habitrol
Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Naltrexone is to be prescribed by, or on the recommendati hitiation – Constipation or the treatment of opioid-induced constipation. IICOTINE – Some items restricted see terms below Patch 7 mg per 24 hours Patch 14 mg per 24 hours Patch 21 mg per 24 hours	on of, a physician working	g in an Ald 28	cohol and Drug Service. Habitrol Habitrol Habitrol Habitrol
Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Nattrexone is to be prescribed by, or on the recommendati itiation – Constipation or the treatment of opioid-induced constipation. IICOTINE – Some items restricted see terms below Patch 7 mg per 24 hours Patch 14 mg per 24 hours Patch 21 mg per 24 hours Oral spray 1 mg per dose	ion of, a physician working 	9 in an Ald 28 28 28 28	cohol and Drug Service. Habitrol Habitrol Habitrol <i>e.g. Nicorette QuickMi</i> <i>Mouth Spray</i>
Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Nattrexone is to be prescribed by, or on the recommendati itiation – Constipation or the treatment of opioid-induced constipation. IICOTINE – Some items restricted see terms below Patch 7 mg per 24 hours Patch 14 mg per 24 hours Patch 21 mg per 24 hours Oral spray 1 mg per dose Lozenge 1 mg	ion of, a physician working 	y in an Ald 28 28 28 28 28 216	cohol and Drug Service. Habitrol Habitrol Habitrol <i>e.g. Nicorette QuickMi</i> <i>Mouth Spray</i> Habitrol
Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Naltrexone is to be prescribed by, or on the recommendati nitiation – Constipation or the treatment of opioid-induced constipation. ICOTINE – Some items restricted see terms below Patch 7 mg per 24 hours Patch 14 mg per 24 hours Patch 14 mg per 24 hours Patch 21 mg per 24 hours Oral spray 1 mg per dose Lozenge 1 mg Lozenge 2 mg	ion of, a physician working 	9 in an Ald 28 28 28 28	cohol and Drug Service. Habitrol Habitrol Habitrol <i>e.g. Nicorette QuickMi</i> <i>Mouth Spray</i> Habitrol Habitrol
Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Naltrexone is to be prescribed by, or on the recommendati nitiation – Constipation or the treatment of opioid-induced constipation. ICOTINE – Some items restricted see terms below Patch 7 mg per 24 hours Patch 14 mg per 24 hours Patch 21 mg per 4 hours Oral spray 1 mg per dose Lozenge 1 mg Lozenge 2 mg Soln for inhalation 15 mg cartridge	ion of, a physician working 	28 28 28 28 28 216 216	cohol and Drug Service. Habitrol Habitrol e.g. Nicorette QuickMii Mouth Spray Habitrol Habitrol e.g. Nicorette Inhalator
Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Naltrexone is to be prescribed by, or on the recommendati nitiation – Constipation or the treatment of opioid-induced constipation. ICOTINE – Some items restricted see terms below Patch 7 mg per 24 hours Patch 14 mg per 24 hours Patch 14 mg per 24 hours Patch 21 mg per 24 hours Oral spray 1 mg per dose Lozenge 1 mg Lozenge 2 mg	ion of, a physician working 	y in an Ald 28 28 28 28 28 216	cohol and Drug Service. Habitrol Habitrol <i>e.g. Nicorette QuickMit</i> <i>Mouth Spray</i> Habitrol Habitrol <i>e.g. Nicorette Inhalatol</i> Habitrol (Fruit)
Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Natrexone is to be prescribed by, or on the recommendati itiation – Constipation or the treatment of opioid-induced constipation. IICOTINE – Some items restricted see terms below Patch 7 mg per 24 hours Patch 14 mg per 24 hours Patch 21 mg per 24 hours Oral spray 1 mg per dose Lozenge 1 mg Lozenge 2 mg Soln for inhalation 15 mg cartridge Gum 2 mg	ion of, a physician working 	y in an Ald 28 28 28 216 216 384	cohol and Drug Service. Habitrol Habitrol <i>e.g. Nicorette QuickMit</i> <i>Mouth Spray</i> Habitrol Habitrol <i>e.g. Nicorette Inhalator</i> Habitrol (Fruit) Habitrol (Mint)
Patient is currently enrolled, or is planned to be enrolled, ir dependence; and Naltrexone is to be prescribed by, or on the recommendati nitiation – Constipation or the treatment of opioid-induced constipation. ICOTINE – Some items restricted see terms below Patch 7 mg per 24 hours Patch 14 mg per 24 hours Patch 21 mg per 4 hours Oral spray 1 mg per dose Lozenge 1 mg Lozenge 2 mg Soln for inhalation 15 mg cartridge	ion of, a physician working 	28 28 28 28 28 216 216	cohol and Drug Service. Habitrol Habitrol <i>e.g. Nicorette QuickMit</i> <i>Mouth Spray</i> Habitrol Habitrol Habitrol e.g. Nicorette Inhalator Habitrol (Fruit)

Any of the following:

- 1 For perioperative use in patients who have a 'nil by mouth' instruction; or
- 2 For use within mental health inpatient units; or
- 3 Patient would be admitted to a mental health inpatient unit, but is unable to due to COVID-19 self-isolation requirement; or
- 4 For acute use in agitated patients who are unable to leave the hospital facilities.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
VARENICLINE - Restricted see terms below	16.67	50	Verenieline Dfizer
 ↓ Tab 0.5 mg × 11 and 1 mg × 42 - 5% DV Jan-22 to 2024 ↓ Tab 1 mg - 5% DV Jan-22 to 2024 		53 56	Varenicline Pfizer Varenicline Pfizer
→ Restricted (RS1702)			

Initiation

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and

3 Either:

- 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
- 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not had a Special Authority for varenicline approved in the last 6 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period.

	(ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
Chemotherapeutic Agents					
Alkylating Agents					
BENDAMUSTINE HYDROCHLORIDE - Restricted see terms below ↓ Inj 25 mg vial - 5% DV Sep-21 to 2024 ↓ inj 100 mg vial - 5% DV Sep-21 to 2024 → Restricted (RS1835) Initiation - treatment naive CLL All of the following: ↓ The patient has Binet stage B or C, or progressive stage A chro		308.00)	1 1 emia regu	Ribomustin Ribomustin
 2 The patient is chemotherapy treatment naive; and 3 The patient is unable to tolerate toxicity of full-dose FCR; and 4 Patient has ECOG performance status 0-2; and 5 Patient has a Cumulative Illness Rating Scale (CIRS) score of 6 Bendamustine is to be administered at a maximum dose of 100 6 cycles. 	< 6; and				
Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocy to comprise a known standard therapeutic chemotherapy regimen and Initiation – Indolent, Low-grade lymphomas Re-assessment required after 9 months All of the following:					rapy treatment is considered
 The patient has indolent low grade NHL requiring treatment; ar Patient has a WHO performance status of 0-2; and Either: 	nd				
 3.1 Both: 3.1.1 Patient is treatment naive; and 3.1.2 Bendamustine is to be administered for a maxim CD20+); or 	num of 6 c	ycles ((in com	bination	with rituximab when
 3.2 All of the following: 3.2.1 Patient has relapsed refractory disease following 3.2.2 The patient has not received prior bendamustine 3.2.3 Either: 			erapy; a	Ind	
 3.2.3.1 Both: 3.2.3.1.1 Bendamustine is to be administered combination with rituximab when C 3.2.3.1.2 Patient has had a rituximab treatme 3.2.3.2 Bendamustine is to be administered as a refractory patients. 	D20+); an ent-free int	d terval	of 12 m	onths or	more; or
Continuation – Indolent, Low-grade lymphomas Re-assessment required after 9 months Both:					
 Patients have not received a bendamustine regimen within the Either: 2.1 Both: 	last 12 m	onths;	and		

- 2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
- 2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or

continued...

	f (ex man.	Price excl.	GST)		Brand or Generic
		\$		Per	Manufacturer
ontinued					
2.2 Bendamustine is to be administered as a monotherapy	/ for a maxi	mum (of 6 cy	cles in ri	ituximab refractory patients
Note: 'indolent, low-grade lymphomas' includes follicular, mantle cel					• •
nacroglobulinaemia.	,		,	F -F	, ,
nitiation – Hodgkin's lymphoma*					
Relevant specialist or medical practitioner on the recommendation of	a relevant	specia	alist		
<i>limited to 6 months</i> treatment					
All of the following:					
1 Patient has Hodgkin's lymphoma requiring treatment; and					
2 Patient has a ECOG performance status of 0-2; and					
3 Patient has received one prior line of chemotherapy; and					
4 Patient's disease relapsed or was refractory following prior ch				(D - O -)	
5 Bendamustine is to be administered in combination with gend		1 vinor	eidine	(BeGev	() at a maximum dose of n
greater than 90 mg/m2 twice per cycle, for a maximum of four	cycles.				
Note: Indications marked with * are unapproved indications.					
BUSULFAN		00.07	_	100	Midawan
Tab 2 mg		.89.25)	100	Myleran
Inj 6 mg per ml, 10 ml ampoule					
	-				5.0.00
Inj 100 mg vial – 5% DV Sep-22 to 2025		/10.00 387.00		1	BiCNU
Bicnu Heritage Inj 100 mg vial to be delisted 1 September 2022)	1,4	387.00	J		Bicnu Heritage
Tab 2 mg					
CYCLOPHOSPHAMIDE					
Tab 50 mg - 5% DV Jan-22 to 2024				50	Cyclonex
Inj 1 g vial – 5% DV Dec-21 to 2024		.35.65	-	1	Endoxan
Inj 2 g vial – 5% DV Dec-21 to 2024		.71.25	0	1	Endoxan
FOSFAMIDE			_		
lnj 1 g vial				1	Holoxan
Inj 2 g vial	······	180.00)	1	Holoxan
OMUSTINE					
Cap 10 mg				20	Ceenu
Cap 40 mg		399.15	5	20	Ceenu
MELPHALAN					
Tab 2 mg					
Inj 50 mg vial					
THIOTEPA					
Inj 15 mg vial					
Inj 100 mg vial					
Anthracyclines and Other Cytotoxic Antibiotics					
BLEOMYCIN SULPHATE		105 12	_		
Inj 15,000 iu vial	······································	185.16	D	1	DBL Bleomycin Sulfate
DACTINOMYCIN [ACTINOMYCIN D]			_		
Inj 0.5 mg vial		255.00)	1	Cosmegen
DAUNORUBICIN					
Inj 2 mg per ml, 10 ml vial	······································	149.50)	1	Pfizer

t Item restricted (see → above); t Item restricted (see → below)

136

e.g. Brand indicates brand example only. It is not a contracted product.

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
DOXORUBICIN HYDROCHLORIDE		-	
Inj 2 mg per ml, 5 ml vial			
Inj 2 mg per ml, 25 ml vial		1	Doxorubicin Ebewe
Inj 50 mg vial			
Inj 2 mg per ml, 50 ml vial		1	Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial - 5% DV Jan-22 to 2024		1	Doxorubicin Ebewe
EPIRUBICIN HYDROCHLORIDE			
Inj 2 mg per ml, 5 ml vial		1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial		1	Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial - 5% DV Jan-22 to 2024		1	Epirubicin Ebewe
DARUBICIN HYDROCHLORIDE			
Inj 5 mg vial		1	Zavedos
Inj 10 mg vial		1	Zavedos
AITOMYCIN C			
Inj 5 mg vial			
Inj 20 mg vial		1	Teva
/ITOZANTRONE	*		
Inj 2 mg per ml, 10 ml vial	97 50	1	Mitozantrone Ebewe
Antimetabolites			
Inj 100 mg vial − 5% DV Dec-21 to 2024 → Restricted (RS1418) nitiation	75.06	1	Azacitidine Dr Reddy's
Inj 100 mg vial - 5% DV Dec-21 to 2024	75.06	1	Azacitidine Dr Reddy's
Inj 100 mg vial – 5% DV Dec-21 to 2024 Restricted (RS1418) nitiation laematologist Re-assessment required after 12 months II of the following:	75.06	1	Azacitidine Dr Reddy's
 Inj 100 mg vial – 5% DV Dec-21 to 2024 Restricted (RS1418) hitiation laematologist Re-assessment required after 12 months III of the following: Any of the following: The patient has International Prognostic Scoring Sy 			
 Inj 100 mg vial - 5% DV Dec-21 to 2024 Restricted (RS1418) nitiation laematologist <i>Re-assessment required after 12 months</i> Il of the following: Any of the following: 	rstem (IPSS) intermediate	-2 or high	n risk myelodysplastic
 Inj 100 mg vial - 5% DV Dec-21 to 2024 Restricted (RS1418) nitiation laematologist <i>Re-assessment required after 12 months</i> NI of the following: Any of the following: The patient has International Prognostic Scoring Sy syndrome; or	rstem (IPSS) intermediate (10%-29% marrow blasts	e-2 or high	n risk myelodysplastic myeloproliferative disorder)
 Inj 100 mg vial - 5% DV Dec-21 to 2024 Restricted (RS1418) nitiation Haematologist Re-assessment required after 12 months NI of the following: Any of the following: The patient has International Prognostic Scoring Sy syndrome; or The patient has chronic myelomonocytic leukaemia or The patient has acute myeloid leukaemia with 20-30 	rstem (IPSS) intermediate (10%-29% marrow blasts 0% blasts and multi-lineag	e-2 or high	n risk myelodysplastic myeloproliferative disorder)
 Inj 100 mg vial - 5% DV Dec-21 to 2024 Restricted (RS1418) nitiation laematologist Re-assessment required after 12 months III of the following: Any of the following: The patient has International Prognostic Scoring Sy syndrome; or	rstem (IPSS) intermediate (10%-29% marrow blasts 0% blasts and multi-lineag 0-2; and	-2 or high s without ge dyspla	n risk myelodysplastic myeloproliferative disorder) sia, according to World
 Inj 100 mg vial – 5% DV Dec-21 to 2024 Restricted (RS1418) nitiation laematologist Re-assessment required after 12 months If the following: Any of the following: The patient has International Prognostic Scoring Sy syndrome; or The patient has chronic myelomonocytic leukaemia or The patient has acute myeloid leukaemia with 20-36 Health Organisation Classification (WHO); and The patient has performance status (WHO/ECOG) grade 0 	rstem (IPSS) intermediate (10%-29% marrow blasts 0% blasts and multi-lineag 0-2; and drome resulting from cher	-2 or high s without ge dyspla	n risk myelodysplastic myeloproliferative disorder sia, according to World
 Inj 100 mg vial – 5% DV Dec-21 to 2024	rstem (IPSS) intermediate (10%-29% marrow blasts 0% blasts and multi-lineag 0-2; and drome resulting from cher	-2 or high s without ge dyspla	n risk myelodysplastic myeloproliferative disorder) sia, according to World
 Inj 100 mg vial – 5% DV Dec-21 to 2024	rstem (IPSS) intermediate (10%-29% marrow blasts 0% blasts and multi-lineag 0-2; and drome resulting from cher	-2 or high s without ge dyspla	n risk myelodysplastic myeloproliferative disorder) sia, according to World
 Inj 100 mg vial – 5% DV Dec-21 to 2024	rstem (IPSS) intermediate (10%-29% marrow blasts 0% blasts and multi-lineag 0-2; and drome resulting from cher	-2 or high s without ge dyspla	n risk myelodysplastic myeloproliferative disorder sia, according to World
 Inj 100 mg vial - 5% DV Dec-21 to 2024	rstem (IPSS) intermediate (10%-29% marrow blasts 0% blasts and multi-lineag 0-2; and drome resulting from cher	-2 or high s without ge dyspla	n risk myelodysplastic myeloproliferative disorder sia, according to World
 Inj 100 mg vial - 5% DV Dec-21 to 2024	rstem (IPSS) intermediate (10%-29% marrow blasts 0% blasts and multi-lineag 0-2; and drome resulting from cher nonths.	-2 or high s without ge dyspla	n risk myelodysplastic myeloproliferative disorder sia, according to World
 Inj 100 mg vial - 5% DV Dec-21 to 2024	rstem (IPSS) intermediate (10%-29% marrow blasts 0% blasts and multi-lineag 0-2; and drome resulting from cher nonths.	-2 or high s without ge dyspla	n risk myelodysplastic myeloproliferative disorder) sia, according to World
 Inj 100 mg vial - 5% DV Dec-21 to 2024	rstem (IPSS) intermediate (10%-29% marrow blasts 0% blasts and multi-lineag 0-2; and drome resulting from cher nonths.	e-2 or high s without ge dyspla nical injur	n risk myelodysplastic myeloproliferative disorder) sia, according to World y or prior treatment with
 → Restricted (RS1418) nitiation Haematologist Re-assessment required after 12 months All of the following: 	vstem (IPSS) intermediate (10%-29% marrow blasts 0% blasts and multi-lineag 0-2; and drome resulting from cher nonths.	-2 or high s without ge dyspla	n risk myelodysplastic myeloproliferative disorder) sia, according to World

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
	φ	Fei	Manufacturer
Inj 2 mg per ml, 5 ml vial Inj 1 mg per ml, 10 ml vial	740.06	1	Leustatin
		1	Leusialin
YTARABINE		_	
Inj 20 mg per ml, 5 ml vial		5	Pfizer
Inj 100 mg per ml, 20 ml vial		1	Pfizer
LUDARABINE PHOSPHATE			
Tab 10 mg		20	Fludara Oral
Inj 50 mg vial - 1% DV Nov-19 to 2022	576.45	5	Fludarabine Ebewe
LUOROURACIL			
Inj 50 mg per ml, 20 ml vial – 5% DV Feb-22 to 2024		1	Flurouracil Accord
Inj 50 mg per ml, 100 ml vial - 5% DV Feb-22 to 2024		1	Flurouracil Accord
EMCITABINE			
Inj 10 mg per ml, 100 ml vial – 1% DV Jul-20 to 2023		1	Gemcitabine Ebewe
		•	
IERCAPTOPURINE Tab 50 mg - 1% DV Jul-19 to 2022	27.00	25	Puri-nethol
		∠5 100 ml	
Oral suspension 20 mg per ml Restricted (RS1635)		100 mi	Allmercap
nitiation			
aediatric haematologist or paediatric oncologist			
le-assessment required after 12 months			
he patient requires a total dose of less than one full 50 mg tablet per da	av		
Continuation	ay.		
aediatric haematologist or paediatric oncologist			
Re-assessment required after 12 months			
he patient requires a total dose of less than one full 50 mg tablet per da	av		
IETHOTREXATE			
Tab 2.5 mg – 5% DV Jan-22 to 2024	9.98	90	Trexate
Tab 10 mg - 5% DV Jan-22 to 2024		90	Trexate
Inj 2.5 mg per ml, 2 ml vial			
Inj 7.5 mg prefilled syringe	14.61	1	Methotrexate Sandoz
Inj 10 mg prefilled syringe	14.66	1	Methotrexate Sandoz
Inj 15 mg prefilled syringe	14.77	1	Methotrexate Sandoz
Inj 20 mg prefilled syringe		1	Methotrexate Sandoz
Inj 25 mg prefilled syringe	14.99	1	Methotrexate Sandoz
Inj 30 mg prefilled syringe		1	Methotrexate Sandoz
Inj 25 mg per ml, 2 ml vial		5	Methotrexate DBL
			Onco-Vial
Inj 25 mg per ml, 20 ml vial	45.00	1	DBL Methotrexate
Ini 100 mg nor ml. 10 ml viol	05.00	4	Onco-Vial
Inj 100 mg per ml, 10 ml vial		1	Methotrexate Ebewe
Inj 100 mg per ml, 50 ml vial – 1% DV Oct-20 to 2023		I	Methotrexate Ebewe
EMETREXED – Restricted see terms below Ini 100 mg vial			
Inj 100 mg vial		1	Juno Pemetrexed
Inj 500 mg vial	217.77	1	Juno Pemetrexed
Restricted (RS1596)			
itiation – Mesothelioma			
e-assessment required after 8 months			

Both:

138

continued...

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

continued...

1 Patient has been diagnosed with mesothelioma; and

2 Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

Continuation – Mesothelioma

Re-assessment required after 8 months

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.

Initiation - Non small cell lung cancer

Re-assessment required after 8 months

Both:

- 1 Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient has chemotherapy-naïve disease; and
 - 2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or
 - 2.2 All of the following:
 - 2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
 - 2.2.2 Patient has not received prior funded treatment with pemetrexed; and
 - 2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

Continuation - Non small cell lung cancer

Re-assessment required after 8 months

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

THIOGUANINE

Tab 40 mg

Other Cytotoxic Agents

AMSACRINE

AMOAURINE		
Inj 50 mg per ml, 1.5 ml ampoule		
Inj 75 mg		
ANAGRELIDE HYDROCHLORIDE		
Cap 0.5 mg		
ARSENIC TRIOXIDE		
Inj 1 mg per ml, 10 ml vial4,817.00	10	Phenasen
BORTEZOMIB – Restricted see terms below		
Inj 2.5 mg vial		
Inj 3.5 mg vial − 1% DV Aug-20 to 2022	1	Bortezomib Dr-Reddy's
(Any Inj 2.5 mg vial to be delisted 1 August 2022)		-
➡ Restricted (RS1725)		
Initiation – multiple myeloma/amyloidosis		
Either:		
1 The patient has symptomatic multiple myeloma; or		

2 The patient has symptomatic systemic AL amyloidosis.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DACARBAZINE	Ŷ		manufacturor
Inj 200 mg vial		1	DBL Dacarbazine
ETOPOSIDE			
Cap 50 mg – 1% DV Jul-19 to 2022		20	Vepesid
Cap 100 mg – 1% DV Jul-19 to 2022		10	Vepesid
Inj 20 mg per ml, 5 ml vial	7.90	1	Rex Medical
ETOPOSIDE (AS PHOSPHATE)			
Inj 100 mg vial		1	Etopophos
HYDROXYUREA [HYDROXYCARBAMIDE]			
Cap 500 mg – 1% DV Feb-21 to 2023		100	Devatis
IRINOTECAN HYDROCHLORIDE			
Inj 20 mg per ml, 5 ml vial – 5% DV Mar-22 to 2024		1	Accord
LENALIDOMIDE – Restricted see terms below			
Cap 5 mg		28	Revlimid
↓ Cap 10 mg		21	Revlimid
	6,207.00	28	Revlimid
	5,429.39	21	Revlimid
_	7,239.18	28	Revlimid
Cap 25 mg.	7,627.00	21	Revlimid

→ Restricted (RS1836)

Initiation - Relapsed/refractory disease

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
- 2 Patient has not previously been treated with lenalidomide; and
- 3 Either:
 - 3.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
 - 3.2 Both:
 - 3.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
 - 3.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
- 4 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Continuation - Relapsed/refractory disease

Haematologist

Re-assessment required after 6 months Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Initiation - Maintenance following first-line autologous stem cell transplant (SCT)

Haematologist

Re-assessment required after 6 months

All of the following:

140

- 1 Patient has newly diagnosed symptomatic multiple myeloma and has undergone first-line treatment that included an autologous stem cell transplantation; and
- 2 Patient has at least a stable disease response in the first 100 days after transplantation; and
- 3 Lenalidomide maintenance is to be commenced within 6 months of transplantation; and

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

4 Lenalidomide to be administered at a maximum dose of 15 mg/day.

Continuation - Maintenance following first-line autologous stem cell transplant (SCT)

Haematologist

Re-assessment required after 6 months Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

OLAPARIB - Restricted see terms below

t	Tab 100 mg	56	Lynparza
t	Tab 150 mg	56	Lynparza

➡ Restricted (RS1722)

Initiation

Medical oncologist

Re-assessment required after 12 months

All of the following:

- 1 Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and
- 3 Patient has received at least two lines of previous treatment with platinum-based chemotherapy; and
- 4 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line of platinum-based chemotherapy; and
- 5 Patient's disease must have achieved partial or complete response to treatment with the immediately preceding platinum-based regimen; and
- 6 Patient's disease has not progressed following prior treatment with olaparib; and
- 7 Treatment will be commenced within 8 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and
- 8 Treatment to be administered as maintenance treatment; and
- 9 Treatment not to be administered in combination with other chemotherapy.

Continuation

Medical oncologist

Re-assessment required after 12 months

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from treatment; and
- 2 No evidence of progressive disease; and
- 3 Treatment to be administered as maintenance treatment; and
- 4 Treatment not to be administered in combination with other chemotherapy.

Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

PEGASPARGASE - Restricted see terms below

→ Restricted (RS1788)

Initiation – Newly diagnosed ALL

Limited to 12 months treatment

Both:

continued...

	Price			Brand or
(e	x man. excl.	GST)		Generic
	\$,	Per	Manufacturer
continued				
1 The patient has newly diagnosed acute lymphoblastic leukaemia; a	and			
2 Pegaspargase to be used with a contemporary intensive multi-age	nt chemothe	rapy tr	eatment	protocol.
Initiation – Relapsed ALL				•
Limited to 12 months treatment				
Both:				
1 The patient has relapsed acute lymphoblastic leukaemia; and				
2 Pegaspargase to be used with a contemporary intensive multi-age	nt chemothe	rapy tr	eatment	protocol.
Initiation – Lymphoma				
Limited to 12 months treatment				
Patient has lymphoma requiring L-asparaginase containing protocol (e.g.	SMILE).			
PENTOSTATIN [DEOXYCOFORMYCIN]				
Inj 10 mg vial				
PROCARBAZINE HYDROCHLORIDE				
Cap 50 mg	980.00)	50	Natulan
TEMOZOL OMIDE – Bestricted see terms below		•	00	
	0.10	,	F	Temaccord
Cap 5 mg - 1% DV May-20 to 2022			5 5	Temaccord
 ↓ Cap 20 mg - 1% DV May-20 to 2022 ↓ Cap 100 mg - 1% DV May-20 to 2022 			5 5	Temaccord
Cap 140 mg – 1% DV May-20 to 2022			5 5	Temaccord
 Cap 140 mg − 1% DV May-20 to 2022 Cap 250 mg − 1% DV May-20 to 2022 			5	Temaccord
→ Restricted (RS1645)		t	5	Temaccoru
Initiation – High grade gliomas				
Re-assessment required after 12 months				

All of the following:

- 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day.

Continuation – High grade gliomas

Re-assessment required after 12 months Either:

- 1 Both:
 - 1.1 Patient has glioblastoma multiforme; and
 - 1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
- 2 All of the following:
 - 2.1 Patient has anaplastic astrocytoma*; and
 - 2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
 - 2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Initiation - Neuroendocrine tumours

Re-assessment required after 9 months

All of the following:

142

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose

ONCOLOCY ACENTS AND IMMUNO ----

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
continued			
of 200 mg/m ² per day; and			
4 Temozolomide to be discontinued at disease progression.			
Continuation – Neuroendocrine tumours			
Re-assessment required after 6 months			
Both:			
1 No evidence of disease progression; and			
2 The treatment remains appropriate and the patient is bene	efitting from treatment.		
Initiation – ewing's sarcoma			
Re-assessment required after 9 months			
Patient has relapse or refractory Ewing's sarcoma.			
Continuation – ewing's sarcoma			
Re-assessment required after 6 months			
Both:			
 No evidence of disease progression; and The treatment remains appropriate and the patient is beneficial. 	ofitting from trootmont		
Note: Indication marked with a * is an unapproved indication. To	-	d for the t	reatment of released high
grade glioma.			realment of relapsed high
THALIDOMIDE – Restricted see terms below			
		28	Thalomid
Cap 100 mg	756.00	28	Thalomid
➡ Restricted (RS1192)			
Initiation			
Re-assessment required after 12 months			
Any of the following:			
1 The patient has multiple myeloma; or			
2 The patient has systemic AL amyloidosis*; or3 The patient has erythema nodosum leprosum.			
Continuation			
Patient has obtained a response from treatment during the initial	approval period		
Notes: Prescription must be written by a registered prescriber in		agement r	programme operated by th
supplier		gomont	singlamine operated by a
Maximum dose of 400 mg daily as monotherapy or in a combinat	ion therapy regimen		
Indication marked with * is an unapproved indication	15 0		
TRETINOIN			
Cap 10 mg		100	Vesanoid
VENETOCLAX – Restricted see terms below			
✓ Tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg		42	Venclexta
 Tab 10 mg Tab 10 mg 		14	Venclexta
Tab 50 mg		7	Venclexta
↓ Tab 100 mg		120	Venclexta
→ Restricted (RS1713)			
Initiation – relapsed/refractory chronic lymphocytic leukaem	ia		
Haematologist			
Re-assessment required after 7 months			
All of the following:			

All of the following:

1 Patient has chronic lymphocytic leukaemia requiring treatment; and

Price			Brand or		
(ex man. e	excl.	GST)		Generic	
9	\$		Per	Manufacturer	

continued...

- 2 Patient has received at least one prior therapy for chronic lymphocytic leukaemia; and
- 3 Patient has not previously received funded venetoclax; and
- 4 The patient's disease has relapsed within 36 months of previous treatment; and
- 5 Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax; and
- 6 Patient has an ECOG performance status of 0-2.

Continuation - relapsed/refractory chronic lymphocytic leukaemia

Haematologist

Re-assessment required after 6 months

Both:

- 1 Treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment; and
- 2 Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity.

Initiation – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has previously untreated chronic lymphocytic leukaemia; and
- 2 There is documentation confirming that patient has 17p deletion by FISH testing or TP53 mutation by sequencing; and
- 3 Patient has an ECOG performance status of 0-2.

Continuation – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*

Haematologist

Re-assessment required after 6 months

The treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL)* and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are unapproved indications.

Platinum Compounds

CARBOPLATIN Inj 10 mg per ml, 45 ml vial45.20	1	Carboplatin Ebewe
CISPLATIN Inj 1 mg per ml, 100 ml vial - 5% DV Mar-22 to 2024	1	DBL Cisplatin
OXALIPLATIN Inj 5 mg per ml, 20 ml vial46.32	1	Oxaliplatin Accord

Protein-Tyrosine Kinase Inhibitors

ALECTINIB – Restricted see terms below Cap 150 mg	7.935.00	224	Alecensa	
→ Restricted (RS1712)				
nitiation				
Re-assessment required after 6 months				
All of the following:				

- 1 Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer; and
- 2 There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test; and

	l (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
continued					
3 Patient has an ECOG performance score of 0-2.					
Continuation					
Re-assessment required after 6 months					
Both:					
 No evidence of progressive disease according to RECIST of The patient is benefitting from and tolerating treatment. 	riteria; and				
DASATINIB – Restricted see terms below					
Tab 20 mg	3,	774.06	;	60	Sprycel
↓ Tab 50 mg	,			60	Sprycel
Tab 70 mg	7,0	692.58	}	60	Sprycel
→ Restricted (RS1685)					
Initiation	of a baamata	logist			
Haematologist or any relevant practitioner on the recommendation Re-assessment required after 6 months	or a naemato	logist			
Any of the following:					
1 Both:					
1.1 The patient has a diagnosis of chronic myeloid leuka	omia (CML) i	in blac	t oricio	or 2000	laratad phace: and
1.2 Maximum dose of 140 mg/day; or		in bias	1 011313	UI AUCE	ieraleu priase, ariu
2 Both:					
2.1 The patient has a diagnosis of Philadelphia chromos	como-nocitivo	acuto	lymph	oid louk	aomia (Ph+ ALL): and
2.2 Maximum dose of 140 mg/day; or	some-positive	acule	iyinpii		aeinia (i n+ ALL), and
3 All of the following:					
3.1 The patient has a diagnosis of CML in chronic phase	a: and				
3.2 Maximum dose of 100 mg/day; and	e, anu				
3.3 Any of the following:					
3.3.1 Patient has documented treatment failure* w	ith imatinih: o	r			
3.3.2 Patient has experienced treatment-limiting to			reclud	lina furth	er treatment with imatinib.
3.3.3 Patient has high-risk chronic-phase CML def					
3.3.4 Patients is enrolled in the KISS study** and r					
Continuation					0 71
Haematologist or any relevant practitioner on the recommendation	of a haemato	ologist			
Re-assessment required after 6 months		Ũ			
All of the following:					
 Lack of treatment failure while on dasatinib*; and 					
2 Dasatinib treatment remains appropriate and the patient is					
3 Maximum dasatinib dose of 140 mg/day for accelerated or	blast phase C	ML an	d Ph+	ALL, an	d 100 mg/day for chronic
phase CML.					
Note: *treatment failure for CML as defined by Leukaemia Net Gu	idelines. **Ki	nase-l	nhibitio	on Study	with Sprycel Start-up
https://www.cancertrialsnz.ac.nz/kiss/					
ERLOTINIB – Restricted see terms below					
Tab 100 mg				30	Tarceva
Tab 150 mg	1,	146.00)	30	Tarceva
→ Restricted (RS1885)					
nitiation					
Re-assessment required after 4 months					

All of the following:

Price			Brand or
(ex man. excl	GST)		Generic
\$		Per	Manufacturer

continued...

- 1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
- 3 Either:
 - 3.1 Patient is treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient has discontinued getitinib due to intolerance; and
 - 3.2.2 The cancer did not progress while on gefitinib; and
- 4 Erlotinib is to be given for a maximum of 3 months.

Continuation

Re-assessment required after 6 months

Both:

- 1 Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
- 2 Erlotinib is to be given for a maximum of 3 months.

Continuation – pandemic circumstances

Re-assessment required after 6 months

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Erlotinib to be discontinued at progression; and
- 3 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

GEFITINIB - Restricted see terms below

t	Tab 250 mg	1,700.00	30	Iressa
⇒	Restricted (RS1887)			

Initiation

Re-assessment required after 4 months

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Either:
 - 2.1 Patient is treatment naive; or
 - 2.2 Both:
 - 2.2.1 The patient has discontinued erlotinib due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on erlotinib; and
- 3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
- 4 Gefitinib is to be given for a maximum of 3 months.

Continuation

Re-assessment required after 6 months Both:

- 1 Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
- 2 Gefitinib is to be given for a maximum of 3 months.

Continuation – pandemic circumstances

Re-assessment required after 6 months

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Gefitinib to be discontinued at progression; and
- 3 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
IMATINIB MESILATE The Glivec brand of imatinib mesilate (supplied by Novartis) is fully unresectable and/or metastatic malignant GIST only, see SA1460 ↓ Tab 100 mg → Restricted (RS1402) Initiation	in Section B of the Ph		
Re-assessment required after 12 months Both: 1 Patient has diagnosis (confirmed by an oncologist) of unresectation tumour (GIST); and	able and/or metastatic	malignai	nt gastrointestinal stromal
2 Maximum dose of 400 mg/day. Continuation <i>Re-assessment required after 12 months</i> Adequate clinical response to treatment with imatinib (prescriber detern Note: The Glivec brand of imatinib mesilate (supplied by Novartis) rem with unresectable and/or metastatic malignant GIST, see SA1460 in S	nains fully subsidised		
Cap 100 mg – 1% DV Jun-21 to 2023 Cap 400 mg – 1% DV Jun-21 to 2023		60 30	Imatinib-Rex Imatinib-Rex
LAPATINIB – Restricted see terms below ↓ Tab 250 mg → Restricted (RS1828) Initiation	1,899.00	70	Tykerb
For continuation use only. Continuation <i>Re-assessment required after 12 months</i> All of the following:			
 The patient has metastatic breast cancer expressing HER-2 IH and The cancer has not progressed at any time point during the pre Lapatinib not to be given in combination with trastuzumab; and Lapatinib to be discontinued at disease progression. 	evious 12 months while	•	0,,,
NILOTINIB - Restricted see terms below ↓ Cap 150 mg ↓ Cap 200 mg → Restricted (RS1437) Initiation Haematologist <i>Re-assessment required after 6 months</i> All of the following:		120 120	Tasigna Tasigna
1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in 2 Either:	blast crisis, accelerate	ed phase	, or in chronic phase; and

- 2.1 Patient has documented CML treatment failure* with imatinib; or
- 2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

	(ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
continued… Continuation Haematologist					
Re-assessment required after 6 months					
All of the following:					
1 Lack of treatment failure while on nilotinib as defined by Leuk					
 Nilotinib treatment remains appropriate and the patient is ben Maximum pilotinib does of 800 mg/day, and 	efiting from	treatr	nent; a	nd	
3 Maximum nilotinib dose of 800 mg/day; and4 Subsidised for use as monotherapy only.					
PALBOCICLIB – Restricted see terms below Tab 75 mg	11		n	21	Ibrance
Tab 100 mg				21	Ibrance
↓ Tab 125 mg				21	Ibrance
→ Restricted (RS1731)					
nitiation					
Medical oncologist					
Re-assessment required after 6 months All of the following:					
 Patient has unresectable locally advanced or metastatic brea 	st cancor: a	nd			
2 There is documentation confirming disease is hormone-recep			IER2-r	egative:	and
3 Patient has an ECOG performance score of 0-2; and		anar		loguito,	
4 Either:					
second or subsequent line setting					
4.1 Disease has relapsed or progressed during prior endo4.2 Both:	crine therap	oy; or			
first line setting					
 Patient is amenorrhoeic, either naturally or industate; and 	uced, with e	ndocr	ine lev	els cons	istent with a postmenopaus
4.2.2 Either:					
4.2.2.1 Patient has not received prior systemic t	reatment fo	r meta	astatic	disease:	or
4.2.2.2 All of the following:				,	
4.2.2.2.1 Patient commenced treatment wit 1 April 2020; and	h palbociclil	b in co	ombina	tion with	an endocrine agent prior to
4.2.2.2.2 Patient has not received prior sys	temic endoo	crine t	reatme	nt for me	etastatic disease; and
4.2.2.2.3 There is no evidence of progressi	ve disease;	and			
5 Treatment must be used in combination with an endocrine pa	rtner.				
Continuation					
Medical oncologist					
Re-assessment required after 12 months All of the following:					
 Treatment must be used in combination with an endocrine pa 	rtner: and				
2 No evidence of progressive disease; and	,				
3 The treatment remains appropriate and the patient is benefitti	ing from trea	atmen	ıt.		
PAZOPANIB – Restricted see terms below					

ŧ	Lab 200 mg	.70	30	Votrient
t	Tab 400 mg2,669	.40	30	Votrient
⇒	Restricted (RS1198)			

Initiation

Re-assessment required after 3 months All of the following:

continued...

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 All of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
 - 5.2 Haemoglobin level < lower limit of normal; and
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
 - 5.5 Karnofsky performance score of less than or equal to 70; and
 - 5.6 2 or more sites of organ metastasis.

Continuation

Re-assessment required after 3 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

RUXOLITINIB - Restricted see terms below

t	Tab 5 mg2,500.00	56	Jakavi
t	Tab 10 mg5,000.00	56	Jakavi
t	Tab 15 mg5,000.00	56	Jakavi
	Tab 20 mg5,000.00		Jakavi

→ Restricted (RS1726)

Initiation

Haematologist

Re-assessment required after 12 months

All of the following:

- The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
- 2 Either:
 - 2.1 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; or
 - 2.2 Both:
 - 2.2.1 A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
 - 2.2.2 Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy; and
- 3 A maximum dose of 20 mg twice daily is to be given.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued Continuation			
Relevant specialist or medical practitioner on the recommenda Re-assessment required after 12 months Both:	tion of a Relevant specialist		
 The treatment remains appropriate and the patient is be A maximum dose of 20 mg twice daily is to be given. 	enefiting from treatment; and		
SUNITINIB – Restricted see terms below			
Cap 12.5 mg - 5% DV Jul-22 to 2024		28	Sunitinib Pfizer
	2,315.38		Sutent
Cap 25 mg – 5% DV Jul-22 to 2024		28	Sunitinib Pfizer
	4,630.77		Sutent
Cap 50 mg - 5% DV Jul-22 to 2024	694.62	28	Sunitinib Pfizer
	9,261.54		Sutent
(Sutent Cap 12.5 mg to be delisted 1 July 2022)			
(Sutent Cap 25 mg to be delisted 1 July 2022)			
(Sutent Cap 50 mg to be delisted 1 July 2022)			
→ Restricted (RS1886)			
Initiation – RCC			
Re-assessment required after 3 months All of the following:			
C C			
 The patient has metastatic renal cell carcinoma; and Any of the following: 			
, , , , , , , , , , , , , , , , , , , ,			
2.1 The patient is treatment naive; or2.2 The patient has only received prior cytokine treatment	tmont: or		
2.2 The patient has only received prior cytokine tee2.3 The patient has only received prior treatment wi trial which has Ethics Committee approval; or		thin the o	confines of a bona fide clinica
2.4 Both:			
2.4.1 The patient has discontinued pazopanib 2.4.2 The cancer did not progress whilst on pa		eatment	due to intolerance; and
3 The patient has good performance status (WHO/ECOG	i grade 0-2); and		
4 The disease is of predominant clear cell histology; and			
5 All of the following:			
5.1 Lactate dehydrogenase level > 1.5 times upper	limit of normal; and		
5.2 Haemoglobin level < lower limit of normal; and			
5.3 Corrected serum calcium level > 10 mg/dL (2.5			
5.4 Interval of < 1 year from original diagnosis to the		nd	
5.5 Karnofsky performance score of less than or eq	ual to 70; and		
5.6 2 or more sites of organ metastasis; and			
6 Sunitinib to be used for a maximum of 2 cycles.			
Notes: RCC - Sunitinib treatment should be stopped if disease			
Poor prognosis patients are defined as having at least 3 of crit	eria 5.1-5.6. Intermediate pro	ognosis p	patients are defined as havin
1 or 2 of criteria 5.1-5.6.			
Continuation – RCC			

Re-assessment required after 3 months

Both:

150

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Price	е		Brand or
(ex man. ex	cl. GST)		Generic
\$		Per	Manufacturer

continued...

Initiation - GIST

Re-assessment required after 3 months

Both:

1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and

- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Continuation – GIST

Re-assessment required after 6 months

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Continuation – GIST pandemic circumstances

Re-assessment required after 6 months

All of the following:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 3 Sunitinib is to be discontinued at progression; and
- 4 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Taxanes

DOCETAXEL			
Inj 10 mg per ml, 8 ml vial	.46.89	1	DBL Docetaxel
PACLITAXEL			
Inj 6 mg per ml, 5 ml vial	.47.30	5	Paclitaxel Ebewe
Inj 6 mg per ml, 16.7 ml vial - 1% DV Nov-20 to 2023	.24.00	1	Paclitaxel Ebewe
Inj 6 mg per ml, 25 ml vial	.26.69	1	Paclitaxel Ebewe
Inj 6 mg per ml, 50 ml vial – 1% DV Nov-20 to 2023	.44.00	1	Paclitaxel Ebewe

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Treatment of Cytotoxic-Induced Side Effects			
CALCIUM FOLINATE			
Tab 15 mg Inj 3 mg per ml, 1 ml ampoule	114.69	10	DBL Leucovorin Calcium
Inj 10 mg per ml, 5 ml ampoule		5	Calcium Folinate Ebewe
Inj 10 mg per ml, 5 ml vial – 1% DV Jan-20 to 2022		1	Calcium Folinate Sandoz
Inj 10 mg per ml, 10 ml vial – 1% DV Jan-20 to 2022	9.49	1	Calcium Folinate Sandoz
Inj 10 mg per ml, 30 ml vial		1	Calcium Folinate Ebewe
Inj 10 mg per ml, 35 ml vial – 1% DV Nov-19 to 2022	25.14	1	Calcium Folinate Sandoz
Inj 10 mg per ml, 100 ml vial – 1% DV Mar-20 to 2022	72.00	1	Calcium Folinate Sandoz
DEXRAZOXANE – Restricted see terms below			
↓ Inj 500 mg → Restricted (RS1695)			e.g. Cardioxane
Initiation			
Medical oncologist, paediatric oncologist, haematologist or paediatric All of the following:	c haematologist		
1 Patient is to receive treatment with high dose anthracycline g			
2 Based on current treatment plan, patient's cumulative lifetime	dose of anthracycline	will excee	d 250mg/m2 doxorubicin
equivalent or greater; and	.		
3 Dexrazoxane to be administered only whilst on anthracycline4 Either:	treatment; and		
4.1 Treatment to be used as a cardioprotectant for a child4.2 Treatment to be used as a cardioprotectant for second			
MESNA			
Tab 400 mg - 1% DV Nov-19 to 2022		50	Uromitexan
Tab 600 mg - 1% DV Nov-19 to 2022		50	Uromitexan
Inj 100 mg per ml, 4 ml ampoule - 1% DV Nov-19 to 2022	177.45	15	Uromitexan
Inj 100 mg per ml, 10 ml ampoule – 1% DV Nov-19 to 2022	407.40	15	Uromitexan
Vinca Alkaloids			
VINBLASTINE SULPHATE			
Inj 1 mg per ml, 10 ml vial	270.37	5	Hospira
VINCRISTINE SULPHATE			
Inj 1 mg per ml, 1 ml vial	74.52	5	DBL Vincristine Sulfate
Inj 1 mg per ml, 2 ml vial	102.73	5	DBL Vincristine Sulfate
VINORELBINE			
Inj 10 mg per ml, 1 ml vial	12.00	1	Navelbine
Inj 10 mg per ml, 5 ml vial		1	Navelbine
Endocrine Therapy			
ABIRATERONE ACETATE - Restricted see terms on the next pag	e		
↓ Tab 250 mg	4,276.19	120	Zytiga

t Item restricted (see \rightarrow above); **t** Item restricted (see \rightarrow below)

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)	Dau	Generic
 \$	Per	Manufacturer

→ Restricted (RS1888)

Initiation

Medical oncologist, radiation oncologist or urologist *Re-assessment required after 6 months* All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:
 - 4.1 All of the following:
 - 4.1.1 Patient is symptomatic; and
 - 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
 - 4.1.3 Patient has ECOG performance score of 0-1; and
 - 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
 - 4.2 All of the following:
 - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
 - 4.2.2 Patient has ECOG performance score of 0-2; and
 - 4.2.3 Patient has not had prior treatment with abiraterone.

Continuation

Medical oncologist, radiation oncologist or urologist

Re-assessment required after 6 months

All of the following:

- 1 Significant decrease in serum PSA from baseline; and
- 2 No evidence of clinical disease progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The treatment remains appropriate and the patient is benefiting from treatment.

Continuation – pandemic circumstances

Re-assessment required after 6 months

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Abiraterone acetate to be discontinued at progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

BICALUTAMIDE

Tab 50 mg - 1% DV Apr-21 to 20234.21	28	Binarex
FLUTAMIDE Tab 250 mg	100	Flutamin
FULVESTRANT – Restricted see terms below	100	riddinin
Inj 50 mg per ml, 5 ml prefilled syringe	2	Faslodex
➡ Restricted (RS1732)		
Initiation		
Medical oncologist		
Re-assessment required after 6 months		
All of the following:		

- 1 Patient has oestrogen-receptor positive locally advanced or metastatic breast cancer; and
- 2 Patient has disease progression following prior treatment with an aromatase inhibitor or tamoxifen for their locally

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued advanced or metastatic disease; and 3 Treatment to be given at a dose of 500 mg monthly following 4 Treatment to be discontinued at disease progression.	loading doses; and		
Continuation Medical oncologist Re-assessment required after 6 months			
 All of the following: 1 Treatment remains appropriate and patient is benefitting fror 2 Treatment to be given at a dose of 500 mg monthly; and 3 No evidence of disease progression. 	n treatment; and		
MEGESTROL ACETATE – Restricted: For continuation only → Tab 160 mg		30	Apo-Megestrol Megace
(Apo-Megestrol Tab 160 mg to be delisted 1 May 2022) (Megace Tab 160 mg to be delisted 1 February 2023)			
OCTREOTIDE – Some items restricted see terms below			
Inj 50 mcg per ml, 1 ml ampoule - 5% DV Jun-22 to 2024		5	DBL Octreotide
Inj 100 mcg per ml, 1 ml ampoule - 5% DV Jun-22 to 2024	27.58	5	Max Health DBL Octreotide
Ing 100 meg per mi, 1 mi ampodie – 5 % DV 301-22 to 2024	32.71	5	Max Health
Inj 500 mcg per ml, 1 ml ampoule – 5% DV Jun-22 to 2024		5	DBL Octreotide
	113.10		Max Health
Inj depot 10 mg prefilled syringe – 5% DV Mar-22 to 2024		1	Octreotide Depot Teva
Inj depot 20 mg prefilled syringe – 5% DV Mar-22 to 2024		1	Octreotide Depot Teva
Inj depot 30 mg prefilled syringe – 5% DV Mar-22 to 2024		1	Octreotide Depot Teva
(DBL Octreotide Inj 50 mcg per ml, 1 ml ampoule to be delisted 1 Ju (DBL Octreotide Inj 100 mcg per ml, 1 ml ampoule to be delisted 1 J			
(DBL Octreotide Inj 100 mcg per ml, 1 ml ampoule to be delisted 1 c → Restricted (RS1889)			
Initiation – Malignant bowel obstruction			
All of the following:			
 The patient has nausea* and vomiting* due to malignant bow Treatment with antiemetics, rehydration, antimuscarinic ager failed; and 		analgesio	cs for at least 48 hours has
3 Octreotide to be given at a maximum dose 1500 mcg daily for	or up to 4 weeks.		
Note: Indications marked with * are unapproved indications			
Initiation – acromegaly			
Re-assessment required after 3 months			
Both:			
 The patient has acromegaly; and Any of the following: 			
2.1 Treatment with surgery, radiotherapy and a dopamine	a anonist has failed: or		
2.2 Treatment with octreotide is for an interim period whil		radiothe	erapy and a dopamine agonis

- 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
- 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Continuation - acromegaly

Both:

154

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

Initiation – Other indications

Any of the following:

- 1 VIPomas and glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
 - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: restriction applies only to the long-acting formulations of octreotide

Initiation - pre-operative acromegaly

Limited to 12 months treatment

All of the following:

- 1 Patient has acromegaly; and
- 2 Patient has a large pituitary tumour, greater than 10 mm at its widest; and
- 3 Patient is scheduled to undergo pituitary surgery in the next six months.

Note: Indications marked with * are unapproved indications

Continuation - Acromegaly - pandemic circumstances

Re-assessment required after 6 months

All of the following:

- 1 Patient has acromegaly; and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and

3 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

TAMOXIFEN CITRATE

Tab 10 mg – 1% DV Nov-20 to 2023 Tab 20 mg – 1% DV Nov-20 to 2023	60 60	Tamoxifen Sandoz Tamoxifen Sandoz
Aromatase Inhibitors		

ANASTROZOLE Tab 1 mg - 1% DV Apr-21 to 2023	4.55	30	Anatrole
EXEMESTANE Tab 25 mg	14.50	30	Pfizer Exemestane
LETROZOLE Tab 2.5 mg - 5% DV Jan-22 to 2024	5.84	30	Letrole

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Imaging Agents			
 MINOLEVULINIC ACID HYDROCHLORIDE - Restricted see terr Powder for oral soln, 30 mg per ml, 1.5 g vial Restricted (RS1565) nitiation - high grade malignant glioma All of the following: Patient has newly diagnosed, untreated, glioblastoma multifo Treatment to be used as adjuvant to fluorescence-guided res Patient's tumour is amenable to complete resection. 	4,400.00 44,000.00 rme; and	1 10	Gliolan Gliolan
Immunosuppressants			
Calcineurin Inhibitors			
CICLOSPORIN Cap 25 mg Cap 50 mg Cap 100 mg Oral liq 100 mg per ml Inj 50 mg per ml, 5 ml ampoule ACROLIMUS - Restricted see terms below Cap 0.5 mg Cap 0.75 mg Cap 1 mg Cap 1 mg Cap 5 mg Inj 5 mg per ml, 1 ml ampoule → Restricted (RS1651) nitiation - organ transplant recipients my specialist For use in organ transplant recipients. nitiation - non-transplant indications*		50 50 50 ml 10 100 100 50	Neoral Neoral Neoral Sandimmun Tacrolimus Sandoz Tacrolimus Sandoz Tacrolimus Sandoz Tacrolimus Sandoz
 Iny specialist Patient requires long-term systemic immunosuppression; and Ciclosporin has been trialled and discontinued treatment becaresponse. Indications marked with * are unapproved indications 		ide effect:	s or inadequate clinical
Fusion Proteins			
TANERCEPT - Restricted see terms below Inj 25 mg autoinjector - 5% DV Feb-21 to 2024 Inj 25 mg vial - 5% DV Sep-19 to 2024 Inj 50 mg autoinjector - 5% DV Sep-19 to 2024 Inj 50 mg syringe - 5% DV Sep-19 to 2024 Restricted (RS1879) initiation - polyarticular course juvenile idiopathic arthritis	690.00 1,050.00	4 4 4 4	Enbrel Enbrel Enbrel Enbrel
Reumatologist or named specialist Re-assessment required after 6 months			continuo

continued...

Either:

156

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for polyarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Continuation - polyarticular course juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - oligoarticular course juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for oligoarticular course juvenile idiopathic arthritis (JIA); and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for oligoarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or

Price		Brand or
(ex man. excl. GST)	_	Generic
 \$	Per	Manufacturer

continued...

- 2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose); or
- 2.3.3 High disease activity (cJADAS10 score greater than 4) after a 6-month trial of methotrexate.

Continuation – oligoarticular course juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baselinee; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - Arthritis - rheumatoid

Rheumatologist

Re-assessment required after 6 months Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit to meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated); and
 - 2.5 Either:
 - 2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

Continuation - Arthritis - rheumatoid

Any relevant practitioner

Re-assessment required after 2 years

All of the following:

158

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

Price		Brand or
(ex man. excl. GST)	_	Generic
 \$	Per	Manufacturer

continued...

- 2 Either:
 - 2.1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment. Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

	Р	rice			Brand or
(e)	ex man.	excl.	GST)		Generic
		\$		Per	Manufacturer

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab or secukinumab for psoriatic arthritis; and 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab or secukinumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab or secukinumab to meet the renewal criteria for adalimumab or secukinumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Price	Brand or
(ex man. excl. GST)	Generic
 \$ Pe	er Manufacturer

Initiation - severe chronic plaque psoriasis, prior TNF use

Dermatologist

Limited to 4 months treatment

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and
- 3 Patient must be reassessed for continuation after 3 doses.

Initiation - severe chronic plaque psoriasis, treatment-naive

Dermatologist

Limited to 4 months treatment

All of the following:

1 Either:

- 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Continuation – severe chronic plaque psoriasis**

Dermatologist

Re-assessment required after 6 months Both:

1 Either:

1.1 Both:

- 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
- 1.1.2 Either:
 - 1.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or
 - 1.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

1.2 Both:

1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

Pi	rice		Brand or	
(ex man.	excl. (GST)	Generic	
	\$	Per	Manufacturer	

- 1.2.2 Either:
 - 1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.
- Note: Indications marked with * are unapproved indications.

Continuation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Initiation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation - adult-onset Still's disease

Rheumatologist

162

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Initiation - undifferentiated spondyloarthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day (or maximum tolerated dose); and
- 4 Patient has tried and not responded to at least three months of leflunomide at a dose of up to 20 mg daily (or maximum tolerated dose); and
- 5 Any of the following:
 - 5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications.

Continuation - undifferentiated spondyloarthritis

Rheumatologist or medical practitioner on the recommendation of a Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg dose every 7 days.

Monoclonal Antibodies

ABCIXIMAB - Restricted see terms below

Inj 2 mg per ml, 5 ml vial

→ Restricted (RS1202)

Initiation

Either:

- 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
- 2 For use in patients undergoing intra-cranial intervention.

ADALIMUMAB (AMGEVITA) - Restricted see terms on the next page

t	Inj 20 mg per 0.4 ml prefilled syringe - 5% DV Oct-22 to 31 Jul 2026 190.00	1	Amgevita
t	Inj 40 mg per 0.8 ml prefilled pen - 5% DV Oct-22 to 31 Jul 2026	2	Amgevita
t	Inj 40 mg per 0.8 ml prefilled syringe - 5% DV Oct-22 to 31 Jul 2026375.00	2	Amgevita

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

➡ Restricted (RS1878)

Initiation - Behcet's disease - severe

Any relevant practitioner

Both:

- 1 The patient has severe Behcet's disease* that is significantly impacting the patient's quality of life; and
- 2 Either:
 - 2.1 The patient has severe ocular, neurological, and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s); or
 - 2.2 The patient has severe gastrointestinal, rheumatological and/or mucocutaneous symptoms and has not responded adequately to two or more treatments appropriate for the particular symptom(s).

Note: Indications marked with * are unapproved indications.

Initiation – Hidradenitis suppurativa

Dermatologist

Re-assessment required after 4 months

All of the following:

- 1 Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
- 2 Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics; and
- 3 Patient has 3 or more active lesions; and
- 4 The patient has a DLQI of 10 or more and the assessment is no more than 1 month old at time of application.

Continuation – Hidradenitis suppurativa

Any relevant practitioner

Re-assessment required after 2 years

Both:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a DLQI improvement of 4 or more from baseline.

Initiation – Plaque psoriasis - severe chronic

Dermatologist

Re-assessment required after 4 months

Either:

164

1 Both:

- 1.1 Patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:

2.1 Either:

- 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2.2 Patient has tried, but had an inadequate response to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 2.3 A PASI assessment or (DLQI) assessment has been completed for at least the most recent prior treatment course

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

but no longer than 1 month following cessation of each prior treatment course and is no more than 1 month old at the time of application.

Continuation - Plaque psoriasis - severe chronic

Any relevant practitioner

Re-assessment required after 2 years

Either:

1 Both:

- 1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
- 1.2 Either:
 - 1.2.1 The patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 1.2.2 The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or
- 2 Both:
 - 2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2 Either:
 - 2.2.1 The patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2 The patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value.

Initiation – pyoderma gangrenosum

Dermatologist

Both:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response.

Note: Indications marked with * are unapproved indications.

Initiation - Crohn's disease - adults

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a CDAI score of greater than or equal to 300 or HBI score of greater than or equal to 10; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – Crohn's disease - adults

Any relevant practitioner

Re-assessment required after 2 years

Any of the following:

1 CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced 3 points, from when the patient was initiated on adalimumab; or

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

2 CDAI score is 150 or less, or HBI is 4 or less; or

3 The patient has demonstrated an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed.

Initiation - Crohn's disease - children

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a PCDAI score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation - Crohn's disease - children

Any relevant practitioner

Re-assessment required after 2 years

Any of the following:

- 1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
- 2 PCDAI score is 15 or less; or
- 3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed.

Initiation - Crohn's disease - fistulising

Gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); or
 - 2.3 Patient has complex peri-anal fistula; and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application.

Continuation - Crohn's disease - fistulising

Any relevant practitioner

Re-assessment required after 2 years

Either:

- 1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initiation - Ocular inflammation - chronic

Any relevant practitioner

Re-assessment required after 4 months

Either:

166

1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; or

2 Both:

- 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2.2 Any of the following:

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
- 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
- 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation - Ocular inflammation - chronic

Any relevant practitioner

Re-assessment required after 2 years

Any of the following:

- 1 The patient has had a good clinical response following 12 weeks' initial treatment; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Initiation - Ocular inflammation - severe

Any relevant practitioner

Re-assessment required after 4 months

Either:

- 1 Patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation - Ocular inflammation - severe

Any relevant practitioner

Re-assessment required after 2 years

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 Patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
- 1.2 Either:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- 1.2.1 The patient has experienced intolerable side effects; or
- 1.2.2 The patient has received insufficient benefit to meet the renewal criteria for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by radiology imaging; and
 - 2.4 Patient has not responded adequately to treatment with two or more NSAIDs, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following BASMI measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender; and
 - 2.6 A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment and is no more than 1 month old at the time of application.

Continuation – ankylosing spondylitis

Any relevant practitioner

Re-assessment required after 2 years

For applications where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less.

Initiation - Arthritis - oligoarticular course juvenile idiopathic

Named specialist or rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for oligoarticular course juvenile idiopathic arthritis (JIA); and
- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for oligoarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and
 - 2.3 Either:
 - 2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose).

Continuation – Arthritis - oligoarticular course juvenile idiopathic

Any relevant practitioner

Re-assessment required after 2 years

Either:

168

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

continued improvement in physician's global assessment from baseline.

Initiation - Arthritis - polyarticular course juvenile idiopathic

Named specialist or rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

- 1.1 Patient has had an initial Special Authority approval for etanercept for polyarticular course juvenile idiopathic arthritis (JIA); and
- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for polyarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Continuation – Arthritis - polyarticular course juvenile idiopathic

Any relevant practitioner

Re-assessment required after 2 years

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - Arthritis - psoriatic

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 Patient has had an initial Special Authority approval for etanercept or secukinumab for psoriatic arthritis; and
- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine or leflunomide at maximum tolerated doses (unless contraindicated); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or

Price		Brand or
(ex man. excl. G	ST)	Generic
 \$	Per	Manufacturer

continued...

- 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
 - 2.5.1 Patient has CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated ESR greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - Arthritis - psoriatic

Any relevant practitioner Re-assessment required after 2 years Fither:

- 1 Following initial treatment, the patient has at least a 50% decrease in swollen joint count from baseline and a clinically significant response in the opinion of the physician; or
- 2 Patient demonstrates at least a continuing 30% improvement in swollen joint count from baseline and a clinically significant response in the opinion of the treating physician.

Initiation - Arthritis - rheumatoid

Rheumatologist

Re-assessment required after 6 months Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated); and
 - 2.5 Either:
 - 2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate; and
 - 2.6 Either:

170

- 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
- 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Continuation - Arthritis - rheumatoid

Any relevant practitioner

Re-assessment required after 2 years

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Initiation - Still's disease - adult-onset (AOSD)

Rheumatologist

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept and/or tocilizumab for (AOSD); and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 Patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria; and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, NSAIDs and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initiation - ulcerative colitis

Rheumatologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has histologically confirmed active ulcerative colitis; and
- 2 Either:
 - 2.1 Patient's SCCAI score is greater than or equal to 4; or
 - 2.2 Patient's PUCAI score is greater than or equal to 65; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation - ulcerative colitis

Any relevant practitioner

Re-assessment required after 2 years Either:

- 1 The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on adalimumab; or
- 2 The PUCAI score has reduced by 30 points or more from the PUCAI score since initiation on adalimumab.

Initiation - undifferentiated spondyloarthiritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of each of methotrexate, sulphasalazine and leflunomide, at maximum tolerated doses (unless contraindicated); and
- 3 Any of the following:

	Price		Brand or
(ex man	. excl.		Generic
	\$	Per	Manufacturer

continued...

- 3.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 3.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
- 3.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications.

Continuation – undifferentiated spondyloarthiritis

Any relevant practitioner

Re-assessment required after 2 years

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response in the opinion of the treating physician.

Initiation - inflammatory bowel arthritis - axial

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has axial inflammatory pain for six months or more; and
- 3 Patient is unable to take NSAIDs; and
- 4 Patient has bilateral sacroiliitis demonstrated by radiological imaging; and
- 5 Patient has not responded adequately to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist; and
- 6 A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment.

Continuation - inflammatory bowel arthritis - axial

Any relevant practitioner

Re-assessment required after 2 years

For applications where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less.

Initiation - inflammatory bowel arthritis - peripheral

Rheumatologist

Re-assessment required after 6 months

All of the following:

172

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular; and
- 3 Patient has tried and not responded to at least three months of methotrexate, or azathioprine at a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of sulphasalazine at a maximum tolerated dose; and
- 5 Any of the following:
 - 5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an ESR greater than 25 mm per hour; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

continued...

Continuation - inflammatory bowel arthritis - peripheral

Any relevant practitioner

Re-assessment required after 2 years

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 Patient demonstrates at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician.

ADALIMUMAB (HUMIRA) - Restricted see terms below

t	Inj 20 mg per 0.4 ml syringe1,599.96	2	Humira
t	Inj 40 mg per 0.8 ml pen1,599.96	2	HumiraPen
t	Inj 40 mg per 0.8 ml syringe 1,599.96	2	Humira

→ Restricted (RS1877)

Continuation - polyarticular course juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Continuation - oligoarticular course juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

- Both:
 - 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Continuation – fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 6 months Either:

- 1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Continuation - Crohn's disease - adults

Gastroenterologist

Re-assessment required after 3 months Both:

1 Either:

Price		Brand or
(ex man. excl. GS	T)	Generic
 \$	Per	Manufacturer

1.1 Either:

1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or

1.1.2 CDAI score is 150 or less; or

1.2 Both:

- 1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
- 1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation - Crohn's disease - children

Gastroenterologist

Re-assessment required after 3 months

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 100 points from the PCDAI score when the patient was initiated on adalimumab; or
 - 1.2 PCDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation – rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks' initial treatment and subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Both:

174

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation – plaque psoriasis

Dermatologist

Re-assessment required after 6 months Both:

1 Either:

- 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Either:
 - 1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

1.2 Both:

- 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
- 1.2.2 Either:
 - 1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Continuation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

Continuation - severe Behcet's disease

Any relevant practitioner

Re-assessment required after 6 months

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation - severe ocular inflammation

Re-assessment required after 12 months Both:

1 Any of the following:

1.1 The patient has had a good clinical response following 3 initial doses; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

Continuation - chronic ocular inflammation

Re-assessment required after 12 months

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

Continuation – hidradenitis suppurativa

Dermatologist

Re-assessment required after 6 months

All of the following:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
- 3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

AFLIBERCEPT - Restricted see terms below

t	Inj 40 mg per ml, 0.1 ml vial1,250.00) 1	Eylea
---	---------------------------------------	-----	-------

➡ Restricted (RS1872)

Initiation – Wet Age Related Macular Degeneration

Ophthalmologist or nurse practitioner

Re-assessment required after 3 months

Either:

176

1 All of the following:

- 1.1 Any of the following:
 - 1.1.1 Wet age-related macular degeneration (wet AMD); or
 - 1.1.2 Polypoidal choroidal vasculopathy; or
 - 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
- 1.2 Either:
 - 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
 - 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and

Price	Brand or	
(ex man. excl. GST)	Generic	
 \$	Per Manufacturer	

continued...

- 1.3 There is no structural damage to the central fovea of the treated eye; and
- 1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or
- 2 Either:
 - 2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
 - 2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Continuation - Wet Age Related Macular Degeneration

Ophthalmologist or nurse practitioner

Re-assessment required after 12 months

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

Initiation - Diabetic Macular Oedema

Ophthalmologist or nurse practitioner

Re-assessment required after 4 months

All of the following:

- 1 Patient has centre involving diabetic macular oedema (DMO); and
- 2 Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
- 3 Patient has reduced visual acuity between 6/9 6/36 with functional awareness of reduction in vision; and
- 4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
- 5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Continuation – Diabetic Macular Oedema

Ophthalmologist or nurse practitioner

Re-assessment required after 12 months

All of the following:

- 1 There is stability or two lines of Snellen visual acuity gain; and
- 2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
- 3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
- 5 After each consecutive 12 months treatment with aflibercept, patient has retrialled with at least one injection of bevacizumab and had no response.

BASILIXIMAB - Restricted see terms below

Inj 20 mg vial	2,560.00	1	Simulect
→ Restricted (RS1203)			
Initiation			
For use in solid organ transplants.			
BEVACIZUMAB – Restricted see terms below			
Inj 25 mg per ml, 4 ml vial			
Inj 25 mg per ml, 16 ml vial			
→ Restricted (RS1691)			
Initiation – Recurrent Respiratory Papillomatosis			
Otolaryngologist			
Re-assessment required after 12 months			
All of the following:			

	(ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
continued					
 Maximum of 6 doses; and The patient has recurrent respiratory papillomatosis; and The treatment is for intra-lesional administration. 					
Continuation – Recurrent Respiratory Papillomatosis					
Dtolaryngologist					
Re-assessment required after 12 months					
1 Maximum of 6 doses; and					
 2 The treatment is for intra-lesional administration; and 3 There has been a reduction in surgical treatments or disease in 	regrowth a	s a res	sult of t	reatment	
nitiation – ocular conditions	regrowthat	5 a lot			
1 Ocular neovascularisation; or 2 Exudative ocular angiopathy.					
CASIRIVIMAB AND IMDEVIMAB - Restricted see terms below					
Inj 120 mg per ml casirivimab, 11.1 ml vial (1) and inj 120 mg per imdevimab, 11.1 ml vial (1)		0.00)	1	Ronapreve
Restricted (RS1874) nitiation – Treatment of profoundly immunocompromised patier imited to 2 weeks treatment All of the following:	nts				
 Patient has confirmed (or probable) COVID-19; and The patient is in the community (treated as an outpatient) with Patient is profoundly immunocompromised** and is at risk of n against COVID-19 or is unvaccinated; and Patient's symptoms started within the last 10 days; and Patient is not receiving high flow oxygen or assisted/mechanic Casirivimab and imdevimab is to be administered at a maximu 	not having i cal ventilation	mount on; an	ed an a	adequate	response to vaccination
Notes: * Mild to moderate disease severity as described on the Minis					-
* Examples include B-cell depletive illnesses or patients receiving tre nitiation – mild to moderate COVID-19-hospitalised patients Any relevant practitioner <i>Limited to 2 weeks</i> treatment All of the following:	eatment the	at is B·	-Cell di	epleting.	
1 Patient has confirmed (or probable) COVID-19; and					
2 Patient is an in-patient in hospital with mild to moderate diseas	se severity	*; and			
3 Patient's symptoms started within the last 10 days; and					
4 Patient is not receiving high flow oxygen or assisted/mechanic	al ventilati	on; an	d		
5 Any of the following:					
5.1 Age > 50; or 5.2 BMI > 30; or					
 5.3 Patient is Māori or Pacific ethnicity; or 5.4 Patient is at increased risk of severe illness from COVI Health website (see Notes); and 	D-19, exclı	uding	pregna	incy, as d	escribed on the Ministry o
6 Either:					

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
continued 6.2 Patient is seronegative where serology testing is readi	ly available or strongly	v suspecte	d to be seronegative where
serology testing is not available; and 7 Casirivimab and imdevimab is to be administered at a maxim	um dose of no greater	than 2.40	0 ma.
Notes: * Mild to moderate disease severity as described on the Minis **(https://www.health.govt.nz/our-work/diseases-and-conditions/covid	stry of Health Website		-
audiences/covid-19-advice-higher-risk-people)			
CETUXIMAB – Restricted see terms below			
Inj 5 mg per ml, 20 ml vial		1	Erbitux
Inj 5 mg per ml, 100 ml vial	1,820.00	1	Erbitux
→ Restricted (RS1613) Initiation			
Medical oncologist			
All of the following:			
1 Patient has locally advanced, non-metastatic, squamous cell	cancer of the head and	d neck; an	d
2 Patient is contraindicated to, or is intolerant of, cisplatin; and			
3 Patient has good performance status; and			
4 To be administered in combination with radiation therapy.			
INFLIXIMAB – Restricted see terms below			
↓ Inj 100 mg		1	Remicade
→ Restricted (RS1862)			
Initiation – Graft vs host disease			
Patient has steroid-refractory acute graft vs. host disease of the gut. Initiation – rheumatoid arthritis			
Rheumatologist			
Re-assessment required after 4 months			
All of the following:			
1 The patient has had an initial Special Authority approval for ac 2 Either:	dalimumab and/or etai	nercept for	rheumatoid arthritis; and

- 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
- 2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
- 3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

Continuation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

- 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 3 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initiation – psoriatic arthritis

Rheumatologist

Re-assessment required after 4 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept and/or secukinumab; or
 - 2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept and/or secukinumab, the patient did not meet the renewal criteria for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Both:

oth:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation - severe ocular inflammation

Re-assessment required after 4 months

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or

	Р	rice			Brand or
(e	ex man.	excl.	GST)		Generic
		\$		Per	Manufacturer

continued...

- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation - severe ocular inflammation

Re-assessment required after 12 months

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation - chronic ocular inflammation

Re-assessment required after 4 months

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and

1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation - chronic ocular inflammation

Re-assessment required after 12 months

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation – Pulmonary sarcoidosis

Both:

- 1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
- 2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

Initiation - Crohn's disease (adults)

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation - Crohn's disease (adults)

Gastroenterologist

Re-assessment required after 6 months Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
 - 1.2 CDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - Crohn's disease (children)

Gastroenterologist

Re-assessment required after 3 months All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Continuation - Crohn's disease (children)

Gastroenterologist

Re-assessment required after 6 months Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 4 months Both:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e).

Continuation – fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 6 months

1 Fither:

- 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - acute severe fulminant ulcerative colitis

Gastroenterologist Limited to 6 weeks treatment Both:

- 1 Patient has acute, severe fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

Continuation - severe fulminant ulcerative colitis

Gastroenterologist

Re-assessment required after 6 months Both:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Price			Brand or
(ex man. excl.	GST)		Generic
\$		Per	Manufacturer

Initiation - ulcerative colitis

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has histologically confirmed ulcerative colitis; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is greater than or equal to 4; or
 - 2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is greater than or equal to 65; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation - ulcerative colitis

Gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
 - 2.2 Patient is under 18 years and the PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab; and
- 3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - plaque psoriasis

Dermatologist

184

Re-assessment required after 3 doses Either:

1 Both:

- 1.1 Patient has had an initial Special Authority approval for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; and
- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or secukinumab; or
 - 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or secukinumab to meet the renewal criteria for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and

Price		Brand or	_
(ex man. excl. GST)		Generic	
 \$	Per	Manufacturer	

continued...

- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – plaque psoriasis

Dermatologist

Re-assessment required after 3 doses Both:

1 Either:

- 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
- 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation – neurosarcoidosis

Neurologist

Re-assessment required after 18 months

All of the following:

- 1 Biopsy consistent with diagnosis of neurosarcoidosis; and
- 2 Patient has CNS involvement; and
- 3 Patient has steroid-refractory disease; and
- 4 Either:
 - 4.1 IV cyclophosphamide has been tried; or
 - 4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

Continuation - neurosarcoidosis

Neurologist

Re-assessment required after 18 months Either:

- 1 A withdrawal period has been tried and the patient has relapsed; or
- 2 All of the following:
 - 2.1 A withdrawal period has been considered but would not be clinically appropriate; and
 - 2.2 There has been a marked reduction in prednisone dose; and

Pr	rice			Brand or
(ex man.)	excl.	GST)		Generic
:	\$		Per	Manufacturer

- 2.3 Either:
 - 2.3.1 There has been an improvement in MRI appearances; or
 - 2.3.2 Marked improvement in other symptomology.

Initiation - severe Behcet's disease

Re-assessment required after 4 months

All of the following:

- 1 The patient has severe Behcet's disease which is significantly impacting the patient's quality of life (see Notes); and
- 2 Either:
 - 2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
 - 2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
- 3 The patient is experiencing significant loss of quality of life.

Notes:

- a) Behcet's disease diagnosed according to the International Study Group for Behcet's Disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al J Rheumatol. 2004;31:931-7.
- b) Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

Continuation - severe Behcet's disease

Re-assessment required after 6 months

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Indications marked with * are unapproved indications.

Continuation - pyoderma gangrenosum

Dermatologist

186

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

MEPOLIZUMAB - Restricted see terms below

t	Inj 100 mg prefilled pen1,63	38.00	1	Nucala
	Inj 100 mg vial		1	Nucala
	Restricted (RS1733)			
Ini	tiation – Severe eosinophilic asthma			

Respiratory physician or clinical immunologist *Re-assessment required after 12 months* All of the following:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than 0.5 × 10⁹ cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the single maintenance and reliever therapy regimen, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment.

Continuation – Severe eosinophilic asthma

Respiratory physician or clinical immunologist *Re-assessment required after 2 years* Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with mepolizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

OBINUTUZUMAB - Restricted see terms below

t	Inj 25 mg per ml, 40 ml vial	5,910.00	1	Gazyva
⇒	Restricted (RS1550)			

Initiation

Haematologist

Limited to 6 months treatment

All of the following:

- 1 The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is obinutuzumab treatment naive; and
- 3 The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
- 4 Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
- 5 Patient has good performance status; and
- 6 Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* greater than or equal to 1.5×10^{9} /L and platelets greater than or equal to 75×10^{9} /L

(ex m	Price an. excl. GST) \$	Per	Brand or Generic Manufacturer
OMALIZUMAB – Restricted see terms below			
Inj 150 mg prefilled syringe	450.00	1	Xolair
Inj 150 mg vial		1	Xolair

➡ Restricted (RS1652)

Initiation – severe asthma

Clinical immunologist or respiratory specialist

Re-assessment required after 6 months

All of the following:

- 1 Patient must be aged 6 years or older ; and
- 2 Patient has a diagnosis of severe asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
 - 6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less; and
- 8 Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Continuation - severe asthma

Respiratory specialist

Re-assessment required after 6 months

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Initiation – severe chronic spontaneous urticaria

Clinical immunologist or dermatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
 - 2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; and
- 3 Any of the following:
 - 3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
 - 3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
 - 3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
- 4 Either:
 - 4.1 Treatment to be stopped if inadequate response* following 4 doses; or
 - 4.2 Complete response* to 6 doses of omalizumab.

continued...

188

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Continuation - severe chronic spontaneous urticaria

Clinical immunologist or dermatologist

Re-assessment required after 6 months

Either:

1 Patient has previously had a complete response* to 6 doses of omalizumab; or

2 Both:

- 2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
- 2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PERTUZUMAB - Restricted see terms below

➡ Restricted (RS1551)

Initiation

Re-assessment required after 12 months All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 Patient is chemotherapy treatment naive; or
 - 2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
- 3 The patient has good performance status (ECOG grade 0-1); and
- 4 Pertuzumab to be administered in combination with trastuzumab; and
- 5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
- 6 Pertuzumab to be discontinued at disease progression.

Continuation

Re-assessment required after 12 months

Both:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RANIBIZUMAB - Restricted see terms below

- Inj 10 mg per ml, 0.23 ml vial
- Inj 10 mg per ml, 0.3 ml vial

⇒ Restricted (RS1870)

Initiation - Wet Age Related Macular Degeneration

Ophthalmologist or nurse practitioner *Re-assessment required after 3 months* Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Wet age-related macular degeneration (wet AMD); or
 - 1.1.2 Polypoidal choroidal vasculopathy; or

Price		Brand or
(ex man. excl. GS		Generic
 \$	Per	Manufacturer

continued...

- 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
- 1.2 Either:
 - 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
 - 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
- 1.3 There is no structural damage to the central fovea of the treated eye; and
- 1.4 Patient has not previously been treated with aflibercept for longer than 3 months; or
- 2 Patient has current approval to use aflibercept for treatment of wAMD and was found to be intolerant to aflibercept within 3 months.

Continuation - Wet Age Related Macular Degeneration

Ophthalmologist or nurse practitioner

Re-assessment required after 12 months

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

RITUXIMAB (MABTHERA) - Restricted see terms below

t	Inj 10 mg per ml, 10 ml vial1,075.50	2	Mabthera
t	Inj 10 mg per ml, 50 ml vial2,688.30	1	Mabthera

⇒ Restricted (RS1785)

Initiation - rheumatoid arthritis - prior TNF inhibitor use

Rheumatologist

Limited to 4 months treatment

All of the following:

- 1 Both:
 - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation - rheumatoid arthritis - TNF inhibitors contraindicated

Rheumatologist

Limited to 4 months treatment

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- continued...
 - 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 5 Any of the following:
 - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 7 Either:
 - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
 - 8 Either:
 - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
 - 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'partial responders' to rituximab

Rheumatologist

- *Re-assessment required after 4 months* All of the following:
 - 1 Any of the following:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
 - 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
 - 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
 - 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'responders' to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

- 1 Either:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

Price			Brand or
ex man. excl.	GST)		Generic
 \$		Per	Manufacturer

continued...

- 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

RITUXIMAB (RIXIMYO) - Restricted see terms below

t	Inj 10 mg per ml, 10 ml vial2	75.33	2	Riximyo
t	Inj 10 mg per ml, 50 ml vial6	88.20	1	Riximyo
	Bestalster (DO1000)			

➡ Restricted (RS1890)

Initiation - haemophilia with inhibitors

Haematologist

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

Continuation - haemophilia with inhibitors

Haematologist

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initiation - post-transplant

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.
- Note: Indications marked with * are unapproved indications.

Continuation – post-transplant

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.
- Note: Indications marked with * are unapproved indications.

Initiation - indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 9 months

Either:

192

- 1 Both:
 - 1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Continuation - indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 12 months

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, Iow-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant. **Initiation – aggressive CD20 positive NHL**

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.
- Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Continuation - aggressive CD20 positive NHL

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Initiation – Chronic lymphocytic leukaemia

Re-assessment required after 12 months

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 Any of the following:
 - 2.1 The patient is rituximab treatment naive; or
 - 2.2 Either:
 - 2.2.1 The patient is chemotherapy treatment naive; or

2.2.2 Both:

- 2.2.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
- 2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or
- 2.3 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; and
- 3 The patient has good performance status; and
- 4 Either:
 - 4.1 The patient does not have chromosome 17p deletion CLL; or
 - 4.2 Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia; and

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 5 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles; and
- 6 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

Continuation – Chronic lymphocytic leukaemia

Re-assessment required after 12 months Both:

- 1 Either:
 - 1.1 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or
 - 1.2 All of the following:
 - 1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
 - 1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
 - 1.2.3 The patient does not have chromosome 17p deletion CLL; and
 - 1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustin; and
- 2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initiation - severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has cold haemagglutinin disease*; and
- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Continuation – severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 8 weeks

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

Initiation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has warm autoimmune haemolytic anaemia*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Continuation - warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 8 weeks

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.
- Note: Indications marked with * are unapproved indications.

Initiation – immune thrombocytopenic purpura (ITP)

Haematologist

Re-assessment required after 8 weeks

- All of the following:
 - 1 Either:
 - 1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
 - 1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
 - 2 Any of the following:
 - 2.1 Treatment with steroids and splenectomy have been ineffective; or
 - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
 - 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy); and
 - 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Continuation - immune thrombocytopenic purpura (ITP)

Haematologist

Re-assessment required after 8 weeks Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

- 2.2 An initial response lasting at least 12 months was demonstrated; and
- 2.3 Patient now requires repeat treatment.
- Note: Indications marked with * are unapproved indications.

Initiation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Re-assessment required after 8 weeks

Both:

- 1 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks; and
- 2 Either:
 - 2.1 Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
 - 2.2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

Continuation - thrombotic thrombocytopenic purpura (TTP)

Haematologist

Re-assessment required after 8 weeks All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initiation – pure red cell aplasia (PRCA)

Haematologist

Re-assessment required after 6 weeks

Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

Continuation - pure red cell aplasia (PRCA)

Haematologist

Re-assessment required after 6 weeks

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initiation – ANCA associated vasculitis

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
- 3 Any of the following:
 - 3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
 - 3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
 - 3.3 Cyclophosphamide and methotrexate are contraindicated; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 3.4 Patient is a female of child-bearing potential; or
- 3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

Continuation – ANCA associated vasculitis

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initiation - treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Continuation - treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Initiation - Antibody-mediated organ transplant rejection

Patient has been diagnosed with antibody-mediated organ transplant rejection*.

Note: Indications marked with * are unapproved indications.

Initiation – ABO-incompatible organ transplant

Patient is to undergo an ABO-incompatible solid organ transplant*.

Note: Indications marked with * are unapproved indications.

Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) Nephrologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient is a child with SDNS* or FRNS*; and
- 2 Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
- 3 Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
- 4 Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
- 5 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Price		Brand or
(ex man. excl. GS	T)	Generic
 \$	Per	Manufacturer

Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) Nephrologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Initiation – Steroid resistant nephrotic syndrome (SRNS)

Nephrologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
- 2 Treatment with tacrolimus for at least 3 months has been ineffective; and
- 3 Genetic causes of nephrotic syndrome have been excluded; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Continuation – Steroid resistant nephrotic syndrome (SRNS)

Nephrologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.
- Note: Indications marked with a * are unapproved indications.

Initiation - Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 6 months

Both:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks; and
- 2 Either:
 - 2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
 - 2.2 All of the following:
 - 2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
 - 2.2.2 The patient is receiving treatment with mycophenolate; and
 - 2.2.3 The patients is receiving treatment with corticosteroids.

Continuation - Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 2 years

All of the following:

1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 375 mg/m2 administered weekly for four weeks; and
- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

Initiation - Severe Refractory Myasthenia Gravis

Neurologist

Re-assessment required after 2 years Both:

Both:

- 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 Either:
 - 2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
 - 2.2 Both:
 - 2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
 - 2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Continuation - Severe Refractory Myasthenia Gravis

Neurologist

Re-assessment required after 2 years

All of the following:

- 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Either:
 - 3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
 - 3.2 Both:
 - 3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
 - 3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Initiation – Severe antisynthetase syndrome

Re-assessment required after 12 months

All of the following:

- 1 Patient has confirmed antisynthetase syndrome; and
- 2 Patient has severe, immediately life or organ threatening disease, including interstitial lung disease; and
- 3 Either:
 - 3.1 Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not be effective at controlling active disease; or
 - 3.2 Rapid treatment is required due to life threatening complications; and

4 Maximum of four 1,000 mg infusions of rituximab.

Continuation - Severe antisynthetase syndrome

Re-assessment required after 12 months

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function; and
- 2 The patient has not received rituximab in the previous 6 months; and

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

3 Maximum of two cycles of 2 × 1,000 mg infusions of rituximab given two weeks apart.

Initiation – graft versus host disease

All of the following:

- 1 Patient has refractory graft versus host disease following transplant; and
- 2 Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not be effective at controlling active disease; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Initiation - severe chronic inflammatory demyelinating polyneuropathy

Neurologist

Re-assessment required after 6 months

All of the following:

1 Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD); and

2 Either:

- 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
- 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Continuation - severe chronic inflammatory demyelinating polyneuropathy

Neurologist or medical practitioner on the recommendation of a Neurologist

Re-assessment required after 6 months

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initiation – anti-NMDA receptor autoimmune encephalitis

Neurologist

Re-assessment required after 6 months All of the following:

- 1 Patient has severe anti-NMDA receptor autoimmune encephalitis; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
 - 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

Continuation - anti-NMDA receptor autoimmune encephalitis

Neurologist

Re-assessment required after 6 months

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 The patient has experienced a relapse and now requires further treatment; and
- 4 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initiation - CD20+ low grade or follicular B-cell NHL

Re-assessment required after 9 months

Either:

- 1 Both:
 - 1.1 The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Continuation - CD20+ low grade or follicular B-cell NHL

Re-assessment required after 24 months

Both:

- 1 Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy; and
- 2 Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m2 every 8 weeks (maximum of 12 cycles).

Initiation – Membranous nephropathy

Re-assessment required after 6 weeks

All of the following:

- 1 Either:
 - 1.1 Patient has biopsy-proven primary/idiopathic membranous nephropathy*; or
 - 1.2 Patient has PLA2 antibodies with no evidence of secondary cause, and an eGFR of > 60ml/min/1.73m2; and
- 2 Patient remains at high risk of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures (see Note); and
- 3 The total rituximab dose would not exceed the equivalent of 375mg/m2 of body surface area per week for a total of 4 weeks.

Continuation - Membranous nephropathy

Re-assessment required after 6 weeks

All of the following:

1 Patient was previously treated with rituximab for membranous nephropathy*; and

2 Either:

- 2.1 Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; or
- 2.2 Patient achieved partial response to treatment and requires repeat treatment (see Note); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Notes:

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

continued...

- a) Indications marked with * are unapproved indications.
- b) High risk of progression to end-stage kidney disease defined as > 5g/day proteinuria.
- c) Conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents unless contraindicated or the patient has experienced intolerable side effects.
- d) Partial response defined as a reduction of proteinuria of at least 50% from baseline, and between 0.3 grams and 3.5 grams per 24 hours.

Initiation - B-cell acute lymphoblastic leukaemia/lymphoma*

Limited to 2 years treatment

All of the following:

- 1 Patient has newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma*; and
- 2 Treatment must be in combination with an intensive chemotherapy protocol with curative intent; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m2 per dose for a maximum of 18 doses.
- Note: Indications marked with * are unapproved indications.

Initiation - desensitisation prior to transplant

Limited to 6 weeks treatment

Both:

- 1 Patient requires desensitisation prior to mismatched allogenic stem cell transplant*; and
- 2 Patient would receive no more than two doses at 375 mg/m2 of body-surface area.

Note: Indications marked with * are unapproved indications.

Initiation - pemiphigus*

Dermatologist or relevant specialist

Re-assessment required after 6 months

Either:

- 1 All of the following:
 - 1.1 Patient has severe rapidly progressive pemphigus; and
 - 1.2 Is used in combination with systemic corticosteroids (20 mg/day); and
 - 1.3 Any of the following:
 - 1.3.1 Skin involvement is at least 5% body surface area; or
 - 1.3.2 Significant mucosal involvement (10 or more mucosal erosions) or diffuse gingivitis or confluent large erosions; or
 - 1.3.3 Involvement of two or more mucosal sites; or

2 Both:

- 2.1 Patient has pemphigus; and
- 2.2 Patient has not experienced adequate clinical benefit from systemic corticosteroids (20 mg/day) in combination with a steroid sparing agent, unless contraindicated.

Note: Indications marked with * are unapproved indications.

Continuation - pemiphigus*

Dermatologist or relevant specialist

Re-assessment required after 6 months

Both:

202

1 Patient has experienced adequate clinical benefit from rituximab treatment, with improvement in symptoms and healing of skin ulceration and reduction in corticosteroid requirement; and

O a a a b b

2 Patient has not received rituximab in the previous 6 months.

Note: Indications marked with * are unapproved indications.

SECUKINUMAB – Restricted see terms on the next page	
Ini 150 ma per ml. 1 ml prefilled svringe	799.50

٠	Inj 150 mg per mi, 1 mi premied synnge	1	Cosemyx
	1,599.00	2	Cosentyx

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

→ Restricted (RS1863)

Initiation - severe chronic plaque psoriasis, second-line biologic

Dermatologist

Re-assessment required after 4 months

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule, for severe chronic plaque psoriasis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
 - 2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
- 3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Continuation - severe chronic plaque psoriasis, second-line biologic

Dermatologist

Re-assessment required after 6 months Both:

1 Either:

- 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
- 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

Initiation – severe chronic plaque psoriasis, first-line biologic

Dermatologist

Re-assessment required after 4 months All of the following:

1 Either:

- 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for enythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Price		Brand or
(ex man. excl. GST		Generic
\$	Per	Manufacturer

Continuation - severe chronic plaque psoriasis, first-line biologic

Dermatologist

Re-assessment required after 6 months

Both:

- 1 Either:
 - 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
 - 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

Initiation - ankylosing spondylitis, second-line biologic

Rheumatologist

Re-assessment required after 3 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Continuation - ankylosing spondylitis, second-line biologic

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks initial treatment of secukinumab treatment, BASDAI has improved by 4 or more points from pre-secukinumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefitted from treatment and that continued treatment is appropriate; and
- 3 Secukinumab to be administered at doses no greater than 150 mg monthly.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 Patient has had an initial Special Authority approval for adalimumab, etanercept or infliximab for psoriatic arthritis; and
- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
 - 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or infliximab to meet the renewal criteria for adalimumab, etanercept or infliximab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior secukinumab treatment in the opinion of the treating physician; and
- 2 Secukinumab to be administered at doses no greater than 300 mg monthly.

SILTUXIMAB - Restricted see terms below

t	Inj 100 mg vial770.57	1	Sylvant
t	Inj 400 mg vial	1	Sylvant

→ Restricted (RS1525)

Initiation

Haematologist or rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Continuation

Haematologist or rheumatologist

Re-assessment required after 12 months

The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

TOCILIZUMAB - Restricted see terms below

t	Inj 20 mg per ml, 4 ml vial	1	Actemra
t	Inj 20 mg per ml, 10 ml vial550.00	1	Actemra
	Inj 20 mg per ml, 20 ml vial1,100.00	1	Actemra

➡ Restricted (RS1875)

Initiation – cytokine release syndrome

Therapy limited to 3 doses

Either:

- 1 All of the following:
 - 1.1 The patient is enrolled in the Children's Oncology Group AALL1731 trial; and
 - 1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
 - 1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg,

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

maximum of 12 mg/kg); or

- 2 All of the following:
 - 2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
 - 2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
 - 2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Initiation – previous use

Any relevant practitioner

Limited to 6 months treatment

Both:

- 1 Patient was being treated with tocilizumab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 rheumatoid arthritis; or
 - 2.2 systemic juvenile idiopathic arthritis; or
 - 2.3 adult-onset Still's disease; or
 - 2.4 polyarticular juvenile idiopathic arthritis; or
 - 2.5 idiopathic multicentric Castleman's disease.

Initiation - Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Limited to 6 months treatment

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and
 - 3.2.2 Either:
 - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
 - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Initiation - Rheumatoid Arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 2 Tocilizumab is to be used as monotherapy; and
- 3 Either:
 - 3.1 Treatment with methotrexate is contraindicated; or
 - 3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
- 4 Either:

206

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

continued...

- 4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
- 4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and

5 Either:

- 5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
- 5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 6 Either:
 - 6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initiation - systemic juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Initiation - adult-onset Still's disease

Rheumatologist or Practitioner on the recommendation of a rheumatologist *Re-assessment required after 6 months* Either:

1 Both:

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initiation - polyarticular juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 4 months

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and

Price		Brand or
(ex man. excl. GST		Generic
\$	Per	Manufacturer

continued...

1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or

2 All of the following:

- 2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
- 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
- 2.3 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.4 Any of the following:
 - 2.4.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Initiation – idiopathic multicentric Castleman's disease

Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist *Re-assessment required after 6 months*

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Initiation - moderate to severe COVID-19*

Therapy limited to 1 dose

All of the following:

- 1 Patient has confirmed (or probable) COVID-19; and
- 2 Oxygen saturation of < 92% on room air, or requiring supplemental oxygen; and
- 3 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
- 4 Tocilizumab is to be administered at doses no greater than 8mg/kg IV for a maximum of one dose; and
- 5 Tocilizumab is not to be administered in combination with barcitinib.

Note: Indications marked with * are unapproved indications.

Continuation – Rheumatoid Arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Continuation - systemic juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist Re-assessment required after 6 months

Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

	Price		Brand or
(ex ma	n. excl. GS		Generic
	\$	Per	Manufacturer

continued...

Continuation – adult-onset Still's disease

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

the patient has a sustained improvement in inflammatory markers and functional status.

Continuation - polyarticular juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Both:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

- 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Continuation - idiopathic multicentric Castleman's disease

Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist *Re-assessment required after 12 months*

the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB - Restricted see terms below

t	Inj 150 mg vial1,350.00	1	Herceptin
t	Inj 440 mg vial	1	Herceptin

→ Restricted (RS1554)

Initiation – Early breast cancer

Limited to 12 months treatment

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
 - 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Initiation - metastatic breast cancer (trastuzumab-naive patients)

Limited to 12 months treatment

All of the following:

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 Both:
 - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or

Price		Brand or
(ex man. excl. GS		Generic
 \$	Per	Manufacturer

- 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

Initiation - metastatic breast cancer (patients previously treated with trastuzumab)

Limited to 12 months treatment

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 Both:
 - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

Continuation - metastatic breast cancer

Re-assessment required after 12 months

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

TRASTUZUMAB EMTANSINE - Restricted see terms below

t	Inj 100 mg vial2,320.00	1	Kadcyla
t	Inj 160 mg vial	1	Kadcyla
-	Destricted (DC1715)		

→ Restricted (RS1715)

Initiation

Re-assessment required after 6 months All of the following:

- 1 Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and

Price		Brand or
(ex man. excl. C	GST)	Generic
\$	Per	Manufacturer

continued...

- 3 Either:
 - 3.1 The patient has received prior therapy for metastatic disease*; or
 - 3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy*; and
- 4 Patient has a good performance status (ECOG 0-1); and
- 5 Either:
 - 5.1 Patient does not have symptomatic brain metastases; or
 - 5.2 Patient has brain metastases and has received prior local CNS therapy; and
- 6 Treatment to be discontinued at disease progression.

Continuation

Re-assessment required after 6 months

Both:

- 1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine; and
- 2 Treatment to be discontinued at disease progression.

Note: *Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

Programmed Cell Death-1 (PD-1) Inhibitors

NIVOLUMAB -	- Restricted se	ee terms below
-------------	-----------------	----------------

t	Inj 10 mg per ml, 4 ml vial1,051.98	1	Opdivo
t	Inj 10 mg per ml, 10 ml vial2,629.96	1	Opdivo

→ Restricted (RS1891)

Initiation

Medical oncologist

Re-assessment required after 4 months

All of the following:

- 1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Patient has measurable disease as defined by RECIST version 1.1; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded pembrolizumab; or
 - 4.2 Both:
 - 4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
 - 4.2.2 The cancer did not progress while the patient was on pembrolizumab; and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that funded treatment with nivolumab will not be continued if their disease progresses.

Continuation

Medical oncologist

Re-assessment required after 4 months Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
 - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and

Price		Brand or
(ex man. excl.	GST)	Generic
 \$	Per	Manufacturer

continued...

- 1.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and
- 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
- 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with nivolumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB - Restricted see terms below

→ Restricted (RS1892) Initiation

Medical oncologist *Re-assessment required after 4 months* All of the following:

- 1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Patient has measurable disease as defined by RECIST version 1.1; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded nivolumab; or
 - 4.2 Both:
 - 4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
 - 4.2.2 The cancer did not progress while the patient was on nivolumab; and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that funded treatment with pembrolizumab will not be continued if their disease progresses.

Price	e		Brand or
(ex man. ex	cl. GST)		Generic
\$		Per	Manufacturer

continued...

Continuation

Medical oncologist *Re-assessment required after 4 months* Fither:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
 - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
 - 1.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and
 - 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
 - 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pembrolizumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Other Immunosuppressants

ANTITHYMOCYTE GLOBULIN (EQUINE) Inj 50 mg per ml, 5 ml ampoule2,7	774.48	5	ATGAM
ANTITHYMOCYTE GLOBULIN (RABBIT) Inj 25 mg vial			
AZATHIOPRINE			
Tab 25 mg – 1% DV Jan-20 to 2022		60	Azamun
Tab 50 mg - 1% DV Jan-20 to 2022	7.60	100	Azamun
Inj 50 mg vial – 1% DV Nov-19 to 2022 (Imuran Inj 50 mg vial to be delisted 1 January 2023)	199.00	1	Imuran
BACILLUS CALMETTE-GUERIN (BCG) - Restricted see terms on the next pa			
Inj 2-8 × 10 [^] 8 CFU vial [↑]	149.37	1	OncoTICE

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	(ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
→ Restricted (RS1206) Initiation For use in bladder cancer.					
EVEROLIMUS – Restricted see terms below					
				30	Afinitor
↓ Tab 10 mg	6,	512.29	9	30	Afinitor
→ Restricted (RS1811)					
Initiation					
Neurologist or oncologist					
Re-assessment required after 3 months Both:					
 Patient has tuberous sclerosis; and Patient has progressively enlarging sub-ependymal giant cel 	laatrooutom	oo (Si		that roa	iro tractmont
Continuation	asirucyi0III	as (31	LUMS)	inai requ	
Neurologist or oncologist					
Re-assessment required after 12 months					
All of the following:					
1 Documented evidence of SEGA reduction or stabilisation by	MRI within t	he las	t 3 moi	oths: and	I
2 The treatment remains appropriate and the patient is benefiti				nno, and	
3 Everolimus to be discontinued at progression of SEGAs.	ing norm aloc		., and		
Note: MRI should be performed at minimum once every 12 months	more frequ	ent sc	anning	should I	ne nerformed with new onse
of symptoms such as headaches, visual complaints, nausea or vom					
MYCOPHENOLATE MOFETIL	lang, or more	0000	11 00120	io dolivit	<i>J</i> .
Tab 500 mg		35 91	n	50	CellCept
Cap 250 mg				100	CellCept
Powder for oral liq 1 g per 5 ml				165 ml	CellCept
Inj 500 mg vial				4	CellCept
		100.00	5	-	0010000
PICIBANIL					
Inj 100 mcg vial					
SIROLIMUS – Restricted see terms below					
Tab 1 mg				100	Rapamune
Tab 2 mg				100	Rapamune
Oral liq 1 mg per ml	•••••••	449.99	9	60 ml	Rapamune
Restricted (RS1812)					
Initiation					
For rescue therapy for an organ transplant recipient.					and a second section of a factor because
Notes: Rescue therapy defined as unresponsive to calcineurin inhit	bitor treatme	nt as (defined	by refra	ctory rejection; or intolerant
to calcineurin inhibitor treatment due to any of the following:					
• GFR < 30 ml/min; or					
 Rapidly progressive transplant vasculopathy; or 					
Rapidly progressive obstructive bronchiolitis; or					

- · HUS or TTP; or
- · Leukoencepthalopathy; or
- Significant malignant disease

Initiation - severe non-malignant lymphovascular malformations*

Re-assessment required after 6 months

All of the following:

214

1 Patient has severe non-malignant lymphovascular malformation*; and

F	Price		Brand or
(ex man.	excl. GST)		Generic
	\$	Per	Manufacturer

continued...

- 2 Any of the following:
 - 2.1 Malformations are not adequately controlled by sclerotherapy and surgery; or
 - 2.2 Malformations are widespread/extensive and sclerotherapy and surgery are not considered clinically appropriate; or
 - 2.3 Sirolimus is to be used to reduce malformation prior to consideration of surgery; and
- 3 Patient is being treated by a specialist lymphovascular malformation multi-disciplinary team; and
- 4 Patient has measurable disease as defined by RECIST version 1.1 (see Note).

Continuation - severe non-malignant lymphovascular malformations*

Re-assessment required after 12 months

All of the following:

- 1 Either:
 - 1.1 Patient's disease has had either a complete response or a partial response to treatment, or patient has stable disease according to RECIST version 1.1 (see Note); or
 - 1.2 Patient's disease has stabilised or responded clinically and disease response to treatment has been clearly documents in patient notes; and
- 2 No evidence of progressive disease; and
- 3 The treatment remains clinically appropriate and the patient is benefitting from the treatment.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer et al. Eur J Cancer 2009;45:228-47)

Indications marked with * are unapproved indications

Initiation - renal angiomyolipoma(s) associated with tuberous sclerosis complex*

Nephrologist or urologist

Re-assessment required after 6 months

Both:

- 1 Patient has tuberous sclerosis complex*; and
- 2 Evidence of renal angiomyolipoma(s) measuring 3 cm or greater and that have shown interval growth.

Continuation - renal angiomyolipoma(s) associated with tuberous sclerosis complex*

Re-assessment required after 12 months

All of the following:

- 1 Documented evidence of renal angiomyolipoma reduction or stability by magnetic resonance imaging (MRI) or ultrasound; and
- 2 Demonstrated stabilisation or improvement in renal function; and
- 3 The patient has not experienced angiomyolipoma haemorrhage or significant adverse effects to sirolimus treatment; and
- 4 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indications marked with * are unapproved indications

Initiation - refractory seizures associated with tuberous sclerosis complex*

Neurologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has epilepsy with a background of documented tuberous sclerosis complex*; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Vigabatrin has been trialled and has not adequately controlled seizures; and
 - 2.1.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least two of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); or
 - 2.2 Both:
 - 2.2.1 Vigabatrin is contraindicated; and

	Price (ex man. excl. GST)		Brand or
			Generic
	\$	Per	Manufacturer

continued...

- 2.2.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least three of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); and
- 3 Seizures have a significant impact on guality of life; and
- 4 Patient has been assessed and surgery is considered inappropriate for this patient, or the patient has been assessed and would benefit from mTOR inhibitor treatment prior to surgery.

Note: "Optimal treatment" is defined as treatment, which is indicated and clinically appropriate for the patient, given in adequate doses for the patients age, weight and other features affecting the pharmacokinetics of the drug, with good evidence of adherence. Women of childbearing age are not required to have a trial of sodium valproate.

Continuation - refractory seizures associated with tuberous sclerosis complex*

Neurologist

Re-assessment required after 12 months

demonstrated significant and sustained improvement in seizure rate (e.g. 50% reduction in seizure frequency) or severity and/or patient quality of life compared with baseline prior to starting sirolimus treatment.

Note: Indications marked with * are unapproved indications

JAK inhibitors

BARICITINIB – Restricted see terms below			
Tab 2 mg	0.00	28	Olumiant
Tab 4 mg			Olumiant
→ Restricted (RS1876)			

Initiation - moderate to severe COVID-19*

Limited to 14 days treatment

All of the following:

- 1 Patient has confirmed (or probable) COVID-19*; and
- 2 Oxygen saturation of < 92% on room air, or requiring supplemental oxygen; and
- 3 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
- 4 Baricitinib is to be administered at doses no greater than 4 mg daily for up to 14 days; and
- 5 Baricitinib is not to be administered in combination with tocilizumab.

Note: Indications marked with * are unapproved indications.

UPADACITINIB - Restricted see terms below

28 RINVOQ

→ Restricted (RS1861)

Initiation - Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)

Rheumatologist

Limited to 6 months treatment

All of the following:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and 2 Fither:

- - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis: and
- 3 Either:

216

- 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the

e.g. Brand indicates brand example only. It is not a contracted product.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Section H rules; and

3.2.2 Either:

3.2.2.1 The patient has experienced intolerable side effects from rituximab; or

3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Continuation – Rheumatoid Arthritis

Rheumatologist

Re-assessment required after 6 months Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
Antiallergy Preparations			
Allergic Emergencies			
ICATIBANT - Restricted see terms below ↓ Inj 10 mg per ml, 3 ml prefilled syringe	haryngeal or severe a -esterase inhibitor de bon an action plan for	ficiency; a	ind
Allergy Desensitisation			
BEE VENOM - Restricted see terms below ↓ Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluer ↓ Inj 550 mcg vial with diluent ↓ Initiation Kit - 5 vials freeze dried venom with diluent ↓ Maintenance Kit - 1 vial freeze dried venom with diluent ↓ Restricted (RS1117) Initiation Both:		1 1	VENOX VENOX
 RAST or skin test positive; and Patient has had severe generalised reaction to the sensitising 	agent.		
PAPER WASP VENOM - Restricted see terms below ↓ Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent ↓ Inj 550 mcg vial with diluent → Restricted (RS1118) Initiation Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising VELLOW_IACKET WASP VENOM	agent.		
YELLOW JACKET WASP VENOM - Restricted see terms below ↓ Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent ↓ Inj 550 mcg vial with diluent → Restricted (RS1119) Initiation Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising	agent.		

	Price		Brand or
	(ex man. excl. GS \$	T) Per	Generic Manufacturer
Allergy Prophylactics			
BUDESONIDE			
Nasal spray 50 mcg per dose – 1% DV Oct-20 to 2023 Nasal spray 100 mcg per dose – 1% DV Oct-20 to 2023		200 dose 200 dose	SteroClear SteroClear
LUTICASONE PROPIONATE Nasal spray 50 mcg per dose – 5% DV Dec-21 to 2024	1.98	120 dose	Flixonase Hayfever & Allergy
PRATROPIUM BROMIDE Aqueous nasal spray 0.03% – 1% DV Apr-21 to 2023	5.23	15 ml	Univent
SODIUM CROMOGLICATE Nasal spray 4%			
Antihistamines			
CETIRIZINE HYDROCHLORIDE			
Tab 10 mg – 1% DV Nov-19 to 2022 Oral lig 1 mg per ml – 5% DV Jan-22 to 2024		100 200 ml	Zista Histaclear
CHLORPHENIRAMINE MALEATE	2.04	200 111	nistacieai
Oral lig 0.4 mg per ml			
Inj 10 mg per ml, 1 ml ampoule			
YPROHEPTADINE HYDROCHLORIDE Tab 4 mg			
EXOFENADINE HYDROCHLORIDE			
Tab 60 mg			
Tab 120 mg Tab 180 mg			
C C			
ORATADINE Tab 10 mg - 1% DV Feb-20 to 2022	1.69	100	Lorafix
Oral liq 1 mg per ml – 1% DV Sep-21 to 2022		100 ml	Haylor Syrup
PROMETHAZINE HYDROCHLORIDE			
Tab 10 mg - 5% DV Sep-22 to 2025	1.39	50	Allersoothe
Tab 25 mg - 5% DV Sep-22 to 2025		50	Allersoothe
Oral liq 1 mg per ml		100 ml	Allersoothe
Inj 25 mg per ml, 2 ml ampoule	17.87	5	Hospira
Anticholinergic Agents			
PRATROPIUM BROMIDE			
Aerosol inhaler 20 mcg per dose			
Nebuliser soln 250 mcg per ml, 1 ml ampoule	11 70	00	Universit
Nebuliser soln 250 mcg per ml, 2 ml ampoule - 1% DV Jan-20	to 2022 11./3	20	Univent
Anticholinergic Agents with Beta-Adrenoceptor Agents	gonists		
SALBUTAMOL WITH IPRATROPIUM BROMIDE			
Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per do			
Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 n		20	Duolin
ampoule - 5% DV Jan-22 to 2024	11.04	20	Duoim

	(ex man	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
Long-Acting Muscarinic Agents					
GLYCOPYRRONIUM Note: inhaled glycopyrronium treatment must not be used if the p or umeclidinium. Powder for inhalation 50 mcg per dose			0	treatment	with subsidised tiotropium
TIOTROPIUM BROMIDE Note: tiotropium treatment must not be used if the patient is also or umeclidinium. Soln for inhalation 2.5 mcg per dose	receiving	treatm	nent wit		
Powder for inhalation 18 mcg per dose UMECLIDINIUM Note: Umeclidinium must not be used if the patient is also receivi		50.3	7 3	30 dose iidised inh	Spiriva
tiotropium bromide. Powder for inhalation 62.5 mcg per dose		61.50	о з	30 dose	Incruse Ellipta

Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

→ Restricted (RS1518)

Initiation

Re-assessment required after 2 years

Both:

- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
- 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Continuation

Re-assessment required after 2 years

Both:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).

Note: Combination long acting muscarinic antagonist and long acting beta-2 agonist must not be used if the patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

GĽ	YCO	PYI	RR	٥N	١IL	JM	WITI	H IND	AC	AT	Έŀ	ROL	. –	Re	es	stricted	see	e ter	ms	abo	ove		
	-																						

Powder for Inhalation 50 mcg with indacaterol 110 mcg	81.00	30 dose	Ultibro Breezhaler	
TIOTROPIUM BROMIDE WITH OLODATEROL – Restricted see terms about Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg		60 dose	Spiolto Respimat	
UMECLIDINIUM WITH VILANTEROL – Restricted see terms above		00 0000	opiono neopiniar	
Powder for inhalation 62.5 mcg with vilanterol 25 mcg	77.00	30 dose	Anoro Ellipta	
Antifibrotics				
NINTEDANIB – Restricted see terms below				Ī
	2,554.00	60	Ofev	
↓ Cap 150 mg	3,870.00	60	Ofev	
➡ Restricted (RS1813)				
Initiation – idiopathic pulmonary fibrosis				
Respiratory specialist				
Re-assessment required after 12 months				
All of the following				

All of the following:

continued...

Price	Brand or	
(ex man. excl. GST)	Generic	
 \$	Per Manufacturer	

- continued...
 - 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
 - 2 Forced vital capacity is between 50% and 90% predicted; and
 - 3 Nintedanib is to be discontinued at disease progression (See Note); and
 - 4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
 - 5 Any of the following:
 - 5.1 The patient has not previously received treatment with pirfenidone; or
 - 5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Continuation - idiopathic pulmonary fibrosis

Respiratory specialist

Re-assessment required after 12 months

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE – **Restricted** see terms below

t	Tab 267 mg1,215.00	90	Esbriet
t	Tab 801 mg3,645.00	90	Esbriet

⇒ Restricted (RS1814)

Initiation - idiopathic pulmonary fibrosis

Respiratory specialist

Re-assessment required after 12 months

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Pirfenidone is to be discontinued at disease progression (See Notes); and
- 4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with nintedanib; or
 - 5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Continuation - idiopathic pulmonary fibrosis

Respiratory specialist

Re-assessment required after 12 months

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

(e:	P x man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
Beta-Adrenoceptor Agonists					
SALBUTAMOL					
Oral liq 400 mcg per ml – 5% DV Mar-22 to 2024 Inj 500 mcg per ml, 1 ml ampoule Inj 1 mg per ml, 5 ml ampoule		.40.0	0	150 ml	Ventolin
Aerosol inhaler, 100 mcg per dose		3.8		200 dose	SalAir Ventolin
Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 5% DV Jan-22 to 2024 Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 5% DV Jan-22 to 2024		8.9	6	20 20	Asthalin Asthalin
TERBUTALINE SULPHATE Powder for inhalation 250 mcg per dose Inj 0.5 mg per ml, 1 ml ampoule Powder for inhalation, 200 mcg per dose (equivalent to 250 mcg					
metered dose), breath activated		22.2	0	120 dose	Bricanyl Turbuhaler
Cough Suppressants					
PHOLCODINE Oral liq 1 mg per ml – 1% DV Jun-20 to 2022		3.0	9	200 ml	AFT Pholcodine Linctus BP
Decongestants					
DXYMETAZOLINE HYDROCHLORIDE Aqueous nasal spray 0.25 mg per ml Aqueous nasal spray 0.5 mg per ml					
PSEUDOEPHEDRINE HYDROCHLORIDE Tab 60 mg					
SODIUM CHLORIDE Aqueous nasal spray isotonic					
SODIUM CHLORIDE WITH SODIUM BICARBONATE Soln for nasal irrigation					
KYLOMETAZOLINE HYDROCHLORIDE Aqueous nasal spray 0.05% Aqueous nasal spray 0.1% Nasal drops 0.05% Nasal drops 0.1%					

BECLOMETHASONE DIPROPIONATE 8.54 200 dose Beclazone 50 Aerosol inhaler 50 mcg per dose 14.01 Qvar Aerosol inhaler 100 mcg per dose 12.50 200 dose Beclazone 100 17.52 Qvar Aerosol inhaler 250 mcg per dose 22.67 200 dose Beclazone 250

\$	Per	Manufacturer
8.67 13.87 13.60 24.62	120 dose 60 dose 60 dose 120 dose 120 dose 60 dose	Flixotide Flixotide Accuhaler Flixotide Accuhaler Flixotide Flixotide Flixotide Accuhaler
4.25	28 28 28	Montelukast Mylan Montelukast Mylan Montelukast Mylan
	30 dose 30 dose	Onbrez Breezhaler Onbrez Breezhaler
	120 dose 60 dose	Serevent Serevent Accuhaler
eptor Aac	onists	
41.50	120 dose	DuoResp Spiromax
82.50	120 dose	DuoResp Spiromax
44.08	30 dose	Breo Ellipta
	61.00 61.00 26.25 26.25	

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer
FLUTICASONE WITH SALMETEROL			
Aerosol inhaler 50 mcg with salmeterol 25 mcg – 1% DV Sep-20 to	2023 25.79	120 dose	Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg		60 dose	Seretide Accuhaler
Aerosol inhaler 125 mcg with salmeterol 25 mcg - 1% DV Sep-20			
to 2023		120 dose	Seretide
Powder for inhalation 250 mcg with salmeterol 50 mcg	44.08	60 dose	Seretide Accuhaler
Methylxanthines			
AMINOPHYLLINE			
Inj 25 mg per ml, 10 ml ampoule		5	DBL Aminophylline
CAFFEINE CITRATE			
Oral liq 20 mg per ml (caffeine 10 mg per ml) - 1% DV Nov-19 to 2	2 022 15.10	25 ml	Biomed
Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule - 1% DV			
Nov-19 to 2022	63.25	5	Biomed
	00.00	100	
Tab long-acting 250 mg – 1% DV Jan-20 to 2022 Oral lig 80 mg per 15 ml – 1% DV Jan-20 to 2022		100 500 ml	Nuelin-SR Nuelin
	10.00	000 111	Huomi
Mucolytics and Expectorants			
DORNASE ALFA – Restricted see terms below			
Vebuliser soln 2.5 mg per 2.5 ml ampoule	250.00	6	Pulmozyme
→ Restricted (RS1787)			
nitiation – cystic fibrosis			
Respiratory physician or paediatrician Re-assessment required after 12 months			
All of the following:			
1 Patient has a confirmed diagnosis of cystic fibrosis; and			
2 Patient has previously undergone a trial with, or is currently being	g treated with, hy	pertonic salir	ne; and
3 Any of the following:			
3.1 Patient has required one or more hospital inpatient respire			
3.2 Patient has had 3 exacerbations due to CF, requiring oral	or intravenous (IV) antibiotics	in in the previous 12 mont
period; or	ar IV antibiation is	a tha arawiaw	a 10 month nariad and a
3.3 Patient has had 1 exacerbation due to CF, requiring oral Brasfield score of < 22/25; or		T the previous	s 12 monun perioù anu a
3.4 Patient has a diagnosis of allergic bronchopulmonary asp	eraillosis (ABPA)).	
Continuation – cystic fibrosis			
Respiratory physician or paediatrician			
The treatment remains appropriate and the patient continues to benefit f	rom treatment.		
nitiation – significant mucus production			
Limited to 4 weeks treatment			
Both:			
1 Patient is an in-patient; and 2. The musus production cannot be cleared by first line about techn	iquos		
2 The mucus production cannot be cleared by first line chest techn nitiation – plaural emphasized	iques.		
nitiation – pleural emphyema Limited to 3 days treatment			
Both:			
1 Patient is an in-patient; and			
0 Detient die meese with glowel employees			

2 Patient diagnoses with pleural emphyema.

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
IVACAFTOR – Restricted see terms below			
↓ Tab 150 mg		56	Kalydeco
Oral granules 50 mg, sachet		56	Kalydeco
I Oral granules 75 mg, sachet		56	Kalydeco
➡ Restricted (RS1818)			
Initiation			
Respiratory specialist or paediatrician			
All of the following:			
1 Patient has been diagnosed with cystic fibrosis; and			
2 Either:			
2.1 Patient must have G551D mutation in the cystic fibr	osis transmembrane co	nductance	regulator (CFTR) gene on at
least 1 allele; or 2.2 Patient must have other gating (class III) mutation (8R, G551S	, S1251N, S1255P, S549N
and S549R) in the CFTR gene on at least 1 allele; a			
3 Patients must have a sweat chloride value of at least 60 m sweat collection system; and	mol/L by quantitative pil	ocarpine io	ntophoresis or by Macroduct
4 Treatment with ivacaftor must be given concomitantly with	standard thorany for thi	c condition:	and
5 Patient must not have an acute upper or lower respiratory			
(including antibiotics) for pulmonary disease in the last 4 w			
6 The dose of ivacaftor will not exceed one tablet or one sac		ng troutinoi	it with wabanton, and
7 Applicant has experience and expertise in the management			
SODIUM CHLORIDE	04.50	00	Diamod
Nebuliser soln 7%, 90 ml bottle - 1% DV Nov-19 to 2022		90 ml	Biomed
Pulmonary Surfactants			
BERACTANT			
Soln 200 mg per 8 ml vial			
PORACTANT ALFA			
Soln 120 mg per 1.5 ml vial		1	Curosurf
Soln 240 mg per 3 ml vial	695.00	1	Curosurf
Respiratory Stimulants			
DOXAPRAM			
Inj 20 mg per ml, 5 ml vial			
ng zo ng por nii, o nii viai			

Sclerosing Agents

TALC

Powder Soln (slurry) 100 mg per ml, 50 ml

	D.		<u> </u>
	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
CHLORAMPHENICOL Eye oint 1% – 1% DV May-20 to 2022	1 55	5 g	Devatis
Ear drops 0.5% – 1% DV Nov-19 to 2022 Eye drops 0.5% – 1% DV Nov-19 to 2022		10 ml	Chlorafast
CIPROFLOXACIN Eye drops 0.3% - 5% DV Nov-21 to 2024		5 ml	Ciprofloxacin Teva
FRAMYCETIN SULPHATE Ear/eye drops 0.5%			
GENTAMICIN SULPHATE Eye drops 0.3%	11.40	5 ml	Genoptic
SODIUM FUSIDATE [FUSIDIC ACID] Eye drops 1%	5.29	5 g	Fucithalmic
SULPHACETAMIDE SODIUM Eye drops 10%			
TOBRAMYCIN Eye oint 0.3% Eye drops 0.3%		3.5 g 5 ml	Tobrex Tobrex
Antifungals			
NATAMYCIN Eye drops 5%			
Antivirals			
ACICLOVIR Eye oint 3% - 5% DV Sep-21 to 2024	14.88	4.5 g	ViruPOS
Combination Preparations			
CIPROFLOXACIN WITH HYDROCORTISONE Ear drops ciprofloxacin 0.2% with 1% hydrocortisone DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN		10 ml	Ciproxin HC Otic
Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramici 50 mcg per ml	din		
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulp	ohate		
6,000 u per g Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b		3.5 g	Maxitrol
sulphate 6,000 u per ml DEXAMETHASONE WITH TOBRAMYCIN		5 ml	Maxitrol
Eye drops 0.1% with tobramycin 0.3% FLUMETASONE PIVALATE WITH CLIOQUINOL Ear drops 0.02% with clioquinol 1%	12.04	5 ml	Tobradex

	Price		Brand or	
(ex man. excl. GS \$	T) Per	Generic Manufacturer	
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND	NYSTATIN			
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg a gramicidin 250 mcg per g		7.5 ml	Kenacomb	
Anti-Inflammatory Preparations				
Corticosteroids				
DEXAMETHASONE				
Eye oint 0.1%		3.5 g	Maxidex	
Eye drops 0.1%	4.50	5 ml	Maxidex	
Ccular implant 700 mcg	1 444 50	1	Ozurdex	

➡ Restricted (RS1606)

Initiation – Diabetic macular oedema

Ophthalmologist

Re-assessment required after 12 months

All of the following:

- 1 Patients have diabetic macular oedema with pseudophakic lens; and
- 2 Patient has reduced visual acuity of between 6/9 6/48 with functional awareness of reduction in vision; and
- 3 Either:
 - 3.1 Patient's disease has progressed despite 3 injections with bevacizumab; or
 - 3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Continuation – Diabetic macular oedema

Ophthalmologist

Re-assessment required after 12 months Both:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Initiation - Women of child bearing age with diabetic macular oedema

Ophthalmologist

Re-assessment required after 12 months

All of the following:

- 1 Patients have diabetic macular oedema; and
- 2 Patient has reduced visual acuity of between 6/9 6/48 with functional awareness of reduction in vision; and
- 3 Patient is of child bearing potential and has not yet completed a family; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Continuation - Women of child bearing age with diabetic macular oedema

Ophthalmologist

Re-assessment required after 12 months

All of the following:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Patient is of child bearing potential and has not yet completed a family; and
- 3 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

	Price (ex man. excl. GS' \$	T) Per	Brand or Generic Manufacturer
FLUOROMETHOLONE Eye drops 0.1%		5 ml	FML
Eye drops 0.12% Eye drops 1%	7.00 5.93	5 ml 10 ml	Pred Forte Prednisolone- AFT
PREDNISOLONE SODIUM PHOSPHATE Eye drops 0.5%, single dose (preservative free)		20 dose	Minims Prednisolone
Non-Steroidal Anti-Inflammatory Drugs			
DICLOFENAC SODIUM Eye drops 0.1% – 5% DV Nov-21 to 2024 KETOROLAC TROMETAMOL Eye drops 0.5%	8.80	5 ml	Voltaren Ophtha
Decongestants and Antiallergics			
Antiallergic Preparations			
LEVOCABASTINE Eye drops 0.05% LODOXAMIDE			
Eye drops 0.1%	8.71	10 ml	Lomide
Eye drops 0.1% – 1% DV Oct-20 to 2022 SODIUM CROMOGLICATE Eye drops 2% – 1% DV Jan-20 to 2022		5 ml 5 ml	Olopatadine Teva Rexacrom
Decongestants			
NAPHAZOLINE HYDROCHLORIDE Eye drops 0.1%	4.15	15 ml	Naphcon Forte
Diagnostic and Surgical Preparations			
Diagnostic Dyes			
FLUORESCEIN SODIUM Eye drops 2%, single dose Inj 10%, 5 ml vial Ophthalmic strips 1 mg FLUORESCEIN SODIUM WITH LIGNOCAINE HYDROCHLORIDE Eye drops 0.25% with lignocaine hydrochloride 4%, single dose LISSAMINE GREEN Ophthalmic strips 1.5 mg ROSE BENGAL SODIUM Ophthalmic strips 1%	125.00	12	Fluorescite

		Price . excl. GST) \$	Per	Brand or Generic Manufacturer
Irrigation Solutions				
MIXED SALT SOLUTION FOR EYE IRRIGATION Eye irrigation solution calcium chloride 0.048% with magnesium of 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, so chloride 0.64% and sodium citrate 0.17%, 15 ml dropper bott Eye irrigation solution calcium chloride 0.048% with magnesium of	odium le	5.00	15 ml	Balanced Salt Solution
0.03%, potassium chloride 0.075%, sodium acetate 0.39%, s chloride 0.64% and sodium citrate 0.17%, 250 ml	odium			e.g. Balanced Salt Solution
Eye irrigation solution calcium chloride 0.048% with magnesium of 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, s chloride 0.64% and sodium citrate 0.17%, 500 ml bag				e.g. Balanced Salt Solution
Eye irrigation solution calcium chloride 0.048% with magnesium of 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, solioride 0.64% and sodium citrate 0.17%, 500 ml bottle	odium	10.50	500 ml	Balanced Salt Solution
Ocular Anaesthetics				
OXYBUPROCAINE HYDROCHLORIDE Eye drops 0.4%, single dose PROXYMETACAINE HYDROCHLORIDE Eye drops 0.5% TETRACAINE [AMETHOCAINE] HYDROCHLORIDE Eye drops 0.5%, single dose Eye drops 1%, single dose				
Viscoelastic Substances				
HYPROMELLOSE Inj 2%, 1 ml syringe Inj 2%, 2 ml syringe SODIUM HYALURONATE [HYALURONIC ACID]				
Inj 14 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022 Inj 18 mg per ml, 0.85 ml syringe – 1% DV Sep-21 to 2022 Inj 23 mg per ml, 0.6 ml syringe – 1% DV Oct-19 to 2022 Inj 10 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022 SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROI	TIN SULPI	50.00 60.00 28.50	1 1 1 1	Healon GV Healon GV Pro Healon 5 Healon
 Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0 syringe Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml s and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0 	.4 ml yringe	64.00	1	Duovisc
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml			1 1	Duovisc Viscoat
Other				

DISODIUM EDETATE

Inj 150 mg per ml, 20 ml ampoule

Inj 150 mg per ml, 20 ml vial

Inj 150 mg per ml, 100 ml vial

	Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer
RIBOFLAVIN 5-PHOSPHATE Soln trans epithelial riboflavin Inj 0.1% Inj 0.1% plus 20% dextran T500			
Glaucoma Preparations			
Beta Blockers			
3ETAXOLOL Eye drops 0.25% Eye drops 0.5% FIMOLOL		5 ml 5 ml	Betoptic S Betoptic
Eye drops 0.25% – 1% DV Dec-20 to 2023 Eye drops 0.5% – 1% DV Dec-20 to 2023 Eye drops 0.5%, gel forming	2.04	5 ml 5 ml 2.5 ml	Arrow-Timolol Arrow-Timolol Timoptol XE
Carbonic Anhydrase Inhibitors			
ACETAZOLAMIDE Tab 250 mg Inj 500 mg BRINZOLAMIDE	17.03	100	Diamox
Eye drops 1% – 5% DV Sep-21 to 2024 DORZOLAMIDE Eye drops 2% DORZOLAMIDE WITH TIMOLOL Eye drops 2% with timolol 0.5% – 5% DV Dec-21 to 2024		5 ml 5 ml	Azopt Dortimopt
Miotics			
ACETYLCHOLINE CHLORIDE Inj 20 mg vial with diluent CARBACHOL Inj 150 mcg vial PILOCARPINE HYDROCHLORIDE			
Eye drops 1% Eye drops 2% Eye drops 2%, single dose	5.35	15 ml 15 ml	Isopto Carpine Isopto Carpine
Eye drops 4%		15 ml	Isopto Carpine
Prostaglandin Analogues			
Eye drops 0.03% – 5% DV Apr-22 to 2024		3 ml	Bimatoprost Multichem
Eye drops 0.005% - 5% DV Feb-22 to 2024 ATANOPROST WITH TIMOLOL Eye drops 0.005% with timolol 0.5% - 1% DV Sep-21 to 2023.		2.5 ml 2.5 ml	Teva Arrow - Lattim
IRAVOPROST Eye drops 0.004% – 5% DV Dec-21 to 2024		2.5 ml	Travatan

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. ex \$		Per	Brand or Generic Manufacturer
Sympathomimetics				
APRACLONIDINE Eye drops 0.5% BRIMONIDINE TARTRATE Eye drops 0.2% – 5% DV Jan-22 to 2024			5 ml 5 ml	lopidine Arrow-Brimonidine
BRIMONIDINE TARTRATE WITH TIMOLOL Eye drops 0.2% with timolol 0.5%				
Mydriatics and Cycloplegics				
Anticholinergic Agents				
ATROPINE SULPHATE Eye drops 0.5% Eye drops 1%, single dose				
Eye drops 1% – 1% DV Oct-20 to 2023 CYCLOPENTOLATE HYDROCHLORIDE Eye drops 0.5%, single dose Eye drops 1%			15 ml	
Eye drops 1% Eye drops 1%, single dose IROPICAMIDE	o	5.70	15 ml	Cyclogyl
Eye drops 0.5% Eye drops 0.5%, single dose	7	.15	15 ml	Mydriacyl
Eye drops 1% Eye drops 1%, single dose	8	.66	15 ml	Mydriacyl
Sympathomimetics				
PHENYLEPHRINE HYDROCHLORIDE Eye drops 2.5%, single dose Eye drops 10%, single dose				
Ocular Lubricants				
CARBOMER Ophthalmic gel 0.3%, single dose Ophthalmic gel 0.2%	8	.25	30	Poly Gel
CARMELLOSE SODIUM WITH PECTIN AND GELATINE Eye drops 0.5% Eye drops 0.5%, single dose Eye drops 1% Eye drops 1%, single dose				
HYPROMELLOSE Eye drops 0.5%	19	.50	15 ml	Methopt
HYPROMELLOSE WITH DEXTRAN Eye drops 0.3% with dextran 0.1% Eye drops 0.3% with dextran 0.1%, single dose	2	2.30	15 ml	Poly-Tears
MACROGOL 400 AND PROPYLENE GLYCOL Eye drops 0.4% with propylene glycol 0.3% preservative free, single	e dose4	.30	24	Systane Unit Dose

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	(ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN Eye oint 42.5% with soft white paraffin 57.3%					
PARAFFIN LIQUID WITH WOOL FAT Eye oint 3% with wool fat 3%		3.6	3	3.5 g	Poly-Visc
POLYVINYL ALCOHOL WITH POVIDONE Eye drops 1.4% with povidone 0.6%, single dose					
RETINOL PALMITATE				-	1/11 DOO
		3.8	0	5 g	VitA-POS
SODIUM HYALURONATE [HYALURONIC ACID] Eye drops 1 mg per ml - 5% DV Jan-22 to 2024		.13.8	5	10 ml	Hylo-Fresh
Other Otological Preparations					

ACETIC ACID WITH PROPYLENE GLYCOL

Ear drops 2.3% with propylene glycol 2.8%

DOCUSATE SODIUM

Ear drops 0.5%

			VARIOUS
	Price (ex man. excl. \$	GST) Per	Brand or Generic Manufacturer
Agents Used in the Treatment of Poisonings			
Antidotes			
ACETYLCYSTEINE Tab eff 200 mg Inj 200 mg per ml, 10 ml ampoule AMYL NITRITE Liq 98% in 3 ml capsule		6 10	DBL Acetylcysteine
DIGOXIN IMMUNE FAB Inj 38 mg vial Inj 40 mg vial			
ETHANOL Liq 96%			
ETHANOL WITH GLUCOSE Inj 10% with glucose 5%, 500 ml bottle			
ETHANOL, DEHYDRATED Inj 100%, 5 ml ampoule Inj 96%			
FLUMAZENIL Inj 0.1 mg per ml, 5 ml ampoule – 5% DV Feb-22 to 2024		2 10	HameIn
HYDROXOCOBALAMIN Inj 5 g vial Inj 2.5 g vial			
NALOXONE HYDROCHLORIDE Inj 400 mcg per ml, 1 ml ampoule) 5	DBL Naloxone Hydrochloride
PRALIDOXIME IODIDE Inj 25 mg per ml, 20 ml ampoule SODIUM NITRITE Inj 30 mg per ml, 10 ml ampoule			

Antitoxins

SOYA OIL

BOTULISM ANTITOXIN Inj 250 ml vial **DIPHTHERIA ANTITOXIN** Inj 10,000 iu vial

Inj 20%, 500 ml bag Inj 20%, 500 ml bottle

SODIUM THIOSULFATE Inj 250 mg per ml, 10 ml vial Inj 250 mg per ml. 50 ml vial Inj 500 mg per ml, 10 ml vial Inj 500 mg per ml, 20 ml ampoule

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

Antivenoms

RED BACK SPIDER ANTIVENOM Inj 500 u vial

SNAKE ANTIVENOM

Inj 50 ml vial

Removal and Elimination

CHARCOAL

Oral liq 200 mg per ml		250 ml	Carbasorb-X
DEFERASIROX – Restricted see terms below			
Tab 125 mg dispersible		28	Exjade
Tab 250 mg dispersible		28	Exjade
Tab 500 mg dispersible	1,105.00	28	Exjade
- Destricted (DO1111)			•

Restricted (RS1444)

Initiation

Haematologist *Re-assessment required after 2 years* All of the following:

1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and

2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and

- 3 Any of the following:
 - 3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
 - 3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
 - 3.3 Treatment with deferiprone has resulted in arthritis; or
 - 3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per μL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 1.0 cells per μL).</p>

Continuation

Haematologist

Re-assessment required after 2 years Either:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical
 - improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement

in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE – Restricted see terms below

t	Tab 500 mg533.17	100	Ferriprox
	Oral liq 100 mg per ml	250 ml	Ferriprox

➡ Restricted (RS1445)

Initiation

Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia. DESFERBIOXAMINE MESILATE

Inj 500 mg vial	81 10	DBL Desferrioxamine
		Mesylate for Inj BP

DICOBALT EDETATE

Inj 15 mg per ml, 20 ml ampoule

	Price		Brand or
	(ex man. excl. GS \$	T) Per	Generic Manufacturer
IMERCAPROL			
Inj 50 mg per ml, 2 ml ampoule			
IMERCAPTOSUCCINIC ACID			
Cap 100 mg			e.g. PCNZ, Optimus Healthcare,
			Chemet
Cap 200 mg			e.g. PCNZ, Optimus
			Healthcare, Chemet
ODIUM CALCIUM EDETATE			
Inj 50 mg per ml, 10 ml ampoule			
Inj 200 mg per ml, 2.5 ml ampoule Inj 200 mg per ml, 5 ml ampoule			
Antiseptics and Disinfectants			
HLORHEXIDINE			
Soln 4%	15 50	500 ml	h a alth □
Soln 5% CHLORHEXIDINE WITH CETRIMIDE		500 ml	healthE
Crm 0.1% with cetrimide 0.5%			
Foaming soln 0.5% with cetrimide 0.5%			
CHLORHEXIDINE WITH ETHANOL			
Soln 0.5% with ethanol 70%			
Soln 2% with ethanol 70% Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml	1 55	1	healthE
DDINE WITH ETHANOL			Healthe
Soln 1% with ethanol 70%			
SOPROPYL ALCOHOL			
Soln 70%, 500 ml	5.65	1	healthE
OVIDONE-IODINE			
Vaginal tab 200 mg			
 Restricted (RS1354) nitiation 			
lectal administration pre-prostate biopsy.			
Oint 10% - 1% DV Oct-20 to 2023	7.40	65 g	Betadine
Soln 10% - 5% DV Mar-22 to 2024	4.15	100 ml	Riodine
Soln 5% Soln 7.5%			
Soln 10%, - 1% DV Dec-19 to 2022		15 ml	Riodine
	5.40	500 ml	Riodine
Pad 10% Swab set 10%			
POVIDONE-IODINE WITH ETHANOL Soln 10% with ethanol 30%			
Soln 10% with ethanol 70%			
ODIUM HYPOCHLORITE			
Soln			

VARIOUS

(Price ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
Contrast Media			
Iodinated X-ray Contrast Media			
DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE			
Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100		100	O status and fire
bottle		100 ml 1	Gastrografin Urografin
Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle		I	ologiallin
DIATRIZOATE SODIUM	156 10	50	lagaan
Oral liq 370 mg per ml, 10 ml sachet	100.12	50	loscan
ODISED OIL	440.00		Linda dal 10000 Eludat
Inj 38% w/w (480 mg per ml), 10 ml ampoule	410.00	1	Lipiodol Ultra Fluid
ODIXANOL			
Inj 270 mg per ml (iodine equivalent), 50 ml bottle		10	Visipaque
Inj 270 mg per ml (iodine equivalent), 100 ml bottle		10	Visipaque
Inj 320 mg per ml (iodine equivalent), 50 ml bottle		10	Visipaque
Inj 320 mg per ml (iodine equivalent), 100 ml bottle		10	Visipaque
Inj 320 mg per ml (iodine equivalent), 200 ml bottle	850.00	10	Visipaque
OHEXOL			
Inj 240 mg per ml (iodine equivalent), 50 ml bottle		10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 20 ml bottle		10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 50 ml bottle		10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 100 ml bottle		10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 20 ml bottle		10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 50 ml bottle		10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 75 ml bottle Inj 350 mg per ml (iodine equivalent), 100 ml bottle		10 10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 100 ml bottle		10	Omnipaque Omnipaque
Inj 350 mg per ml, 500 ml bottle		6	Omnipaque
		0	Ommpaque
Non-iodinated X-ray Contrast Media			
BARIUM SULPHATE			
Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet		50	E-Z-Cat Dry
Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle		148 g	Varibar - Thin Liquid
Oral liq 600 mg per g (60% w/w), tube		454 g	E-Z-Paste
Oral liq 400 mg per ml (40% w/v), bottle		250 ml	Varibar - Honey
	38.40	240 ml	Varibar - Nectar
	145.04	230 ml	Varibar - Pudding
Enema 1,250 mg per ml (125% w/v), 500 ml bag		12	Liquibar
Oral liq 22 mg per g (2.2% w/w), 250 ml bottle		24	CT Plus+
Oral liq 22 mg per g (2.2% w/w), 450 ml bottle Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle		24 24	CT Plus+
Oral lig 20.9 mg per ml (2.1% w/v, 0.1% w/w), 450 ml bottle		24 24	VoLumen Readi-CAT 2
Powder for oral soln 97.65% w/w, 300 g bottle		24 24	X-Opaque-HD
Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle		3	Tagitol V
Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle		1	Liquibar
BARIUM SULPHATE WITH SODIUM BICARBONATE	~		
Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4	-	EO	E Z Goo II
sachet	102.93	50	E-Z-Gas II

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
	ð	Fei	Manulaciulei
CITRIC ACID WITH SODIUM BICARBONATE			
Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 sachet	g		e.g. E-Z-GAS II
Paramagnetic Contrast Media			
•			
GADOBENIC ACID	204 74	10	Multihonoo
Inj 334 mg per ml, 10 ml vial Inj 334 mg per ml, 20 ml vial		10 10	Multihance Multihance
	030.20	10	Wullhance
GADOBUTROL			
Inj 1 mmol per ml, 15 ml vial			
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 5 ml prefilled	100.00	-	Onderviet 1.0
syringe Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled		5	Gadovist 1.0
syringe	180.00	5	Gadovist 1.0
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled		5	
syringe	700.00	10	Gadovist 1.0
GADODIAMIDE			
Inj 287 mg per ml, 10 ml prefilled syringe	200.00	10	Omniscan
Inj 287 mg per ml, 10 ml vial		10	Omniscan
Inj 287 mg per ml, 5 ml vial		10	Omniscan
Inj 287 mg per ml, 15 ml prefilled syringe		10	Omniscan
GADOTERIC ACID			
Inj 279.30 mg per ml, 10 ml prefilled syringe			e.g. Clariscan
Inj 279.30 mg per ml, 10 ml vial			e.g. Clariscan
Inj 279.30 mg per ml, 15 ml prefilled syringe			e.g. Clariscan
Inj 279.30 mg per ml, 20 ml vial			e.g. Clariscan
Inj 279.30 mg per ml, 5 ml vial			e.g. Clariscan
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe		10	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle		1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe		10	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe		10 1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle		1	Dotarem Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle		1	Dotarem
			Dotaroni
GADOXETATE DISODIUM	d		
Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefille syringe		1	Primovist
		1	FIIIIOVISI
	05.00	5	Magnaviat
Inj 469 mg per ml, 10 ml prefilled syringe Inj 469 mg per ml, 10 ml vial		5 10	Magnevist Magnevist
		10	waynevisi
MEGLUMINE IOTROXATE Inj 105 mg per ml, 100 ml bottle	150.00	100 ml	Biliscopin
Ultrasound Contrast Media			
PERFLUTREN	100.00		Deficitie
Inj 1.1 mg per ml, 1.5 ml vial		1 4	Definity Definity
	720.00	4	Definity

VARIOUS

ARIOUS		

....

	Price (ex man. excl. GST) \$) Per	Brand or Generic Manufacturer
Diagnostic Agents			
ARGININE Inj 50 mg per ml, 500 ml bottle Inj 100 mg per ml, 300 ml bottle HISTAMINE ACID PHOSPHATE Nebuliser soln 0.6%, 10 ml vial Nebuliser soln 2.5%, 10 ml vial Nebuliser soln 5%, 10 ml vial MANNITOL Powder for inhalation METHACHOLINE CHLORIDE Powder 100 mg SECRETIN PENTAHYDROCHLORIDE Inj 100 u ampoule			e.g. Aridol
SINCALIDE Inj 5 mcg per vial			
Diagnostic Dyes			
BONNEY'S BLUE DYE Soln			
INDIGO CARMINE Inj 4 mg per ml, 5 ml ampoule Inj 8 mg per ml, 5 ml ampoule INDOCYANINE GREEN			
Inj 25 mg vial METHYLTHIONINIUM CHLORIDE (METHYLENE BLUE)			
Inj 5 mg per ml, 10 ml ampoule	240.35	5	Proveblue
PATENT BLUE V Inj 2.5%, 2 ml ampoule		5	Obex Medical
Inj 2.5%, 5 ml prefilled syringe	420.00	5	InterPharma

CHLORHEXIDINE WITH CETRIMIDE

Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle

→ Restricted (RS1683)

Initiation

Re-assessment required after 3 months All of the following:

- 1 Patient has burns that are greater than 30% of total body surface area (BSA); and
- 2 For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting; and
- 3 The use of 30 ml ampoules is impractical due to the size of the area to be covered.

Continuation

Re-assessment required after 3 months

The treatment remains appropriate for the patient and the patient is benefiting from the treatment.

t Item restricted (see → above); ↓ Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

VARIOUS

Pric (ex man. ex	cl. GST)	_	Brand or Generic
\$		Per	Manufacturer
GLYCINE			
Irrigation soln 1.5%, 3,000 ml bag33	3.50	4	B Braun
SODIUM CHLORIDE			
Irrigation soln 0.9%, 3,000 ml bag28	3.80	4	B Braun
Irrigation soln 0.9%, 30 ml ampoule7	7.00	20	Interpharma
Irrigation soln 0.9%, 1,000 ml bottle14		10	Baxter Sodium Chloride
Irrigation soln 0.9%, 250 ml bottle17	7.64	12	Fresenius Kabi
WATER			
Irrigation soln, 3,000 ml bag30).95	4	B Braun
Irrigation soln, 1,000 ml bottle17	7.30	10	Baxter Water for Irrigation
Irrigation soln, 250 ml bottle17	7.64	12	Fresenius Kabi

Surgical Preparations

BISMUTH SUBNITRATE AND IODOFORM PARAFFIN Paste DIMETHYL SULFOXIDE

Soln 50% Soln 99%

PHENOL

Inj 6%, 10 ml ampoule

PHENOL WITH IOXAGLIC ACID Inj 12%, 10 ml ampoule

inj 12%, 10 mi ampo

TROMETAMOL

Inj 36 mg per ml, 500 ml bottle

	(ex man.	rice excl. \$	GST)	Per	Bran Gene Manu	
Cardioplegia Solutions						
ELECTROLYTES Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride, 1 mm potassium hydrogen 2-ketoglutarate, 4 mmol/l magnesium c 18 mmol/l histidine hydrochloride, 180 mmol/l histidine, 2 mm tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium chlorid	hloride, nol/l					
1,000 ml bag Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.807 per ml, sodium hydroxide 6.31 mg per ml and trometamol	glutamic				e.g.	Custodiol-HTK
11.2369 mg per ml, 364 ml bag					e.g.	Cardioplegia Enriched Paed. Soln.
Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, gl acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg p sodium hydroxide 5.133 mg per ml and trometamol 9.097 m ml, 527 ml bag	er ml,				e.g.	Cardioplegia
Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg potassium chloride 2.181 mg per ml, sodium chloride 1.788 sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per	ng ml,					Enriched Solution
523 ml bag					e.g.	Cardioplegia Base Solution
Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag					e.g.	Cardioplegia Solution AHB7832
Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesi 1.2 mmol/l calcium, 1,000 ml bag	um and				e.g.	Cardioplegia Electrolyte Solution
MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bott MONOSODIUM L-ASPARTATE Inj 14 mmol per 10 ml, 10 ml	le					

Cold Storage Solutions

240

SODIUM WITH POTASSIUM Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

(ex m	Price an. excl	GST)		Brand or Generic
	\$		Per	Manufacturer
Extemporaneously Compounded Preparations				
ACETIC ACID				
Liq				
ALUM Powder BP				
ARACHIS OIL [PEANUT OIL] Liq				
ASCORBIC ACID Powder				
BENZOIN				
Tincture compound BP BISMUTH SUBGALLATE Powder				
BORIC ACID Powder				
CARBOXYMETHYLCELLULOSE Soln 1.5%				
CETRIMIDE Soln 40%				
CHLORHEXIDINE GLUCONATE Soln 20 %				
CHLOROFORM Liq BP				
CITRIC ACID Powder BP				
CLOVE OIL Liq				
COAL TAR Soln BP - 1% DV Nov-19 to 2022	36.2	25	200 ml	Midwest
CODEINE PHOSPHATE Powder				
COLLODION FLEXIBLE				
COMPOUND HYDROXYBENZOATE Soln – 1% DV Aug-19 to 2022	30.0	00	100 ml	Midwest
CYSTEAMINE HYDROCHLORIDE Powder			-	
DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHO Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule	SPHAT	E		
DITHRANOL Powder				
GLUCOSE [DEXTROSE] Powder				

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price		Brand or		
	(ex man. excl. GS	T)	Generic		
	\$	Per	Manufacturer		
GLYCERIN WITH SODIUM SACCHARIN					
Suspension – 1% DV Jul-19 to 2022	30.95	473 ml	Ora-Sweet SF		
		770111	Old-Oweel Ol		
GLYCERIN WITH SUCROSE					
Suspension – 1% DV Jul-19 to 2022		473 ml	Ora-Sweet		
GLYCEROL					
Liq - 1% DV Oct-20 to 2023		500 ml	healthE Glycerol BP		
			Liquid		
HYDROCORTISONE			4		
Powder	40.05	0E a	ABM		
		25 g	ADIVI		
LACTOSE					
Powder					
MAGNESIUM HYDROXIDE					
Paste					
MENTHOL					
Crystals					
METHADONE HYDROCHLORIDE					
Powder					
METHYL HYDROXYBENZOATE					
	0.00	05 -	Mishusat		
Powder - 1% DV Jul-19 to 2022	8.98	25 g	Midwest		
METHYLCELLULOSE					
Powder - 1% DV Jul-19 to 2022		100 g	Midwest		
Suspension - 1% DV Jul-19 to 2022		473 ml	Ora-Plus		
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN					
Suspension – 1% DV Jul-19 to 2022	20.05	473 ml	Ora-Blend SF		
		475111	Ola-Dieliu SF		
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE					
Suspension - 1% DV Jul-19 to 2022		473 ml	Ora-Blend		
OLIVE OIL					
Liq					
•					
PARAFFIN					
Liq					
PHENOBARBITONE SODIUM					
Powder					
PHENOL					
Liq					
PILOCARPINE NITRATE					
Powder					
POLYHEXAMETHYLENE BIGUANIDE					
Liq					
POVIDONE K30					
Powder					
SALICYLIC ACID					
Powder					
SILVER NITRATE					
Crystals					
SODIUM BICARBONATE					
Powder BP - 1% DV Jan-20 to 2022	10.05	500 g	Midwest		

t Item restricted (see → above); t Item restricted (see → below)

242

e.g. Brand indicates brand example only. It is not a contracted product.

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
SODIUM CITRATE Powder			
SODIUM METABISULFITE Powder			
STARCH Powder			
SULPHUR Precipitated Sublimed			
SYRUP Liq (pharmaceutical grade) – 1% DV Jan-20 to 2022		500 ml	Midwest
THEOBROMA OIL Oint			
TRI-SODIUM CITRATE Crystals			
TRICHLORACETIC ACID Grans			
UREA Powder BP			
WOOL FAT Oint, anhydrous			
XANTHAN Gum 1%			
ZINC OXIDE Powder			

Price Br (ex man. excl. GST) Gr \$ Per M

Brand or Generic Manufacturer

Food Modules

Carbohydrate

➡ Restricted (RS1467)

Initiation – Use as an additive

Any of the following:

- 1 Cystic fibrosis; or
- 2 Chronic kidney disease; or
- 3 Cancer in children; or
- 4 Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 5 Faltering growth in an infant/child; or
- 6 Bronchopulmonary dysplasia; or
- 7 Premature and post premature infant; or
- 8 Inborn errors of metabolism.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

CARBOHYDRATE SUPPLEMENT - Restricted see terms above

- Powder 95 g carbohydrate per 100 g, 368 g can
- Powder 96 g carbohydrate per 100 g, 400 g can

e.g. Polycal

Fat

→ Restricted (RS1468)

Initiation – Use as an additive

Any of the following:

- 1 Patient has inborn errors of metabolism; or
- 2 Faltering growth in an infant/child; or
- 3 Bronchopulmonary dysplasia; or
- 4 Fat malabsorption; or
- 5 Lymphangiectasia; or
- 6 Short bowel syndrome; or
- 7 Infants with necrotising enterocolitis; or
- 8 Biliary atresia; or
- 9 For use in a ketogenic diet; or
- 10 Chyle leak; or
- 11 Ascites; or
- 12 Patient has increased energy requirements, and for whom dietary measures have not been successful.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

LONG-CHAIN TRIGLYCERIDE SUPPLEMENT - Restricted see terms above

- Liquid 50 g fat per 100 ml, 200 ml bottle
- Liquid 50 g fat per 100 ml, 500 ml bottle

e.g. Calogen e.g. Calogen

	SI	PECIAL FOODS
Price (ex man. excl. \$	GST) Per	Brand or Generic Manufacturer
MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted see terms on the pre Liquid 50 g fat per 100 ml, 250 ml bottle Liquid 95 g fat per 100 ml, 500 ml bottle WALNUT OIL – Restricted see terms on the previous page Liq	vious page	e.g. Liquigen e.g. MCT Oil
Protein		
 → Restricted (RS1469) Initiation – Use as an additive Either: Protein losing enteropathy; or High protein needs. Initiation – Use as a module For use as a component in a modular formula made from at least one nutrient module Section D of the Pharmaceutical Schedule or breast milk Note: Patients are required to meet any Special Authority criteria associated with all of PROTEIN SUPPLEMENT – Restricted see terms above Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can Powder 6 g protein per 7 g, can	of the products us	
Other Supplements		
 BREAST MILK FORTIFIER Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet CARBOHYDRATE AND FAT SUPPLEMENT - Restricted see terms below Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can Restricted (RS1212) Initiation Both: Infant or child aged four years or under; and Any of the following: Cancer in children; or Faltering growth; or Fornchopulmonary dysplasia; or Premature and post premature infants. 		e.g. FM 85 e.g. S26 Human Milk Fortifier e.g. Nutricia Breast Milk Fortifer e.g. Super Soluble Duocal

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

Food/Fluid Thickeners

NOTE:

While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:

- · use was established prior to 1 July 2013; and
- · the product has not been specifically considered and excluded by Pharmac; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

Pharmac intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN

Powder	e.g.	Feed Thickener Karicare Aptamil
GUAR GUM Powder	e.g.	Guarcol
MAIZE STARCH Powder	e.g.	Resource Thicken Up; Nutilis
MALTODEXTRIN WITH XANTHAN GUM Powder MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID	e.g.	Instant Thick
Powder	e.g.	Easy Thick

Metabolic Products

→ Restricted (RS1232)

Initiation

246

Any of the following:

- 1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
- 2 Patient has adrenoleukodystrophy; or
- 3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN) - Restricted see terms above

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can

- e.g. GA1 Anamix Infant
- e.g. XLYS Low TRY Maxamaid

			SPECIAL FOODS
	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
Homocystinuria Products			
 AMINO ACID FORMULA (WITHOUT METHIONINE) - Restricted set Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fib 100 g, 400 g can Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle 	re per	ous page	e.g. HCU Anamix Infant e.g. XMET Maxamaid e.g. XMET Maxamum e.g. HCU Anamix Junior LQ
Isovaleric Acidaemia Products			
 AMINO ACID FORMULA (WITHOUT LEUCINE) - Restricted see tel Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fib 100 g, 400 g can Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can 		oage	e.g. IVA Anamix Infant e.g. XLEU Maxamaid e.g. XLEU Maxamum
Maple Syrup Urine Disease Products			
AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND V Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fib 100 g, 400 g cap	,	d see term	ns on the previous page e.g. MSUD Anamix
 100 g, 400 g can Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle 			e.g. MSUD Anamix Infant e.g. MSUD Maxamum e.g. MSUD Anamix Junior LQ

Price (ex man. excl. GST) \$ Per	Brand or Generic Manufacturer
Phenylketonuria Products	
 MINO ACID FORMULA (WITHOUT PHENYLALANINE) – Restricted see terms on page 246 Tab 8.33 mg Powder 20 g protein, 3.8 g carbohydrate and 0.23 g fibre per 28 g sachet Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet Powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle 	e.g. Phlexy-10 e.g. PKU Lophlex Powder (unflavoured) e.g. PKU Anamix Junio (van/choc/unfl) e.g. PKU Anamix Infan e.g. XP Maxamum e.g. Phlexy-10 e.g. PKU Lophlex LQ 1
 Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle	e.g. PKU Lophlex LQ 2 PKU Anamix Junior LQ (Berry) PKU Anamix Junior LQ (Orange) PKU Anamix Junior LQ
 Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton Semi-solid 18.3 g protein, 18.5 g carbohydrate and 0.92 g fibre per 	(Unflavoured) e.g. PKU Lophlex LQ 2 e.g. PKU Lophlex LQ 1 e.g. PKU Lophlex LQ 2 e.g. PKU Lophlex LQ 1 e.g. Easiphen
100 g, 109 g pot	e.g. PKU Lophlex Sensations 20 (berries)

Propionic Acidaemia and Methylmalonic Acidaemia Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) - Restricted see terms on page 246

- Powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
- 1 Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can
- t Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can

- e.g. MMA/PA Anamix Infant
- e.g. XMTVI Maxamaid
- e.g. XMTVI Maxamum

SPECIAL FOODS

	(ex man.	Price excl. \$	GST)	Per	Bran Gene Man	
Protein Free Supplements						
PROTEIN FREE SUPPLEMENT – Restricted see terms on page 246 Powder nil added protein and 67 g carbohydrate per 100 g, 400 g					e.g.	Energivit
Tyrosinaemia Products						
 AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSI Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 3 sachet Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibr 100 g, 400 g can Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle Urea Cycle Disorders Products 	36 g	estric	ted see	e terms or	e.g. e.g. e.g.	e 246 TYR Anamix Junio. TYR Anamix Infant XPHEN, TYR Maxamaid TYR Anamix Junio. LQ
AMINO ACID SUPPLEMENT – Restricted see terms on page 246 Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can Powder 79 g protein per 100 g, 200 g can						Dialamine Essential Amino Acid Mix
X-Linked Adrenoleukodystrophy Products						
GLYCEROL TRIERUCATE – Restricted see terms on page 246 Liquid, 1,000 ml bottle GLYCEROL TRIOLEATE – Restricted see terms on page 246 Liquid, 500 ml bottle						

Specialised Formulas

Diabetic Products

➡ Restricted (RS1215)

Initiation

Any of the following:

- 1 For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
- 2 For patients with pancreatic insufficiency; or
- 3 For patients who have, or are expected to, eat little or nothing for 5 days; or
- 4 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- 5 For use pre- and post-surgery; or
- 6 For patients being tube-fed; or
- 7 For tube-feeding as a transition from intravenous nutrition.

LOW-GI ENTERAL FEED 1 KCAL/ML - Restricted see terms above

- t Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 500 ml

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	P (ex man.	rice excl. G \$	ST) Per	Brand or Generic Manufacturer
LOW-GI ORAL FEED 1 KCAL/ML - Restricted see terms on the previ	ious page			
Liquid 7 g protein, 10.9 g carbohydrate, 2.7 g fat and 2 g fibre per 100 ml, bottle		2.10	200 ml	Nutren Diabetes (Vanilla)
Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle	r			e.g. Diasip
Elemental and Semi-Elemental Products				
→ Restricted (RS1216)				
Initiation Any of the following:				
1 Malabsorption; or				
2 Short bowel syndrome; or				
3 Enterocutaneous fistulas; or				
4 Eosinophilic enteritis (including oesophagitis); or				
 5 Inflammatory bowel disease; or 6 Acute pancreatitis where standard feeds are not tolerated; or 				
7 Patients with multiple food allergies requiring enteral feeding.				
AMINO ACID ORAL FEED – Restricted see terms above t Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet		4 50	80 g	Vivonex TEN
AMINO ACID ORAL FEED 0.8 KCAL/ML – Restricted see terms above		1.00	00 g	
 Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 25 carton 				e.g. Elemental 028 Extra
PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML - Restricted see term	ns above			0
Liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml,				
1,000 ml bag				e.g. Nutrison Advanced Peptisorb
PEPTIDE-BASED ENTERAL FEED 1.5 KCAL/ML – Restricted see te Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml			1,000 ml	Vital
PEPTIDE-BASED ORAL FEED – Restricted see terms above				
Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 400 g can	0.			e.g. Peptamen Junior
Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 4 can	00 g			e.g. MCT Pepdite; MCT
Call				Pepdite 1+
PEPTIDE-BASED ORAL FEED 1 KCAL/ML - Restricted see terms at	oove			, opuno , i
Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, car		4.95	237 ml	Peptamen OS 1.0 (Vanilla)
Fat Modified Products				
FAT-MODIFIED FEED - Restricted see terms below				
Powder 12.8 g protein, 68.6 g carbohydrate and 12.9 g fat per 100	g,			
400 g can				e.g. Monogen
→ Restricted (RS1470) Initiation				
Any of the following:				
-				

	(ex man	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
 continued Patient has metabolic disorders of fat metabolism; or Patient has a chyle leak; or Modified as a modular feed, made from at least one nutried the Pharmaceutical Schedule, for adults. Note: Patients are required to meet any Special Authority criteria 					
Hepatic Products					
 → Restricted (RS1217) Initiation For children (up to 18 years) who require a liver transplant. HEPATIC ORAL FEED - Restricted see terms above t Powder 12 g protein, 56 g carbohydrate and 22 g fat per 100 	g, can	78.97	7	400 g	Heparon Junior
High Calorie Products					
 → Restricted (RS1317) Initiation Any of the following: Patient is fluid volume or rate restricted; or Patient requires low electrolyte; or Both: 	rements.				
ENTERAL FEED 2 KCAL/ML – Restricted see terms above Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 m Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fat		5.50)	500 ml	Nutrison Concentrated
100 ml, bottle ORAL FEED 2 KCAL/ML − Restricted see terms above Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g f 100 ml, bottle	ibre per			,000 ml 200 ml	Ensure Two Cal HN RTI Two Cal HN
High Protein Products					
HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML - Restricted s ↓ Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 1,000 ml bottle → Restricted (RS1327) Initiation Both:		N			e.g. Nutrison Protein Plus
1 The patient has a high protein requirement; and					

2 Any of the following:

continued...

SPECIAL FOODS

Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
continued		
 2.1 Patient has liver disease; or 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or 2.3 Patient is fluid restricted; or 2.4 Patient is fluid restricted; or 	-4	
2.4 Patient's needs cannot be more appropriately met using high calorie produ	CI.	
HGH PROTEIN ENTERAL FEED 1.26 KCAL/ML – Restricted see terms below Liquid 10 g protein, 10.4 g carbohydrate and 4.9 g fat per 100 ml, bottle5.78 → Restricted (RS1327) nitiation Both:	500 ml	Nutrison Protein Intense
 The patient has a high protein requirement; and Any of the following: 		
 2.1 Patient has liver disease; or 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or 2.3 Patient is fluid restricted; or 2.4 Patient's needs cannot be more appropriately met using high calorie produ 	ct.	
IIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – Restricted see terms below Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per		
100 ml, 1,000 ml bag		e.g. Nutrison Protein Plus Multi Fibre
→ Restricted (RS1327) nitiation Soth:		
 The patient has a high protein requirement; and Any of the following: Patient has liver disease; or Patient is obese (BMI > 30) and is undergoing surgery; or Patient is fluid restricted; or Patient's needs cannot be more appropriately met using high calorie produ 	ct.	
Infant Formulas		
MINO ACID FORMULA – Restricted see terms on the next page Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml,		
400 g can Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100 g, 400 g		e.g. Neocate
can Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g		e.g. Neocate SYNEO unflavoured
Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can		e.g. Neocate Junior Unflavoured
 Powder 13.3 g protein, 57 g carbohydrate and 24.6 g fat per 100 g, can43.60 Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can53.00 	400 g 400 g	Alfamino Neocate Gold (Unflavoured)
Powder 14.8 g protein, 51.4 g carbohydrate and 23 g fat per 100 g, can53.00 Powder 15 g protein, 56 g carbohydrate and 20 g fat per 100 g, can43.60	400 g 400 g	Neocate Junior Vanilla Alfamino Junior
Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can53.00	400 g	Elecare LCP (Unflavoured)
Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can53.00	400 g	Elecare (Unflavoured) Elecare (Vanilla)

 Price (ex man. excl. GST)		Brand or Generic
 \$	Per	Manufacturer

→ Restricted (RS1867)

Initiation

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows' milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis; or
- 4 Ultra-short gut; or
- 5 Severe Immune deficiency.

Continuation

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 3 Amino acid formula is required for a nutritional deficit.

Initiation - patients who are currently funded under RS1502 or SA1557

Limited to 3 months treatment

All of the following:

- 1 Patient has a valid initiation or renewal approval for extensively hydrolysed formula (RS1502); and
- 2 Patient is unable to source funded Aptamil powder at this time; and
- 3 The approval only applies to funded dispensings of Neocate Gold and Neocate Syneo.

Note: This criteria is short term funding to cover an out-of-stock situation on some extensively hydrolysed formula powder funded under Hospital Restriction RS1502. There is no continuation criteria under this criterion.

ENTERAL LIQUID PEPTIDE FORMULA - Restricted see terms below

- Liquid 2.75 g protein, 13.7 g carbohydrate and 3.89 g fat per 100 ml......10.45 500 ml Nutrini Peptisorb
- ➡ Restricted (RS1775)

Initiation

All of the following:

- 1 Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable; and
- 2 Any of the following:
 - 2.1 Severe malabsorption; or
 - 2.2 Short bowel syndrome; or
 - 2.3 Intractable diarrhoea; or
 - 2.4 Biliary atresia; or
 - 2.5 Cholestatic liver diseases causing malabsorption; or
 - 2.6 Cystic fibrosis; or
 - 2.7 Proven fat malabsorption; or
 - 2.8 Severe intestinal motility disorders causing significant malabsorption; or
 - 2.9 Intestinal failure; or
 - 2.10 Both:
 - 2.10.1 The patient is currently receiving funded amino acid formula; and
 - 2.10.2 The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula; and
- 3 Either:
 - 3.1 A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable; or
 - 3.2 For step down from intravenous nutrition.

continued...

	l (ex man.	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
ontinued lote: A reasonable trial is defined as a 2-4 week trial. Continuation soth:					
 An assessment as to whether the patient can be transition hydrolysed formula has been undertaken; and The outcome of the assessment is that the patient continu 					
EXTENSIVELY HYDROLYSED FORMULA - Restricted see ter	ms below				
Powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 10 can		30.42	2	900 g	Aptamil AllerPro SYNE
				0	· 1
Powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 10 can	-	. 30.42	2	900 g	Aptamil AllerPro SYNE
Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per	100 a.				2
450 g can					e.g. Aptamil Gold+ Pe Junior
→ Restricted (RS1502)					
nitiation Any of the following:					
1 Both:					
 1.1 Cows' milk formula is inappropriate due to severe in 1.2 Either: 	ntolerance or a	allergy	to its p	orotein co	ontent; and
1.2.1 Soy milk formula has been reasonably trialle 1.2.2 Soy milk formula is considered clinically ina					or
2 Severe malabsorption; or	ppropriate of c	Unitiali	luicate	u, ui	
3 Short bowel syndrome; or					
4 Intractable diarrhoea; or					
5 Biliary atresia; or					
 6 Cholestatic liver diseases causing malsorption; or 7 Cystic fibrosis; or 					
8 Proven fat malabsorption; or					
9 Severe intestinal motility disorders causing significant male	absorption; or				
 Intestinal failure; or For step down from Amino Acid Formula. 					
lote: A reasonable trial is defined as a 2-4 week trial, or signs of	an immediate	laF m	nediate	d alleroid	c reaction
Continuation		.9=		a anorgi	
Both:					
1 An assessment as to whether the infant can be transitione	d to a cows' m	ilk pro	tein or	soy infa	nt formula has been
undertaken; and 2 The outcome of the assessment is that the infant continue	s to require an	exter	sivelv	hvdrolvs	ed infant formula
RUCTOSE-BASED FORMULA	o to require un	o/tor	loively	nyaroiyo	
	er 100 a.				
Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat pe	,				e.g. Galactomin 19
Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat pe 400 g can					
400 g can ACTOSE-FREE FORMULA					
400 g can ACTOSE-FREE FORMULA Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 10	00 ml, 900 g				
400 g can ACTOSE-FREE FORMULA	00 ml, 900 g				e.g. Karicare Aptamil
400 g can ACTOSE-FREE FORMULA Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 10	-				e.g. Karicare Aptamil Gold De-Lact

254

		Price excl. GST \$) Per	Brand or Generic Manufacturer
LOW-CALCIUM FORMULA				
Powder 14.6 g protein, 55.2 g carbohydrate and 25.8 g fat per	⁻ 100 g,			
400 g can				e.g. Locasol
PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML - Restricted s		W		
Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fi				
100 ml, bottle → Restricted (RS1614)		2.35	125 ml	Infatrini
Initiation – Fluid restricted or volume intolerance with faltering	a arowth			
Both:	5 5			
1 Either:				
1.1 The patient is fluid restricted or volume intolerant; or				
1.2 The patient has increased nutritional requirements of	due to faltering	g growth; a	nd	
2 Patient is under 18 months old and weighs less than 8kg.				
Note: 'Volume intolerant' patients are those who are unable to tole				
growth rate. These patients should have first trialled appropriate or and adjusting the frequency of feeding.	clinical alterna	tive treatm	ents, such	as concentrating, fortifying
PRETERM FORMULA – Restricted see terms below Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 l	ml hottla	0.75	100 ml	S26 LBW Gold RTF
 Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 		0.75	100 111	
bottle	ini, 50 ini			e.g. Pre Nan Gold RTF
Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100	ml, 70 ml			0
bottle				e.g. Karicare Aptamil
→ Restricted (RS1224)				Gold+Preterm
Initiation				
For infants born before 33 weeks' gestation or weighing less than	1.5 kg at birth			
THICKENED FORMULA	•			
Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100	0 ml, 900 g			
can	•			e.g. Karicare Aptamil
				Thickened AR
Ketogenic Diet Products				
•				
HIGH FAT FORMULA – Restricted see terms below	100 a con	05 50	200 ~	Ketocal
Powder 14.4 g protein, 2.9 g carbohydrate and 69.2 g fat per	100 g, cari	.35.50	300 g	4:1 (Unflavoured)
				Ketocal 4:1 (Vanilla)
Powder 15.4 g protein, 7.2 g carbohydrate and 68.6 g fat per	100 g, can	.35.50	300 g	Ketocal
				3:1 (Unflavoured)
→ Restricted (RS1225) Initiation				
Initiation For patients with intractable epilepsy, pyruvate dehydrogenase de	ficiency or alu	cose trans	oorted type	-1 deficiency and other
conditions requiring a ketogenic diet.	noionoy or giu	0000 11010	solica type	i acholonoy and outor

Paediatric Products

→ Restricted (RS1473) Initiation Both:

continued...

SPECIAL FOODS

	Price (ex man. excl. GS	T)	Brand or Generic
	\$	Per	Manufacturer
continued			
1 Child is aged one to ten years; and			
2 Any of the following:			
2.1 The child is being fed via a tube or a tube is to be inserte	d for the purposes	of feeding;	or
2.2 Any condition causing malabsorption; or2.3 Faltering growth in an infant/child; or			
2.4 Increased nutritional requirements; or			
2.5 The child is being transitioned from TPN or tube feeding	to oral feeding; or		
2.6 The child has eaten, or is expected to eat, little or nothing	g for 3 days.		
PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML - Restricted see terms	on the previous p	age	
t Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre p	er		
100 ml, bag		500 ml	Nutrini Low Energy Multifibre RTH
PAEDIATRIC ENTERAL FEED 1 KCAL/ML - Restricted see terms or			
Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, ba	ıg2.68	500 ml	Pediasure RTH
Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag			e.g. Nutrini RTH
PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – Restricted see terms	on the providue ne		e.y. Nuullii HTT
Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre p		ye	
100 ml, bag		500 ml	Nutrini Energy Multi
			Fibre
Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml,			o a Nutrini Enormy DTU
500 ml bag			e.g. Nutrini Energy RTH
PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms on the Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bc		200 ml	Pediasure (Chocolate)
		200 111	Pediasure (Strawberry)
			Pediasure (Vanilla)
Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, ca	n1.34	250 ml	Pediasure (Vanilla)
PAEDIATRIC ORAL FEED 1.5 KCAL/ML - Restricted see terms on the	ne previous page		
Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml,			
500 ml bottle Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml.			e.g. Pediasure Plus
Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle			e.g. Fortini
t Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre p	er		eigi i eilin
100 ml, 200 ml bottle			e.g. Fortini Multifibre
Renal Products			
LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML - Restricted se	e terms below		
Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fib	re		
per 100 ml, bottle		500 ml	Nepro HP RTH
→ Restricted (RS1229)			
Initiation For patients with acute or chronic kidney disease.			
LOW ELECTROLYTE ORAL FEED – Restricted see terms below			
Powder 7.5 g protein, 57.6 g carbohydrate and 25.9 g fat per 100 g			
400 g can	,,		e.g. Kindergen
→ Restricted (RS1227)			
Initiation			
For children (up to 18 years) with acute or chronic kidney disease.			

256

SPECIAL FOODS

(ex mar	Price n. excl. GST \$) Per	Brand or Generic Manufacturer
LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML ↓ Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton	2.67	220 ml	Nepro HP (Strawberry) Nepro HP (Vanilla)
 LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – Restricted see terms below Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml bottle Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml 		237 ml	Novasource Renal (Vanilla)
carton Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, 200 ml bottle	13.24	4	e.g. Renilon 7.5 Novasource Renal (Vanilla)
 (Novasource Renal (Vanilla) Liquid 9.1 g protein, 19 g carbohydrate and 10 g fa 2022) → Restricted (RS1228) Initiation For patients with acute or chronic kidney disease. 	at per 100 r	nl, carton to	be delisted 1 September
Surgical Products			
 HIGH ARGININE ORAL FEED 1.4 KCAL/ML − Restricted see terms below Liquid 10.1 g protein, 15 g carbonhydrate, 4.5 g fat and 0 g fibre per 100 ml, carton Liquid 10.4 g protein, 8 g carbonhydrate, 4.4 g fat and 0 g fibre per 	4.00	178 ml	Impact Advanced Recovery
Liquid 10.4 g protein, 8 g carbohydrate, 4.4 g fat and 0 g fibre per 100 ml, 250 ml carton	56.00	10	Impact Advanced Recovery
(Impact Advanced Recovery Liquid 10.1 g protein, 15 g carbonhydrate, 4.5 g fa July 2022) → Restricted (RS1231) Initiation Three packs per day for 5 to 7 days prior to major gastrointestinal, head or nec PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML – Restricted see te ↓ Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml	k surgery.	bre per 100	
 → Restricted (RS1415) Initiation Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) pr surgery. 		4 3 hours bef	preOp ore major abdominal

Price Brand or (ex man. excl. GST) Generic \$ Per Manufacturer

Standard Feeds

→	Restricted	(RS1214)
----------	------------	---------	---

Initiation

Any of the following:

For patients with malnutrition, defined as any of the following:

- 1 Any of the following:
 - 1.1 BMI < 18.5; or
 - 1.2 Greater than 10% weight loss in the last 3-6 months; or
 - 1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
- 2 For patients who have, or are expected to, eat little or nothing for 5 days; or
- 3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- 4 For use pre- and post-surgery; or
- 5 For patients being tube-fed; or
- 6 For tube-feeding as a transition from intravenous nutrition; or
- 7 For any other condition that meets the community Special Authority criteria.

ENTERAL FEED 1.5 KCAL/ML - Restricted see terms above

t	Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bag	1,000 ml	Nutrison Energy
t	Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag		e.g. Nutrison Energy Multi Fibre
t	Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can 1.75	250 ml	Ensure Plus HN
t	Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag7.00	1,000 ml	Ensure Plus HN RTH
τ	Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag7.00	1,000 ml	Jevity HiCal RTH
FN	TERAL FEED 1 KCAL/ML – Restricted see terms above	1,000 111	
t	Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle	1,000 ml	Osmolite RTH
t	Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per		
t	100 ml, bottle	1,000 ml	Jevity RTH
·	1,000 ml bag		e.g. NutrisonStdRTH; NutrisonLowSodium
t	Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bottle		e.g. Nutrison Low Sodium
t	Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per		
	100 ml, 1000 ml bag		e.g. Nutrison Multi Fibre
	TERAL FEED 1.2 KCAL/ML - Restricted see terms above		
L	Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag		e.g. Jevity Plus RTH
EN	TERAL FEED WITH FIBRE 0.83 KCAL/ML – Restricted see terms above		. ,
t	Liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per		
	100 ml, bottle	1,000 ml	Nutrison 800 Complete Multi Fibre

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

Price (ex man. excl. C \$	GST) Per	Brand or Generic Manufacturer
HIGH PROTEIN ORAL FEED 2.4 KCAL/ML - Restricted see terms on the previous particular only to be used for patients currently on or would be using Fortisip or Fortisip Multi		
Liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle		e.g. Fortisip Compact Protein
(e.g. Fortisip Compact Protein Liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat July 2022)	per 100 ml, 12	25 ml bottle to be delisted 1
ORAL FEED – Restricted see terms on the previous page		
Powder 15.9 g protein, 57.4 g carbohydrate and 14 g fat per 100 g, can 26.00	850 g	Ensure (Chocolate) Ensure (Vanilla)
Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can 14.00	840 g	Sustagen Hospital Formula (Chocolate) Sustagen Hospital Formula (Vanilla)
ORAL FEED 1 KCAL/ML - Restricted see terms on the previous page		
t Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml,		
237 ml carton		e.g. Resource Fruit Beverage
ORAL FEED 1.5 KCAL/ML - Restricted see terms on the previous page		
 Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can 1.33 Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, 	237 ml	Ensure Plus (Vanilla)
carton1.26	200 ml	Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest) Ensure Plus (Vanilla)
t Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle		e.g. Fortijuice
Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml		
bottle		e.g. Fortisip
Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle		o a Eartiain Multi Fibra
		e.g. Fortisip Multi Fibre

SPECIAL FOODS

	(ex man	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
Bacterial and Viral Vaccines					
DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – R	estricted s	ee ter	ms <mark>bel</mark> o	WC	
Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pert	ussis				
toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg]				
pertactin and 80 D-antigen units poliomyelitis virus in 0.5 m					
– 0% DV Oct-20 to 2024		0.0	0	10	Infanrix IPV
Initiation					
Any of the following:					
1 A single dose for children up to the age of 7 who have compl	eted primar	v imm	unisatio	on: or	
2 A course of up to four vaccines is funded for catch up program primary immunisation; or					10 years) to complete full
3 An additional four doses (as appropriate) are funded for (re-) or post splenectomy; pre- or post solid organ transplant, rena or				•	
4 Five doses will be funded for children requiring solid organ tra	ansplantatio	on.			
Note: Please refer to the Immunisation Handbook for appropriate so	chedule for	catch	up prog	grammes	;
DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND	HAEMOPH	HILUS	INFLU	JENZAE	TYPE B VACCINE -
Restricted see terms below					
Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg per					
toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg	,				
pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hep – 0% DV Oct-20 to 2024		0.0	0	10	Infanrix-hexa
→ Restricted (RS1478)		0.0	0	10	inidinix-nexa
Initiation					
Any of the following:					
1 Up to four doses for children up to and under the age of 10 for	or primary ir	nmuni	sation;	or	

- 2 An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 3 Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Bacterial Vaccines

BACILLUS CALMETTE-GUERIN VACCINE - Restricted see terms below

⇒ Restricted (RS1233)

Initiation

All of the following:

- For infants at increased risk of tuberculosis defined as:
- 1 Living in a house or family with a person with current or past history of TB; and
- 2 Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; and

10

BCG Vaccine

3 During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.

Note: A list of countries with high rates of TB are available at http://www.health.govt.nz/tuberculosis (Search for Downloads) or www.bcgatlas.org/index.php

t Item restricted (see → above); ↓ Item restricted (see → below)
a a Prandindicates brand example only. It is not a contracted produ

VACCINES

	(Price	-	Brand or
	(ex mai	n. excl. GST \$) Per	Generic Manufacturer
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE - Restricted	d see term	shelow		
Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertu		3 DCIOW		
toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5				
pertactin in 0.5 ml syringe – 0% DV Oct-20 to 2024	•	0.00	1	Boostrix
			10	Boostrix
→ Restricted (RS1790)				
nitiation Any of the following:				
 A single dose for pregnant women in the second or third trim 	lester of ea	ch nroanan	ov: or: or	
2 A single dose for parents or primary caregivers of infants ad				re Unit or Specialist Care
Baby Unit for more than 3 days, who had not been exposed				
3 A course of up to four doses is funded for children from age	7 up the ag	e of 18 yea	rs inclusive	e to complete full primary
immunisation; or				
4 An additional four doses (as appropriate) are funded for (re-)			•	
transplantation or chemotherapy; pre or post splenectomy; p	re- or post	solid organ	transplant	, renal dialysis and other
severely immunosuppressive regimens; or 5 A single dose for vaccination of patients aged from 65 years	old: or			
 6 A single dose for vaccination of patients aged from 65 years 6 A single dose for vaccination of patients aged from 45 years 		ve not had	4 previous	tetanus doses: or
7 For vaccination of previously unimmunised or partially immu			i pieriede	
8 For revaccination following immunosuppression; or				
9 For boosting of patients with tetanus-prone wounds.				
lote: Please refer to the Immunisation Handbook for the appropria	te schedule	e for catch ι	p program	mes.
AEMOPHILUS INFLUENZAE TYPE B VACCINE - Restricted se	e terms <mark>be</mark>	low		
Haemophilus Influenzae type B polysaccharide 10 mcg conjuga				
tetanus toxoid as carrier protein 20-40 mcg; prefilled syring				
vial 0.5 ml → Restricted (RS1520)		0.00	1	Hiberix
nitiation				
Therapy limited to 1 dose				
Any of the following:				
1 For primary vaccination in children; or				
2 An additional dose (as appropriate) is funded for (re-)immun				
transplantation, or chemotherapy; functional asplenic; pre or			•	olid organ transplant, pre- o
post cochlear implants, renal dialysis and other severely imm 3 For use in testing for primary immunodeficiency diseases, or				nal medicine nhvsician or
paediatrician.		mendation		a medicine priysician or
/ENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE	_ Postric	had soo tor	ne holow	
Inj 4 mcg of each meningococcal polysaccharide conjugated to		leu see len		
approximately 48 mcg of diphtheria toxoid carrier per 0.5 m				
0% DV Oct-20 to 2024		0.00	1	Menactra
→ Restricted (RS1848)				
nitiation Either:				
1 Any of the following:				
, ,	notionte a	and set	nlonetra	and for noticets with UN
1.1 Up to three doses and a booster every five years for complement deficiency (acquired or inherited), function				

- complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
- 1.2 One dose for close contacts of meningococcal cases of any group; or

continued...

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

- 1.3 One dose for person who has previously had meningococcal disease of any group; or
- 1.4 A maximum of two doses for bone marrow transplant patients; or
- 1.5 A maximum of two doses for person pre and post-immunosuppression*; or

2 Both:

- 2.1 Person is aged between 13 and 25 years, inclusive; and
- 2.2 Either:
 - 2.2.1 One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; or
 - 2.2.2 One dose for individuals who are currently living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, from 1 December 2019 to 30 November 2021.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL B MULTICOMPONENT VACCINE - Restricted see terms below

Inj 175 mcg per 0.5 ml prefilled syringe......0.00 1 Bexsero

→ Restricted (RS1851)

Initiation - Infants under one year of age

Any of the following:

- 1 up to three doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
- 2 up to three doses for close contacts of meningococcal cases of any group; or
- 3 up to three doses for child who or has previously had meningococcal disease of any group; or
- 4 up to three doses for bone marrow transplant patients; or
- 5 up to three doses for person pre- and post-immunosuppression* .

Initiation - Person is one year of age or over

Any of the following:

- 1 up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
- 2 up to two doses for close contacts of meningococcal cases of any group; or
- 3 up to two doses for person who has previously had meningococcal disease of any group; or
- 4 up to two doses for bone marrow transplant patients; or
- 5 up to two doses for person pre- and post-immunosuppression* .

Note: *Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL C CONJUGATE VACCINE - Restricted see terms below

t	Inj 10 mcg in 0.5 ml syringe0.00	1	Neisvac-C
---	----------------------------------	---	-----------

→ Restricted (RS1849)

Initiation - Children under 9 months of age

Any of the following:

262

- 1 Up to three doses for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
- 2 Two doses for close contacts of meningococcal cases of any group; or
- 3 Two doses for child who has previously had meningococcal disease of any group; or
- 4 A maximum of two doses for bone marrow transplant patients; or
- 5 A maximum of two doses for child pre- and post-immunosuppression*.

Notes: children under nine months of age require two doses 8 weeks apart. Refer to the Immunisation Handbook for booster schedules with meningococcal ACWY vaccine.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

VACCINES

(ex r	Price nan. excl. \$	GST)	Per	Brand or Generic Manufacturer
PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE - Restricted see terr	ns below			
 I mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe - 0% DV Oct-20 to 2024 → Restricted (RS1768) Initiation 			10	Synflorix
A primary course of three doses for previously unvaccinated individuals up to Note: Please refer to the Immunisation Handbook for the appropriate sched	•			
PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – Restricted see terr Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A,	ns <mark>below</mark>			
6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe	0.00		1 10	Prevenar 13 Prevenar 13
➡ Restricted (RS1871) Initiation – High risk children who have received PCV10 Therapy limited to 1 dose				
Two doses are funded for high risk children (over the age of 12 months and doses of the primary course of PCV10.	under 18	years)	who ha	we previously received two
Initiation – High risk children aged under 5 years Therapy limited to 4 doses Both:				
 Up to an additional four doses (as appropriate) are funded for children Any of the following: 	n aged und	der 5 y	ears fo	r (re-)immunisation; and
2.1 On immunosuppressive therapy or radiation therapy, vaccinat response; or	e when the	ere is e	xpecte	d to be a sufficient immune
2.2 With primary immune deficiencies; or2.3 With HIV infection; or				
2.3 With renal failure, or nephrotic syndrome; or				
2.5 Who are immune-suppressed following organ transplantation	(includina	haema	topoiet	ic stem cell transplant): or
2.6 With cochlear implants or intracranial shunts; or	(····/, ···/,
2.7 With cerebrospinal fluid leaks; or				
2.8 Receiving corticosteroid therapy for more than two weeks, and prednisone of 2 mg/kg per day or greater, or children who wei ar areater or				
or greater; or 2.9 With chronic pulmonary disease (including asthma treated wit 2.10 Pre term infants, born before 28 weeks gestation; or	h high-dos	e corti	costero	id therapy); or
2.11 With cardiac disease, with cyanosis or failure; or				
2.12 With diabetes; or				
2.13 With Down syndrome; or				
2.14 Who are pre-or post-splenectomy, or with functional asplenia.				
nitiation – High risk adults and children 5 years and over				
Therapy limited to 4 doses				and a construction to the table of the section of
Up to an additional four doses (as appropriate) are funded for (re-)immunisat pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- solid organ transplant, renal dialysis, complement deficiency (acquired or inh cerebrospinal fluid leaks or primary immunodeficiency.	or post spl	enecto	, my; fur	nctional asplenia, pre- or post
Initiation – Testing for primary immunodeficiency diseases				
For use in testing for primary immunodeficiency diseases, on the recommen-	dation of a	n inter	nal me	dicine physician or
paediatrician.				

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE - Restricted see terms on the next page

 Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) - 0% DV Oct-20 to 2024......0.00
 1
 Pneumovax 23

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

Price		Brand or
(ex man. excl.		Generic
\$	Per	Manufacturer

➡ Restricted (RS1587)

Initiation – High risk patients

Therapy limited to 3 doses

For patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy; or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

Initiation - High risk children

Therapy limited to 2 doses

Both:

- 1 Patient is a child under 18 years for (re-)immunisation; and
- 2 Any of the following:
 - 2.1 On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
 - 2.2 With primary immune deficiencies; or
 - 2.3 With HIV infection; or
 - 2.4 With renal failure, or nephrotic syndrome; or
 - 2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
 - 2.6 With cochlear implants or intracranial shunts; or
 - 2.7 With cerebrospinal fluid leaks; or
 - 2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
 - 2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
 - 2.10 Pre term infants, born before 28 weeks gestation; or
 - 2.11 With cardiac disease, with cyanosis or failure; or
 - 2.12 With diabetes; or
 - 2.13 With Down syndrome; or
 - 2.14 Who are pre-or post-splenectomy, or with functional asplenia.

Initiation - Testing for primary immunodeficiency diseases

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

SALMONELLA TYPHI VACCINE - Restricted see terms below

Inj 25 mcg in 0.5 ml syringe

➡ Restricted (RS1243)

Initiation

For use during typhoid fever outbreaks.

Viral Vaccines

HEPATITIS A VACCINE – Restricted see terms below			
Inj 720 ELISA units in 0.5 ml syringe – 0% DV Oct-20 to 20240.00	1	Havrix Junior	
Inj 1440 ELISA units in 1 ml syringe – 0% DV Oct-20 to 20240.00	1	Havrix	
➡ Restricted (RS1638)			
Initiation			
Any of the following:			
 Two vaccinations for use in transplant patients; or 			
2 Two vaccinations for use in children with chronic liver disease; or			
3 One dose of vaccine for close contacts of known hepatitis A cases.			
HEPATITIS B RECOMBINANT VACCINE			
Inj 10 mcg per 0.5 ml prefilled syringe0.00	1	Engerix-B	
, · · · · · · · · · · · · · · · · · · ·		3	

e.g. Brand indicates brand example only. It is not a contracted product.

Price Brand or (ex man. excl. GST) Generic \$ Per Manufacturer
--

→ Restricted (RS1588)

Initiation

Any of the following:

- 1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
- 2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
- 3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
- 4 For HIV positive patients; or
- 5 For hepatitis C positive patients; or
- 6 for patients following non-consensual sexual intercourse; or
- 7 For patients following immunosuppression; or
- 8 For solid organ transplant patients; or
- 9 For post-haematopoietic stem cell transplant (HSCT) patients; or
- 10 Following needle stick injury.
- Inj 20 mcg per 1 ml prefilled syringe − 0% DV Oct-20 to 2024......0.00 1
 Engerix-B
 Restricted (RS1671)

Restricted (RS1)

Initiation

Any of the following:

- 1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
- 2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
- 3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
- 4 For HIV positive patients; or
- 5 For hepatitis C positive patients; or
- 6 for patients following non-consensual sexual intercourse; or
- 7 For patients following immunosuppression; or
- 8 For solid organ transplant patients; or
- 9 For post-haematopoietic stem cell transplant (HSCT) patients; or
- 10 Following needle stick injury; or
- 11 For dialysis patients; or
- 12 For liver or kidney transplant patients.

HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] - Restricted see terms below Inj 270 mcg in 0.5 ml syringe - 0% DV Oct-20 to 2024......0.00 10 Gardasil 9

- Inj 270 mcg in 0.5 mi syringe 0% DV Oct-20 to 2024......0.00 10 Gardasii S
- → Restricted (RS1693)

Initiation – Children aged 14 years and under Therapy limited to 2 doses Children aged 14 years and under. Initiation – other conditions

Either:

- 1 Up to 3 doses for people aged 15 to 26 years inclusive; or
- 2 Both:
 - 2.1 People aged 9 to 26 years inclusive; and
 - 2.2 Any of the following:
 - 2.2.1 Up to 3 doses for confirmed HIV infection; or
 - 2.2.2 Up to 3 doses for transplant (including stem cell) patients; or
 - 2.2.3 Up to 4 doses for Post chemotherapy.

continued...

Pri (ex man. e \$	excl.	GST)	Per	Brand or Generic Manufacturer
continued nitiation – Recurrent Respiratory Papillomatosis All of the following:				
1 Either:				
1.1 Maximum of two doses for children aged 14 years and under; or				
1.2 Maximum of three doses for people aged 15 years and over; and				
2 The patient has recurrent respiratory papillomatosis; and				
3 The patient has not previously had an HPV vaccine.				
NFLUENZA VACCINE	1 00		1	Afluria Quad Junior
Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine)	1.00		I	(2022 Formulation)
→ Restricted (RS1675)				
nitiation - cardiovascular disease for patients aged 6 months to 35 months				
Any of the following:				
1 Ischaemic heart disease; or				
 Congestive heart failure; or Rheumatic heart disease; or 				
4 Congenital heart disease; or				
5 Cerebro-vascular disease.				
Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is		cludeo	l from fu	inding.
nitiation – chronic respiratory disease for patients aged 6 months to 35 mon	nths			
Either:				
1 Asthma, if on a regular preventative therapy; or				
2 Other chronic respiratory disease with impaired lung function. Note: asthma not requiring regular preventative therapy is excluded from funding.				
nitiation – Other conditions for patients aged 6 months to 35 months				
Any of the following:				
1 Diabetes; or				
2 Chronic renal disease; or				
 3 Any cancer, excluding basal and squamous skin cancers if not invasive; or 4 Autoimmune disease; or 				
5 Immune suppression or immune deficiency; or				
6 HIV; or				
7 Transplant recipient; or				
8 Neuromuscular and CNS diseases/ disorders; or				
9 Haemoglobinopathies; or10 Is a child on long term aspirin; or				
11 Has a cochlear implant; or				
12 Errors of metabolism at risk of major metabolic decompensation; or				
13 Pre and post splenectomy; or				
14 Down syndrome; or				
15 Child who has been hospitalised for respiratory illness or has a history of si	ignifi	cant r	espirato	ory illness.
Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)11	0.00		10	Afluria Quad (2022 Formulation)
→ Restricted (RS1895) ritiation – Decade over 25				
nitiation – People over 65 The patient is 65 years of age or over.				
The patient is 03 years of age of over.				

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

Initiation - People of Māori or any Pacific ethnicity

People 55 to 64 years of age (inclusive) and is Māori or any Pacific ethnicity. Initiation – cardiovascular disease for patients 3 years and over

Any of the following:

- 1 Ischaemic heart disease; or
- 2 Congestive heart failure; or
- 3 Rheumatic heart disease; or
- 4 Congenital heart disease; or
- 5 Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

Initiation – chronic respiratory disease for patients 3 years and over Either:

- 1 Asthma, if on a regular preventative therapy; or
- 2 Other chronic respiratory disease with impaired lung function.
- Note: asthma not requiring regular preventative therapy is excluded from funding.

Initiation – Other conditions for patients 3 years and over

Either:

- 1 Any of the following:
 - 1.1 Diabetes; or
 - 1.2 chronic renal disease; or
 - 1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
 - 1.4 Autoimmune disease; or
 - 1.5 Immune suppression or immune deficiency; or
 - 1.6 HIV; or
 - 1.7 Transplant recipient; or
 - 1.8 Neuromuscular and CNS diseases/ disorders; or
 - 1.9 Haemoglobinopathies; or
 - 1.10 Is a child on long term aspirin; or
 - 1.11 Has a cochlear implant; or
 - 1.12 Errors of metabolism at risk of major metabolic decompensation; or
 - 1.13 Pre and post splenectomy; or
 - 1.14 Down syndrome; or
 - 1.15 Is pregnant; or
 - 1.16 Is a child 3 to 4 years of age (inclusive) who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or
- 2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a DHB hospital.

MEASLES, MUMPS AND RUBELLA VACCINE - Restricted see terms below

t	Injection, measles virus 1,000 CCID50, mumps virus 5,012 CCID50,			
	Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent			
	0.5 ml - 0% DV Oct-20 to 2024	0.00	10	Priorix
•	Restricted (RS1487)			
Ini	tiation – first dose prior to 12 months			
Th	erapy limited to 3 doses			
An	y of the following:			
	,			

1 For primary vaccination in children; or

continued...

VACCINES

Price			Brand or
(ex man. excl. \$	GST)	Per	Generic Manufacturer
continued			
2 For revaccination following immunosuppression; or3 For any individual susceptible to measles, mumps or rubella.			
Initiation – first dose after 12 months			
Therapy limited to 2 doses			
Any of the following:			
 For primary vaccination in children; or For revaccination following immunosuppression; or 			
3 For any individual susceptible to measles, mumps or rubella.			
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch	up prog	grammes.	
POLIOMYELITIS VACCINE – Restricted see terms below			
 Inj 80 D-antigen units in 0.5 ml syringe - 0% DV Oct-20 to 20240.0 → Restricted (RS1398) 	0	1	IPOL
Initiation Therapy limited to 3 doses			
Either:			
1 For partially vaccinated or previously unvaccinated individuals; or			
2 For revaccination following immunosuppression.			
Note: Please refer to the Immunisation Handbook for the appropriate schedule for ca	itch up j	programm	ies.
RABIES VACCINE Inj 2.5 IU vial with diluent			
ROTAVIRUS ORAL VACCINE – Restricted see terms below			
 ↓ Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator – 0% DV Oct-20 to 20240.0 → Restricted (RS1590) 	0	10	Rotarix
Initiation			
Therapy limited to 2 doses Both:			
 First dose to be administered in infants aged under 14 weeks of age; and No vaccination being administered to children aged 24 weeks or over. 			
VARICELLA VACCINE [CHICKENPOX VACCINE]			
Inj 1350 PFU prefiiled syringe - 0% DV Oct-20 to 20240.0	0	1	Varivax
➡ Restricted (RS1591)		10	Varivax
Initiation – primary vaccinations			
Therapy limited to 1 dose Either:			
 Any infant born on or after 1 April 2016; or For previously unvaccinated children turning 11 years old on or after 1 July 20 infection (chickenpox). 	17, who	have not	previously had a varicella
Initiation – other conditions Therapy limited to 2 doses Any of the following:			
1 Any of the following:			
for non-immune patients: 1.1 With chronic liver disease who may in future be candidates for transpla	intation:	or	

	Price	e		Brand or
(ex r	nan. ex	cl. GST)		Generic
	\$		Per	Manufacturer

continued...

- 1.2 With deteriorating renal function before transplantation; or
- 1.3 Prior to solid organ transplant; or
- 1.4 Prior to any elective immunosuppression*; or
- 1.5 For post exposure prophylaxis who are immune competent inpatients; or
- 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
- 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
- 4 For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
- 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or
- 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
- 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

Inj 2000 PFU prefilled syringe plus vial

➡ Restricted (RS1777)

Initiation - infants between 9 and 12 months of age

Therapy limited to 2 doses

Any of the following:

- 1 Any of the following:
 - for non-immune patients:
 - 1.1 With chronic liver disease who may in future be candidates for transplantation; or
 - 1.2 With deteriorating renal function before transplantation; or
 - 1.3 Prior to solid organ transplant; or
 - 1.4 Prior to any elective immunosuppression*; or
 - 1.5 For post exposure prophylaxis who are immune competent inpatients; or
- 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
- 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
- 4 For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
- 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or
- 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
- 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] - Restricted see terms below

t	Varicella zoster virus (Oka strain) live attenuated vaccine [shingles			
	vaccine]0.00	1 10	Zostavax Zostavax	
	Restricted (RS1882)	10	ZUSIAVAX	

Initiation – people aged 65 years

Therapy limited to 1 dose One dose for all people aged 65 years.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Diagnostic Agents			
TUBERCULIN PPD [MANTOUX] TEST Inj 5 TU per 0.1 ml, 1 ml vial – 0% DV Oct-20 to 2024	0.00	1	Tubersol

PART III: OPTIONAL PHARMACEUTICALS

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer

Optional Pharmaceuticals

NOTE:

In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a range of hospital medical devices are listed in an addendum to Part III which is available at schedule.pharmac.govt.nz. The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them. ------

BLOOD GLUCOSE DIAGNOSTIC TEST METER		
1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips20.00 10.00	1	CareSens N Premier Caresens N Caresens N POP
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP		
Blood glucose test strips 10.56	50 test	CareSens N
Test strips 10.56	50 test	CareSens PRO
BLOOD KETONE DIAGNOSTIC TEST STRIP		
Test strips	10 strip	KetoSens
DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER		
Meter with 50 lancets, a lancing device, and 10 blood glucose diagnostic		
test strips	1	CareSens Dual
MASK FOR SPACER DEVICE		
Small	1	e-chamber Mask
PEAK FLOW METER		
Low Range	1	Mini-Wright AFS Low
•		Range
Normal Range9.54	1	Mini-Wright Standard
PREGNANCY TEST - HCG URINE		
Cassette	40 test	Smith BioMed Rapid Pregnancy Test
SODIUM NITROPRUSSIDE		
Test strip22.00	50 strip	Ketostix
SPACER DEVICE		
220 ml (single patient)	1	e-chamber Turbo
510 ml (single patient)	1	e-chamber La Grande
800 ml	1	Volumatic

Symbols -

8-methoxypsoralen60
- A -
A-Scabies
Abacavir sulphate
Abacavir sulphate with
lamivudine
Abciximab163
Abiraterone acetate 152
Acarbose
Accarb9
Accuretic 1041
Accuretic 2041
Acetazolamide230
Acetec41
Acetic acid
Extemporaneously Compounded
Preparations241
Genito-Urinary63
Acetic acid with hydroxyquinoline,
glycerol and ricinoleic acid 63
Acetic acid with propylene
glycol 232
Acetylcholine chloride230
Acetylcysteine233
Aciclovir
Infections94
Sensory
Aciclovir-Baxter
Acid Citrate Dextrose A
Acidex
Acipimox
Acitretin
Aclasta
Actinomycin D
Adalimumab (Amgevita)
Adalimumab (Humira)
Adapalene
Adenocor
Adenosine
Adrenaline
Advantan
Advate
Adynovate
Aerrane111
Afinitor
Aflibercept176
Afluria Quad
(2022 Formulation) 266
Afluria Quad Junior
(2022 Formulation) 266
AFT Pholcodine Linctus BP222
Agents Affecting the

Renin-Angiotensin System 41
Agents for Parkinsonism and Related
Disorders 110
Agents Used in the Treatment of
Poisonings 233
Ajmaline
Albendazole
Alchemy Oxybutynin
Aldurazyme18
Alecensa144
Alectinib144
Alendronate sodium101
Alendronate sodium with
colecalciferol 101
Alfacalcidol25
Alfamino252
Alfamino Junior252
Alfentanil115
Alglucosidase alfa15
Alinia
Allersoothe219
Allmercap
Allopurinol
Alpha tocopheryl
Alpha tocopheryl acetate
Alpha-Adrenoceptor Blockers42
Alphamox82
Alphamox 12582
Alphamox 25082
Alprolix
Alprostadil hydrochloride51
Alteplase
Alum241
Aluminium chloride29
Aluminium hydroxide5
Aluminium hydroxide with
magnesium hydroxide and
simeticone 5
Amantadine hydrochloride
AmBisome
Ambrisentan52
Ambrisentan Mylan52
Amethocaine
Nervous114
Sensory229
Amgevita163
Amikacin78
Amiloride hydrochloride47
Amiloride hydrochloride with
furosemide
Amiloride hydrochloride with
hydrochlorothiazide
Aminolevulinic acid
hydrochloride 156
Tyuruchionue156

Aminophylline	.224
Amiodarone hydrochloride	43
Amisulpride	
Amitriptyline	
Amlodipine	45
Amorolfine	56
Amoxicillin	
Amoxicillin with clavulanic acid	
Amoxiclav multichem	
Amphotericin B	
Alimentary	22
Infections	
Amsacrine	
Amyl nitrite	
Anabolic Agents	
Anaesthetics	111
Anagrelide hydrochloride	130
Analgesics	
Anastrozole	
Anatrole	
Andriol Testocaps	67
Androderm	
Androgen Agonists and	07
Antagonists	67
Aniagonisis	07
Antabuse	
Antacids and Antiflatulents	
Anti-Infective Agents	63
Anti-Infective Preparations	
Dermatological	
Sensory	
Anti-Inflammatory Preparations	.227
Antiacne Preparations	57
Antiallergy Preparations	
Antianaemics	27
Antiarrhythmics	
Antibacterials	78
Anticholinergic Agents	
Anticholinesterases	
Antidepressants	. 118
Antidiarrhoeals and Intestinal	_
Anti-Inflammatory Agents	5
Antiepilepsy Drugs	. 119
Antifibrinolytics, Haemostatics and	
Local Sclerosants	29
Antifibrotics	
Antifungals	
Antihypotensives	44
Antimigraine Preparations	
Antimycobacterials	88
Antinausea and Vertigo Agents	
Antiparasitics	<mark>8</mark> 9
Antipruritic Preparations	
Antipsychotic Agents	.124

Antiretrovirals91
Antirheumatoid Agents 101
Antiseptics and Disinfectants
Antispasmodics and Other Agents
Altering Gut Motility7
Antithrombotics
Antithymocyte globulin
(equine) 213
Antithymocyte globulin (rabbit) 213
Antiulcerants
Antivirals
Anxiolytics127
Apidra
Apidra Solostar
Apo-Azithromycin
Apo-Ciclopirox
Apo-Diclo SR 108
Apo-Dicio Sh
Apo-Diltiazem CD
Apo-Doxazosin
Apo-Folic Acid
Apo-Megestrol
Apo-Oxybutynin
Apo-Pindolol
Apo-Prazosin43
Apo-Prednisone
Apo-Pyridoxine
Apomorphine hydrochloride110
Apraclonidine231
Aprepitant 123
Apresoline51
Aprotinin29
Aptamil AllerPro SYNEO 1 254
Aptamil AllerPro SYNEO 2 254
Aqueous cream58
Arachis oil [Peanut oil]241
Aratac
Arava 101
Arginine
Alimentary16
Various
Argipressin [Vasopressin]77
Aripiprazole124
Aripiprazole Sandoz 124
Aristocort
Arrotex-Prazosin S2943
Arrow - Lattim
Arrow-Amitriptyline118
Arrow-Bendrofluazide
Arrow-Brimonidine
Arrow-Diazepam
Arrow-Losartan &
Hydrochlorothiazide
Arrow-Norfloxacin
Arrow-Ornidazole
Arrow-Quinapril 1041
Arrow-Quinapril 2041
Anow-Quinapin 20

A second contract of the	
Arrow-Quinapril 5	
Arrow-Roxithromycin	
Arrow-Timolol	
Arrow-Topiramate	121
Arrow-Tramadol	117
Arsenic trioxide	
Artemether with lumefantrine	100
Artesunate	
Articaine hydrochloride	112
Articaine hydrochloride with	
adrenaline	112
Asacol	6
Ascorbic acid	
Alimentary	25
Extemporaneously Compounde	20
Preparations	5U 041
	241
Aspen Adrenaline	50
Aspirin	
Blood	
Nervous	114
Asthalin	
Atazanavir sulphate	93
Atenolol	
Atenolol-AFT	
ATGAM	
Ativan	
Atomoxetine	
Atorvastatin	48
Atovaquone with proguanil	
, noraquono man proguam	
hydrochloride	
hydrochloride Atracurium besylate	
hydrochloride	
hydrochloride Atracurium besylate	107
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular	107 43
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory	107 43 231
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt	107 43 231 231
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio	107 43 231 231 129
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin	107 43 231 231 129 82
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Aurorix	107 43 231 231 129 82 118
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Aurorix Avelox	107 43 231 231 129 82 118 83
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Aurorix Avelox Avonex	107 231 231 129 82 118 83 129
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Aurorix Avelox Avonex Avonex Pen	107 231 231 129 82 118 129 129 129
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Augmentin Avelox Avonex Pen Azacitidine	107 43 231 231 129 82 118 83 129 129 129 137
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Aurorix Avelox Avonex Avonex Pen	107 43 231 231 129 82 118 83 129 129 129 137
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Augmentin Avelox Avonex Pen Azacitidine	107 43 231 231 129 82 118 83 129 129 137 137
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Augmentin Avelox Avonex Pen Azacitidine Dr Reddy's	107 43 231 231 129 129 129 129 129 137 137 84
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Aubagio Aubagio Aubagio Aubagio Aubagio Aubagio Aubagio Aubagio Aubagio Aubagio Aubagio Aubagio Aubagio Aubagio Aubagio Aurorix Avonex Azacitidine Dr Reddy's Azactam Azamun	107 43 231 231 231 129 129 129 129 137 137 137 84 213
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Aucorix Avonex Azacitidine Dr Reddy's Azactam Azamun Azathioprine	107 231 231 129 82 118 83 129 129 137 137 84 213 213
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Aurorix Avonex Avonex Azacitidine Dr Reddy's Azactam Azathioprine Azilect	107 43 231 129 82 118 83 129 129 137 137 84 213 213 111
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Avonex Avonex Avonex Pen Azacitidine Dr Reddy's Azactam Azamun Azathioprine Azilect Azithromycin	107 43 231 231 231 231 129 82 118 83 129 129 129 137 84 213 213 213 213 213
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Aubagio Avonex Avonex Avonex Avonex Azactidine Dr Reddy's Azactam Azathioprine Azihoprine Azihoprine Azopt	107
hydrochloride	107
hydrochloride	107
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Aurorix Avelox Avonex Avonex Avonex Avonex Avonex Pen Azacitidine Dr Reddy's Azacitidine Dr Reddy's Azactam Azathioprine Azathioprine Azilect Azithromycin Aztreonam - B -	107
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Aubagio Augmentin Aurorix Avelox Avelox Avonex Pen Azonex Pen Azacitidine Dr Reddy's Azacitidine Dr Reddy's Azactam Azactam Azactam Azathioprine Azitect Azithromycin Aztreonam B - Bacillus calmette-guerin (BCG)	107
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Aurorix Avonex Avonex Avonex Pen Azacitidine Dr Reddy's Azacitidine Dr Reddy's Azactam Azactam Azathioprine Azathioprine Azilect Azilect Azilect Azilect Aztreonam B - Bacillus calmette-guerin (BCG) Bacillus calmette-guerin	107
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Aurorix Avelox Avonex Avonex Avonex Avonex Avonex Azacitidine Dr Reddy's Azactam Azactidine Dr Reddy's Azactam Azactam Azathioprine Azathioprine Azilect Azilect Azilect Azilect Azilect Azilect Azilect Aztreonam - B - Bacillus calmette-guerin (BCG) Bacillus calmette-guerin	107
hydrochloride Atracurium besylate Atropine sulphate Cardiovascular Sensory Atropt Aubagio Augmentin Aurorix Avonex Avonex Avonex Pen Azacitidine Dr Reddy's Azacitidine Dr Reddy's Azactam Azactam Azathioprine Azathioprine Azilect Azilect Azilect Azilect Aztreonam B - Bacillus calmette-guerin (BCG) Bacillus calmette-guerin	107

Bacterial and Viral Vaccines	
Bacterial Vaccines	
Balanced Salt Solution	229
Baricitinib	216
Barium sulphate	236
Barium sulphate with sodium	
bicarbonate	236
Barrier Creams and Emollients	57
Basiliximab	
BCG Vaccine	
BD PosiFlush	
Beclazone 100	
Beclazone 250	
Beclazone 50	222
Beclomethasone dipropionate	222
Bee venom	
Bendamustine hydrochloride	135
Bendrofluazide	47
Bendroflumethiazide	
[Bendrofluazide]	47
Benzathine benzylpenicillin	
Benzatropine mesylate	110
Benzbromaron AL 100	
Benzbromarone	
Benzocaine	
Benzocaine with tetracaine	
hydrochloride	112
Benzoin	
Benzoyl peroxide	
Benztrop	
Benzydamine hydrochloride	22
Benzydamine hydrochloride with	
cetylpyridinium chloride	22
Benzylpenicillin sodium [Penicillin	
G]	82
Beractant	
Beta Cream	
Beta Ointment	
Beta Scalp	
Beta-Adrenoceptor Agonists	.222
Beta-Adrenoceptor Blockers	44
Betadine	235
Betahistine dihydrochloride	123
Betaine	16
Betaloc CR	45
Betamethasone	
Betamethasone dipropionate	
Betamethasone dipropionate with	
calcipotriol	60
Betamethasone sodium phosphate	
with betamethasone acetate	68
Betamethasone valerate	
Betamethasone valerate with	, •
clioquinol	60
Betamethasone valerate with sodiu	m
fusidate [Fusidic acid]	

Betnovate59
Betoptic230
Betoptic S
Bevacizumab177
Bexsero
Bezafibrate
Bezalip
Bezalip Retard
Bicalutamide
Bicillin LA
BiCNU
Bicnu Heritage 136
Bile and Liver Therapy9
Biliscopin
Bimatoprost
Bimatoprost Multichem
Binarex
Binocrit
Biodone
Biodone Extra Forte116
Biodone Forte
Biotin
Bisacodyl
Bismuth subgallate
Bismuth subnitrate and iodoform
paraffin
Bisoprolol fumarate
Bisoprolol Mylan
Bivalirudin
Bleomycin sulphate 136
Blood glucose diagnostic test
meter 271
meter
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Boric acid 241
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Boric acid 241 Bortezomib 139
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Bortezomib 139 Bortezomib Dr-Reddy's 139
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Boney's blue dye 238 Boostrix 261 Boric acid 241 Bortezomib 139 Bortezomib Dr-Reddy's 139 Bosentan 52
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Boney's blue dye 238 Boostrix 261 Boric acid 241 Bortezomib 139 Bosentan 52 Bosentan Dr Reddy's 52
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Boney's blue dye 238 Boostrix 261 Boric acid 241 Bortezomib 139 Bosentan 52 Bosentan Dr Reddy's 52 Bosvate 44
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Bortezomib 139 Bortezomib Dr-Reddy's 139 Bosentan Dr Reddy's 52 Bosvate 44 Botox 107
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Bortezomib 139 Bosentan 52 Bosentan Dr Reddy's 52 Bosvate 44 Botox 107 Botulism antitoxin 233
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Boric acid 241 Bortezomib 139 Bosentan 52 Bosentan Dr Reddy's 52 Bosvate 44 Botox 107 Botulism antitoxin 233 Bplex 25
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Bortezomib 139 Bortezomib Dr-Reddy's 139 Bosentan 52 Bosvate 44 Botsvate 44 Botzomib Dr-Reddy's 139 Bostentan Dr Reddy's 52 Bosvate 44 Botz 203 Botulism antitoxin 233 Bplex 25 Breo Ellipta 223
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Boric acid 241 Bortezomib 139 Bostram 52 Bosentan Dr Reddy's 52 Bosvate 44 Botox 107 Botlism antitoxin 233 Bplex 25 Breo Ellipta 223 Brevinor 1/28 63
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Boric acid 241 Bortezomib 139 Bostentan 52 Bosentan 52 Bosvate 44 Botox 107 Botlism antitoxin 233 Bplex 25 Breo Ellipta 223 Bricanyl Turbuhaler 222
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Boric acid 241 Bortezomib 139 Bostram 52 Bosentan Dr Reddy's 52 Bosvate 44 Botx 107 Botz 233 Bplex 25 Breo Ellipta 223 Bricanyl Turbuhaler 222 Bridion 108
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Boric acid 241 Bortezomib 139 Bortezomib 139 Bosentan 52 Bosvate 44 Botox 107 Botlism antitoxin 233 Bplex 25 Breo Ellipta 223 Bricanyl Turbuhaler 222 Bricanyl Turbuhaler 222 Bridion 108 Brilinta 35
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Blood ketone diagnostic test 271 Boney's blue dye 238 Boostrix 261 Boric acid 241 Bortezomib 139 Bosentan 52 Bosvate 44 Botox 107 Botulism antitoxin 233 Bplex 25 Brevinor 1/28 63 Bricanyl Turbuhaler 222 Bridinta 35 Brimonidine tartrate 231
meter 271 Blood glucose diagnostic test 271 Blood ketone diagnostic test 271 Bonney's blue dye 238 Boostrix 261 Boric acid 241 Bortezomib 139 Bortezomib 139 Bosentan 52 Bosvate 44 Botox 107 Botlism antitoxin 233 Bplex 25 Breo Ellipta 223 Bricanyl Turbuhaler 222 Bridion 108 Brilinta 35

Brinzolamide230
Bromocriptine110
Brufen SR 109
Budesonide
Alimentary5
Respiratory219, 223
Budesonide with eformoterol 223
Bumetanide
Bupafen 113
Bupivacaine hydrochloride
Bupivacaine hydrochloride with adrenaline
Bupivacaine hydrochloride with
fentanyl113
Bupivacaine hydrochloride with
glucose 113
Buprenorphine Naloxone BNM
Buprenorphine with naloxone
Bupropion hydrochloride
Burinex
Buscopan
Buserelin
Buspirone hydrochloride
Buspirone Viatris
Busulfan136
- C -
Cabergoline70
Caffeine 130
Caffeine
Caffeine citrate
Caffeine citrate
Caffeine citrate 224 Calamine 57 Calamine-AFT 57 Calci-Tab 500 20
Caffeine citrate 224 Calamine 57 Calamine-AFT 57 Calci-Tab 500 20 Calcipotriol 60
Caffeine citrate 224 Calamine 57 Calamine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67
Caffeine citrate 224 Calamine 57 Calamine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25
Caffeine citrate224Calamine57Calamine-AFT57Calci-Tab 50020Calcipotriol60Calcitonin67Calcitriol25Calcitriol-AFT25
Caffeine citrate224Calamine57Calamine-AFT57Calci-Tab 50020Calcipotriol60Calcitonin67Calcitriol25Calcitriol-AFT25Calcium carbonate5, 20
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium chloride 38
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium chloride 38 Calcium folinate 152
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium chloride 38 Calcium folinate 152 Calcium Folinate Ebewe 152
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium choride 38 Calcium choride 38 Calcium folinate 152 Calcium Folinate Ebewe 152 Calcium Folinate Sandoz 152
Caffeine citrate 224 Calamine 57 Calamine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium Folinate 152 Calcium Folinate Ebewe 152 Calcium Folinate Sandoz 152 Calcium Folinate 152 Calcium Gulconate 152
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium folinate 152 Calcium Folinate Ebewe 152 Calcium Folinate Sandoz 152 Calcium gluconate 38
Caffeine citrate 224 Calamine 57 Calamine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium Folinate 152 Calcium Folinate Ebewe 152 Calcium Folinate Sandoz 152 Calcium Guiconate 152 Calcium Folinate Sandoz 152 Calcium Guiconate 38 Blood 38 Dermatological 62
Caffeine citrate 224 Calamine 57 Calamine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium Folinate 152 Calcium Folinate Ebewe 152 Calcium Folinate Sandoz 152 Calcium gluconate 152 Blood 38 Dermatological 62 Calcium Homeostasis 67
Caffeine citrate 224 Calamine 57 Calamine-AFT 57 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium Folinate 152 Calcium Folinate Ebewe 152 Calcium Gluconate 152 Calcium Homeostasis 67 Calcium Homeostasis 67
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium chloride 38 Calcium Folinate 152 Calcium Folinate Ebewe 152 Calcium Folinate Sandoz 152 Calcium Holinate 38 Dermatological 62 Calcium Homeostasis 67 Calcium lactate gluconate with 67 Calcium carbonate 20
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium Choride 38 Calcium Folinate 152 Calcium Folinate Ebewe 152 Calcium Folinate Sandoz 152 Calcium Holinate 62 Calcium Homeostasis 67 Calcium lactate gluconate with 67 Calcium polystyrene sulphonate 40
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium chloride 38 Calcium Folinate 152 Calcium Folinate Ebewe 152 Calcium Folinate Sandoz 152 Calcium Jourdate 88 Dermatological 62 Calcium Homeostasis 67 Calcium acrbonate 20 Calcium polystyrene sulphonate 40 Calcium Resonium 40
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calci-Tab 500 20 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium Choride 38 Calcium Folinate 152 Calcium Folinate Ebewe 152 Calcium Folinate Sandoz 152 Calcium Jolinate Sandoz 62 Calcium Jolinate Sandoz 62 Calcium Folinate Sandoz 62 Calcium Jolycal 62 Calcium Jolycal 62 Calcium actate gluconate with calcium calcium carbonate Calcium polystyrene sulphonate 40 Calcium Resonium 40
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calcipotriol 60 Calcipotriol 60 Calcitonin 67 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium chloride 38 Calcium Folinate Ebewe 152 Calcium Folinate Ebewe 152 Calcium Holinate 62 Calcium Holinate 62 Calcium Folinate Blood 38 Dermatological 62 Calcium actate gluconate with 67 Calcium polystyrene sulphonate 40 Calcium Resonium 40 Calcium Resonium 40 Candesartan cilexetil 41
Caffeine citrate 224 Calamine 57 Calamine-AFT 57 Calcipotriol 60 Calcipotriol 60 Calcitonin 67 Calcitriol 25 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium choride 38 Calcium Folinate Blockers 45 Calcium Folinate Ebewe 152 Calcium Folinate Sandoz 152 Calcium Homeostasis 67 Calcium Resonium 40 Calcium Resonium 40 Calcium Resonium 41 Candesatan cilexetil 41 Capeitabine 137
Caffeine citrate 224 Calamine 57 Calarine-AFT 57 Calcipotriol 60 Calcipotriol 60 Calcitonin 67 Calcitriol-AFT 25 Calcium carbonate 5, 20 Calcium Channel Blockers 45 Calcium chloride 38 Calcium Folinate Ebewe 152 Calcium Folinate Ebewe 152 Calcium Holinate 62 Calcium Holinate 62 Calcium Folinate Blood 38 Dermatological 62 Calcium actate gluconate with 67 Calcium polystyrene sulphonate 40 Calcium Resonium 40 Calcium Resonium 40 Candesartan cilexetil 41

Capsaicin	
Musculoskeletal 10	
Nervous11	
Captopril4	1
Carbachol23	
Carbamazepine 11	
Carbasorb-X23	
Carbimazole7	
Carbomer23	
Carboplatin 14	4
Carboplatin Ebewe 14	
Carboprost trometamol6	4
Carboxymethylcellulose	
Alimentary	2
Extemporaneously Compounded	
Preparations24	
Cardinol LA4	
Cardizem CD4	6
CareSens Dual27	1
Caresens N27	1
Caresens N POP27	1
CareSens N Premier	1
CareSens PRO27	
Carglumic acid1	7
Carmellose sodium with pectin and	
gelatine	
Alimentary 2	
Sensory23	1
Carmustine 13	6
Carmustine	6 4
Carmustine	6 4 4
Carmustine	6 4 4 8
Carmustine	6 4 4 8 7
Carmustine	6 4 4 7 6
Carmustine	644 87 6
Carmustine	64487669
Carmustine	644876699
Carmustine	6448766999
Carmustine 130 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 17 Caspofungin 8 Catapres 44 Ceenu 130 Cefaclor 70 Cefalexin 77 Cefalexin Sandoz 77 Cefalexin 77 Cefalexin 77 Cefalexin 77 Cefalexin 77 Cefalexin 77	64487669999 9
Carmustine 131 Carvedilol 44 Carvedilol Sandoz 44 Casirivimab and imdevimab 177 Caspofungin 88 Catapres 44 Ceenu 133 Cefaclor 77 Cefalexin 77 Cefale	644876699999
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 177 Caspofungin 8 Catapres 44 Ceenu 131 Cefaclor 71 Cefalexin 71 Cefalexin 71 Cefazolin 77 Cefapime 77 Cefapime 77 Cefapime 77 Cefepime 77 Cefepime 77 Cefapime 77	64487669999999
Carmustine 130 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 177 Caspofungin 8 Catapres 44 Cenu 130 Cefaclor 70 Cefalexin 77 Cefazolin 77 Cefazolin 77 Cefapime 77 Cefazolin 77 Cefepime 77 Cefepime 77 Cefazolin 77 Cefazolin 77 Cefepime 77 Cefepime 77 Cefepime 77 Cefotaxime 78	644876699999999
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 177 Caspofungin 8 Catapres 44 Cenu 131 Cefaclor 71 Cefalexin 71 Cefazolin 71 Cefazolin 72 Cefepime 77 Cefepime Kabi 71 Cefotaxime 72 Cefotaxime 74	6448766999999999999
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 171 Caspofungin 8 Catapres 44 Ceenu 131 Cefaclor 71 Cefalexin 71 Cefalexin Sandoz 71 Cefalexin Sandoz 71 Cefepime 71 Cefopime Kabi 71 Cefotaxime 71 Cefotaxime 71 Cefotaxime 71 Cefotaxime 71 Cefotaxime 71 Cefotaxime Sandoz 71 Cefotaxime Sandoz 71	64487669999999999999
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 177 Caspofungin 8 Catapres 44 Cefaclor 71 Cefalexin 71 Cefalexin 71 Cefacolin 71 Cefazolin 71 Ceforime Kabi 77 Cefotaxime 71 Cefotaxime 71 Cefotaxime 71 Cefotaxime 71 Cefotaxime Sandoz 71 Cefatorine fosamil 81	6448766999999999990 0
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 171 Caspofungin 8 Catapres 44 Ceenu 131 Cefaclor 71 Cefalexin 71 Cefalexin Sandoz 71 Cefazolin 71 Cefopime Kabi 71 Cefotaxime 71 Cefotaxime 71 Cefotaxime 72 Cefotaxime 72 Cefotaxime Sandoz 71 Ceftaroline fosamil 88 Ceftazidime 72	644876699999999999099
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 177 Caspofungin 8 Catapres 44 Ceenu 131 Cefaclor 77 Cefalexin 77 Cefalexin 77 Cefalexin Sandoz 77 Cefopime 77 Cefopime Kabi 77 Cefotaxime 77 Ceftazidime 78 Ceftazidime 78 Ceftazidime 78 Ceftazidime 78 Ceftazidime 78	64487669999999999099
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 17 Caspofungin 8 Catapres 44 Ceenu 133 Cefaclor 74 Cefaclor 74 Cefazolin 74 Cefazolin 74 Cefepime 74 Cefazolin 74 Cefazolin 74 Cefotaxime 74 Ceftazidime 74 Ceftazidime 74 Ceftazidime 74 Ceftazidime 74 Ceftazidime 74	644876699999999999999999
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 171 Caspofungin 8 Catapres 44 Ceenu 133 Cefaclor 74 Cefaclor 74 Cefaclor 74 Cefazolin 74 Cefazolin 74 Cefepime 74 Cefotaxime 74 Ceftotaxime 74 Ceftazidime 74 Ceftazidime 74 Ceftazidime 74 Ceftriaxone 74 Ceftriaxone 74 Ceftriaxone 74 Ceftriaxone 74	64487669999999999999999999
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 17 Caspofungin 8 Catapres 44 Ceenu 133 Cefaclor 74 Cefalexin 77 Cefalexin 77 Cefalexin 77 Cefazolin 77 Cefepime 77 Cefotaxime 77 Cefotaxime 77 Cefotaxime 77 Cefotaxime Sandoz 77 Cefotaxime Sandoz 77 Cefotaxime Sandoz 77 Cefotaxime Sandoz 77 Cefotaxime AFT 77 Ceftazidime-AFT 77 Ceftriaxone 77 Ceftriaxone 77 Ceftriaxone 77 Cefurixone 77 Cefurixone 77 Cefurixone 78	644876699999999999999999999999
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 17 Caspofungin 8 Catapres 44 Ceenu 133 Cefaclor 74 Cefalexin 77 Cefalexin 77 Cefalexin 77 Cefazolin 77 Cefepime 77 Cefotaxime 77 Cefotaxime 77 Cefotaxime Sandoz 77 Cefotaxime AFT 77 Ceftazidime-AFT 77 Ceftriaxone 77 Ceftriaxone 77 Cefuroxime 77 Cefuroxime 78	6448766999999999999999999999
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 17 Caspofungin 8 Catapres 44 Cenu 131 Cefaclor 71 Cefalexin 71 Cefazolin 72 Cefazolin 71 Cefotaxime 71 Ceftazidime-AFT 71 Ceftrazidime-AFT 71 Ceftrazole-AFT 71	64487669999999999999999999999
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 17 Caspofungin 8 Catapres 44 Ceenu 131 Cefaclor 71 Cefalexin 74 Cefazolin 77 Cefazolin 77 Cefazolin 77 Cefazolin 77 Cefotaxime 77 Ceftaroline fosamil 8 Ceftazidime-AFT 77 Ceftrazidime-AFT 77 Ceftriaxone-AFT 77 Cefuroxime 77 Cefuroxime-AFT 77 Celecoxib 100 Celecoxib Pfizer 10	6448766999999999999999999988
Carmustine 131 Carvedilol 4 Carvedilol Sandoz 4 Casirivimab and imdevimab 17 Caspofungin 8 Catapres 44 Cenu 131 Cefaclor 71 Cefalexin 71 Cefazolin 72 Cefazolin 71 Cefotaxime 71 Ceftazidime-AFT 71 Ceftrazidime-AFT 71 Ceftrazole-AFT 71	64487669999999999999999999884

Centrally-Acting Agents46
Cephalexin ABM79
Cetirizine hydrochloride219
Cetomacrogol58
Cetomacrogol with glycerol58 Cetomacrogol-AFT58
Cetomacrogol-AFT
Cetrimide
Cetuximab 179
Charcoal
Chemotherapeutic Agents
Chickenpox vaccine
Chlorafast
Chloral hydrate 129
Chlorambucil136
Chloramphenicol
Infections84
Sensory226
Chlorhexidine235
Chlorhexidine gluconate
Alimentary22
Extemporaneously Compounded
Preparations
Genito-Urinary63
Chlorhexidine with
cetrimide
Chlorhexidine with ethanol235, 238
Chloroform
Chloroquine phosphate90
Chlorothiazide48
Chlorpheniramine maleate219
Chlorpromazine hydrochloride124
Chlortalidone [Chlorthalidone] 48
Chlorthalidone
Choice Load 375
Choice TT380 Short63
Choice TT380 Standard63
Cholestyramine
Choline salicylate with cetalkonium
chloride
Choriogonadotropin alfa
Ciclopirox olamine
Ciclosporin156
Cidofovir94
Cilazapril41
Cilicaine
Cilicaine VK82
Cimetidine8
Cinacalcet67
Cinacalet Devatis
Cinchocaine hydrochloride with
hydrocortisone
Cipflox
Ciprofloxacin
Infections83
•
Sensory

Ciprofloxacin with	
hydrocortisone 226	3
Ciproxin HC Otic226	ô
Cisplatin144	
Citalopram hydrobromide119	9
Citanest 114	4
Citrate sodium	3
Citric acid241	
Citric acid with magnesium oxide and	
sodium picosulfate	3
Citric acid with sodium	1
bicarbonate	7
Cladribine	
Clarithromycin	
Clexane	
Clexane Forte	
Clindamycin	
Clinect)
Clinicians Multivit & Mineral	_
Boost	3
Clinicians Renal Vit	
Clobazam119	•
Clobetasol propionate59, 61	1
Clobetasone butyrate59	9
Clofazimine88	3
Clomazol	
Dermatological 56	3
Genito-Urinary63	
Clomifene citrate70)
Clomipramine hydrochloride118	3
Clomipramine Teva 118	3
Clonazepam 119-120, 127	7
Clonidine46	
Clonidine BNM46	
Clonidine hydrochloride	6
Clonidine Teva46	6
Clopidogrel	5
Clopidogrel Multichem	5
Clopine	
Clopixol126-127	7
Clostridium botulinum type A	
toxin107	7
Clotrimazole	
Dermatological56	3
Genito-Urinary63	3
Clove oil241	1
Clozapine125	ō
Clozaril125	5
Co-trimoxazole85	5
Coal tar241	
Coal tar with salicylic acid and	
sulphur)
Cocaine hydrochloride113	
Cocaine hydrochloride with	
adrenaline113	3

· · · · · ·
Codeine phosphate
Extemporaneously Compounded
Preparations241
Nervous115
Coenzyme Q1017
Colchicine 106
Colecalciferol
Colestimethate
Colestipol hydrochloride
Colgout
Colifoam
Colistin sulphomethate
[Colestimethate]
Colistin-Link
Collodion flexible
Colloidal bismuth subcitrate8
Colofac7
Colony-Stimulating Factors
Coloxyl14
Compound electrolytes
Compound electrolytes with glucose
[Dextrose]
Compound hydroxybenzoate241
Compound sodium lactate
[Hartmann's solution]
Comtan
Concerta
Condyline
Contraceptives
Contrast Media
Copaxone
Corticorelin (ovine)71
Corticosteroids
Dermatological 59
Hormone Preparations68
Cosentyx202
Cosmegen 136
Cough Suppressants 222
Coversyl
Creon 1000012
Creon 2500012
Creon Micro12
Crotamiton
Crystaderm56
CT Plus+
Cubicin
Curam
Curam Duo 500/125
Curosurf
Cvite
Cyclizine hydrochloride
Cyclizine lactate
Cyclogyl
Cyclonex136
Cyclopentolate hydrochloride231

Cyclophosphamide 136
Cycloserine
Cymevene
Cyproheptadine hydrochloride219
Cyproterone acetate
Cyproterone acetate with
ethinyloestradiol
Cystadane
Cysteamine hydrochloride241
Cytarabine 138
Cytotec7
- D -
D-Penamine101
Dabigatran33
Dacarbazine140
Dactinomycin [Actinomycin D]136
Daivobet60
Daivonex60
Dalacin C84
Danaparoid34
Dantrium
Dantrium IV107
Dantrolene
Daonil
Dapa-Tabs
Dapsone
Daptomycin
Darunavir
Darunavir Mylan93
Dasatinib145
Daunorubicin 136
DBL Acetylcysteine233
DBL Adrenaline50
DBL Amikacin78
DBL Aminophylline
DBL Bleomycin Sulfate136
DBL Cefotaxime
DBL Cisplatin144
DBL Dacarbazine
DBL Desferrioxamine Mesylate for Inj
BP234
DBL Docetaxel
DBL Docelaxel
DBL Ergometrine
DBL Gentamicin
DBL Leucovorin Calcium152
DBL Methotrexate Onco-Vial138
DBL Morphine Sulphate 116
DBL Naloxone Hydrochloride
DBL Octreotide 154
DBL Pethidine Hydrochloride 117
DBL Vincristine Sulfate152
Decongestants
Decongestants and
Antiallergics
Decozol
Deferasirox
DeletasitUX

Deferiprone234
Defibrotide
Definity237
Demeclocycline hydrochloride
Denosumab 104
Deolate
Deoxycoformycin 142
Depo-Medrol69
Depo-Provera64
Depo-Testosterone67
Deprim
Dermol
Desferrioxamine mesilate
Desflurane111
Desmopressin77
Desmopressin acetate
Desmopressin-PH&T77
Dexamethasone
Hormone Preparations
Sensory
Dexamethasone phosphate
Dexamethasone Phosphate
Panpharma
Dexamethasone with framycetin and
gramicidin 226
Dexamethasone with neomycin sulphate and polymyxin B
sulphate 226
Dexamethasone with
tobramycin
Dexamfetamine sulfate
Dexmedetomidine
Dexmedetomidine-Teva
Dexmethsone
Dexrazoxane152
Dextrose
Alimentary9
Blood
Extemporaneously Compounded
Preparations
Dextrose with sodium citrate and
citric acid [Acid Citrate Dextrose
A]34
DHC Continus115
Diabetes9
Diacomit121
Diagnostic Agents
Vaccines270
Various238
Diagnostic and Surgical
Preparations 228
Diamide Relief
Diamox
Diatrizoate meglumine with sodium
amidotrizoate 236
Diatrizoate sodium236

Diazepam 119, 127
Diazoxide
Alimentary9
Cardiovascular51
Dichlorobenzyl alcohol with
amylmetacresol 22
Diclofenac Sandoz108
Diclofenac sodium
Musculoskeletal 108
Sensory228
Dicobalt edetate
Diflucan
Diflucortolone valerate
Digestives Including Enzymes
Digoxin
Digoxin immune Fab233
Dihydrocodeine tartrate
Dihydroergotamine mesylate
Diltiazem hydrochloride
Dimercaprol
Dimercaptosuccinic acid
Dimethicone
Dimethyl fumarate
Dimethyl sulfoxide
Dinoprostone
Dipentum
Diphemanil metilsulfate
Diphenoxylate hydrochloride with
atropine sulphate 5
Diphtheria antitoxin
Diphtheria, tetanus and pertussis
vaccine
Diphtheria, tetanus, pertussis and
polio vaccine260
Diphtheria, tetanus, pertussis, polio,
hepatitis B and haemophilus
influenzae type B vaccine 260
Diprosone59
Dipyridamole35
Disodium edetate
Disodium hydrogen phosphate with
sodium dihydrogen
phosphate241
Disopyramide phosphate 43
Disulfiram
Disuillian
Dithranol
Dithranol
Dithranol 241 Diuretics 47 Dobutamine 51 Dobutamine-hameln 51 Docetaxel 151 Docusate sodium Alimentary Alimentary 14
Dithranol 241 Diuretics 47 Dobutamine 51 Dobutamine-hameln 51 Docetaxel 151 Docusate sodium 14 Sensory 232

INDEX:	Generic	Chemicals	and	Brands
--------	---------	-----------	-----	--------

Domperidone 123	3
Donepezil hydrochloride 132	2
Donepezil-Rex	
Dopamine hydrochloride5	1
Dornase alfa	4
Dortimopt	
Dorzolamide	0
Dorzolamide with timolol	0
Dostinex	0
Dosulepin [Dothiepin]	
hydrochloride 118	8
Dosulepin Mylan 118	8
Dotarem23	
Dothiepin118	8
Doxapram22	5
Doxazosin42	
Doxazosin Clinect42	
Doxepin hydrochloride118	
Doxine84	4
Doxorubicin Ebewe13	7
Doxorubicin hydrochloride 13	
Doxycycline84	
DP Lotn HC	
DP-Allopurinol106	6
Dr Reddy's Omeprazole	
Drofate4	
Droleptan 123	3
Droperidol123	3
Drugs Affecting Bone	
Metabolism 10	
Metabolism	1
Metabolism	1 1
Metabolism	1 1 1
Metabolism	1 1 1
Metabolism	1 1 5 9
Metabolism	1 1 5 9
Metabolism	1 1 5 9 3
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter 27 Dulaglutide 1 Dulcolax SP Drop 12 Duolin 213 DuoResp Spiromax 223 Duovisc 223 Duride 50	1 1159390
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter 27 Dulaglutide 1 Dulcolax SP Drop 12 Duolin 213 DuoResp Spiromax 223 Duovisc 223 Duride 50	1 1159390
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter 27 Dulaglutide 1 Dulcolax SP Drop 12 Duolin 215 DuoResp Spiromax 225 Duovisc 225	1 11593909
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter 27 Dulaglutide 1 Dulcolax SP Drop 14 Duolin 219 DuoResp Spiromax 229 Duovisc 229 Duride 50 Dynastat 109 Dysport 107 - E -	1 115939097
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter 27 Dulaglutide 11 11 Dulcolax SP Drop 14 12 Duolin 213 12 Duolin 214 14 Duolin 215 225 Duovisc 226 226 Duride 50 50 Dynastat 105 105 Oysport 107 - E - e-chamber La Grande 27	1 115939097 1
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter 27 Dulaglutide 1 Dulcolax SP Drop 14 Duolin 219 DuoResp Spiromax 229 Duovisc 229 Duride 50 Dynastat 109 Dysport 107 - E -	1 115939097 1
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter 27 Dulaglutide 11 11 Dulcolax SP Drop 14 12 Duolin 213 12 Duolin 214 14 Duolin 215 225 Duovisc 226 226 Duride 50 50 Dynastat 105 105 Oysport 107 - E - e-chamber La Grande 27	1 115939097 11
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter diagnostic test meter 27 Dulaglutide 11 Dulcolax SP Drop 14 Duolin 213 DuoResp Spiromax 223 Duride 50 Dynastat 10 Dysport 10 e-chamber La Grande 27 e-chamber Turbo 27 E-Mycin 8	1 115939097 1111
Metabolism 10 Dual blood glucose and blood ketone 10 diagnostic test meter 27 Dulaglutide 11 Dulcolax SP Drop 14 Duolin 214 DuoResp Spiromax 225 Duride 50 Dynastat 10 Dysport 10 e-chamber La Grande 27 e-chamber Turbo 27 E-Mycin 8 E-Z-Cat Dry 236	1 115939097 11116
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter diagnostic test meter 27 Dulaglutide 11 Dulcolax SP Drop 14 Duolin 213 DuoResp Spiromax 223 Duride 50 Dynastat 10 Dysport 10 e-chamber La Grande 27 e-chamber Turbo 27 E-Mycin 8	1 115939097 11116
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter diagnostic test meter 27 Dulaglutide 11 Dulcolax SP Drop 14 Duolin 214 DuoResp Spiromax 222 Duvisc 224 Duride 50 Dynastat 10 Dysport 107 e-chamber La Grande 277 e-chamber Turbo 277 E-Mycin 8 E-Z-Cat Dry 236 E-Z-Gas II 236	1 115939097 1111666
Metabolism 10° Dual blood glucose and blood ketone diagnostic test meter diagnostic test meter 27° Dulaglutide 1° Duloclax SP Drop 18 Duolin 213 DuoResp Spiromax 223 Duroise 223 Duroise 224 Duroise 226 Duroise 56 Dynastat 100 Dysport 107 - E - e e-chamber La Grande 27° e-chamber Turbo 27° E-Mycin 8° E-Z-Cat Dry 236 E-Z-Gas II 236 E-Z-Paste 236 E-Conazole nitrate 56	1 115939097 111166666
Metabolism 10° Dual blood glucose and blood ketone diagnostic test meter diagnostic test meter 27° Dulaglutide 1° Dulcolax SP Drop 18 Duolin 213 DuoResp Spiromax 223 Duvisc 224 Dynastat 100 Pysport 10 - E - e-chamber La Grande e-chamber Mask 27° E-Mycin 8° E-Z-Gas II 236 E-Z-Paste 236 E-Z-Paste 236 Econazole nitrate 56 Edrophonium chloride<	1 115939097 111166661
Metabolism 10° Dual blood glucose and blood ketone diagnostic test meter diagnostic test meter 27° Dulaglutide 1° Dulcolax SP Drop 18 Duolosep Spiromax 22° Duovisc 22° Duride 56° Dynastat 10° - E - e-chamber La Grande e-chamber Turbo 27° E-Mycin 8° E-Z-Gas II 23° E-Z-Paste 23° Econazole nitrate 56° Edrophonium chloride 10° Efavirenz 9°	1 115939097 111166661
Metabolism 10° Dual blood glucose and blood ketone diagnostic test meter 27° Dulaglutide 1° 1° Dulcolax SP Drop 18 Duoloin 21° DuoResp Spiromax 22° Duvisc 22° Duvisc 22° Duvisc 22° Duvisc 22° Dynastat 10° - E - - e-chamber La Grande 27° e-chamber Turbo 27° E-Mycin 8° E-Z-Cat Dry 23° E-Z-Cat Dry 23° E-Z-Cas II 23° E-Zonzole nitrate 5° Edrophonium chloride 10° Efavirenz 9° Efavirenz 9°	1 115939097 1111666611
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter diagnostic test meter 27 Dulaglutide 11 Dulcolax SP Drop 18 DuoResp Spiromax 223 Duorisc 224 Duride 56 Dynastat 100 Dysport 100 - E - - e-chamber La Grande 277 e-chamber Turbo 277 E-Mycin 8 E-Z-Cat Dry 236 E-Z-Cas II 236 E-Z-Paste 236 Edrophonium chloride 100 Efavirenz 9 Efavirenz 9 Efavirenz 9 Efavirenz 9	1 115939097 1111666611 2
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter 27 Dulaglutide 11 11 Dulcolax SP Drop 12 12 Duolin 213 223 Duolin 214 214 DuoResp Spiromax 223 224 Duorisc 224 224 Duorisc 225 244 Dynastat 105 50 Dynastat 106 50 Dysport 107 - E - e-chamber La Grande 277 e-chamber Mask 277 e-Mycin 8 277 e-chamber Turbo 277 E-Mycin 8 102 102 102 E-Z-Cat Dry 236 236 102 102 E-Z-Gas II 236 236 102 102 Edrophonium chloride 107 102 102 102 102 Edrophonium chloride 107 103 102 102 102 <td>1 115939097 11116666611 23</td>	1 115939097 11116666611 23
Metabolism 10 Dual blood glucose and blood ketone diagnostic test meter diagnostic test meter 27 Dulaglutide 11 Dulcolax SP Drop 18 DuoResp Spiromax 223 Duorisc 224 Duride 56 Dynastat 100 Dysport 100 - E - - e-chamber La Grande 277 e-chamber Turbo 277 E-Mycin 8 E-Z-Cat Dry 236 E-Z-Cas II 236 E-Z-Paste 236 Edrophonium chloride 100 Efavirenz 9 Efavirenz 9 Efavirenz 9 Efavirenz 9	1 115939097 11116666611 23

=

factor IX]	31
Efudix	
Elaprase	
Elecare (Unflavoured)	252
Elecare (Vanilla)	
Elecare LCP (Unflavoured)	050
Electrol	.202
Electral	40
Electrolytes	.240
Elelyso	
Elidel	
Elocon	60
Elocon Alcohol Free	60
Eltrombopag	29
Emend Tri-Pack	.123
Emicizumab	30
EMLA	
Empagliflozin	
Empagliflozin with metformin	
hydrochloride	10
Emtricitabine	12
Emtricitabine with tenofovir	92
	05
disoproxil	95
Emtriva	92
Emulsifying ointment	58
Emulsifying Ointment ADE	58
Enalapril maleate	41
Enbrel	.156
Endocrine Therapy	.152
Endoxan	
Engerix-B264	-265
Enlafax XR	
Enoxaparin sodium	
Enstilar	
Ensure (Chocolate)	250
Ensure (Vanilla)	.259
Ensure Plus (Banana)	.259
Ensure Plus (Chocolate)	.259
Ensure Plus (Fruit of the	050
Forest)	. 259
Ensure Plus (Vanilla)	.259
Ensure Plus HN	.258
Ensure Plus HN RTH	.258
Ensure Two Cal HN RTH	.251
Entacapone	.111
Entecavir	94
Entecavir Sandoz	94
Entresto 24/26	
Entresto 49/51	42
Entresto 97/103	
Enzymes	
Ephedrine	
Epilim IV	
Epirubicin Ebewe	
Epirubicin hydrochloride	
Eplerenone	47
Epoetin alfa	27

Epoprostenol
Eptacog alfa [Recombinant factor
VIIa]32
Eptifibatide35
Erbitux
Ergometrine maleate64
Erlotinib145
Ertapenem
Erythrocin IV81
Erythromycin (as
Elythioniychi (ds
ethylsuccinate)
Erythromycin (as lactobionate)
Erythromycin (as stearate)81
Esbriet221
Escitalopram119
Escitalopram (Ethics)119
Esmolol hydrochloride44
Essential Prednisolone7
Estradot70
Etanercept 156
Ethambutol hydrochloride
Ethanol
Ethanol with glucose
Ethanol, dehydrated
Ethics Aspirin
Ethics Aspirin EC
Ethics Aspirit Ed
Ethics Lisinopril
Ethinyloestradiol
Ethinyloestradiol with
desogestrel 63
Ethinyloestradiol with
levonorgestrel 63
Ethinyloestradiol with
norethisterone 63
Ethosuximide 120
Ethyl chloride 113
Etomidate 111
Etopophos 140
Etoposide140
Etoposide (as phosphate)140
Etoricoxib108
Etravirine91
Everet 120
Everolimus214
Evista105
Exemestane155
Exjade
Extemporaneously Compounded
Preparations
Eylea
Ezetimibe Sandoz
Ezetimibe with simvastatin
Factor eight inhibitor bypassing

fraction32
Famotidine8
Faslodex153
Fatty Cream AFT58
Febuxostat106
Febuxostat multichem 106
FEIBA NF
Felo 10 ER45
Felo 5 ER45
Felodipine45
Fentanyl116
Fentanyl Sandoz116
Ferinject21
Ferodan21
Ferric subsulfate
Ferriprox 234
Ferro-F-Tabs21
Ferro-tab21
Ferrograd21
Ferrosig21
Ferrous fumarate21
Ferrous fumarate with folic acid21
Ferrous gluconate with ascorbic
acid
Ferrous sulfate21
Ferrous sulfate with ascorbic
acid21
Fexofenadine hydrochloride219
Filgrastim
Finasteride65
Fingolimod 129
Firazyr218
Flagyl90
FlagyI-S90
Flamazine56
Flecainide acetate43
Flecainide BNM43
Flecainide Controlled Release
Teva43
Fleet Phosphate Enema15
Fleet Phosphate Enema15 Flixonase Hayfever & Allergy219
Fleet Phosphate Enema
Fleet Phosphate Enema
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Flixotide Accuhaler 223 Florinef 69
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Flixotide Accuhaler 223 Florinef 69 Fluanxol 126
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Flixotide Accuhaler 223 Florinef 69 Fluanxol 126 Flucil 82
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Flixotide Accuhaler 223 Florinef 69 Fluanxol 126 Flucil 82 Flucloxacillin 82
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Flixotide Accuhaler 223 Florinef 69 Fluanxol 126 Flucil 82 Flucloxacillin 82 Flucloxacillin 82
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Florinef 69 Fluanxol 126 Flucil 82 Flucloxacillin 82 Flucloxin 82
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Flixotide Accuhaler 223 Florinef 69 Fluanxol 126 Flucin 82 Flucloxacillin 82 Flucloxacillin-AFT 82 Fluconazole 86
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Flixotide Accuhaler 223 Florinef 69 Fluanxol 126 Flucil 82 Flucloxacillin 82 Flucloxacillin 82 Flucloxacillin 82 Fluconazole 86 Fluconazole 86
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Flixotide Accuhaler 223 Florinef 69 Fluanxol 126 Flucin 82 Flucloxacillin 82 Flucloxacillin 82 Flucloxacillin 82 Fluconazole 86 Fluconazole 86 Fluconazole-Claris 86
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Flixotide Accuhaler 223 Florinef. 69 Fluanxol 126 Flucil 82 Flucloxacillin 82 Flucloxacillin-AFT 82 Fluconazole 86 Fluconazole-Baxter. 86 Fluconazole-Claris 86 Flucytosine 88
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Flixotide Accuhaler 223 Florinef 69 Fluanxol 126 Flucil 82 Flucokacillin 82 Flucokacillin-AFT 82 Fluconazole 86 Fluconazole-Baxter 86 Flucytosine 88 Fludara Oral 138
Fleet Phosphate Enema 15 Flixonase Hayfever & Allergy 219 Flixotide 223 Flixotide Accuhaler 223 Florinef. 69 Fluanxol 126 Flucil 82 Flucloxacillin 82 Flucloxacillin-AFT 82 Fluconazole 86 Fluconazole-Baxter. 86 Fluconazole-Claris 86 Flucytosine 88

Fludrocortisone acetate	69
Fluids and Electrolytes	
Flumazenil	.233
Flumetasone pivalate with	
clioquinol	226
Fluocortolone caproate with	
fluocortolone pivalate and	
cinchocaine	7
Fluorescein sodium	
Fluorescein sodium with lignocaine	. 220
hydrochloride	220
Fluorescite	
Fluorometholone	
Fluorouracil	
Fluorouracil sodium	
Fluox	
Fluoxetine hydrochloride	
Flupenthixol decanoate	. 126
Flurouracil Accord	
Flutamide	
Flutamin	
Fluticasone	.223
Fluticasone furoate with	
vilanterol	
Fluticasone propionate	
Fluticasone with salmeterol	
FML	
Foban	
Folic acid	
Folic Acid multichem	28
Folic Acid Mylan	28
Fondaparinux sodium	
Food Modules	.244
Food/Fluid Thickeners	
Forteo	
Fosamax	
Fosamax Plus	
Foscarnet sodium	95
Fosfomycin	84
Framycetin sulphate	.226
Fresenius Kabi	
Blood3	
Various	.239
Fresofol 1% MCT/LCT	
Frusemide	
Fucidin	
Fucithalmic	
Fulvestrant	
Fungilin	
Furosemide [Frusemide]	
Furosemide-Baxter	47
Fusidic acid	
Dermatological	
Infections	
Sensory - G -	.226
- G -	

Gabapentin 120
Gacet 115
Gadobenic acid237
Gadobutrol237
Gadodiamide237
Gadoteric acid237
Gadovist 1.0 237
Gadoxetate disodium237
Galsulfase17
Galvumet 11
Galvus11
Ganciclovir95
Gardasil 9
Gastrodenol8
Gastrografin236
Gazyva
Gefitinib146
Gelatine, succinylated40
Gelofusine40
GEM Aqueous Cream58
Gemcitabine138
Gemcitabine Ebewe 138
Genoptic
Gentamicin sulphate
Infections
Sensory226
Gestrinone
Gilenya 129
Ginet
Glatiramer acetate 129
Glaucoma Preparations230
Glecaprevir with pibrentasvir94
Glibenclamide10
Gliclazide10
Gliolan
Glipizide10
Glivec
Glizide10
Glucagen Hypokit9
Glucagon hydrochloride9
Glucerna Select249
Glucose [Dextrose]
Alimentary9
Blood
Extemporaneously Compounded
Preparations
Glucose with potassium chloride 38
Glucose with potassium chloride and
sodium chloride
Glucose with sodium chloride
Glucose with sucrose and
fructose
Glycerin with sodium saccharin 242
Glycerin with sucrose
Glycerol
Alimentary14

	_
Extemporaneously Compounded	
Preparations24	2
Glycerol with paraffin5	8
Glyceryl trinitrate	
Alimentary	7
Cardiovascular5	0
Glycine23	9
Glycoprep-C1	3
Glycopyrronium	
Glycopyrronium bromide	
Glycopyrronium with	
indacaterol 22	0
Glypressin	7
Gonadorelin	4
Goserelin	
Granisetron	
- H -	3
Habitrol	3
Habitrol (Fruit)13	3
Habitrol (Mint)	
Haem arginate 1	
Haemophilus influenzae type B	'
vaccine	4
Haldol	
Haldol Concentrate	0
Haloperidol12	5
Haloperidol decanoate12	6
Hartmann's solution3	
Harvoni9	
Havrix	
Havrix Junior26	
Haylor Syrup21	9
Healon	
Healon 5	9
Healon GV22	
Healon GV Pro22	9
healthE Calamine Aqueous Cream	
BP5	7
healthE Dimethicone 10%5	7
healthE Dimethicone 4% Lotion5	6
healthE Dimethicone 5%5	7
healthE Fatty Cream5	8
healthE Glycerol BP Liquid24	2
healthE Urea Cream	9
Hemlibra	
Heparin sodium	
Heparinised saline	7
Heparon Junior	1
Hepatitis A vaccine	4
Hepatitis B recombinant	
vaccine	
Herceptin	
Hiberix	
Hiprex	
Histaclear21	9
Histamine acid phosphate23	8

Holoxan	136
Hormone Replacement Therapy	
HPV	
Humalog Mix 25	10
Humalog Mix 50	10
Human papillomavirus (6, 11, 16, 18,	
31, 33, 45, 52 and 58) vaccine	
[HPV]	265
Humatin	
Humira	./0 170
	170
HumiraPen	173
Hyaluronic acid	~~
Alimentary	.23
Sensory	232
Hyaluronic acid with lidocaine	
[lignocaine]	. 23
Hyaluronidase	106
Hydralazine hydrochloride	.51
Hydrocortisone	
Dermatological	. 59
Extemporaneously Compounded	
Preparations	242
Hormone Preparations	. 69
Hydrocortisone (PSM)	
Hydrocortisone acetate	
Hydrocortisone acetate with	
pramoxine hydrochloride	6
Hydrocortisone and paraffin liquid	
and lanolin	59
Hydrocortisone butyrate	
Hydrocortisone with miconazole	
Hydrocortisone with natamycin and	.00
neomycin	60
Hydrogen peroxide	. 50
Hydroxocobalamin	0.4
Alimentary	
Various	
hydroxycarbamide	
Hydroxychloroquine	101
Hydroxyurea	
[hydroxycarbamide]	140
Hygroton	.48
Hylo-Fresh	232
Hyoscine butylbromide	7
Hyoscine hydrobromide	123
Hyperuricaemia and Antigout	
HypoPak Glucose	
Hypromellose229,	
Hypromellose with dextran	231
-1-	
lbiamox	. 82
Ibrance	
Ibuprofen	109
Icatibant	218
Idarubicin hydrochloride	
Idarucizumab	

Idursulfase	10
Ifosfamide	
Ikorel	52
lloprost	55
Imaging Agents	
Imatinib mesilate	
Imatinib-Rex	
	147
Imigran	
Imipenem with cilastatin	
Imipenem+Cilastatin RBX	78
Imipramine hydrochloride	118
Imiquimod	
Immune Modulators	00
Immunosuppressants	
Impact Advanced Recovery	
Imuran	213
Incruse Ellipta	220
Indacaterol	
Indapamide	
	40
Indigo carmine	
Indinavir	
Indocyanine green	
Indomethacin	109
Infanrix IPV	
Infanrix-hexa	
Infatrini	
Infliximab	
Influenza vaccine	
Inholod Cortingatoroida	
Inhaled Corticosteroids	222
Inspra	47
Inspra Instillagel Lido	47 113
Inspra Instillagel Lido Insulin aspart	47 113
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart	47 113 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine	47 113 10 9
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine	47 113 10 9 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine	47 113 10 9 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin glulisine	47 113 10 9 10 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin glulisine Insulin isophane	47 113 10 9 10 10 9
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin glulisine Insulin isophane Insulin lispro	47 113 10 9 10 10 9
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin gluisine Insulin isophane Insulin lispro Insulin lispro with insulin lispro	47 113 10 9 10 10 9 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin gluisine Insulin isophane Insulin lispro. Insulin lispro with insulin lispro protamine	47 113 10 10 10 10 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin gluisine Insulin isophane Insulin lispro. Insulin lispro with insulin lispro protamine Insulin neutral	47 113 10 10 10 10 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin glulisine Insulin ispohane Insulin lispro Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral	47 113 10 10 10 10 10 10 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin glulisine Insulin ispohane Insulin lispro Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral	47 113 10 10 10 10 10 10 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin glargine Insulin ispophane Insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral with insulin isophane	47 113 10 10 10 10 10 10 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin gluisine Insulin ispophane Insulin lispro protamine. Insulin neutral Insulin neutral Insulin neutral with insulin isophane Integrilin	47 113 10 9 10 10 10 10 10 10 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin glulisine Insulin isophane Insulin lispro protamine Insulin inspro with insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral Insulin isophane Integrilin Intelence	47 113 10 9 10 10 10 10 10 10 10 10 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin glulisine Insulin isophane Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral Insulin neutral Insulin neutral Integrilin Intelence Interferon alfa-2b	47 113
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin glulisine Insulin isophane Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral Insulin neutral Integrilin Integrilin Intelence Interferon alfa-2b Interferon beta-1-alpha	47
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin glulisine Insulin isophane Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral Insulin neutral Integrilin Integrilin Interferon alfa-2b Interferon beta-1-alpha Interferon beta-1-beta	47 113 10
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin gluisine Insulin isophane Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral Integrilin Interferon alfa-2b Interferon beta-1-alpha Interferon beta-1-beta Interferon gamma	
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin glulisine Insulin isophane Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral Insulin neutral Integrilin Integrilin Interferon alfa-2b Interferon beta-1-alpha Interferon beta-1-beta	
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glugisine Insulin isophane Insulin lispro. Insulin lispro. Insulin neutral Insulin neutral Insulin neutral with insulin isophane Integrilin Integrilin Interferon alfa-2b Interferon beta-1-alpha Interferon beta-1-beta Interferon gamma Intra-uterine device	
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glugisine Insulin isophane Insulin lispro. Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral with insulin isophane Integrilin Interferon alfa-2b Interferon beta-1-alpha Interferon beta-1-beta Interferon gamma Intra-uterine device Invanz	
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glugisine Insulin glugisine Insulin lispro Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral Insulin neutral Insulin neutral Integrilin Integrilin Inteferon alfa-2b Interferon beta-1-alpha Interferon beta-1-beta Interferon gamma Intra-uterine device Intra-uterine device Invaga Sustenna	
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin gluisine Insulin lispro Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral Insulin neutral Insulin neutral Integrilin Inteferon alfa-2b Interferon beta-1-alpha Interferon beta-1-beta Interferon gamma Intra-uterine device Invarz Invaz Invaz Invega Sustenna Iodine	
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin gluisine Insulin lispro Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral Insulin neutral Insulin neutral Integrilin Interferon alfa-2b Interferon beta-1-alpha Interferon beta-1-beta Interferon beta-1-beta Interferon gamma Intra-uterine device Invaz Invaga Sustenna Iodine with ethanol	
Inspra Instillagel Lido Insulin aspart Insulin aspart with insulin aspart protamine Insulin glargine Insulin gluisine Insulin lispro Insulin lispro with insulin lispro protamine Insulin neutral Insulin neutral Insulin neutral Insulin neutral Insulin neutral Integrilin Inteferon alfa-2b Interferon beta-1-alpha Interferon beta-1-beta Interferon gamma Intra-uterine device Invarz Invaz Invaz Invega Sustenna Iodine	

lohexol236
lopidine
loscan
IPCA-Frusemide
IPCA-Metoprolol
IPCA-Propranolol45
IPOL
Ipratropium bromide219
Iressa146
Irinotecan hydrochloride 140
Iron (as ferric carboxymaltose)21
Iron (as sucrose)21
Iron polymaltose21
Irrigation Solutions238
Isentress94
Isentress HD94
Ismo 2050
Ismo 40 Retard50
Isoflurane111
Isoniazid
Isoniazid with rifampicin
Isoprenaline [Isoproterenol]51
Isopropyl alcohol
Isoproterenol51
Isoptin
Isoptin SR
Isopto Carpine
Isosorbide mononitrate50
Isotretinoin
Ispaghula (psyllium) husk14
Isradipine45
Itch-Soothe57
Itraconazole86
Itrazole86
Ivabradine43
lvacaftor225
Ivermectin
- J -
Jadelle64
Jakavi149
Jardiamet12
Jardiance12
Jaydess64
Jevity HiCal RTH
Jevity RTH258
Juno Pemetrexed
- K -
Kaletra
Kalydeco
Kenacomb
Kenacort-A 1069
Kenacort-A 4069
Kenalog in Orabase22
Ketalar 111
Ketamine 111

Ketamine-Baxter111
Ketocal 3:1 (Unflavoured)255
Ketocal 4:1 (Unflavoured)255
Ketocal 4:1 (Vanilla)
Ketoconazole
Dermatological56
Infections86
Ketoprofen 109
Ketorolac trometamol
KetoSens271
Ketostix
Keytruda
Kivexa
Klacid81
Klean Prep14
Kogenate FS33
Konakion MM33
Konsyl-D14
Kuvan
- L -
L-ornithine L-aspartate9
Labetalol44
Lacosamide 120
Lactose
Lactulose14
Laevolac14
Lagevrio97
Lamictal
Lamivudine
Lamivudine Alphapharm
Lamotrigine
Lanoxin
Lanoxin PG43
Lansoprazole8
Lantus10
Lantus SoloStar10
Lanzol Relief8
Lapatinib147
Largactil
Largacii 124 Laronidase
Lasix
Latanoprost230
Latanoprost with timolol230
Lax-Suppositories15
Lax-Tabs15
Laxatives13
Laxsol
Ledipasvir with sofosbuvir
Leflunomide
Lenalidomide
Letrole155
Letrozole155
Leukotriene Receptor
Antagonists 223
Leuprorelin acetate71
Leustatin

Levetiracetam	120
Levetiracetam-AFT	120
Levlen ED	
Levocabastine	228
Levocarnitine	
Levodopa with benserazide	111
Levodopa with carbidopa	
Levomepromazine	
Levomepromazine	
hydrochloride	125
Levonorgestrel	
Levosimendan	
Levothyroxine	.76
Lidocaine [Lignocaine]	113
Lidocaine [Lignocaine]	
hydrochloride	113
Lidocaine [Lignocaine] hydrochloride	
with adrenaline	113
Lidocaine [Lignocaine] hydrochloride	
with adrenaline and tetracaine	
hydrochloride	114
Lidocaine [Lignocaine] hydrochloride	
with chlorhexidine	114
Lidocaine [Lignocaine] hydrochloride	
with phenylephrine	
hydrochloride	114
Lidocaine [Lignocaine] with	
prilocaine	114
Lidocaine-Baxter	113
Lidocaine-Claris	
lignocaine	
Alimentary	.23
Nervous	
Lincomycin	
Linezolid	
Linezolid Kabi	85
Lioresal Intrathecal	
Liothyronine sodium	.76
Lipid-Modifying Agents	
Lipiodol Ultra Fluid	
Liquibar	
Lisinopril	
Lissamine green	
Lithium carbonate	
LMX4	
Local Preparations for Anal and	
Rectal Disorders	7
Locoid59,	
Locoid Crelo	
Locoid Lipocream	
Lodoxamide	
Logem	
Lomide	
Lomustine	136
Long-Acting Beta-Adrenoceptor	
Agonists	223

Loniten51
Loperamide hydrochloride5
Lopinavir with ritonavir
Lopinavir/Ritonavir Mylan93
Lorafix
Loratadine
Lorazepam
Lormetazepam129
Lorstat
Losartan Actavis
Losartan potassium42
Losartan potassium with
hydrochlorothiazide 42
Lovir
Loxamine
Lucrin Depot 1-month71
Lucrin Depot 3-month71
Lyderm
Lynparza141
Lysine acetylsalicylate [Lysine
asprin]
Lysine asprin
- M -
m-Eslon
Mabthera 190
Macrobid
Macrogol 3350 with ascorbic acid,
potassium chloride and sodium
chloride
Macrogol 3350 with ascorbic acid,
potassium chloride, sodium
chloride and citric acid with
magnesium oxide and sodium
picosulfate 14
Macrogol 3350 with potassium
chloride, sodium bicarbonate and
sodium chloride
Macrogol 3350 with potassium
chloride, sodium bicarbonate,
sodium chloride and sodium
sulphate 14
Macrogol 400 and propylene
glycol
Madopar 125 111
Madopar 125
Madopar 230
Madopar HBS111
Madopar Rapid
Mafenide acetate
Magnesium amino acid chelate
Magnesium chloride
Magnesium hydroxide
Alimentary21
Extemporaneously Compounded
Preparations242
Magnesium oxide
IVIAYI 10310111 UXIUE

Magnesium oxide with magnesium	
aspartate, magnesium amino acio chelate and magnesium	1
citrate	22
Magnesium sulphate	22
Magnevist	
Malarone	
Malarone Junior	90
Malathion [Maldison]	57
Maldison	57
Mannitol	
Cardiovascular	47
Various	238
Mantoux	
Maprotiline hydrochloride	
Marcain	110
Marcain Heavy	112
	113
Marcain Isobaric	112
Marcain with Adrenaline	
Marevan	35
Marine Blue Lotion SPF 50+	61
Mask for spacer device	271
Maviret	. 94
Maxidex	
Maxitrol	226
Measles, mumps and rubella	220
wasies, mumps and rubella	067
vaccine	207
Mebendazole	89
Mebeverine hydrochloride	7
Medrol	
Medroxyprogesterone	71
Medroxyprogesterone acetate	
Genito-Urinary	64
Hormone Preparations	70
Mefenamic acid	109
Mefloquine	
Megace	15/
Megestrol acetate	154
Meglestiol acetate	104
Meglumine gadopentetate	237
Meglumine iotroxate	237
Melatonin	129
Melphalan	136
Menactra	261
Meningococcal (A, C, Y and W-135)	
conjugate vaccine	261
Meningococcal B multicomponent	
vaccine	262
Meningococcal C conjugate	
vagaina	000
vaccine	202
Menthol	
Mepivacaine hydrochloride	114
Mepivacaine hydrochloride with	
adrenaline	
Mepolizumab	
Mercaptopurine	138
Meropenem	79

Meropenem-AFT	
Mesalazine	
Mesna	152
Mestinon	101
Metabolic Disorder Agents	15
Metabolic Products	
Metaraminol	
Metformin hydrochloride	
Metformin Mylan	11
Methacholine chloride	
Methadone hydrochloride	
Extemporaneously Compounded	4
Preparations	242
Nervous	
Methatabs	
Methenamine (Hexamine)	
hippurate	05
Methohexital sodium	00
Methopt	
Methotrexate	. 138
Methotrexate DBL Onco-Vial	
Methotrexate Ebewe	. 138
Methotrexate Sandoz	. 138
Methoxsalen	
[8-methoxypsoralen]	60
Methoxyflurane	115
Methyl aminolevulinate	
hydrochloride	
Methyl hydroxybenzoate	242
Methylcellulose	242
Methylcellulose with glycerin and	
sodium saccharin	. 242
Methylcellulose with glycerin and	
sucrose	
Methyldopa	46
Methyldopa Mylan	46
Methylene blue	
Methylnaltrexone bromide	14
Methylphenidate ER - Teva	. 131
Methylphenidate hydrochloride	. 131
Methylprednisolone (as sodium	
succinate)	69
Methylprednisolone aceponate	
Methylprednisolone acetate	69
Methylthioninium chloride [Methyler	ne
blue]	. 238
Methylxanthines	224
Metoclopramide Actavis 10	. 123
Metoclopramide hydrochloride	. 123
Metoclopramide hydrochloride with	
paracetamol	122
Metolazone	
Metoprolol IV Mylan	
Metoprolol succinate	
Metoprolol tartrate	
Metrogyl	

Metronidazole
Dermatological56
Infections90
Metyrapone71
Mexiletine hydrochloride44
Miacalcic
Mianserin hydrochloride118
Micolette
Miconazole
Miconazole nitrate
Dermatological
Genito-Urinary
Micreme
Micreme H
Microgynon 20 ED63
Microlut
Midazolam
Midodrine
Mifepristone
Milrinone
Minerals
Mini-Wright AFS Low Range
Mini-Whyfit AFS Low Range
Mini-Wright Standard
Minidiab10 Minims Prednisolone
Minirin
Minirin Melt
Minocycline
Minoxidil
Mirena
Mirtazapine 118
Misoprostol
Mitomycin C 137
Mitozantrone137
Mitozantrone Ebewe137
Mivacron 107
Mivacurium chloride107
Mixed salt solution for eye
irrigation
Moclobemide118
Modafinil
Modavigil 132
Molaxole 15
Molnupiravir97
Mometasone furoate60
Monosodium glutamate with sodium
aspartate 240
Monosodium I-aspartate240
Montelukast 223
Montelukast Mylan223
Moroctocog alfa [Recombinant factor
VIII]
Morphine hydrochloride 116
Morphine sulphate 116
Morphine tartrate 116

Votetis	.110
Nouth and Throat	22
Иочаро	. 110
Moxifloxacin	83
Moxifloxacin Kabi	83
Mozobil	37
Nucolytics and Expectorants	.224
Mucosoothe	.113
Multihance	
Multiple Sclerosis Treatments	. 128
Multivitamin and mineral supplement	
supplement	23
Multivitamin renal	23
Multivitamins	
Mupirocin	56
Muscle Relaxants and Related	
Agents	107
Nvite	24
Myambutol	
Mycobutin	89
MycoNail	56
Nycophenolate mofetil	
Mydriacyl	.231
Mydriatics and Cycloplegics	.231
Mylan (24 hr release)	46
Mylan Atenolol	
Nylan Clomiphen	70
Nylan Italy (24 hr release)	46
Mylan Midazolam	. 130
Nyleran	. 136
Nyozyme	15
- N - Nadolol	45
Nadolol BNM	40
Vaglazyme	40
Naloxone hydrochloride	17 222
Valtraccord	122
Valtrexone hydrochloride	122
Vaphazoline hydrochloride	228
Naphcon Forte	220
Vaprosyn SR 1000	109
Vaprosyn SR 750	109
Vaproxen	
Varopin	
Vatalizumab	
Vatamycin	226
Vatulan	
Nausafix	
Vausicalm	
Vausicann	
Nefopam hydrochloride	
Veisvac-C	.262
Neo-B12	. 24
Neo-Mercazole	
Neocate Gold (Unflavoured)	
Neocate Junior Vanilla	.252

Neoral	156
Neostigmine metilsulfate	101
Neostigmine metilsulfate with	
glycopyrronium bromide	101
Neosynephrine HCL	51
Nepro HP (Strawberry)	257
Nepro HP (Vanilla)	
Nepro HP RTH	256
Neulastim	
Neupogen	
NeuroTabs	07 21
Nevirapine	21
Nevirapine Alphapharm	
Nicardipine hydrochloride	
Nicorandil	40
Nicotine	100
Nifedipine	40
Nifuran	
Nilotinib	147
Nilstat	
Alimentary	
Genito-Urinary	
Infections	
Nimodipine	46
Nimotop	46
Nintedanib	220
Nirmatrelvir with ritonavir	98
Nitazoxanide	90
Nitrates	50
Nitroderm TTS 10	50
Nitroderm TTS 5	
Nitrofurantoin	
Nitrolingual Pump Spray	50
Nivestim	3/
Nivolumab	
Nodia	
Noflam 250	109
Noflam 500	105
Non-Steroidal Anti-Inflammatory	400
Drugs	108
Nonacog gamma, [Recombinant	
factor IX]	32
Noradrenaline	
Noradrenaline BNM	51
Norethisterone	~
Genito-Urinary	64
Hormone Preparations	
Norflex	
Norfloxacin	
Noriday 28	64
Normison	
Norpress	
Nortriptyline hydrochloride	
Norvir	
Noumed	118

Noumed Paracetamol115
Novasource Renal (Vanilla)257
Novatretin60
NovoMix 30 FlexPen9
NovoRapid FlexPen10
NovoSeven RT
Noxafil
Nozinan
Nucala
Nuelin
Nuelin-SR 224
Nupentin120
Nutren Diabetes (Vanilla)
Nutrini Energy Multi Fibre
Nutrini Low Energy Multifibre
RTH
Nutrini Dentioerh
Nutrini Peptisorb
Nutrini Peptisorb Energy253
Nutrison 800 Complete Multi
Fibre
Nutrison Concentrated251
Nutrison Energy258
Nutrison Protein Intense
Nyefax Retard
Nystatin
Alimentary22
Dermatological56
Genito-Urinary63
Infections
Infections

Oily phenol [Phenol oily]
Olanzapine 125-126
Olaparib 141
Olive oil242
Olopatadine
Olopatadine Teva
Olsalazine
Olumiant
Omalizumab188
Omeprazole
Omeprazole actavis 10
Omeprazole actavis 20
Omeprazole actavis 40
Omezol IV
Omnipaque
Omniscan
Omnitrope
Onbrez Breezhaler
Oncaspar LYO141
OncoTICE
Ondansetron
Ondansetron Kabi
Ondansetron ODT-DRLA
Ondansetron-Baxter
One-Alpha
Ondition 011
Opdivo
Optional Pharmaceuticals
Ora-Blend
Ora-Blend SF242
Ora-Plus
Ora-Sweet
Ora-Sweet SF242
Oratane
Ornidazole
Orphenadrine citrate107
Oruvail SR 109
Oseltamivir
Osmolite RTH258
Other Cardiac Agents
Other Endocrine Agents70
Other Oestrogen Preparations
Other Otological Preparations
Other Progestogen
Preparations 71
Other Skin Preparations61
Ovestin
Genito-Urinary65
Hormone Preparations71
Oxaliplatin144
Oxaliplatin Accord144
Oxandrolone
Oxpentifylline
Oxybuprocaine hydrochloride
Oxybutynin
Oxycodone hydrochloride117

Oxycodone Sandoz	117
Oxymetazoline hydrochloride	
	222
OxyNorm	
Oxytocin	
Oxytocin BNM	64
Oxytocin with ergometrine	
maleate	
Ozurdex	227
- P -	
Pacifen	107
Pacimol	. 115
Paclitaxel	
Paclitaxel Ebewe	
Palbociclib	
Paliperidone	
Pamidronate disodium	100
Pamisol	
Pancreatic enzyme	
Pancuronium bromide	
Pantoprazole	8
Panzop Relief	8
Papaverine hydrochloride	
Paper wasp venom	218
Para-aminosalicylic Acid	
Paracare	115
Paracare Double Strength	. 115
Paracetamol	115
Paracetamol Kabi	
Paracetamol with codeine	
Paraffin	
Alimentary	14
Dermatological	
Extemporaneously Compounded	1
Preparations	242
Paraffin liquid with soft white	
paraffin	232
Paraffin liquid with wool fat	
Paraffin with wool fat	
Paraldehyde	
Parecoxib	
Paromomycin	
Paroxetine	
Paser	89
Patent blue V	238
Paxam	127
Paxlovid	98
Pazopanib	148
Peak flow meter	
Peanut oil	
Pedialyte - Bubblegum	
Pediasure (Chocolate)	
Pediasure (Strawberry)	
Pediasure (Vanilla)	256
Pediasure RTH	200
Pegaspargase	
Pegasys	9 0

Pegfilgrastim
Pegylated interferon alfa-2a98
Pembrolizumab212
Pemetrexed 138
Penicillamine101
Penicillin G82
Penicillin V82
Pentacarinat
Pentagastrin71
Pentamidine isethionate
Pentasa
Pentostatin [Deoxycoformycin]142
Pentoxifylline [Oxpentifylline]52
Peptamen OS 1.0 (Vanilla)250
Perflutren
Perhexiline maleate
Pericyazine
Perindopril
Perjeta
Permethrin
Perrigo
Pertuzumab
Peteha
Pethidine hydrochloride
Pexsig
Pfizer Exemestane
Pheburane
Phenasen
Phenelzine sulphate 118
Phenindione
Phenobarbitone 120, 130
Phenobarbitone sodium
Phenol
Extemporaneously Compounded
Preparations
Various
Phenol oily7
Phenol with ioxaglic acid
Phenothrin
Phenoxybenzamine
hydrochloride
Phenoxymethylpenicillin [Penicillin
V]
Phentolamine mesylate
Phenylephrine hydrochloride
Cardiovascular
Sensory
Phenytoin
Phenytoin sodium
Pholcodine
Phosphorus40
Phytomenadione
Picibanil
Pilocarpine hydrochloride
Pilocarpine nitrate
Pimafucort60

D' I' 00
Pimecrolimus60
Pindolol45
Pine tar with trolamine laurilsulfate
and fluorescein 61
Pinetarsol61
Pioglitazone11
Piperacillin with tazobactam
PiperTaz Sandoz82
Pipothiazine palmitate
PipTaz Sandoz
Pirfenidone
Pituitary and Hypothalamic
Hormones and Analogues
Pivmecillinam
Pizotifen
PKU Anamix Junior LQ (Berry)248
PKU Anamix Junior LQ
(Orange) 248
PKU Anamix Junior LQ
(Unflavoured)248
Plaquenil101
Plasma-Lyte 14838
Plasma-Lyte 148 & 5% Glucose 38
Plendil ER45
Plerixafor
Pneumococcal (PCV10) conjugate
vaccine
Pneumococcal (PCV13) conjugate
vaccine
Pneumococcal (PPV23)
polysaccharide vaccine
polysaccharide vaccine 263
Pneumovax 23263
Podophyllotoxin61
Polidocanol31
Poliomyelitis vaccine268
Poloxamer 14
Poly Gel231
Poly-Tears231
Poly-Visc232
Polyhexamethylene biguanide242
Polyvinyl alcohol with povidone 232
Poractant alfa 225
Posaconazole86
Postinor-164
Potassium chloride
Potassium chloride with sodium
chloride
Potassium citrate
••••••
Potassium dihydrogen
phosphate
Potassium iodate
Alimentary21
Hormone Preparations76
Potassium iodate with iodine21
Potassium perchlorate76
Potassium permanganate61
· •

Povidone K30	
Povidone-iodine	
Povidone-iodine with ethanol	235
Pradaxa	
Pralidoxime iodide	
Pramipexole hydrochloride	111
Pravastatin	48
Pravastatin Mylan	48
Praxbind	
Praziquantel	 80
Prazosin	
Pred Forte	
Prednisolone	60 22
Prednisolone acetate	
Prednisolone sodium	220
Prednisolone sodium	
phosphate	000
priospriate	220
Prednisolone- AFT	
Prednisone	
Prednisone Clinect	
Pregabalin	121
Pregabalin Pfizer	
Pregnancy test - hCG urine	271
preOp	257
Prevenar 13	
Priadel	125
Prilocaine hydrochloride	114
Prilocaine hydrochloride with	
felypressin	114
Primaquine	90
Primidone	
Primolut N	71
Primovist	237
Priorix	267
Probenecid	
Procaine penicillin	82
Procarbazine hydrochloride	
Prochlorperazine	
Proctosedyl	7
Procyclidine hydrochloride	
Progesterone	64
Proglicem	
Proglycem	
Progynova	
Prolia	104
Promethazine hydrochloride	
Propafenone hydrochloride	213 44
Propofol	
Propranolol	
Propylthiouracil	40 70
Prostin E2	04
Prostin VR	51
Protamine sulphate	
Protionamide	89
Protirelin Proveblue	76

Provera70
Provera HD71
Proxymetacaine hydrochloride229
Pseudoephedrine
hydrochloride
PSM Citalopram
Psoriasis and Eczema
Preparations
PTU
Pulmonary Surfactants
Pulmozyme224
Puri-nethol138
Puria25
Pyrazinamide89
Pyridostigmine bromide 101
Pyridoxal-5-phosphate18
Pyridoxine hydrochloride24
Pyridoxine multichem24
Pyrimethamine90
Pytazen SR
- Q -
Quetapel
Quetiapine
Quinapril
Quinapril with
hydrochlorothiazide 41
Quinine dihydrochloride
Qvar
- R -
- R - RA-Morph116
- R -
- R - RA-Morph
- R - RA-Morph
- R - RA-Morph
- R - RA-Morph 116 Rabies vaccine 268 Raloxifene 105 Raltegravir potassium 94 Ramipex 111 Ranbaxy-Cefaclor 79 Ranibizumab 189 Rapamune 214 Rasagiline 111 Raburicase 107 Readir-CAT 2 236 Reandron 1000 67 Recombinant factor VIIa 32 Recombinant factor VIIa 32 Recombinant factor VIIa 32 Redigesic 77 Red back spider antivenom 234 Redipred 69
- R - RA-Morph 116 Rabies vaccine 268 Raloxifene 105 Raltegravir potassium 94 Ramipex 111 Ranbaxy-Cefaclor 79 Ranibizumab 189 Ranitidine 8 Rapamune 214 Rasagiline 107 Readir-CAT 2 236 Recombinant factor IX 31–32 Recombinant factor VIII 32–33 Rectogesic 7 Red back spider antivenom 234 Redipred 69 Relenza Rotadisk 97
- R - RA-Morph 116 Rabies vaccine 268 Raloxifene 105 Raltegravir potassium 94 Ramipex 111 Ranbaxy-Cefaclor 79 Ranibizumab 189 Rapamune 214 Rasagiline 111 Raburicase 107 Readir-CAT 2 236 Reandron 1000 67 Recombinant factor VIIa 32 Recombinant factor VIIa 32 Recombinant factor VIIa 32 Redigesic 77 Red back spider antivenom 234 Redipred 69
- R - RA-Morph 116 Rabies vaccine 268 Raloxifene 105 Raltegravir potassium 94 Ramipex 111 Rabaxy-Cefaclor 79 Raibizumab 189 Ranitidine 8 Rapamune 214 Rasagiline 111 Rasburicase 107 Readi-CAT 2 236 Reandron 1000 67 Recombinant factor IX 31–32 Recombinant factor VIII 32–33 Rectogesic 7 Red back spider antivenom 234 Redipred 69 Relenza Rotadisk 97 Relistor 14 Remicade 179
- R - RA-Morph 116 Rabies vaccine 268 Raloxifene 105 Raltegravir potassium 94 Ramipex 111 Rabaxy-Cefaclor 79 Raibizumab 189 Ranitidine 8 Rapamune 214 Rasagiline 111 Rasburicase 107 Readi-CAT 2 236 Reandron 1000 67 Recombinant factor IX 31–32 Recombinant factor VIIa 32–33 Rectogesic 7 Red back spider antivenom 234 Redipred 69 Relenza Rotadisk 97 Relistor 14 Remicade 179 Remifertanil 117
- R - RA-Morph 116 Rabies vaccine 268 Raloxifene 105 Raltegravir potassium 94 Ramipex 111 Rabaxy-Cefaclor 79 Raibizumab 189 Ranitidine 8 Rapamune 214 Rasagiline 111 Rasburicase 107 Readi-CAT 2 236 Reandron 1000 67 Recombinant factor IX 31–32 Recombinant factor VIII 32–33 Rectogesic 7 Red back spider antivenom 234 Redipred 69 Relenza Rotadisk 97 Relistor 14 Remicade 179
- R - RA-Morph 116 Rabies vaccine 268 Raloxifene. 105 Raltegravir potassium 94 Ramipex 111 Ranbaxy-Cefaclor 79 Raibizumab 189 Ranitidine 8 Rapamune 214 Rasagiline. 111 Rasburicase. 107 Readi-CAT 2 236 Reandron 1000 67 Recombinant factor IX 31–32 Recombinant factor VIIa 32–33 Rectogesic 7 Red back spider antivenom 234 Redipred 69 Relenza Rotadisk 97 Relistor 14 Remicade 179 Remifentanil. 117 Remifentanil. 117
- R - RA-Morph 116 Rabies vaccine 268 Raloxifene. 105 Raltegravir potassium 94 Ramipex 111 Ranbaxy-Cefaclor 79 Raibizumab 189 Rantidine 8 Rapamune 214 Rasagiline 111 Rasburicase 107 Readi-CAT 2 236 Reandron 1000 67 Recombinant factor IX 31–32 Recombinant factor VIIa 32–33 Rectogesic 7 Red back spider antivenom 234 Redipred 69 Relenza Rotadisk 97 Relistor 14 Remicade 117 Remifentanil 117 Remifentanil 117 Resonium A 40
- R - RA-Morph 116 Rabies vaccine 268 Raloxifene. 105 Raltegravir potassium 94 Ramipex 111 Ranbaxy-Cefaclor 79 Raibizumab 189 Ranitidine 8 Rapamune 214 Rasagiline. 111 Rasburicase. 107 Readi-CAT 2 236 Reandron 1000 67 Recombinant factor IX 31–32 Recombinant factor VIIa 32–33 Rectogesic 7 Red back spider antivenom 234 Redipred 69 Relenza Rotadisk 97 Relistor 14 Remicade 179 Remifentanil. 117 Remifentanil. 117

Retinol	24
Retinol Palmitate	.232
ReTrieve	57
Retrovir	92
Retrovir IV	
Revlimid	
Revolade	
Rexacrom	
Riboflavin	
Riboflavin 5-phosphate	230
Ribomustin	
Ricit	65
Rifabutin	
Rifadin	
Rifampicin	
Rifaximin	
Rifinah	
Rilutek	
Riluzole	
Ringer's solution	
RINVOQ	216
Riodine	
Risedronate Sandoz	102
Risedronate sodium	
Risperdal Consta	
Risperidone	127
Risperidone (Teva)	127
Risperon	
Ritalin	
Ritalin LA	
Ritonavir	
Rituximab (mabthera)	
Rituximab (riximyo)	
Rivaroxaban	. 192
Rivastigmine	
Rivastigmine Patch BNM 10	102
Rivastigmine Patch BNM 5	
Riximyo	
RIXUBIS	
Rizamelt	
Rizatriptan	100
Rocuronium bromide	
Ronapreve	. 10/
Ropin	
Ropinirole hydrochloride	
Ropivacaine hydrochloride	
Ropivacaine hydrochloride with	
fentanyl	
Ropivacaine Kabi	
Rose bengal sodium	
Rosuvastatin	
Rosuvastatin Viatris	
Rotarix	
Rotavirus oral vaccine	
Roxane	
Roxithromycin	

Rubifen
Rubifen SR 131
Rulide D
Rurioctocog alfa pegol [Recombinant
factor VIII]
Ruxolitinib149
-\$-
S26 LBW Gold RTF255
Sacubitril with valsartan
SalAir
Salazopyrin7
Salazopyrin EN7
Salbutamol
Salbutamol with ipratropium
bromide219
Salicylic acid242
Salmeterol
Salmonella typhi vaccine
Sandimmun
Sandomigran
Sapropterin Dihydrochloride
Scalp Preparations
Scalp Fleparations
Scandonest 3%
Sclerosing Agents
Scopoderm TTS 123
Sebizole56
Secretin pentahydrochloride238
Secukinumab
Sedatives and Hypnotics 129
Seebri Breezhaler
Selegiline hydrochloride 111
Sennosides15
Serc 123
Serenace 125
Seretide
Seretide Accuhaler
Serevent
Serevent Accuhaler
Sertraline
Setrona
Sevoflurane
Sevredol
Shingles vaccine
Sildenafil53
Siltuximab 205
Silver nitrate
Dermatological61
Extemporaneously Compounded
Preparations242
Simeticone5
Simulect
Simvastatin
Simvastatin Mylan
Sincalide
Sinemet
Sinemet CR 111

Sirolimus
Siterone67
Slow-Lopresor45
Smith BioMed Rapid Pregnancy
Test
Snake antivenom234
Sodibic40
Sodium acetate
Sodium acid phosphate40
Sodium alginate with magnesium
alginate5
Sodium alginate with sodium
bicarbonate and calcium
carbonate5
Sodium aurothiomalate101
Sodium benzoate19
Sodium bicarbonate
Blood
Extemporaneously Compounded
Preparations
Sodium calcium edetate
Sodium chloride
Blood
Respiratory222, 225
Various239
Sodium chloride with sodium
bicarbonate 222
Sodium citrate
Alimentary5
Extemporaneously Compounded
Preparations
Sodium citrate with sodium chloride
and potassium chloride
Sodium citrate with sodium lauryl
sulphoacetate 15
Sodium citro-tartrate
Sodium cromoglicate
Alimentary7
Respiratory219
Sensory228
Sodium dihydrogen phosphate
[Sodium acid phosphate] 40
Sodium fluoride21
Sodium fusidate [Fusidic acid]
Dermatological56
Infections85
Sensory226
Sodium hyaluronate [Hyaluronic acid]
Alimentary23
Sensory
Sodium hyaluronate [Hyaluronic acid]
with chondroitin sulphate 229
Sodium hypochlorite
Sodium metabisulfite
Sodium nitrite

Sodium nitroprusside	
Cardiovascular	52
Optional Pharmaceuticals	
Sodium phenylbutyrate	20
Sodium phosphate with phosphoric	
acid	15
Sodium picosulfate	15
Sodium polystyrene sulphonate	40
Sodium stibogluconate	91
Sodium tetradecyl sulphate	31
Sodium thiosulfate	233
Sodium valproate	
Sodium with potassium	
Solifenacin Mylan	66
Solifenacin succinate	. 66
Solu-Cortef	
Solu-Medrol	. 69
Solu-Medrol Act-O-Vial	69
Somatropin	
Sotalol	
Soya oil	
Spacer device	271
Span-K	40
Specialised Formulas	2/0
Spiolto Respimat	290
Spiractin	
Spiramycin	
Spiriva	
Spiriva Respimat	220
Spironolactone	
Sprycel	1/5
Standard Feeds	
Staphlex	
Starch	
Stavudine Sterculia with frangula	
SteroClear	
Stesolid Stimulants / ADHD Treatments	119
Stimulants / ADHD Treatments	130
Stiripentol	
Stocrin	91
Streptomycin sulphate	/8
Stromectol	
Sucralfate	
Sucrose	
Sugammadex	
Sugammadex BNM	108
Sulfadiazine silver	56
Sulfasalazine	
Sulindac	
Sulphacetamide sodium	226
Sulphadiazine	85
Sulphur	243
Sulprix	
Sumagran	122

	_
Sumatriptan 12	22
Sunitinib15	50
Sunitinib Pfizer	
Sunscreen, proprietary	
Suprane	
Surgical Preparations	20
Sustagen Hospital Formula	13
(Chocolate)25	:0
Sustagen Hospital Formula	19
(Vanilla) 25	:0
Sutent)U
Suxamethonium chioride)/ _
Sylvant	15
Symmetrel 11	0
Sympathomimetics	0
Synacthen7	1
Synacthen Depot7	1
Synflorix26	3
Syntometrine	
Syrup24	13
Systane Unit Dose23	31
- T -	
Tacrolimus	
Dermatological6	51
Oncology15	
Tacrolimus Sandoz15	
Tagitol V23	36
Talc	
Taliglucerase alfa	
Tambocor4	
Tamoxifen citrate	
Tamoxifen Sandoz15	
Tamsulosin hydrochloride	35
Tamsulosin-Rex	5
Tarceva14	
Targocid	
Tasigna14	
Tasmar	
Taurine	
Tecfidera	.0 20
Tegretol	
Tegretol CR 11	
Teicoplanin	
Teicoplanin Mylan	
Temaccord14	
Temazepam	50
Temozolomide14	
Tenecteplase	
Tenofovir disoproxil	
Tenofovir Disoproxil Teva	94
Tenoxicam)9
Tensipine MR104	
Terazosin4	
Terbinafine	
Terbutaline6	
Terbutaline sulphate	22

Teriflunomide129
Teriparatide105
Terlipressin77
Testosterone67
Testosterone cipionate67
Testosterone esters
Testosterone undecanoate67
Tetrabenazine110
Tetracaine [Amethocaine] hydrochloride
Nervous114
Sensory229
Tetracosactide [Tetracosactrin]71
Tetracosactrin
Tetracycline
Thalidomide143
Thalomid143
Theobroma oil243
Theophylline
Thiamine hydrochloride
Thioguanine
Thiopental [Thiopentone]
sodium
Thiopentone
Thiotepa
Thrombin
Thyroid and Antithyroid
Preparations
Thyrotropin alfa71
Ticagrelor
Ticarcillin with clavulanic acid
Ticlopidine
Tigecycline
Tilcotil
Timolol
Timoptol XE
Tiotropium bromide
Tiotropium bromide with
olodaterol
Tivicay
TMP
Tobradex
Tobramycin
Infections
Sensory
Tobramycin BNM
Tobramycin Mylan
Tobrex
Tocilizumab
Tofranil
Tolcapone
Topamax
Topicaine
Topical Products for Joint and
Muscular Pain 109
Topiramate
Topiramate Actavis
1 opiralitato Autavio

Torbay51
Tracrium 107
Tramadol hydrochloride117
Tramal 100 117
Tramal 50 117
Tramal SR 100 117
Tramal SR 150 117
Tramal SR 200 117
Trandate
Tranexamic acid31
Tranexamic-AFT31
Tranylcypromine sulphate118
Trastuzumab209
Trastuzumab emtansine210
Travatan
Travoprost230
Treatments for Dementia132
Treatments for Substance
Dependence 132
Tretinoin
Dermatological57
Oncology143
Trexate
Tri-sodium citrate243
Triamcinolone acetonide
Alimentary 22
Dermatological 60
Hormone Preparations69
Triamcinolone acetonide with
gramicidin, neomycin and
nystatin 227
Triamcinolone acetonide with
neomycin sulphate, gramicidin
and nystatin 60
Triamcinolone hexacetonide69
Triazolam130
Trichloracetic acid243
Trientine dihydrochloride20
Trimethoprim85
Trimethoprim with
sulphamethoxazole
[Co-trimoxazole] 85
Trisul
Trometamol
Tropicamide
Tropisetron
Trulicity11
Tuberculin PPD [Mantoux] test270
Tubersol
Two Cal HN251
Tykerb
Tysabri129
- U -
Ultibro Breezhaler
Ultraproct
Umeclidinium

Umeclidinium with vilanterol220
Univent
Upadacitinib216
Ural
Urea
Dermatological
Extemporaneously Compounded
Preparations 243
Preparations
Urografin
Urokinase
Urologicals
Uromitexan
Ursodeoxycholic acid12
Ursosan
Utrogestan 64
- v - Vaclovir
Valaciclovir
Valganciclovir
Valganciclovir Mylan
Vancomycin
Varenicline
Varenicline Pfizer134
Varibar - Honey236
Varibar - Nectar
Varibar - Pudding236
Varibar - Thin Liquid236
Varicella vaccine [Chickenpox
Varicella vaccine [Chickenpox vaccine]
Varicella vaccine [Chickenpox 268 Varicella zoster vaccine [Shingles 269 Varivax. 268 Vasodilators. 51 Vasopressin 77 Vasopressin Agents. 77 Vasopressin Agents. 77 Vecuronium bromide 108 Vedafil. 53 Veletri 54 Venclexta. 143 Vendoclax. 143 Venofer 21 VENOX 218 Ventavis 55 Ventolin 222 Vepesid 140
Varicella vaccine [Chickenpox 268 Varicella zoster vaccine [Shingles 269 Varicella zoster vaccine [Shingles 268 Vascine] 268 Vasodilators 51 Vasopressin Agents 77 Vasorex 45 Vecuronium bromide 108 Vedafil 53 Veletri 54 Venclexta 143 Venetoclax 143 Venofer 218 Ventavis 525 Ventolin 222 Vepesid 140 Verapamil hydrochloride 46
Varicella vaccine [Chickenpox 268 Varicella zoster vaccine [Shingles 269 Varivax. 268 Vasodilators. 51 Vasopressin 77 Vasopressin Agents. 77 Vasopressin Agents. 77 Vecuronium bromide 108 Vedafil. 53 Veletri 54 Venclexta. 143 Vendoclax. 143 Venofer 21 VENOX 218 Ventavis 55 Ventolin 222 Vepesid 140
Varicella vaccine [Chickenpox vaccine] 268 Varicella zoster vaccine [Shingles vaccine] 269 Varivax 268 Vasodilators 51 Vasopressin 77 Vasopressin 77 Vasopressin 45 Vecuronium bromide 108 Vedafil 53 Veletri 54 Venclexta 143 Venetoclax 143 Venetoclax 218 Ventavis 552 Ventolin 222 Vepesid 140 Verapamil hydrochloride 46 Vergo 16 123
Varicella vaccine [Chickenpox vaccine] 268 Varicella zoster vaccine [Shingles vaccine] 269 Varivax 268 Vasopressin 51 Vasopressin Agents 77 Vasopressin Agents 77 Vasorex 45 Vecuronium bromide 108 Vedafil. 53 Veletri 54 Venclexta 143 Venetoclax 143 Venlafaxine 119 Venofer 218 Ventavis 55 Ventolin 222 Vepesid 140 Verapamil hydrochloride 46 Vergo 16 123 Vermox 89
Varicella vaccine [Chickenpox 268 Varicella zoster vaccine [Shingles 269 Varivax 268 Vasopressin 51 Vasopressin Agents 77 Vasopressin Agents 77 Vasorex 45 Vecuronium bromide 108 Vedafil 53 Veletri 54 Venclexta 143 Venetoclax 143 Venetoclax 218 Ventorionium 222 Vepesid 140 Verapamil hydrochloride 40 Verago 16 123 Vermox 89 Versacloz 125 Vesanoid 143
Varicella vaccine [Chickenpox 268 Varicella zoster vaccine [Shingles 269 Varivax. 268 Vasodilators. 51 Vasopressin 77 Vasopressin Agents. 77 Vasorex 45 Vecuronium bromide 108 Vedafil. 53 Veletri 54 Venclexta 143 Venetoclax. 143 Venetoclax. 143 Ventofer 218 Ventolin. 222 Vepesid. 140 Verapamil hydrochloride. 46 Vergo 16. 123 Vermox 89 Vesanoid. 143 Vexazone. 11
Varicella vaccine [Chickenpox 268 Varicella zoster vaccine [Shingles 269 Varivax 268 Vasopressin 51 Vasopressin Agents 77 Vasopressin Agents 77 Vasorex 45 Vecuronium bromide 108 Vedafil 53 Veletri 54 Venclexta 143 Venetoclax 143 Venetoclax 218 Ventorionium 222 Vepesid 140 Verapamil hydrochloride 40 Verago 16 123 Vermox 89 Versacloz 125 Vesanoid 143

Vigisom129
Vildagliptin11
Vildagliptin with metformin
hydrochloride 11
Vimpat 120
Vinblastine sulphate 152
Vincristine sulphate 152
Vinorelbine
Viral Vaccines264
Viramune Suspension91
ViruPOS226
Viscoat
Visipaque236
Vit.D3
VitA-POS
Vital
Vitamin B complex25
Vitamin B6 25
Vitamins
Vivonex TEN
Voltaren
Voltaren D108
Voltaren Ophtha
Voltaren SR
Volumatic
VoLumen
Voriconazole
Votrient
Vttack
- W -
Warfarin sodium
Wart Preparations61
Water
Blood40
Various239
Wool fat
Dermatological 59
Extemporaneously Compounded
Preparations243
- X -
X-Opaque-HD236
Xanthan
Xarelto
Xifaxan9
Xolair
Xylocaine 113
Xylometazoline hydrochloride
Xyntha
- Y -
Yellow jacket wasp venom218
-Z-
Zanamivir
Zapril41
Zarontin
Zavedos
Zeffix
LONIA

Zematop61
Zetlam94
Ziagen92
Zidovudine [AZT]
Zidovudine [AZT] with
lamivudine
Zimybe49
Zinc
Alimentary22
Dermatological
Zinc and castor oil58
Zinc chloride22
Zinc oxide243
Zinc sulphate22
Zinc with wool fat58
Zincaps22
Zinforo80
Zinnat79
Ziprasidone126
Zista219
Zithromax80
Zoledronic acid
Hormone Preparations68
Musculoskeletal 102
Zoledronic acid Mylan68
Zopiclone 130
Zostavax269
Zostrix109
Zostrix HP114
Zuclopenthixol acetate126
Zuclopenthixol decanoate 127
Zuclopenthixol hydrochloride
Zusdone
Zyban133
Zypine125
Zypine ODT 125
Zyprexa Relprevv126
Zytiga152
Zvvox















